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ABSTRACT 
CD8
+
 T-cells are essential for the immune control of pathogens and the natural eradication of 
cancer. CD8
+
 T-cells also play a major role in the pathogenesis of autoimmunity and 
alloreactivity. CD8
+
 T-cells recognize short peptide fragments (8-13 amino acids) presented 
at the target cell surface bound to Major Histocompatability Class I (MHCI) molecules. T-
cell antigen recognition is unique in nature because it involves the binding of a single ligand 
(peptide–MHC [pMHC]) by two receptors (TCR and CD8). The CD8 glycoprotein, which 
serves as the coreceptor on MHCI-restricted T-cells, acts to enhance the antigen sensitivity of 
T-cells by binding to a largely invariant region of MHCI at a site distinct from the TCR 
docking platform. CD8 has been shown to have multiple roles including enhancing effects on 
early T-cell activation events and also in controlling the level of T-cell cross-reactivity. The 
pMHCI/CD8 interaction is classified as having a very weak binding affinity and very fast 
kinetics. I discovered that this low solution binding affinity is essential in maintaining 
homeostasis as dramatically increasing the strength of this interaction resulted in total loss of 
T-cell specificity and activation independent of TCR engagement. This led me to examine the 
possibility that anti-CD8 antibodies could also bypass the normal requirements for T-cell 
activation. I identified one specific clonotype of antibody capable of this phenomenon but 
simultaneously discovered multiple effector phenotypes of other anti-CD8 antibodies. These 
included both enhancing and inhibitory effects on pMHCI tetramer binding and CD8
+
 T-cell 
activation. Subsequently, I explored the possibility of using these inhibitory anti-CD8 
antibodies to block T-cell function in systems which are highly dependent on CD8 such as 
autoreactive CD8
+
 T-cells. I demonstrated that targeting CD8 can be used as a strategy to 
block autoreactive CD8
+
 T-cell activation in the absence of any effect on pathogen specific 
immunity. This highlights a novel therapeutic strategy that warrants further investigation. 
Finally, I demonstrated that CD8 can alter the functional avidity of a CD8
+ 
T-cell for its 
agonists and act to re-arrange the relative potencies of each of its potential agonists, a novel 
“focussing mechanism” for CD8 in T cell activation. These results provide new insight to the 
biological role of CD8 in T-cells and even predict a novel mechanism for CD8 in controlling 
T-cell function. My results also highlight the potential of targeting CD8 for 
immunotherapeutic design in autoimmune disorders. 
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1. Introduction 
1.1 Overview of the Immune system 
The primary role of the immune system is the eradication of pathogens and tumours to 
protect against disease. The immune system is a diverse network of cell types, lymphoid 
organs and many other factors involved in immune control. The immune system can be 
divided into two arms, determined by the speed and specificity of the response to pathogen 
attack: (i) innate (natural) immunity, which provides the first line of anti-microbial defence 
(Tosi 2005), and; (ii) acquired (adaptive) immunity, which acts in concert with innate 
immunity in order to eliminate the invading pathogen.  
 
1.1.1 Innate Immunity 
The innate immune system provides the first line of defence. If pathogens breach physical 
barriers such as skin, mucosal surfaces and the respiratory tract then the innate immune 
response is activated and recognizes pathogens through ‘pattern recognition receptors’ (PRR) 
(Medzhitov 2007). PRRs concentrate on the recognition of highly conserved structures 
expressed by large groups of micro-organisms (Suzuki, Kurihara et al. 1997; Fraser, Koziel et 
al. 1998; Thomas, Li et al. 2000). The major cellular effectors of the innate immune system 
are dendritic cells (DC), neutrophils, monocytes and macrophages (which are all involved 
with phagocytosis) (Janeway and Medzhitov 2002), and natural killer cells (NK) (which are 
involved with removal of virally infected and transformed cells) (Smyth, Cretney et al. 2005). 
In addition, mast cells, eosinophils and basophils are involved in the release of inflammatory 
mediators and molecular components. Another important cellular effector of the innate 
immune system is the complement system. The activated complement system recognizes and 
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eliminates invading microorganisms. In addition, complement facilitates the elimination of 
dead or modified self cells, such as apoptotic particles and cellular debris. The alternative 
pathway of complement forms a spontaneously and constantly activated immune surveillance 
system as reviewed in (Zipfel and Skerka 2009). Effector function of the innate immune 
system is activated immediately on exposure to antigen and occurs to the same extent even on 
repeated exposure to the same antigen (Medzhitov and Janeway 2000).  
 
1.1.2 Acquired Immunity 
Aquired or ‘Adaptive’ immunity can be separated into either humoral or cell-mediated 
responses. Humoral immunity is mediated by the secretion of antibodies by B-cells. 
Antibodies bind to antigens present at the surface of invading pathogens (such as viruses or 
bacteria), which identifies them for removal via cell-mediated immunity. Cell-mediated 
immunity does not involve antibodies or complement but involves the activation of T-cells 
(Delves and Roitt 2000; Delves and Roitt 2000). Both B-cells and T-cells are derived from 
progenitor hematopoietic stem cells in the bone marrow (Janeway, Murphy et al. 2008). B 
and T-cells express receptors that are generated by somatic re-arrangement during T-cell 
development, as a result approximately 10
14
 B-cell receptors (BCRs) and 10
18
 T-cell 
receptors (TCRs) can be generated. B and T-cells express only one clonal antigen receptor 
and on recognition of specific antigen proliferate by a process called ‘clonal expansion’ 
which can take 3-5 days (Pancer and Cooper 2006). The adaptive response improves on 
repeated antigen exposure, a property called ‘immunological memory’.  
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1.2 T-cell antigen recognition, processing and activation  
1.2.1 T-cell activation and antigen recognition 
T-cells are characterized by the surface expression of the lymphocyte marker CD45 and more 
specifically by the expression of the T-cell marker CD3. Approximately 95% of circulating 
T-cells will express a unique αβ T-Cell Receptor (TCR) at their cell surface (Lefranc and 
Lefranc 2001). These αβ T-cells are able to recognize short peptide fragments presented at 
the cell surface of an antigen presenting cell (APC) in association with the Major 
Histocompatability complex molecule (MHC) known as Human Leukocyte antigen (HLA) in 
humans (Engelhard 1994) (Rudensky, Preston-Hurlburt et al. 1991) (Davis, Boniface et al. 
1998). T-cells can also exclusively express a γδ TCR. These cells are far less in number than 
αβ T-cells, i.e. <5% circulating T-cells will express a γδ TCR (Kabelitz, Wesch et al. 2007) 
(Lefranc and Lefranc 2001). The γδ T-cells role is less well understood in immunity than the 
αβ T-cells. It is believed that they can recognize specific microbial and viral antigens, and 
may play a role in tumor immunology (Kabelitz, Wesch et al. 2007).  
 
MHC Class I (MHCI), molecules in complex with short peptides (8-13 amino acids) are 
expressed at the surface of all nucleated cells as peptide-MHCI (pMHCI). These presented 
peptides are mostly derived from endogenously processed intracellular proteins. In a healthy 
cell the peptides that are presented are host-derived. Intracellular infection or tumourigenesis 
results in presentation of foreign pMHCI at the cell surface. Foreign pMHCI molecules are 
recognised by CD8
+
 T-cells which eradicate the target cell. Therefore, CD8
+
 T-cells are 
important mediators of immunity to intracellular pathogens such as viruses, protozoa and 
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parasites, and play an important role in the elimination of tumour transformed cells (Harty, 
Tvinnereim et al. 2000). 
 
MHC Class II (MHCII), molecules are expressed by ‘professional’ or ‘bone marrow derived’ 
APCs (dendritic cells, macrophages, B-cells and in the human T-cells) and present small 
peptide fragments (13-25 amino acids) processed from extracellular pathogens. Foreign 
peptide-MHCII is recognised by CD4
+
 helper T-cells (Th). Activated CD4
+
 helper T-cells 
exist as three types: (i) Type 1 (Th1) helper T-cells secrete cytokines that facilitate cell-
mediated immunity such as macrophage activation and T-cell mediated cytotoxicity; (ii) 
Type 2 (Th2) helper T-cells secrete cytokines that help B-cells produce antibodies (Delves 
and Roitt 2000; Delves and Roitt 2000); and,  (iii) Th17 T-cells which produce IL-17 and are 
involved with autoimmune disorders but their precise role is still unknown (Veldhoen and 
Seddon 2010). There are also regulatory forms of CD4
+
 T-cells (Treg) that are important in 
immune regulation. My work focused on CD8
+
 T-cells so these Th cell types will not be 
discussed further here. 
 
1.2.2 Antigen processing and presentation 
In the cytosol, proteins become polyubiquitinated which targets them for proteasomal 
degradation (Ciechanover 1994).  The proteasome is a central cytoplasmic processing unit 
and is required for the generation of the majority of MHCI-associated peptides (Rock, 
Gramm et al. 1994). Peptide fragments generated by the proteasome are translocated into the 
Endoplasmic Reticulum (ER) via the transporter associated with antigen processing complex 
(TAP), where they bind to newly synthesised MHCI molecules (Pamer and Cresswell 1998).  
These new pMHCI molecules associate with a number of chaperone proteins, including 
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tapasin, calnexin, calreticulin and ERp57 to form the peptide-loading complex. This complex 
then facilitates the loading of peptides into the MHCI peptide binding groove  (Capps and 
Zuniga 1994; Sadasivan, Lehner et al. 1996; Peaper and Cresswell 2008; Purcell and Elliott 
2008; Sadegh-Nasseri, Chen et al. 2008). The pMHCI complex then traverses the ER and 
Golgi apparatus, before transport to the plasma membrane and expression on the APC surface 
(Figure 1.1). The co-factor tapasin additionally edits the peptide repertoire that is loaded onto 
MHCI molecules in favour of those with slow dissociation kinetics (Howarth, Williams et al. 
2004; Thirdborough, Roddick et al. 2008). Recognition of pMHCI is mediated by the αβ 
TCR which is expressed by CD8
+ 
T-cells (Antoniou, Powis et al. 2003). Alternatively, 
specialised professional antigen-presenting cells (including dendritic cells, B-cells, and 
macrophages) might have taken up exogenous antigen by endocytosis. Exogenous antigen is 
processed via a different pathway to endogenous antigen, and presented at the cell surface in 
complex with MHCII molecules (Figure 1.2). Briefly antigens are derived from extracellular 
pathogens and proteins internalised by phagocytosis or endocytosis. Internalised protein 
antigens are degraded in acidic endosomes. MHCII molecules in the endoplasmic reticulum 
are exported in vesicles. Vesicles fuse in cell cytoplasm so that MHCII molecules can bind 
antigen peptides. Antigenic peptides presented at the cell surface by MHCII molecules are 
recognised by CD4
+
 T-cells (Parkin and Cohen 2001). 
 
1.3 Structural and Molecular features of MHC and the TCR 
1.3.1 MHC class I and II structure 
MHCI and MHCII are cell surface glycoproteins with distinct subunit structures. The MHCI 
molecule is a membrane bound heterodimer consisting of two polypeptide chains, i.e. an α  
 Chapter 1 
36 
 
 
Figure 1.1: MHCI processing and presentation pathway. Peptides fragments are generated 
via proteasome digestion of bacterial, viral and tumour associated proteins, then transported 
into the endoplasmic reticulum (ER) where they associate with MHC molecules using TAP, 
peptide loading complex, and other chaperone proteins. Upon release from the ER, the 
pMHCI complex is transported to the cell surface by the Golgi apparatus where it is 
expressed, figure reprinted from The Lancet, 357(9270): 1777-89, Parkin and Cohen, An 
overview of the immune system, © 2001, with permission from Elsevier. 
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Figure 1.2: MHCII processing and presentation pathway. Antigens are internalised by 
phagocytosis or endocytosis where they are degraded in increasing acidic conditions and 
subsequently fuse to MHCII molecules preformed in the ER. Once released from the ER 
pMHCII molecules are presented on the cell surface and are recognised by CD4
+
 T-cells, 
figure reprinted from The Lancet, 357(9270): 1777-89, Parkin and Cohen, An overview of 
the immune system, © 2001, with permission from Elsevier. 
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chain, which is non-covalently associated with the smaller β2-microglobulin light chain 
(Figure 1.3 A). The α chain contains three globular domains, α1, α2 and α3 and it is only this 
chain that spans the cell membrane. The α3 domain and β2-microglobulin are membrane 
proximal whereas the α1 and α2 domains form the peptide binding groove. The MHCII 
molecule consists of two non-covalently associated chains, α and β chain (Figure 1.3 B). Both 
these chains span the cell membrane, and consist of a transmembrane domain and 
cytoplasmic tail. The α2 and β2 domains are membrane proximal domain whereas the α1 and 
β1 domains form the peptide binding groove. These subtle yet important differences between 
the MHC molecules do not deter from the fact that they both have similar structures and 
functions. The walls of the peptide binding groove are formed by 2 α-helices, whilst the base 
of the groove consists of 8 anti-parallel -pleated sheets (Wolf and Ploegh 1995). 
 
MHC molecules are unstable in the absence of peptide. Polymorphic amino acids in MHC 
molecules are mainly found and clustered in the peptide binding groove. These amino acids 
contribute to the formation of peptide binding pockets and side chains that project from 
certain amino acid residues into these binding pockets can stabilise the MHC molecule. The 
amino acid residues of the peptide epitope that sit in the pockets of the binding groove are 
known as the MHC anchor residues. These peptide binding pockets differ between MHC 
allelic variants in their spatial and chemical characteristics (Nielsen, Lundegaard et al. 2004). 
MHC molecules are known to be highly polymorphic at the peptide binding site and 
subsequently different MHC alleles will be able to bind different peptides. 
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Figure 1.3: Structure of MHCI and MHCII molecules. (A) The MHCI molecule consists 
of an α domain (α1, α2 and α3) and β2-microglobulin. The α1 and α2 domain form the 
peptide binding groove. The α chain also contains a transmembrane domain and a short 
cytoplasmic tail. (B)  The MHCII molecule consists of non-covalently linked α and  chains. 
The α2 and β2 chains form the membrane proximal domain whereas the α1 and β1 chain 
form the peptide binding groove. Both α and β chains contain a transmembrane domain and a 
cytoplasmic tail.  
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MHCI restricted peptides are normally 8-13 amino acids in length (Rammensee 1995), where 
residues at position 2 and the C- terminus act as MHCI anchor residues (Rammensee, 
Bachmann et al. 1999). The ends of the peptide binding groove are closed (Bjorkman, Saper 
et al. 1987) restricting the length of the peptide that can be accommodated, therefore the 
longer peptides must adopt a bulged conformation. MHCII molecules can bind peptides that 
range from 13-25 amino acids in length (Rammensee 1995) although the most commonly 
found length ranges from 13-17 amino acids (Rudensky, Preston-Hurlburt et al. 1991). In 
contrast to the MHCI molecules, the peptide binding groove is open. As a consequence, 
anchor residue positions can vary (Brown, Jardetzky et al. 1993) and the peptide sits in a 
universally flat conformation. 
 
The MHC encoding region is located on chromosome 6 and extends to over four million base 
pairs of DNA (Marsh 2000). It is divided into different gene encoding regions, i.e. (i) MHCI -
A, -B, -C, -E, -F and -G genes. (ii) MHC class II -DP, -DQ and -DR genes, as well as -DM. 
MHC genes can be highly polymorphic allowing the presentation of a large range of potential 
peptide epitopes. In humans, there are over 5518 MHCI alleles and 1612 MHCII alleles 
known to exist to date (EMBL-EBI 2012). 
 
1.3.2 TCR structure and pMHC recognition 
Recognition of peptide-MHC (pMHC) molecules is mediated by T-cells bearing an αβ TCR 
(Unanue 1984; Townsend and Bodmer 1989). The TCR α and β chain are covalently linked 
by disulphide bonds (van der Merwe and Davis 2003). Each TCR chain consists of a 
membrane distal variable region (Vα or Vβ) and a membrane proximal immunoglobulin like 
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constant region (Cα or Cβ). The chains also contain a transmembrane region and a 
cytoplasmic tail (Bentley and Mariuzza 1996). The TCR chains are glycoproteins, with the α 
chain containing between four and five N-linked oligosaccharides and the  chain containing 
up to two N-linked glycans (Lefranc and Lefranc 2001) (Figure 1.4). The Vα and Vβ domains 
each contain three hypervariable regions known as the complementarity determining loops 
(CDR1, CDR2 and CDR3) which are involved in the recognition of the pMHC complex 
(Lefranc and Lefranc 2001). The CDR3 loops of the Vα and Vβ chains interact with the 
peptide-binding region of the MHC whereas the CDR1 and CDR2 loops make contacts with 
the MHC molecule (Figure 1.5). Data suggests that the CDR1 loop may also be making 
contact with the peptide (Tynan, Burrows et al. 2005; Cole, Yuan et al. 2009). Approximately 
28 human class I and class II TCR/pMHC co-crystal structures have been solved to date. This 
comprises of 21 TCR/pMHCI and 7 TCR/pMHCII structures, whereas as of 2006 only 10 
structures had been solved (Bulek, Madura et al. 2012; Rudolph, Stanfield et al. 2006). Data 
suggests that the TCR binds in a diagonal conformation to pMHC with the Vα domain of the 
TCR positioned over the N-terminus of the peptide and the Vβ domain over the C-terminus 
(Hennecke and Wiley 2001; Rudolph and Wilson 2002). A docking angle of approximately 
35° is most often observed and classed as within the normal range of binding when referring 
to other classified TCR/pMHC complexes previously solved. There are extremes which are 
known including A6 TCR-A2-Tax complex which binds with an angle of 32° (Garboczi, 
Ghosh et al. 1996) and 1G4 TCR-A2-NY-ESO complex which binds with an angle of 62° 
(Chen, Stewart-Jones et al. 2005), highlighting the variation that can occur between different 
complexes. 
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Figure 1.4: Structure of αβ TCR chains. The TCR α and β chain are covalently linked by 
disulphide bonds. Each TCR chain consists of an N-terminal region which consists of a 
membrane distal variable region (Vα or Vβ) and a membrane proximal immunoglobulin like 
constant region (Cα or Cβ). Each chain also contains a transmembrane region and a 
cytoplasmic tail. 
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Figure 1.5: Crystal structure of TCR binding to pMHCI molecule. (A) The co-crystal 
structure of MEL5 (α chain shown as a yellow schematic diagram, β chain shown as a salmon 
schematic diagram) bound to the HLA-A*0201 (shown as green and blue schematic 
diagrams) molecule complexed with the ELAGIGILTV peptide (shown as blue sticks).  (B) 
Expanded view of the interface between the MEL5 variable domain bound to the A2-ELA 
surface (colours as in A). The overall conformation of the ELAGIGILTV peptide (N to C 
terminus, left to right), including the central peptide bulge, is displayed. (C) View from above 
of the MEL5 CDR loops bound to the A2-ELA surface (colors as in A; MEL5 CDR loops 
shown as spheres). The MEL5 TCR binds toward the N terminus of the peptide, making 
contacts with the peptide via its CDR1 and CDR3 loops and contacts with the MHC surface 
via its CDR1 and CDR2 loops. This figure was originally published in The Journal of 
Biological Chemistry, (Cole, Yuan et al. 2009), © The American Society for Biochemistry 
and Molecular Biology. 
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1.3.3 T-cell generation and thymic selection 
The initial stages of T-cell development involves the migration of bone marrow progenitor 
stem cells to the thymus where they undergo a selection process before maturing into 
different T-cell subsets. During thymocyte development the TCR α and β chains undergo a 
sequence of ordered somatic recombination events giving rise to T-cells with functional 
TCRs. These recombination events of the Variable (V), Diversity (D), and Joining (J), gene 
segments, known as VDJ recombination are mediated by VDJ recombinase enzymes such as 
Recombinase activating genes 1 and 2 (RAG1 and RAG2) (Schatz, Oettinger et al. 1992; 
Agrawal and Schatz 1997). These enzymes associate with each other and bring the V, D and J 
segments together cleaving the DNA at specific sites. DNA repair has to occur after RAG1 
and RAG2 activity, which is achieved using DNA repair enzymes such as the DNA-
dependent protein kinase complex (DNA-PK) that repairs double stranded DNA. (Ma, 
Pannicke et al. 2002). DNA-PK, among other enzymes, aligns the two DNA ends together 
and then recruits another enzyme, terminal deoxynucleotidyl transferase (TdT), which adds 
nucleotides randomly to the DNA ends. This process provides junctional diversity which can 
subsequently lead to TCR diversity. The process of VDJ recombination leads to an extremely 
diverse TCR repertoire and determines the antigen binding specificity of individual TCRs. 
 
Double positive (DP) thymocytes, i.e. thymocytes that express both the CD4 and CD8 co-
receptors are the first cells in the T-cell developmental pathway to express fully assembled 
successfully genetically rearranged αβ TCR on their cell surface. These DP thymocytes will 
then undergo positive selection, which is a process during which TCRs with minimal 
affinities for self-pMHC convey survival signals that permit continued thymocyte 
development (Huesmann, Scott et al. 1991). At the DP and single positive (SP) stages, cells 
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that express TCRs with high affinities for self-pMHC are deleted by the process of negative 
selection (Kappler, Roehm et al. 1987). The T-cell clonotypes that exist in the periphery post-
thymic development therefore express TCRs with weak/intermediate affinities to self pMHC 
whilst ensuring a strong affinity for foreign pMHCI antigen. This reduces the potential for 
autoreactivity (Werlen, Hausmann et al. 2003). During the final stages in thymocyte 
development, immature DP thymocytes shut off expression of either one of their co-
receptors. This gives rise to single positive mature CD8
+
 and CD4
+
 thymocytes as reviewed 
in (Basson and Zamoyska 2000). Van Laetham and colleagues showed that the MHC 
specificity of αβ TCRs is ultimately controlled by the CD4 and CD8 co-receptors during 
thymic development. Co-receptor deficient thymocytes can differentiate into mature αβ T-
cells that can recognise antigenic ligands independently of MHC. The co-receptors can 
therefore control MHC specificity of αβ T-cells by preventing thymocytes from being 
signalled by non-MHC ligands. This data is consistent with the sequestration of intra-cellular 
Lck by CD4 and CD8, which would ensure that co-engagement of MHCI or MHCII by both 
the TCR and CD8 or CD4, respectively, is required to trigger the signals that elicit positive or 
negative selection in the thymus (Van Laethem, Sarafova et al. 2007). 
 
Multiple models for CD4/CD8 lineage choice have been proposed (as reviewed in (Singer, 
Adoro et al. 2008). These include classical models such as stochastic or instructive, whereby 
termination of co-receptor transcription is either random or instructed, respectively. In 
addition, Singer et al suggest that lineage choice can be best described using a kinetic 
signalling model, which is a non-classical model. This postulates that the CD4/CD8 lineage 
choice is determined by TCR-signal duration and that cytokines such as IL-7 serve as sensors 
that detect the duration of the TCR signal. Singer et al suggest that CD8 gene expression is 
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terminated to create a CD4
+
CD8
-
 intermediate thymocyte in which lineage choice is made. 
Persistence of TCR signalling blocks IL-7R signal transduction and thymocytes differentiate 
into CD4
+
 T-cells. Cessation or disruption to the TCR signalling allows IL-7R mediated 
signalling enabling the CD4
+
CD8
-
 intermediate thymocytes to undergo co-receptor reversal 
and differentiate into CD8
+
 T-cells (Singer, Adoro et al. 2008). Indeed, CD8 lineage choice 
has recently been shown to be controlled by the intrathymic signalling by IL-7 and other γ-
chain cytokines (Park, Adoro et al. 2007).  
 
1.3.4 Kinetics of TCR/pMHCI interaction 
The flexibility of antigenic peptide (ligand) recognition is essential for the function and 
development of T-cells (Kersh and Allen 1996). Some peptide ligands can partially activate 
the cell (partial agonists), others can inhibit activation (antagonists) and others will fully 
activate the cell to send a complete signal to the T-cell (agonists) (Sloan-Lancaster and Allen 
1996). The affinity and kinetics of the TCR/pMHCI interaction can be studied using a 
technique known as Surface Plasmon Resonance (SPR). Typical antibody-antigen 
interactions have fast association rates of 10
5
-10
6 
M
-1
 x s
-1
 with dissociation rates of 10
-5
-10
-3 
s
-1
 (Mason and Williams 1980). However, compared with conventional cell-cell recognition 
molecules the TCR has a relatively low affinity for peptide-MHC ligand (values range KD= 
0.13-278 μM, with typical values from 1-50 μM) (Mason and Williams 1980; Gao and 
Jakobsen 2000; Bridgeman, Sewell et al. 2011) (Figure 1.6). In contrast to other cell-cell 
recognition molecules the low affinity of the TCR/pMHC interaction is due to slow 
association rate constants (10
-2
-10
-4
 M
-1
 x s
-1
) rather than as a consequence of fast 
dissociation rates. The slow TCR/pMHC association rates are a consequence of the flexibility 
at the TCR/pMHC interface (Willcox, Gao et al. 1999). TCR/pMHC off rates fall into a  
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Figure 1.6: Typical wild-type affinity constants measured for TCR/pMHCI and 
pMHCI/CD8 interactions as measured via SPR. TCR/pMHCI interaction kinetics have 
been characterised using SPR and are typically of low affinity, i.e. typical wild-type values 
from 1-50 μM. Biophysical analysis has revealed that the pMHCI/CD8 interaction is much 
weaker than the TCR/pMHCI, i.e. typical wild-type values ~146 μM. 
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relatively narrow window (Koff = 0.63-0.01 s
-1
 with a mean of 0.24 s
-1
) or a t1/2 of 12-30 secs 
at 25
°
C (Davis, Boniface et al. 1998; Bridgeman, Sewell et al. 2011). In its simplest 
reversible form, the interaction of the TCR and pMHC can be described by the reaction; 
 kon 
TCR + pMHC ⇌ TCR:pMHC 
koff 
 
involving an association rate (kon) and a dissociation rate (koff). The half-life of the interaction 
(t1/2) is derived from the dissociation rate. At equilibrium, a binding constant (KD = 1/KA) can 
activate the cell to send a complete signal to the T-cell (agonists) (Sloan-Lancaster and Allen 
1996). This binding constant can be determined for the interaction using standard Scatchard 
approaches (or the kinetic parameters, KD = koff/kon), KD = [TCR][pMHC]/[TCR:pMHC] 
(Rudolph, Stanfield et al. 2006). 
 
1.4 T-cell activation 
1.4.1 TCR/CD3 interaction 
The αβ TCR transmembrane domains are non-covalently associated with the CD3 invariant 
polypeptide complex (-γ, -δ, -ε, and –ζ) (Kersh, Shaw et al. 1998). The transmembrane 
domains of the αβ TCR chains contain charged residues that maintain ionic interactions with 
the CD3 chains. Each TCR is associated with CD3-δε, CD3-γε heterodimeric and CD3-ζζ 
homodimeric signalling chains (Weiss and Littman 1994). Recent data also suggest that 
extracellular loops of the TCR α and β constant domains can interact with CD3-δε and CD3-
γε heterodimers (Kuhns and Davis 2007). An additional CD3-η domain has also been 
identified. The CD3-η chain is a splice variant of CD3-ζ lacking the C-terminal signalling 
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motif and is believed to be involved in thymic selection (Blumberg, Alarcon et al. 1990; 
Love, Shores et al. 1994; Yamamoto, Isobe et al. 2005). The TCR-CD3 complex is 
assembled in the ER in a series of defined steps that begins with a CD3 core of CD3-δεγ 
(Alarcon, Berkhout et al. 1988). The CD3 chains contain signalling motifs called immune 
receptor tyrosine based activation motifs (ITAMs) which contains the consensus sequence 
YXX(L/I)X6-8YXXL/I. The γ, δ and ε chains each contain 1 ITAM and the CD3ζ chain 
contains 3 ITAMs. Phosphorylation of these multiple ITAMs is sufficient to transduce and 
amplify signals from the TCR (Samelson, Harford et al. 1985; Reth 1989; Chan and Shaw 
1996; Wange and Samelson 1996). The CD3-ζ subunits are important in stable accumulation 
of the TCR/CD3 complex at the immunological synapse. The CD3ζ chain contains clusters of 
arginine and lysine residues enabling the chain to complex to phosphoinositides. Elimination 
of the phosphoinositide binding function of CD3-ζ impaired the CD3-ζ to stabilise at the 
immunological synapse during T-cell/pMHC interaction (DeFord-Watts, Dougall et al. 2011). 
 
After the TCR binds to pMHC antigen, one of the first intracellular events observed is the 
phosphorylation of the CD3-ζζ homodimer (Samelson, Patel et al. 1986; Koyasu, McConkey 
et al. 1992). This phosphorylation is induced by p56
lck 
(a member of the Src tyrosine kinase 
family) (Barber, Dasgupta et al. 1989). The CD3-ζ polypeptide contains three ITAM motifs 
with a total of six tyrosines. CD3-ζ is phosphorylated in resting T-cells in the 21 kD isoform 
and upon full phosphorylation gives rise to the 23 kD isoform (Kersh, Shaw et al. 1998). The 
CD3-ζ ITAMs become phosphorylated in an ordered manner after recognition of a strong 
agonist ligand (Kersh, Kersh et al. 1998). Recognition of a less potent ligand leads to 
phosphorylation of a partial subset of tyrosines and non-complete ITAM phosphorylation 
(Kersh, Kersh et al. 1998). 
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The complete phosphorylation events are therefore controlled by the potency of the 
TCR/pMHC interaction. It is these phosphorylation events that determine the thresholds that 
are required for T-cell activation (Kersh, Kersh et al. 1998). A recent study has provided new 
data on the events that lead to CD3- phosphorylation on TCR ligation. Using optical 
tweezer experiments Kim et al suggest that the TCR is an anisotropic mechanosensor which 
upon specific pMHCI ligation, converts mechanical energy into biochemical signals. In this 
study a tangential force is applied to the TCR complex post-ligation which exerts a torque 
effect on CD3 as a consequence of the cell surface molecular movements. This change is 
thought to convert ectodomain ligation into the earliest intracellular signalling events (Kim, 
Shin et al. 2012). 
 
1.4.2 Protein tyrosine kinases 
The immediate result of specific TCR/pMHC engagement is the phosphorylation and 
subsequent activation of protein tyrosine kinases (PTKs). At the early stages of signal 
transduction two families of PTKs exist: (i) Src PTK and, (ii) Syk PTK (Chan, Iwashima et 
al. 1992; Chan, Desai et al. 1994; Iwashima, Irving et al. 1994). These PTKs are able to 
phosphorylate a range of substrates which signal multiple downstream targets. Upon 
phosphorylation of these targets, combined with appropriate signals from the T-cell co-
receptors, T-cell activation will then commence (Iwashima, Irving et al. 1994). The Src 
family of kinases includes the family members p56
lck
 (Lck) and Fyn (Wange and Samelson 
1996). Both of these PTKs are co-localised to membranes as a result of myristoylation and 
palmitoylation modifications (Resh and Ling 1990; Kabouridis, Magee et al. 1997). Lck 
contains a di-cysteine motif which mediates association to the CD4 and CD8 co-receptors 
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(Turner, Brodsky et al. 1990; Kim, Sun et al. 2003). The Lck molecule contains single Src 
homology domains, (SH1, SH2 and SH3).  The SH1 domain is a kinase domain which 
contains an ATP binding site and an autophosphorylation site at position Tyr394 (Abraham 
and Veillette 1990; Luo and Sefton 1990). Both SH2 and SH3 domains mediate intra and 
inter molecular protein to protein interactions via recognition of polyproline and 
phosphotyrosine motifs, respectively (Fantl, Escobedo et al. 1992; Zamoyska, Basson et al. 
2003) (reviewed in (Salmond, Filby et al. 2009). The C-terminus of Lck contains a regulatory 
tyrosine residue at position Tyr505 which is specifically targeted by the Src C-terminal 
kinase (Csk) which will inhibit Lck function (Bergman, Mustelin et al. 1992). This is caused 
when Tyr505 becomes phosphorylated by the kinase Csk, resulting in a molecular association 
with the SH2 domain rendering Lck inactivated and non-functional (Weiss and Littman 1994; 
Sicheri and Kuriyan 1997), highlighting the importance of Tyr505 in T-cell activation and its 
requirement for full Lck activation (Caron, Abraham et al. 1992). Lck Tyr394 is another 
tyrosine residue required for T-cell activation which is also involved in enzymatic activity 
and is commonly referred to as the activating Tyr residue (reviewed in (Salmond, Filby et al. 
2009). This Tyr residue is located in the activating loop (A-loop) of the kinase (Xu, Doshi et 
al. 1999). Upon activation of the Src family kinases via interactions through their SH2 and 
SH3 domains, the A-loop becomes exposed due to displacement by the now open kinase 
domains which contain the activating Tyr
394
 promoting enzymatic activity (Veillette and 
Fournel 1990). 
 
Activated Lck phosphorylates the CD3-ζ ITAMs resulting in the recruitment of the ζ chain-
associated protein ZAP-70 kinase via its SH2 domain (van Oers, Killeen et al. 1994; van 
Oers, Killeen et al. 1996; Wange and Samelson 1996). ZAP-70 is a member of the Syk 
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family of kinases which contain two tandemly arranged SH2 domains (Chan, Iwashima et al. 
1992; Weiss and Littman 1994). It is believed the ZAP-70 only associates with 
diphosphorylated ITAMS (Mustelin and Tasken 2003) and once associated, ZAP-70 is 
phosphorylated at Tyr493 by Lck resulting in activation (Chan, Dalton et al. 1995). Studies 
have shown that point mutations in the ZAP-70 molecule can lead to autoimmune disorders 
such as rheumatoid arthritis and IgE-hyper autoimmune syndrome highlighting the impact 
that these defects can have on TCR driven T-cell signalling (Sakaguchi, Takahashi et al. 
2003; Siggs, Miosge et al. 2007). 
 
1.4.3 Role of CD45 in T-cell activation 
CD45 is one of the most abundant cell surface glycoproteins comprising up to 10% of the cell 
surface (Thomas 1989). CD45 has a constant domain consisting of two tyrosine-specific 
phosphatase domains in tandem. In resting cells CD45 has been shown to associate with Lck
 
(Guttinger, Gassmann et al. 1992). It is thought that CD45 activates Lck
 
by its ability to 
selectively dephosphorylate the negative regulatory tyrosine at position 505 (Ostergaard, 
Shackelford et al. 1989; Ostergaard and Trowbridge 1990). Indeed, studies of CD45 deficient 
cell lines demonstrate that CD45 is required for the induction of PTK activity and TCR signal 
transduction. Csk, a cytoplasmic PTK acts to phosphorylate the inhibitory carboxyl-terminal 
tyrosine of Lck and is therefore a potent inhibitor of TCR signalling (Chow and Veillette 
1995). Therefore Lck
 
activity is thought to be regulated by the opposing phosphorylation 
effects of CD45 and Csk on the inhibitory Tyr505. Csk phosphorylates Tyr505 therefore 
inactivating Lck whereas CD45 de-phosphorylates Lck
 
at this site thus priming PTK activity. 
CD45 is also thought to have an inhibitory effect which is mediated by the dephosphorylation 
of the activatory Tyr394 residue of Lck which subsequently suppresses kinase activity and T-
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cell activation (D'Oro and Ashwell 1999; Palacios and Weiss 2004; Zhao, Yang et al. 2004) . 
It is known that other phosphatases act at the same site as CD45 such as PEST-domain 
enriched tyrosine phosphatase (PEP) which is also referred to as protein tyrosine phosphatase 
non-receptor type 22 (PTPN22) (Hasegawa, Martin et al. 2004; McNeill, Salmond et al. 
2007), and Src homology region 2 domain-containing phosphatase-1 (SHP-1) (Chiang and 
Sefton 2001) thereby exerting an inhibitory effect. This inhibition leads to a severe block in 
T-cell differentiation and profound impairment of activation in mature T-cells (Ashwell and 
D'Oro 1999; Hermiston, Xu et al. 2003; Zamoyska, Basson et al. 2003). Therefore, CD45 has 
a role as both a positive and negative regulator of T-cell signalling and acts as a ‘rheostat’ 
which regulates the threshold of activation of T-cells (McNeill, Salmond et al. 2007; 
Zamoyska 2007). 
 
1.4.4 T-cell transduction signalling 
As previously mentioned activated Lck phosphorylates the CD3-ζ ITAMs resulting in the 
recruitment of the CD3ζ chain associated protein ZAP-70 kinase (Chan, Dalton et al. 1995). 
ZAP-70 becomes phosphorylated and recruits adaptor proteins which will propagate the 
signal transduction pathway (Zhang, Sloan-Lancaster et al. 1998). One of the substrates of 
phosphorylated ZAP-70 is the adaptor molecule LAT (linker for activation in T-cells). LAT 
consists of a short extracellular domain, a transmembrane region and a long cytoplasmic tail. 
When the cytoplasmic tail becomes phosphorylated at conserved tyrosine residues by 
activated ZAP-70, this then recruits various signalling molecules to the plasma membrane 
including PLC-γ1, Grb2, Grap, Gads, SLP-76, Vav-1, Cbl and the regulatory subunit of PI3K 
forming a multi-protein complex known as the “LAT signalasome” (Malissen, Aguado et al. 
2005; Brownlie and Zamoyska 2009). Gads uses the LAT adaptor protein to form a complex 
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with SLP-76, Vav-1 and Itk which will mediate the phosphorylation of PLC-γ1 (Beach, 
Gonen et al. 2007; Bogin, Ainey et al. 2007; Seet, Berry et al. 2007) (Figure 1.7). LAT is an 
important adaptor protein in linking the TCR to downstream signalling events including 
activation of the transcription factor NFAT and ultimately proliferation and expression of 
cytokine genes (Brownlie and Zamoyska 2009). Subsequent tyrosine kinase phosphorylation 
activates downstream secondary messenger pathways through the cytoplasm directly into the 
cell nucleus activating multiple transcription factors. These include Activator protein 1 (AP-
1), Nuclear factor of activated T-cells (NFAT) and Nuclear factor Kappa B (NFκB) which are 
three transcription factors important for the regulation of cytokine production including IL-2. 
The activation of the Ras/MAPK pathway by Grb2 is another important pathway that plays 
an important role in T-cell development and activation by activating the Extracellular signal-
regulated kinase (ERK) (Salojin, Zhang et al. 2000; Werlen and Palmer 2002). Sustained 
signalling required for complete T-cell activation is thought to be achieved by a positive 
feedback loop activating ERK. ERK will phosphorylate serine residues in Lck barring the 
recruitment of the SHP-1 (a phosphatase used to dephosphorylate Lck and inhibit activation). 
Lck is no longer de-phosphorylated and the T-cell signalling cascade can continue 
(Stefanova, Hemmer et al. 2003). 
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Figure 1.7: A model of T-cell activation. TCR stimulation via pMHCI results in 
phosphorylation of CD3 chain ITAMs by kinases such as Lck. Diphosphorylated ITAMs 
recruit ZAP-70 which is in turn phosphorylated by Lck. ZAP-70 then phosphorylates LAT. 
LAT recruits various adaptor molecules which in turn activates multiple protein cascades and 
transcription factors. 
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1.4.5 Cytoskeletal rearrangement 
The Vav-1 protein which interacts with ZAP-70 contains a domain known to be involved in 
binding to the actin cytoskeleton. TCR/pMHC engagement leads to recruitment of Vav-1 and 
adaptor proteins that stimulate the polymerisation of filamentous actin. Once actin is 
polymerised, cytoskeletal movement takes place that facilitates the coalescence of membrane 
rafts, TCR clustering and Supramolecular activation clusters (SMAC) formation providing a 
dynamic scaffold for TCR signalling (Mak and Saunders 2005). Actin polymerisation 
promotes the assembly of signalling microclusters at the periphery of the immunological 
synapse and drives their centripetal flow toward the central-supramolecular activation cluster 
(c-SMAC) (see section 1.6) (Burkhardt, Carrizosa et al. 2008). 
 
1.5 Plamsa membrance lipid rafts 
The plasma membrane of T-cells is made up of a combination of phospholipids and proteins 
organised as glycolipoprotein microdomains termed lipid rafts. These phospholipids are rich 
in glycosphingolipids and protein receptors (Thomas, Kumar et al. 2004). These lipid rafts 
are specialised membrane microdomains which have important roles in T-cell signalling 
events. The post-translational addition of lipids by myristylation, palmitoylation or 
farnesylation can target proteins to lipid rafts within the plasma membrane (Viola 2001). It 
has been suggested that one way to consider a lipid raft is that they form concentrating 
platforms for individual receptors activated by ligand binding (Simons and Toomre 2000). 
Evidence from several studies have suggested that lipid rafts will cluster upon T-cell 
activation and that this is an essential feature in the formation of an immunological synapse 
(Janes, Ley et al. 2000; Langlet, Bernard et al. 2000). Several kinase molecules are recruited 
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to lipid rafts which are essential for T-cell activation. These include Lck and Csk (Resh 
1994). Upon T-cell activation Csk is dephosphorylated and is removed from the lipid rafts 
(Cary and Cooper 2000; Latour and Veillette 2001). Also removed from lipid rafts on T-cell 
activation is CD45 molecule which would otherwise be inhibitory to full T-cell activation 
(Hermiston, Xu et al. 2003). Cytoplasmic proteins including ZAP-70, Vav-1, PLC-γ1, Grb2, 
PI3K and also LAT are also associated with lipid rafts upon T-cell activation (Xavier, 
Brennan et al. 1998; Harder and Kuhn 2000; Simons and Toomre 2000). Therefore raft 
binding recruits proteins to a new microenvironment where the phosphorylation state can be 
modified by local kinases and phosphatases and thus are acting as specialised membrane 
microdomains which are preferential sites for T-cell signalling. 
 
1.6 Formation of the immunological synapse 
The interface or contact zone between the T-cell and the APC where membrane protein re-
organisation occurs is referred to as the immunological synapse (IS), a site which favours T-
cell signalling (Lee, Holdorf et al. 2002). Rapid polarisation of molecules by the 
accumulation of stabilised lipid rafts and triggered TCR/pMHC complexes to the centre of 
the contact zone is observed (as reviewed in (Delon and Germain 2000; Bromley, Burack et 
al. 2001). This structure is also referred to as being the SMAC. This structure becomes highly 
stable which can explain the long TCR/pMHC contact time (Monks, Freiberg et al. 1998). 
SMACs have two discrete zones. The innermost ring, known as the central zone (c-SMAC) 
contains the TCR, MHC and co-receptors (CD4 or CD8) and also accessory molecules such 
as CD28 and CD2. The c-SMAC also contains the lipid rafts, which include additional 
enzymes and molecules required for signal transduction and co-stimulation (section 1.5). 
There are multiple changes to the actin cytoskeleton that are established by adhesive contacts 
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and extended by co-stimulatory molecules. Surrounding the central zone is a second zone, the 
peripheral-SMAC (p-SMAC) which is enriched for the integrin LFA-1 (Monks, Freiberg et 
al. 1998; Grakoui, Bromley et al. 1999). The p-SMAC contains outer and inner p-SMAC 
layers and it is these layers that ensure the T-cell and APC remain in prolonged contact 
sufficient to complete signal transduction.  
 
The full and precise role of the IS is still unclear. Freiberg and colleagues suggested that pre-
SMAC signals are sufficient to activate cell adhesion but not productive T-cell responses 
which require orchestrated signalling in SMACs (Freiberg, Kupfer et al. 2002). However data 
suggests that T-cells can still activate intracellular kinase signalling prior to the formation of 
the IS suggesting that many hours of T-cell signalling are not required for T-cell activation 
(Davis and van der Merwe 2001; Lee, Holdorf et al. 2002). This is further supported by data 
suggesting that immediately after pMHC recognition and prior to formation of the c-SMAC, 
hundreds of T-cell receptor microclusters (TCR-MC), containing the TCR and signalling 
molecules (kinases and adaptor proteins) are generated and function as a signalasome to 
transduce the initial signals for T-cell activation (Bunnell, Hong et al. 2002; Campi, Varma et 
al. 2005; Yokosuka, Kobayashi et al. 2008). After their generation, TCR-MCs move toward 
the centre of the IS and generate the c-SMAC. TCRs are internalised at the c-SMAC and 
TCR signalling is terminated. TCR-MCs are generated continuously at the periphery resulting 
in a sustained activation signal. Therefore the translocation of TCR-MCs from the periphery 
maintains the balance between the generation of new TCR-MCs and their degradation at the 
c-SMAC and is critical in sustaining T-cell activation (Varma, Campi et al. 2006; Yokosuka, 
Kobayashi et al. 2008).  
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1.7 T-cell co-stimulation 
Accessory signals generated during TCR/pMHCI engagement leads to enhanced survival and 
proliferation signals. The signal generated through the TCR/CD3 complex is termed signal 1 
whereas the signal generated through co-stimulatory molecules is termed signal 2 (Baxter and 
Hodgkin 2002). There is also evidence of a signal 3 which is provided by IL-12 cytokine 
stimulation in CD8
+
 T-cells and by the cytokine IL-1 in CD4
+
 T-cells (Curtsinger, Schmidt et 
al. 1999). The absence of necessary accessory signals upon T-cell activation results in T-cell 
death and apoptosis (Kabelitz and Janssen 1997). Multiple co-stimulatory molecules are 
associated with full T-cell activation including CD28 (Thompson, Lindsten et al. 1989) and 
CD2 (Howard, Moingeon et al. 1992). Other co-stimulatory molecules do exist but are less 
well studied such as the TNF receptor superfamily and CD27. 
 
1.8 Co-receptors CD8 and CD4 
The CD4 and CD8 molecules were initially identified as phenotypic markers on T 
lymphocytes restricted by MHCII and MHCI proteins, respectively. Treatment of T-cells 
with anti-CD4 or anti-CD8 antibodies resulted in the blockade of Th-cell and CD8
+
 T-cell 
activation, respectively (MacDonald, Glasebrook et al. 1982). Subsequent data suggested that 
CD4 and CD8 were functional components of the T-cell antigen recognition machinery.  CD4 
and CD8 physically engage the same ligand as the TCR and thereby “co-receive” this ligand  
(Meuer, Schlossman et al. 1982). This unique role resulted in these glycoproteins being called 
“co-receptors” (Janeway 1992). CD4 or CD8 binding to MHC facilitates downstream 
proximal signalling events triggered by TCR ligation through interaction with the Lck (Rudd, 
Trevillyan et al. 1988; Veillette, Bookman et al. 1988). Both CD4 and CD8 are involved in 
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thymic development and selection of either CD4
+
 or CD8
+ 
T-cells by their association with 
Lck (Fung-Leung, Schilham et al. 1991; Rahemtulla, Fung-Leung et al. 1991).  
 
1.8.1 CD8 and CD4 structure 
CD4 and CD8 both interact with structurally homologous sites on their respective MHC 
ligands using basic immunoglobulin domains. These domains are arranged quite differently 
in the two molecules (Zamoyska 1998). CD8 is a transmembrane, disulfide-linked 
glycoprotein that exists on the cell surface in either αα homodimeric or αβ heterodimeric 
form (Ledbetter, Seaman et al. 1981; Norment and Littman 1988; Terry, DiSanto et al. 1990). 
Each chain consists of a short cytoplasmic region, a single transmembrane domain, a long 
glycosylated stalk region and a globular variable Immunoglobulin-like domain. The αβ 
isoform of CD8 is exclusively expressed by conventional MHCI-restricted αβ T-cells. In 
contrast, the CD8αα homodimer has a more promiscuous expression pattern in both humans 
and rodents; distinct lymphoid cells, such as intra-epithelial lymphocytes (IELs),  T-cells 
and NK cells, and also certain myeloid cell types, all express the αα isoform of CD8 
(Zamoyska 1994; Gangadharan and Cheroutre 2004; Gibbings and Befus 2009). The CD8 α 
and β chains are encoded by distinct genes that are physically linked and are predicted to 
show conserved overall structural topology although they share only approximately 20% 
residue identity (Parnes 1989). Both chains have an immunoglobulin like amino terminal 
domain. This domain is linked by an extended polypeptide region which contains a number 
of O-linked sugars to the transmembrane domain (Zamoyska 1998). Crystal structures 
currently solved reveal that the amino-terminal immunoglobulin like domains fold very 
similarly to an Fv-like homodimer (Zamoyska 1998). CD4 however is a single polypeptide 
Chapter 1 
61 
 
which consists of four external immunoglobulin-related domains D1 to D4 (Wang, Yan et al. 
1990; Lange, Lewis et al. 1994; Brady and Barclay 1996; Wu, Kwong et al. 1997). There is a 
unique strand topology between domains 1 and 2 (D1 and D2) and between domains 3 and 4 
(D3 and D4) (Zamoyska 1998) and due to interactions between adjacent D4 domains, this 
may allow for CD4 to dimerise on the cell surface (Wu, Kwong et al. 1997). There is also a 
hydrophobic transmembrane domain, and a highly basic cytoplasmic tail which contains three 
serine residues which can be phosphorylated (Mak and Saunders 2005). 
 
1.8.2 pMHCI/CD8 interaction 
The involvement of CD8 in the recognition of target cells by CD8
+
 T-cells was appreciated 
prior to the identification of the TCR. Early reports showed that antibodies recognizing either 
the α or β sub-unit of CD8 were able to block the killing of target cells by CD8+ T-cells in-
vitro (Nakayama, Shiku et al. 1979; Ledbetter, Seaman et al. 1981). This hinted that CD8 was 
involved in the molecular process of antigen recognition. CD8 binds MHCI molecules via 
interactions with largely non-polymorphic amino acid residues situated in the α3 and to a 
lesser extent the α2 domain of the heavy chain and β2-microglobulin (Salter, Norment et al. 
1989; Salter, Benjamin et al. 1990). Gao and colleagues solved the co-crystal structure of the 
human pMHCI/CD8αα interaction confirming the binding interactions that had been 
classified previously (Figure 1.8). Similarly to the TCR, CD8 contains a number of flexible 
complementarity determining loops (CDR) that are involved in MHCI binding. Gao et al 
showed that the interaction between the CDR3 loops of human CD8αα (residues 51-55) and a 
finger-like loop in the α3-domain of HLA-A*0201 (residues 223-229) form the main contact 
zone of the complex by clamping asymmetrically, with each dimer contributing differently to 
the overall binding (Gao, Tormo et al. 1997). Although murine CD8αα binds to H2-Kb in a  
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Figure 1.8: Overview of the molecular interactions between human CD8αα and MHCI 
molecule. CD8αα is shown in red (α1) and purple (α2), binding mainly to the α3 domain of 
MHCI (green). The CDR like loops of the CD8 molecule binds the MHCI α3 domain at 
residues 223–227 forming the main binding interface. When enlarging this interface between 
CD8 and MHCI the two CDR like loops of the CD8 molecule form a "clamp" - like topology 
around the MHCI loop encompassing residues 223–227 of the α3 domain. The most 
important contacts are made between the CD8 α1 chain Thr31/Ser100 and the MHCI α chain 
Gln226/Asp227 and between the CD8 α2 chain Ser34/Tyr51 and the MHCI α chain 
Thr225/Gln226. Figure taken from (Laugel et al 2011). © 2013 by the Society for Leukocyte 
Biology.  
 
Chapter 1 
63 
 
similar overall fashion compared to human CD8αα/HLA-A*0201 interaction (Kern, Teng et 
al. 1998), there are some key differences in the fine specificity of the two interactions. For 
example, in the murine system; more contacts are made between CD8 and the MHCI α3-
domain, at the interface between CD8 and the MHCI α2-domain a number of unique bonds 
are formed between the interface between CD8 and β2m. These differences may explain the 
higher binding affinity of murine CD8 compared human CD8 for their species specific MHCI 
(Purbhoo, Boulter et al. 2001). 
 
Gao et al predicted, based on electrostatic surface analysis of the human pMHCI/CD8αα, that 
the CD8β chain would replace the CD8α2 subunit (Gao, Tormo et al. 1997). This was also 
supported by data suggesting that mutating the CD8α chain severely impaired binding  
whereas a similar mutation in the CD8β chain did not (Devine, Sun et al. 1999). The 
orientation of the human CD8αβ heterodimer in complex remained speculative until Wang 
and colleagues solved the co-crystal structure of the murine CD8αβ in complex with H-2Dd 
(Wang, Natarajan et al. 2009). This study demonstrated that the binding mode of the CD8αβ 
heterodimer was largely homologous with CD8αα (Wang, Natarajan et al. 2009). The CDR-
like loops of the CD8αβ predominantly bound to the conserved H-2Dd α3 domain 
Importantly, the H-2D
d/CD8αβ co-complex also revealed that CD8αβ adopted a single 
orientation, with the β chain in the equivalent position of the CD8α1-chain proximal to the T-
cell membrane, and the CD8α chain in the equivalent position of the CD8α2 chain in the T-
cell distal position (Wang, Natarajan et al. 2009), in contrast to the prediction made by Gao et 
al. However, it is important to note that Gao et al had made that hypothesis based on the 
human pMHCI/CD8αα interaction. Key differences exist between the murine pMHCI/CD8αα 
and pMHCI/CD8αβ complexes. For example, CD8αβ does not make contact with the α2 and 
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β2m domains of H-2D
d
 which reduces the buried surface area of this complex compared to 
murine pMHCI/CD8αα (Wang, Natarajan et al. 2009).  
 
1.8.3 Low solution binding affinity of the pMHCI/CD8 interaction  
The average human pMHCI/CD8αα interaction exhibits very low solution binding affinities 
(KD ~146 µM) (Table 1.1) and is characterised by extremely rapid kinetics (Koff ~18 s
-1
) 
(Wyer, Willcox et al. 1999; Gao, Willcox et al. 2000; Cole, Dunn et al. 2008). Despite these 
seemingly unfavourable binding characteristics, the engagement of MHCI molecules by CD8 
at the cell surface both enhances the association rate of pMHCI complexes with TCRs and 
increases the half-life of cognate TCR/pMHCI interactions (Gakamsky, Luescher et al. 2005; 
Wooldridge, van den Berg et al. 2005; Laugel, van den Berg et al. 2007). It seems unlikely 
that the striking biophysical characteristics of the pMHCI/CD8 interaction have occurred by 
accident and it has been hypothesised that the kinetics are essential for maintaining antigen 
specificity. However, to date there has been no study to probe the significance of the low 
solution binding affinity that characterises the pMHCI/CD8 interaction. This will be 
addressed in chapter 3. 
 
It is interesting to note that the average murine pMHCI/CD8 interaction is significantly 
stronger (KD ~ 30µM) (Table 1.2 A&B) than the equivalent human interaction (KD ~ 146µM) 
(Purbhoo, Boulter et al. 2001). Murine studies have concluded that CD8αα and CD8αβ bind 
murine pMHCI with similar affinity (Sun and Kavathas 1997) (Arcaro, Gregoire et al. 2001; 
Wang, Natarajan et al. 2009). 
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1.8.4 MHCII/CD4 interaction 
The N-terminal immunoglobulin-like domains of CD4 interact with the non-polymorphic α2 
and β2 domains of MHCII. This interaction mediates both recognition and adhesive functions 
of the CD4 Th-cell. The cytoplasmic tail of the CD4 has sites that facilitate the physical 
association with Lck (Mak and Saunders 2005). 
 
1.8.5 CD8/CD4 T-cell activation profiles 
On recognition of specific pMHCI, CD8
+
 T-cells become activated, as outlined above, then 
subsequently kill the target cell. The principal mechanism of killing is through the release of 
pre-formed cytotoxic granules which contain perforin and granzyme  
 
Table 1.1: Binding affinities of human CD8αα to pMHCI using surface plasmon 
resonance.  
#
 values are averages from cited studies 
Human pMHCI/human CD8αα KD (µM) 
HLA-A*0201-GILGFVFTL 
(Wyer, Willcox et al. 1999; Cole, Dunn et al. 2008) 
166
#
 
HLA-A*0201-FIDSYICQV 
(Wyer, Willcox et al. 1999) 
173 
HLA-A*0201-VLHDDLLEA 
(Wyer, Willcox et al. 1999) 
107 
HLA-A*0201-ILKEPVHGV 
(Wyer, Willcox et al. 1999) 
126 
HLA-A*0201-ILAKFLHWL 
(Cole, Dunn et al. 2008) 
183 
HLA-A*0201-SLLMWITQC 
(Cole, Dunn et al. 2008) 
125 
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HLA-A*0201-YLEPGPVTV 
(Cole, Dunn et al. 2008) 
144 
HLA-A*0201-LLFGYPVYV 
(Cole, Rizkallah et al. 2007; Cole, Dunn et al. 2008) 
149
#
 
HLA-A*1101-AIFQSSMTK 
(Gao, Willcox et al. 2000) 
100 
HLA-A*2402-PYLFWLAAI 
(Cole, Rizkallah et al. 2007; Cole, Dunn et al. 2008) 
154
#
 
HLA-B*0801-FLRGRAYGL 
(Cole, Dunn et al. 2008) 
135 
HLA-B*3501-TPEGIIPTL 
(Gao, Willcox et al. 2000) 
130 
HLA-C*0702-KYFDEHYEY 
(Gao, Willcox et al. 2000) 
220 
Average CD8αα KD (µM) 146 
 
Table 1.2 A: Binding affinities of murine CD8αα to pMHCI using surface plasmon 
resonance. 
#
 values are averages from cited studies. 
Murine pMHCI/murine CD8αα KD (µM) 
H-2K
b
-SIINFEKL 
(Leishman, Naidenko et al. 2001) 
91.6 
H-2K
b
-IFSK8 
(Wang, Natarajan et al. 2009) 
34.7 
H-2K
b
-VSV8 
(Kern, Hussey et al. 1999) 
64
#
 
H-2K
b
-RGYVYQGL 
(Garcia, Scott et al. 1996) 
39.3 
H-2K
b
-OVA 
(Garcia, Scott et al. 1996) 
30.4 
H-2K
d
-P18I10 
(Wang, Natarajan et al. 2009) 
6.7 
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Average CD8αα KD (µM) 44 
 
Table 1.2 B: Binding affinities of murine CD8αβ to pMHCI using surface plasmon 
resonance. 
#
 values are averages from cited studies. 
Murine pMHCI/murine CD8αβ KD (µM) 
H-2K
b
-SIINFEKL 
(Leishman, Naidenko et al. 2001) 
135 
H-2K
b
-IFSK8 
(Wang, Natarajan et al. 2009) 
38.4 
H-2K
b
-VSV8 
(Kern, Hussey et al. 1999) 
40
#
 
H-2K
b
-RGYVYQGL 
(Garcia, Scott et al. 1996) 
11.8 
H-2D
b
-FAGHNLDLI 
(Garcia, Scott et al. 1996) 
14.1 
H-2K
b
-OVA 
(Garcia, Scott et al. 1996) 
14 
H-2K
d
-SYIPSAEK 
(Arcaro, Gregoire et al. 2001) 
99 
H-2K
d
-P18I10 
(Wang, Natarajan et al. 2009) 
8.2 
H-2L
d
-p2Ca 
(Garcia, Scott et al. 1996) 
11.2 
Average CD8αβ KD 41 
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(Podack, Konigsberg et al. 1985). Perforin creates pores in the membrane of the target cell 
which can allow the transition of granzymes into the target cell inducing apoptosis (Heusel, 
Wesselschmidt et al. 1994). A new model of killing was suggested by Pipkin et al. Here 
perforin creates pores in the membrane of the target cell which allow an influx of Ca
2+
, then 
granzymes are endocytosed by the target cell and induce apoptosis (Pipkin and Lieberman 
2007). CD8
+
 T-cells can also induce killing through the interaction between the Fas-death 
receptor on the target cell (CD95), and its counterpart on the T-cell surface FasL (CD95L) 
(Bossi and Griffiths 1999). The Fas-FasL interaction allows for dimerisation of procaspases 
which induce apoptosis (Thorburn 2004). Activated CD8
+
 T-cells can differentiate into two 
effector phenotypes (Tc1 and Tc2) each with different cytokine profiles and both of which 
are cytotoxic. The cytokine profile expressed by CD8
+
 effector Tc1 cells is similar to that 
seen of the Th1 subset of CD4
+
 T-cells (Kelso and Glasebrook 1984; Fong and Mosmann 
1990). These include IFN-γ, TNF-α and IL-2 (Mosmann, Li et al. 1997). CD8+ T-cells also 
release a broad profile of chemokines, including Macrophage Inflammatory Protein-1α (MIP-
1α), Macrophage Inflammatory Protein-1β (MIP-1β) and Regulated on Activation, Normal T 
Expressed and Secreted (RANTES) among others. Data does suggest the some CD8
+
 T-cells, 
Tc2 cells, have been shown to release IL-4, IL-5 and IL-10, common Th2 response cytokines, 
when patients are infected with leprosy (Salgame, Abrams et al. 1991; Mosmann, Li et al. 
1997). 
 
CD4
+
 Th-cells play an important role in the activation and co-ordination of CD8
+
 T-cell and 
B-cell responses. CD4
+
 Th-cells can be classified into different subsets which have different 
roles and are characterised by different cytokine and chemokine profiles. Th1 responses are 
characterised by the secretion of IL-2, IFN- and lymphotoxin.  IL-2 is a T-cell growth factor 
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and is important for the proliferation of activated CD8
+
 T-cells (Morgan, Ruscetti et al. 
1976).  IFN-γ release by a Th1 response is believed to activate the anti-microbial activity of 
macrophages (Taylor, Martinez-Pomares et al. 2005). Th2 responses are characterised by the 
production of IL-4, IL-5, IL-6 and IL-13 which results in the activation of the B-cell antibody 
response (Salgame, Abrams et al. 1991) and influences the isotype switching of antibodies 
(Tangye, Ferguson et al. 2002). Another Th subset known as Th17 are characterised by the 
production of IL-17, IL-21 and IL-23 which result in the activation and migration of 
neutrophils (Weaver, Harrington et al. 2006). This thesis is concerned with the role of CD8 in 
CD8
+
 T-cell activation and the introduction from this point will concentrate on aspects of 
CD8 roles and functions. 
 
1.8.6 The co-receptor model of CD8 function 
It was initially suggested that CD8 binds to MHCI independently of the TCR/pMHCI 
interaction subsequently increasing the binding affinity of the T-cell for the target cell and 
allowing T-cells to respond to lower numbers of antigen. This was also known as the 
accessory molecule hypothesis (Marrack, Endres et al. 1983; Gay, Coeshott et al. 1986; 
Bierer, Sleckman et al. 1989). The accessory molecule theory was replaced by Janeway et al 
who proposed the co-receptor model for CD8 function. The co-receptor model suggested that 
CD8 is a physical component of the TCR complex contributing directly to signal transduction 
on T-cell activation, and for optimal T-cell activation both CD8 and the TCR must bind to the 
same pMHCI molecule at the APC surface. Hence, Janeway suggested that it would be more 
appropriate to describe CD8 as a co-receptor rather than accessory molecule (Janeway 1988; 
Janeway 1989). The existence of a physical association between the TCR and CD8 on the T-
cell surface was first suggested by studies using co-modulation (Takada and Engleman 1987), 
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co-precipitation (Beyers, Spruyt et al. 1992; Suzuki, Kupsch et al. 1992) and affinity 
chromatography (Gallagher, Fazekas de St Groth et al. 1989). One study actually suggests 
that the majority of TCRs are associated with CD8 (~90%) even in non-activated cells 
(Suzuki, Kupsch et al. 1992). Data also suggested that the TCR and CD8 can engage a single 
pMHCI molecule simultaneously because both bind at distant non-overlapping sites. In 
addition, studies demonstrated that when peptide is presented by targets bearing point 
mutations in the MHC Class I α3 domain loop mutations that knock out the pMHCI/CD8 
interaction in a CD8-dependent setting, CD8
+
 T-cell activation is lost (Potter, Rajan et al. 
1989; Purbhoo, Boulter et al. 2001). CD8
+
 T-cell antigen responsiveness is not restored by 
the presence of non-cognate pMHCI with intact CD8 binding sites in both human (Salter, 
Benjamin et al. 1990) or murine systems (Potter, Rajan et al. 1989; Connolly, Hansen et al. 
1990; Schott and Ploegh 2002). Furthermore, the conserved α-chain connecting peptide motif 
(α-CPM), located on the membrane proximal domain of the TCR α-chain, facilitates the 
recruitment of CD8 in close proximity to the TCR/CD3 complex (Naeher, Luescher et al. 
2002; Mallaun, Naeher et al. 2008) (Figure 1.9). All of this data highlighted that CD8 can 
form a physical part of the TCR complex and that CD8 and TCR could engage the same 
pMHCI complex at the same time which is critical for optimal T-cell activation. 
 
1.8.7 Roles of CD8 in T-cell activation 
Multiple roles for CD8 in T-cell activation have been highlighted. It was originally proposed 
that CD8 played the role of an adhesion molecule ensuring that the CD8
+
 T-cell and the APC 
would bind together (Norment and Littman 1988). However, the weak solution binding 
affinity of the pMHCI/CD8 interaction excludes the possibility that CD8 plays a major role in 
T-cell/target cell adhesion. 
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Figure 1.9: Schematic representation of CD8 co-receptor functions in early T-cell 
activation events. (A) The classical view of T-cell activation is that CD8 is recruited to the 
TCR complex before phosphorylation takes place and that Lck bound to the CD8α 
cytoplasmic tail catalyses the initial CD3-ζ ITAM phosphorylation events which then allow 
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for the recruitment of additional Lck molecules and signal amplification. (B) Alternatively 
recent experimental data favour a model whereby free Lck is responsible for the initial 
phosphorylation events. Phosphorylated CD3-ζ ITAMs then allow for the recruitment of Lck 
bound to CD8α in close proximity to CD3. In this scenario, the interaction between the TCR 
and CD8 occurs after the initial phosphorylation events and is driven intra-cellularly by 
interactions between CD3 and CD8α bound Lck. Figure taken from (Laugel, Cole et al. 
2011). © 2013 by the Society for Leukocyte Biology. 
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Subsequently, it was suggested that CD8 plays a major role in stabilising the TCR/pMHCI 
interaction. Initial data suggested that the TCR/pMHCI off rate was significantly reduced in 
the presence of CD8 which led the authors to posit that CD8 may induce conformational 
changes to favour the TCR/pMHCI interaction (Garcia, Scott et al. 1996). However crystal 
structures of pMHCI/CD8αα revealed that there is no change in the TCR/pMHCI binding 
platform (Gao, Tormo et al. 1997) and also the presence of CD8 does not affect the TCR 
binding to the same pMHCI when analysed via SPR (Wyer, Willcox et al. 1999). More recent 
data using mutated pMHCI tetramers with altered CD8 binding have shown that CD8 has a 
role in altering TCR/pMHCI avidity at the T-cell surface (Wooldridge, Hutchinson et al. 
2003; Wooldridge, van den Berg et al. 2005; Wooldridge, Scriba et al. 2006; Laugel, van den 
Berg et al. 2007). By abrogating the pMHCI/CD8 interaction both the tetramer association  
rate and the half-life of binding decreased compared to wild-type tetramers (Laugel, van den 
Berg et al. 2007). This study also showed that the intensity of steady-state tetramer binding 
was substantially reduced using CD8 null tetramers compared to wild-type reagents. These 
data highlight that, despite the weak pMHCI/CD8 interaction, pMHCI/CD8 binding has an 
important role in stabilizing the TCR/pMHCI complex at the cell surface. In support of this 
notion, a recent investigation by Jiang et al, using a novel approach for measuring the 2D 
binding affinity between TCR, pMHCI and CD8, demonstrates that the TCR and CD8 bind 
cooperatively to pMHCI which modulates antigen discrimination (Jiang, Huang et al. 2010). 
 
CD8 has also been shown to play an extremely important role in T-cell signalling. The 
binding of CD8 to pMHCI drives the recruitment of CD8-associated Lck to the vicinity of an 
engaged TCR/CD3 signalling complex, resulting in phosphorylation of the CD3ζ ITAMs 
(Purbhoo, Boulter et al. 2001). This role is achieved through the association of the CD8 α 
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chain with Lck, via two vicinal cysteines, that interact through a zinc chelate complex to 
produce a co-activation signal (Veillette, Bookman et al. 1988; Turner, Brodsky et al. 1990). 
This interaction leads to a signalling cascade, which recruits ZAP-70 to the CD3/TCR 
complex leading to the amplification or enhancement of T-cell activation signals. Further 
studies into the nature of the TCR/CD8 interaction were revealed by the finding that the 
signalling role of the CD8 α chain can be enhanced by palmitoylation of the CD8 β chain at a 
membrane-proximal cysteine. This enables the co-receptor to interact directly with CD3δ and 
recruit TCR/CD3 complexes to membrane microdomains that promote signalling through the 
exclusion of inhibitory phosphatase proteins (Arcaro, Gregoire et al. 2000; Arcaro, Gregoire 
et al. 2001; Doucey, Goffin et al. 2003).  
 
These lipid rafts are made up of ordered microdomains, enriched with sphingolipids and 
cholesterol which exclude molecules such as phosphatases (CD45), but recruit Lck and LAT; 
molecules vital to T-cell activation. Lipid raft formation is thought to allow Lck 
phosphorylation, mobilization of intracellular calcium and ZAP-70/CD3 activation to occur 
more efficiently, leading to a stronger co-activation signal (Zhang, Trible et al. 1998; 
Bosselut, Zhang et al. 1999; Bosselut, Kubo et al. 2000). Thus, the tripartite interaction 
between the TCR and CD8 with the same pMHCI molecule (Figure 1.9) allows the 
intracellular signalling domains of CD8 and the TCR/CD3 complex to interact, leading to T-
cell activation (Grakoui, Bromley et al. 1999).  
 
A recent study demonstrated a new role for CD8 in controlling levels of crossreactive peptide 
recognition by CD8
+
 T-cells by examining recognition of combinatorial peptide libraries in 
the presence of altered MHC/CD8 interaction. This study made use of APCs that express 
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HLA-A2*0201 molecules mutated to interact with CD8 at slightly enhanced (KD = 85 µM) 
(Wooldridge, Lissina et al. 2007), decreased (KD = 500 µM) (Hutchinson, Wooldridge et al. 
2003), normal (KD = ~146 µM) or abrogated interaction with CD8 (KD < 10,000 µM). A 
direct positive correlation between the pMHCI/CD8 binding affinity and the number of 
ligands eliciting T-cell activation was identified (Wooldridge, Laugel et al. 2010). These 
findings revealed that CD8 extends the range of pMHCI ligands that can be recognised by an 
individual cell surface-bound TCR, a feature that is essential for effective immune coverage.  
 
In a recent study, Chervin et al found that activation of CD8
+
 T-cells that expressed high and 
intermediate affinity TCRs (KD 14 nM and 1.5 μM respectively) to pMHCI that lacked the 
ability to bind CD8 was greatly reduced compared to CD8-negative T-cells. The authors 
proposed that mechanism of CD8 inhibition is likely due to the sequestration of Lck. Even 
though the TCR has high-affinity for the pMHCI, engagement of the TCR alone without 
colocalisation of CD8 and associated Lck leads to impairment of T-cell activation (Chervin, 
Stone et al. 2009). This identifies a novel role for CD8 in T-cell activation where the ability 
of CD8 to sequester Lck maintains appropriate TCR-mediated MHC restriction in peripheral 
T-cell activity. 
 
Despite recent advances in understanding CD8 biology, there are still aspects of CD8 
function that we do not understand. For example, it is possible that CD8 can exert a novel 
focussing mechanism on T-cell recognition of antigen which has never been tested 
experimentally before (van den Berg and Rand 2007). A combination of all the described 
roles above are all important for T-cell activation, however which precise role dominates for 
successful T-cell activation is still unclear. In addition, we have failed to harness the potent 
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ability of CD8 to tune the antigen specific CD8 T-cell response which has immense 
therapeutic benefit. This thesis aims to address some of the remaining gaps in our knowledge. 
 
1.8.8 Distinct functions of CD8αα versus CD8αβ 
CD8αβ is exclusively expressed on Cytotoxic T-Lymphocytes (CTLs). The binding of the co-
receptor to the pMHCI molecule drives the recruitment of CD8α cytoplasmic tail associated 
Lck (Veillette, Bookman et al. 1988). As a result of this association early hybridoma studies 
demonstrated that CD8αα was enough to restore co-receptor function leading Gabert et al. 
(Gabert, Langlet et al. 1987) to question the role of the CD8 chain. However subsequent 
studies demonstrated that CD8αβ functions as a more efficient co-receptor than CD8αα 
(Wheeler, von Hoegen et al. 1992; Renard, Delon et al. 1996; Holler and Kranz 2003) and 
can actually broaden the range of T-cell antigen recognition (Karaki, Tanabe et al. 1992). At 
first the exact mechanism by which CD8 endows CD8 with efficient co-receptor function 
was unclear. Initially, it was thought that the CD8 chain contributed this increased function 
by increasing the strength of the pMHCI/CD8 interaction however cell-cell adhesion assays 
and SPR studies found that MHCI molecules interact with CD8αα and CD8αβ with similar 
affinities (Garcia, Scott et al. 1996; Sun and Kavathas 1997). It was then posited that the 
CD8 chain increased co-receptor function by increasing TCR/pMHCI binding which would 
enhance the association of the CD8α chain with essential signalling molecules such as Lck 
and LAT (Irie, Ravichandran et al. 1995; Renard, Romero et al. 1996; Bosselut, Zhang et al. 
1999). Arcaro et al then provided key data showing that these effects are mediated by 
palmitoylation of the CD8 chain which allows association with membrane microdomains 
called lipid rafts. Interaction between CD3 and CD8 ensures that palmitoylation of the 
CD8 also enriches TCR in these domains. Lipid rafts act as privileged sites T-cell signal 
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transduction because they are enriched in signalling machinery and exclude negative 
phosphatases such as CD45. Thus, CD8-mediated enrichment of TCR in lipid rafts has an 
important positive effect on TCR-mediated signal transduction (Arcaro, Gregoire et al. 2000; 
Arcaro, Gregoire et al. 2001; Doucey, Goffin et al. 2003). 
 
In contrast, CD8αα is expressed on a specialised subset of IELs associated with the gut,  T-
cells, NK cells (Gangadharan and Cheroutre 2004) or memory αβ T-cells (Madakamutil, 
Christen et al. 2004). CD8αα has also been shown to possess a strong preference to interact 
with the thymic leukaemia antigen (TL), a 2M independent non-classical MHCI expressed 
by epithelial cells of the small intestine. This interaction modifies signalling via the TCR 
which results in reduced proliferation and cytotoxicity but enhanced IEL cytokine production. 
As a result CD8αα T-cells can provide protection without destroying the epithelial cell layer. 
This suggests that CD8αα may play more of an immunomodulatory role (Leishman, 
Naidenko et al. 2001; Liu, Xiong et al. 2003).  CD8αα has also been shown to be up-
regulated when a subset of conventional CD8αβ T-cells are activated and survive and 
differentiate into memory precursor cells (Madakamutil, Christen et al. 2004). Therefore 
CD8αα and CD8αβ have distinct functions. CD8αβ functions as a more efficient co-receptor 
than CD8αα (Holler and Kranz 2003), allowing for a wider range of agonists available for 
recognition by the TCR (Karaki, Tanabe et al. 1992). In contrast, CD8αα has been suggested 
to play a more immunomodulatory role. (Leishman, Naidenko et al. 2001) (Liu, Xiong et al. 
2003). 
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1.8.9 Models of co-receptor function 
The timing of the co-receptor activity during pMHCI recognition is crucial for a full 
understanding of the mechanics involved in this process. CD8 and TCR have been shown to 
be constitutively associated on resting primary CD8
+
 T-cells suggesting that pre-existing bi-
specific receptors might engage pMHCI agonist ligands in a co-ordinate manner (Beyers, 
Spruyt et al. 1992; Suzuki, Kupsch et al. 1992; Doucey, Goffin et al. 2003; Demotte, 
Stroobant et al. 2008). Studies of the interaction between CD8 and TCR/CD3 using forster 
resonance energy transfer (FRET) technique suggest a chronological binding event. It was 
shown that the TCR binds to the pMHCI molecule first followed by the recruitment of the 
CD8 molecule subsequently (Yachi, Ampudia et al. 2005; Yachi, Ampudia et al. 2006). This 
data suggests that the TCR will perform an antigen-specific proof reading event. This will 
then ensure that signalling cascades activated by the CD8 co-receptor will only occur when 
the TCR will bind the pMHCI with suitable affinity and kinetics. This serves to discriminate 
between agonist and non-agonist pMHCI complexes with the recruitment of the CD8 only 
being enabled on encounter of TCR with agonist pMHCI. 
 
1.9 T-cell receptor triggering 
The process by which TCR binding to pMHCI molecules leads to phosphorylation events in 
the cytoplasmic tail of the TCR/CD3 complex is referred to as TCR triggering. Considerable 
controversy about the mechanisms of TCR triggering still exist with multiple mechanisms 
proposed to explain the process (van der Merwe and Dushek 2011). To evaluate possible 
models of TCR triggering, it is important to consider some unique features that distinguish it 
from other cell-surface receptor recognition events. First, TCR triggering is highly sensitive 
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allowing T-cells to sense a single pMHCI (Sykulev, Joo et al. 1996; Irvine, Purbhoo et al. 
2002; Purbhoo, Irvine et al. 2004). Second, the TCR is able to discriminate between very 
similar ligands and binds to self peptide-MHC molecules or altered peptides with a range of 
affinities to produce different responses. Third, the TCR differs from other receptors due to 
the enormous structural diversity that exists between the interface of a TCR and pMHCI 
complex (van der Merwe and Dushek 2011). Several mechanisms to explain TCR triggering 
have been proposed: 
 
1.9.1 Aggregation model  
This model can be separated into two models that account for aggregation of the TCR/CD3 
complex following TCR engagement: (i) The co-receptor heterodimerisation model suggests 
that CD4 and CD8 co-receptor can bind to the same agonist pMHCI complex as the TCR 
which will recruit co-receptor associated Lck into close proximity with the CD3 associated 
ITAMs to mediate phosphorylation as reviewed in (Trautmann and Randriamampita 2003). 
(ii) The pseudodimer model suggests a role for self pMHCI molecules in TCR triggering 
(Irvine, Purbhoo et al. 2002; Krogsgaard, Li et al. 2005). According to this model, one TCR 
can bind an agonist pMHCI molecule and a second TCR binds a self pMHCI molecule. 
Dimerisation is enhanced when the co-receptor associated with the TCR that is complexed 
with self pMHC binds to the agonist pMHCI molecule. A pseudodimer is then formed by the 
dual interaction of a second TCR with the self pMHC and its co-receptor with the agonist. 
This model then predicts that self pMHCI molecules would enhance TCR triggering as 
reviewed in (van der Merwe and Dushek 2011). 
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1.9.2 Conformational change model  
Several models have been proposed which suggest conformational change as a mechanism 
for TCR triggering. Conformational change models describe the changes in the CD3 
cytoplasmic domains upon TCR/pMHCI interaction. Recent data suggests that differences in 
mechanical effects of the TCR/pMHCI interaction such as a pulling or shearing forces can 
induce TCR triggering (Li, Chen et al. 2010; Sun, Kim et al. 2001; Choudhuri and van der 
Merwe 2007). This could be generated as a result of the small size of the TCR/pMHCI 
complex which would generate a force as large molecules are either compressed or removed 
from the contact area (van der Merwe 2001). It has been proposed that TCR/pMHCI binding 
could push and/or twist the TCR (Davis 2002; Kuhns, Davis et al. 2006). Mechanical pulling 
is suggested when TCR/pMHCI binding leads to a piston like movement of the CD3 
cytoplasmic tails, relative to the plasma membrane that could alter the conformation. Also the 
pulling could induce a conformational change in the structure of the CD3 ecto-domains 
and/or transmembrane domains that leads to clustering of the engaged TCR/CD3 complex 
with other TCR/CD3 complexes (van der Merwe and Dushek 2011) which in turn would 
enhance kinase activity. The conformational change in the cytoplasmic region of the 
TCR/CD3 complex is determined by the dissociation of ITAMs from phospholipids in the 
cell membrane exposing them to phosphorylation (reviewed in (van der Merwe and Dushek 
2011). 
 
1.9.3 Segregation and redistribution model  
The kinetic segregation model predicts that upon TCR/pMHCI recognition TCR/CD3 
complexes are trapped in close contact zones, which exclude larger inhibitory tyrosine 
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phosphatases such as CD45, leading to stable phosphorylation of TCR/CD3 ITAMs by Lck. 
The lipid raft model predicts that TCR/pMHCI recognition leads to an association of 
TCR/CD3 complex with lipid rafts which are privileged sites for phosphorylation. 
 
Van der Merwe and Dushek suggest that TCR triggering can be induced by any mechanism 
that aids the complex in favour of phosphorylation. They suggest that, aggregation, 
segregation, conformational change and clustering of TCR are all involved in the TCR 
triggering event (van der Merwe and Dushek 2011). A recent study by Manz and colleagues 
provide new data on TCR triggering. They show that T-cell triggering thresholds are 
modulated by the number of activating ligands available to individual TCR clusters, not by 
the total amount encountered by the cell. They also demonstrated that the minimal triggering 
unit is at least four pMHC in a single cluster when measuring activity by Ca
2+
 (Manz, 
Jackson et al. 2011). Overall, the precise mechanism of this initial triggering event still 
remains elusive. 
 
1.9.4 TCR triggering/kinetics and co-receptor dependency 
To achieve efficient T-cell signalling then the TCR/pMHCI interaction must be of long 
enough duration to allow for a series of ordered phosphorylation events of the CD3-ζ chains 
(McKeithan 1995; Rabinowitz, Beeson et al. 1996; Kersh, Shaw et al. 1998). It has been 
postulated previously that the TCR is a T-cell signalling unit which can trigger T-cell 
activation in the complete absence of CD8 suggesting that the co-receptor is not required for 
TCR triggering to occur (Janeway 1992). Recent work by Van der Merwe and Dushek, 
support this theory by demonstrating that TCR triggering can occur in the complete absence 
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of co-receptors and agonist pMHCI monomers cannot induce TCR triggering. As a result 
they state that the co-receptor heterodimerisation model is not sufficient for TCR triggering 
(Locksley, Reiner et al. 1993; Schilham, Fung-Leung et al. 1993; van der Merwe and Dushek 
2011). Kinetic models of TCR triggering such as kinetic segregation model also suggest that 
the co-receptor only plays a role in amplifying signals from already triggered TCRs and not 
in the primary initial signalling event (van der Merwe and Davis 2003).  
 
Data does suggest however that CD8 may indeed be playing a role in the TCR triggering 
event. The off-rate (koff) of the TCR/pMHCI interaction and hence its half life, is the principal 
kinetic feature that determines the feature of biological outcome. CD8 has been shown to 
generate a stabilising factor that preferentially increases the predicted TCR triggering rate 
suggesting an important role for CD8 in T-cell triggering and controlling T-cell 
crossreactivity (Wooldridge, van den Berg et al. 2005). When further studying the kinetics of 
the CD8 molecule, Gakamsky et al found that the CD8 molecule kinetically promotes ligand 
binding to the TCR (Gakamsky, Luescher et al. 2005). It is important that we undertake 
further studies to define the role of CD8 in TCR triggering (discussed in chapter 6). 
 
1.10 The physiological importance of CD8 in CD8
+
 T-cell biology 
The biochemical mechanisms involved during CD8
+
 T-cell responses and activation to 
antigens have been extensively studied and provide a wealth of data. However the only firmly 
proven physiological role for CD8 is with regards to the events that transpire during thymic 
development and T-cell selection in the thymus (see section 1.3.3).  
 
Chapter 1 
83 
 
Evidence however does suggest that CD8 helps in driving the priming and expansion of 
CD8
+
 T-cell clonotypes with low functional avidities for cognate antigen which will enhance 
the clonotypic diversity of CD8
+
 T-cell responses to microbial and potentially against self 
determinants in an autoimmune system. This was supported by Price et al where they showed 
that ex-vivo activation of sub-dominant CD8
+
 T-cell clonotypes specific for epitopes derived 
from Epstein-Barr virus and human cytomegalovirus relied more heavily on CD8 
engagement compared to numerically dominant clonotypes with the same antigen specificity. 
This suggests that CD8 is augmenting clonotypic diversity within the antigen-specific CD8
+
 
T-cell pool during chronic viral infections (Price, Brenchley et al. 2005). Surh and Sprent 
demonstrated that sub-optimal TCR engagement by self-ligands, resulted in low level 
signalling without associated activation, and is required for the survival of naïve CD8
+
 T-
cells in the periphery (Surh and Sprent 2008). However memory CD8
+
 T-cell persistence 
only requires the presence of homeostatic cytokines and does not rely on sub-optimal TCR 
stimuli which suggest that CD8 is required for the survival of naïve, but not memory, CD8
+
 
T-cells. It is clear that more studies are required in the future to define the role that CD8 plays 
in-vivo. 
 
1.11 Research Aims 
Despite major advances in terms of understanding the multiple roles of CD8 in T-cell 
activation, important questions still remain unanswered. Overall, the aim of this thesis was to 
further our understanding of the role that CD8 plays in T-cell activation and also the 
therapeutic potential of targeting CD8 for the treatment of CD8
+
 T-cell mediated diseases 
such as autoimmunity. 
Chapter 1 
84 
 
My specific aims were to:  
1. Probe the biological significance of the low solution binding affinity of the pMHCI/CD8 
interaction for the first time. 
2. Examine the possibility that anti-CD8 antibodies can trigger CD8
+
 T-cell effector function 
in the absence of TCR engagement. In addition, the aim of this study was to phenotype a 
panel of anti-CD8 antibodies and classify antibodies that have either an activatory or 
inhibitory function. 
3. Examine the possibility that anti-CD8 antibodies with an inhibitory phenotype can be used 
to block T-cell activation that is highly dependent on CD8. This could be potentially useful 
for blocking autoreactive CD8
+
 T-cells which are characterized by low affinity TCR/pMHCI 
interactions and are highly dependent on CD8. 
4. Finally, examine the possibility that CD8 can alter the functional avidity of a CD8
+ 
T-cell 
for its agonists and act to re-arrange the relative potencies of each of its potential agonists. If 
so this would suggest a novel “focussing mechanism” for CD8 in T-cell activation. 
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2.1 Reagents and consumables 
2.1.2 Mammalian Cell culture and reagents 
The following media were used to culture the cells required for this thesis: 
R10: Roswell Park Memorial Institute medium-1640 (RPMI-1640) supplemented with 10% 
heat inactivated foetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin and 100 
μg/ml streptomycin.  
PSG: RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 units/ml penicillin 
and 100 μg/ml streptomycin.  
R2: RPMI-1640 medium supplemented with 2% heat inactivated foetal calf serum (FCS), 2 
mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin.  
CK media: R10 supplemented with 2.5% Cellkines (Helvetica Healthcare, Geneva), 200 
IU/ml IL-2 and 25 ng/ml IL-15 (PeproTech, London, U.K.).  
D10: 293T cell culture media, Dulbecco modified Eagle’s medium (DMEM), supplemented 
with 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 1% sodium 
pyruvate and 10% heat inactivated FCS.  
I10: Iscove`s Modified Dulbecco medium (IMDM), supplemented with 2 mM L-glutamine, 
100 units/ml penicillin, 100 μg/ml streptomycin, 1% sodium pyruvate and 10% heat 
inactivated IgG low FCS. 
I0: IMDM media supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml 
streptomycin and 1% sodium pyruvate. 
Freezer mix: FCS supplemented with 10% sterile dimethyl sulfoxide (DMSO; Sigma-
Aldrich, Poole, U.K.).  
Chapter 2 
 
90 
 
RPMI-1640, DMEM, IMDM, FCS, L-glutamine, penicillin, streptomycin, and sodium 
pyruvate were purchased from Gibco, Life Technologies (Paisley, U.K.).  
 
2.2 Mammalian Cell culture 
2.2.1. Preparation of peripheral blood mononuclear cells (PBMC) 
Typically 50 ml of peripheral blood, obtained from the Welsh Blood Transfusion Service or 
healthy donors, was collected into a sterile 50 ml Falcon tube (BD Biosciences) containing 
the anti-coagulant heparin (Unihep Leo) at 1000 units/ml. PBMC were generated by Ficoll-
Hypaque density gradient centrifugation. Peripheral blood was gently layered onto an equal 
volume of Ficoll-Hypaque solution (Lymphoprep, Nycomed) and centrifuged for 20 minutes 
at 693 x g (Heraeus megafuge 1.0 R, Bucks, UK) with the break off. The buffy coat layer was 
gently removed from the gradient interface using a sterile Pasteur pipette. Cells were washed 
twice in PSG by centrifugation at 561 x g for 10 minutes followed by 561 x g for 6 minutes 
with maximum break. After the final wash, cells were re-suspended in R10 and kept in the 
incubator at 37°C/5% CO2 prior to use for the generation of human CD8 T-cell lines/clones 
or kept at 4°C prior to use as human γ-irradiated (30Gy) allogeneic feeders. 
 
2.2.2 Counting cells with Trypan blue 
Cells were counted and analysed for viability by combining 10 μl of cell suspension with an 
equal volume of 0.1% Trypan blue in PBS (w/v) (Sigma-Aldrich) and loaded on to an 
improved Neubauer haemocytometer (Weber Scientific International Limited, Lancing, 
U.K.). Viable cells remain colourless, whilst non-viable cells appear blue at 100 times 
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magnification on a light microscope (Nikon Eclipse TS100). The percentage of total cells 
counted that remained white equates to the viability of the cell culture. 
 
2.2.3 Generation of Human CD8
+
 T-cell peptide specific lines 
Blood from HLA A*0201 (HLA A2 from hereon) positive donors was used to generate CD8
+
 
T-cell lines. CD8
+
 T-cells specific for (i) Melan-A derived epitope ELAGIGILTV (residues 
26-35) (Laugel, van den Berg et al. 2007; Purbhoo, Li et al. 2007); and (ii) EBV BMLF1-
derived epitope GLCTLVAML (residues 259-267) (Lissina, Ladell et al. 2009) were 
generated by pulsing 6 x 10
6
 PBMC from a HLA A2 individual with cognate peptide at 
concentrations of 1 μM, 10 μM or 100 μM for 1 hour at 37°C. Cells were subsequently 
washed and resuspended in R10 only. After 3 days, increasing amounts of Interleukin-2 (IL-
2) (Peprotech) were gradually added to the media, reaching a maximum concentration of 20 
IU/ml by day 14. Expansion of antigen specific CD8
+
 T-cells was assessed by FACS staining 
with cognate HLA A2/peptide tetramers and anti-CD8 antibody conjugated to a fluorochrome 
(see section 2.7.8). 
 
2.2.4 Generation of human T-cell clones by limiting dilution 
Clones were all generated by limiting dilution culture from peptide-specific T-cell lines. 
Cloning mix consisting of 2 x 10
6
 PBMCs and 2 x 10
5
 peptide-pulsed allogeneic B cells 
(optional) per ml of R10 supplemented with T-STIM (BD Biosciences) and 200 IU/ml IL-2 
was made then γ-irradiated (30 Gy). Cells to be cloned were added to the cloning mix at a 
concentration of 1 cell per 600 µl mix, then plated out at 200 μl per well of a round-bottomed 
96 well plate (i.e. 1 cell per 3 wells). Control wells at 10 and 100 cells per well were 
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included. Plates were cultured at 37°C/5% CO2 and after 14-21 days examined for clones. 
Clones were re-stimulated as necessary, transferring them first to a 48 well plate, then at a 
second re-stimulation to a 24 well plate. Since the discontinuation of T-STIM in 2007, all 
clones and lines were subsequently cultured in CK media (ZeptoMatrix, NY, USA). 
 
2.2.5 Human CD8
+
 and CD4
+
 T-cell clones used in this thesis 
The following HLA A2 restricted CD8
+
 T-cell clones were used in this study (Table 2.2.6); 
(i) ILA1, specific for the human telomerase reverse transcriptase (hTERT)-derived epitope 
ILAKFLHWL (residues 540-548) (Laugel, van den Berg et al. 2007; Purbhoo, Li et al. 2007); 
(ii) ALF3, specific for the influenza A matrix protein (M1)-derived epitope GILGFVFTL 
(residues 58-66) (Cole, Edwards et al. 2010); (iii) MEL5 and MEL187.c5, specific for the 
Melan-A-derived epitope ELAGIGILTV (residues 26-35) (Laugel, van den Berg et al. 2007; 
Purbhoo, Li et al. 2007); (iv) 003 specific for the HIV-1 p17 Gag-derived epitope 
SLYNTVATL (residues 77–85) (Sewell, Harcourt et al. 1997; Choi, Chen et al. 2003; 
Gostick, Cole et al. 2007); (v) 1E6 and 3F2 specific for the restricted autoantigen 
preproinsulin peptide ALWGPDPAAA (PPI15–24) (Skowera, Ellis et al. 2008); and (vi) NLV2 
specific for the CMV-pp65 derived epitope NLVPMVATV (residues 495-503). In addition, 
the following non-HLA A2–restricted CD8+ T-cell clones were used: (i) HLA A*6801-
restricted clone c23, specific for the HIV-1 Tat-derived epitope ITKGLGISYGR (residues 
38–48) (Gostick, Cole et al. 2007); (ii) HLA B*0702-restricted clone KD4, specific for the 
EBV EBNA3A-derived epitope RPPIFIRRL (residues 379–387) (Burrows, Silins et al. 1995; 
Kjer-Nielsen, Clements et al. 2003); (iii) HLA B*0801-restricted clone LC13, specific for the 
EBV EBNA3A-derived epitope FLRGRAYGL (residues 339–347); (iv) HLA B*3508-
restricted clones SB27, SBS1 specific for the EBV BZLF1-derived epitope 
Chapter 2 
 
93 
 
LPEPLPQGQLTAY (residues 52–64) and SB10 specific for the EBV BZLF1-derived 
epitope CPSQEPMSIYVY (Green, Miles et al. 2004; Tynan, Borg et al. 2005; Tynan, 
Burrows et al. 2005; Wynn, Fulton et al. 2008); (v) HLA A*2402-restricted clone 4C6, 
specific for the restricted autoantigen preproinsulin peptide LWMRLLPLL (PPI3-11) (Knight, 
Kronenberg et al. 2012),; and (vi) The HLA DR*0101-restricted CD4
+
 T-cell clone C6 
recognizes the influenza A hemagglutinin (HA)-derived epitope PKYVKQNTLKLAT 
(residues 307-319) was generated as described previously (Lissina, Ladell et al. 2009). 
 
Table 2.2.6 Human CD8
+
 and CD4
+
 T-cell clones 
Clone name MHCI restriction Epitope Residue 
number 
Origin 
ILA1 HLA*0201 ILAKFLHWL 540-548 hTERT 
ALF3 HLA*0201 GILGFVFTL 58-66 Influenza 
ALF8 HLA*0201 GILGFVFTL 58-66 Influenza 
MEL5 HLA*0201 ELAGIGILTV 26-35 Melan-A 
MEL187.c5 HLA*0201 ELAGIGILTV 26-35 Melan-A 
1E6 HLA*0201 ALWGPDPAAA 15–24 Type-1 diabetes 
3F2 HLA*0201 ALWGPDPAAA 15–24 Type-1 diabetes 
4C6 HLA*2402 LWMRLLPLL 3-11 Type-1 diabetes 
003 HLA*0201 SLYNTVATL 77–85 HIV-1 Gag p17-18 
NLV2 HLA*0201 NLVPMVATV 495-503 CMV 
c23 HLA A*6801 ITKGLGISYGR 38–48 HIV-1 Tat 
KD4 HLA B*0702 RPPIFIRRL 379–387 EBV 
LC13 HLA B*0801 FLRGRAYGL 339–347 EBV 
SB27 HLA B*3508 LPEPLPQGQLTAY 52–64 EBV 
SBS1 HLA B*3508 LPEPLPQGQLTAY 52–64 EBV 
SB10 HLA B*3508 CPSQEPMSIYVY 103-111 EBV 
C6 HLA DR*0101 PKYVKQNTLKLAT 307-319 Influenza 
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Table 2.2.7 Human CD8
+
 and CD4
+
 T-cell lines 
Name MHCI restriction Epitope Residue 
number 
Origin 
MEL5 HLA*A0201 ELAGIGILTV 26-35 Melan-A 
EBV HLA*A0201 GLCTLVAML 259-267 EBV 
 
Table 2.2.8 Murine CD8
+
 transgenic T-cell lines 
Name MHCI restriction Epitope Residue 
number 
Origin 
F5 H2-D
b
 ASNENMDAM Influenza H17 Influenza 
 
 
2.2.9 Culture of human CD8
+
 T-cell lines and clones 
CD8
+
 T-cells were grown from cryopreserved stocks in 24-well tissue culture plates in 2.5% 
CK media following re-stimulation using 1 µg/ml PHA with 5 x 10
6
 irradiated allogeneic 
PBMC from 2-3 different individuals in 2 ml of media per well of a 24 well tissue culture 
plate. Following this, the cells were maintained in 2.5% CK media for several months 
without the need for re-stimulation with antigen and/or irradiated autologous PBMC feeders.  
 
2.2.10 Generation of Murine CD8
+
 T-cell peptide specific lines 
Naïve mouse CD8
+
 T-cells were obtained by harvesting splenocytes from transgenic F5 mice. 
A significant percentage of CD8
+
 T-cells within the splenic population of these mice express 
the F5 TCR, which recognizes the H-2D
b
-restricted influenza H17 nucleoprotein-derived 
epitope ASNENMDAM.(Table 2.2.8) (Mamalaki, Elliott et al. 1993). Naïve mouse CD8
+
 T-
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cells were obtained by harvesting splenocytes from Balbc mice (Mosier 1974). Cells were 
also stimulated with 10 μg/ml anti-mouse CD3 (clone 500A2, eBioscience) and 0.5 μg/ml 
anti-mouse CD28 antibodies (clone 37.51, eBioscience) and cultured in D10 media for 7 
days. 
 
2.2.11 Cryopreservation storage of cells 
2 – 10 x 106 lymphocytes were centrifuged at 389 x g for 5 minutes then re-suspended in 1 ml 
freezer mix and transferred to a cryovial (Nunc). Cryovials were stored in 100% Propan-2-ol 
(Mr.Frosty™, ThermoScientific, UK) storage containers at -80°C for 48 hours before being 
transferred to liquid nitrogen containers for long term storage. When required, cell stocks 
were rapidly thawed at 37°C to minimize cell death, washed once in PSG to remove the 
DMSO and resuspended in appropriate culture media.  
 
2.2.12 Generation and culture of C1R B cell clones expressing HLA A*0201 
Endotoxin free pcDNA3.1 mammalian expression vectors (Life Technologies) with inserts 
encoding either full length HLA A2 or one of the following mutants: HLA A2 DT227/8KA 
(Purbhoo, Boulter et al. 2001), HLA A2 Q115E (Wooldridge, Lissina et al. 2007), HLA A2 
K
b
/245V and chimeric HLA A2/K
b
 were generated then linearised before transfection into the 
C1R B cell line by electroporation. The C1R B cell line is a Class I A and B allele negative, 
Epstein-Barr
 
virus (EBV) transformed B cell line (Storkus, Howell et al. 1987) that can be 
cultured in R10. C1R cells were split and fed 24 hours before transfection as transfection 
efficiency is increased if C1R B cells are actively dividing and the population is >90% viable. 
For each transfection 10 x 10
6
 C1R B cells were washed twice in PSG (ensuring all absence 
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of serum), by centrifuging at 292 x g for 6-7 minutes at room temperature, and subsequently 
resuspended in 500 μl of PSG then transferred to a sterile 0.4 cm electroporation cuvette 
(Bio-Rad, Herts, UK) with 10 μg endotoxin free linearalised DNA (10 μl of 1 μg/μl). After 
gently mixing the cell suspension and DNA using a pasteur pipette the cuvette was placed on 
ice for 5 minutes. Electroporation was performed using the following conditions for each 
DNA construct; Voltage = 250 V, Capacitance = 400 μF. 
 
Electroporation was performed using a GenePulser Xcell electroporator (Bio-Rad). The 
electroporated cells were then rested at room temperature for 10 minutes. After the addition 
of 500 μl warm R10, the suspension was gently transferred into a T25 flask with a further 12 
ml R10 and subsequently cultured at 37°C/5% CO2. Stable transfectants were selected by 
adding 0.5 mg/ml G418 (Sigma-Aldrich) 72 hours after transfection. Significant cell death 
occurred within the first 5 days (>90% death) following G418 addition but cell viability 
began to recover at 10 days. The transfected C1R cell lines were cloned by limited dilution. 
The clones were then regularly tested for HLA A2 expression by staining with Fluorescein 
Isothiocyanate (FITC) conjugated anti-human HLA A2 conformation specific antibody clone 
BB7.2 (Serotec; Oxford, U.K.) and analysed by flow cytometry. All clones showed 100% 
HLA A2 expression, with equal Mean Fluorescence Intensities (MFI`s) in the FL1 channel.   
 
2.2.13 293T (HEK 293) lentiviral packaging cell line 
The 293T cell line was originally derived from human embryonic kidney (HEK) cells by 
transformation of cultured cells with sheared adenovirus-5 DNA (Graham, Smiley et al. 
1977). Cultures reaching 100% confluency were removed from the tissue culture plastic by 
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incubation with 0.5% trypsin in HBSS (Life Technologies) due to the fact that 293T cells are 
an adherent cell line then washed with 293T culture media to remove the trypsin and split. 
Cells were cultured in DMEM supplemented with 20% FCS, 1 mM sodium pyruvate, 100 
units/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. The 293T CD8α 
transfected cells used in this study (a kind gift from Dr Reno Debets) were manufactured by 
introducing pBullet-human CD8α into 293T cells using vesicular stomatitis virus-
pseudotyped Moloney murine leukaemia virus particles (Willemsen, Ronteltap et al. 2005; 
Willemsen, Sebestyen et al. 2006). 
 
2.2.14 Generation of whole antibody IgG from hybridomas 
The following hybridomas were used in this study: anti-human CD8 antibody clone OKT8 
IgG2a (MRC cooperative facility, ATCC), anti-human CD3 antibody clone OKT3 IgG2a 
(MRC cooperative facility ATCC) and anti-mouse CD8 antibody clone KT112 IgG2a (a kind 
gift provided by Professor Rose Zamoyska). OKT8 hybridoma was originally generated by 
three separate fusions between CAF mice which were immunised intraperitoneally at 2 to 3 
week intervals with either 2 x 10
7
 thymocytes, ConA activated sheep red blood cell rosetting 
(E
+
) cells or ConA activated E
+
 cells depleted of OKT4
+
 cells by OKT4 and rabbit 
complement. Four days after the third injection splenocytes were fused with P3 x 63 Ag8U1 
myeloma cells (Kung, Goldstein et al. 1979; Biddison, Rao et al. 1984). KT112 hybridomas 
were originally generated from a fusion between NSO myeloma cells and spleen from a 
Spraque-Dawley rat hyperimmunised with cells from the T-cell clone AK1 (specific for the 
non H2 antigen plus D
k
) (Tomonari and Spencer 1990). OKT3 hybridomas were originally 
generated by female mice of strain BALBcJ or CAF mice were immunised intraperitoneally 
with 2 x 10
7
 E rosette-purified peripheral T cells in PBS at 14-day intervals. Four days after 
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the third immunization the spleens were removed and a suspension of single cells was 
prepared. For each fusion, 1 x 10
8
 splenocytes were fused in 35% PEG in 5% DMSO and 
RPMI 1640 with 2 x 10
7
 P3 x 63 Ag8U, myeloma cells. After cell fusion, the cells were 
distributed into 100 to 400 wells and cultured in selective medium. The wells were observed 
regularly under an inverted phase microscope and as cells grew up supernatants from those 
wells were harvested and tested for binding to human peripheral lymphocytes separated into 
E rosette-positive (E
+
) and E rosette-negative (E
-
) populations. Binding was detected both by 
radioimmunosassay and indirect immunofluorescence techniques (Kung, Goldstein et al. 
1979). 
 
Hybridomas were cultured in I10 media (FCS IgG low) within the main compartment of a 
two compartment Celline flask (Integra, NH, USA). In the large body of the flask I0 media 
was used. Every 7-10 days the hybridoma was harvested for antibody and both compartments 
of the flasks were cultured in fresh media, i.e. in the main compartment of the flask, 
approximately 20 mls of hybridoma supernatant was harvested and fresh I10 media was 
added. This 20 mls was then centrifuged at 693 x g for 10 minutes at 4°C. The subsequent 
antibody in the supernatant was removed and stored at -20°C prior to purification. To the 
large body compartment, fresh I0 media was added. 
 
2.2.15 Purification of whole antibody IgG from hybridomas 
Whole IgG antibody was purified by first filtering whole antibody generated as above 
through a 0.4 μM filter. Antibody was then loaded to a protein G column (GE healthcare) 
with the use of a peristaltic pump. Once this had been completed the antibody was eluted 
Chapter 2 
 
99 
 
with the use of Elution buffer (0.1 M Glycine/HCl pH 2.5 (both Fisher Scientific, 
Loughborough, UK) and neutralised immediately with Neutralising buffer (1 M Tris pH 10.5 
Fisher Scientific). Antibody purity was then checked by SDS-PAGE electrophoresis (section 
2.5.6). 
 
2.2.16 Generation of OKT8 and OKT3 Fab, F(ab´)2 and Fc´ fragments 
250 µg of the anti-human CD8 antibody OKT8 or anti-human CD3 antibody OKT3 (IgG) 
was digested to yield Fab and Fc´ fragments using a Pierce Fab micro preparation kit 
(Thermo scientific, Rockford IL, USA) or digested to yield F(ab´)2 fragments using a Pierce 
F(ab´)2 micro preparation kit (Thermo scientific). IgG fragmentation was performed 
according to the manufacturer’s instructions and purity was checked via SDS-PAGE 
electrophoresis. 
 
2.3 Bacterial Cell culture 
2.3.1 Bacterial culture media 
Agar plates: 15 g Bacto-agar in 1 litre milliQ d.H20 (Fisher Scientific) supplemented with 
100 µg/ml ampicillin/carbenicillin or Kanamycin (Fisher Scientific).  
LB low salt media: 1% Bacto-tryptone (Difco), 0.5% NaCl (Sigma-Aldrich), 0.5% yeast 
extract (Difco).  
TYP media: 1.6% yeast extract (Difco), 1.6% Bacto-tryptone (Difco), 0.5% NaCl, 0.25% K2 
HPO4 (Sigma-Aldrich). 
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(All media was autoclaved on a liquid cycle at 121°C for 60 minutes and supplemented with 
100 µg/ml ampicillin/carbenicillin (Fisher Scientific) prior to use). 
 
Table 2.3.2 Bacterial strains 
Strain Description/Application Antibiotic Resistance Supplier 
Top10 
Plasmid amplification for 
transformation, sequencing 
or transfection. 
Ampicillin/Carbenicillin 
Life 
Technologies 
XL10-Gold 
Plasmid amplification for 
transformation, sequencing 
or transfection. 
Ampicillin/Carbenicillin 
Agilent 
Technologies 
BL21 (DE3) 
pLysS 
High stringency expression 
in bacterial cell culture under 
the control of the T7 
promoter. 
Ampicillin/Carbenicillin 
Life 
Technologies 
 
 
2.3.3 Transformation of competent bacterial cells by heat shock method 
Aliquots of competent bacteria were thawed slowly on ice. 50 - 100 ng of plasmid DNA 
(quantified by absorbance at 260 nm) was added to 50 µl thawed competent bacteria, kept on 
ice for 5 minutes, before being transferred to 42°C for 90 seconds then replaced on ice for 2 
minutes. Following this heat shock procedure, 100 μl of SOC media (Life Technologies) was 
added to the bacteria, and the mixture placed in an orbital incubator (Sanyo, Leics, UK) at 
37°C for 60 minutes. Cells were then streaked out on LB agar plates supplemented with 100 
µg/ml ampicillin/carbenicillin or kanamycin (Fisher Scientific) and incubated overnight at 
37°C. A negative control tube containing bacteria alone was plated out for every 
transformation.  
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2.3.4 Target gene expression in bacterial cell culture 
A single colony from a plate of freshly transformed BL21 bacteria was used to inoculate 30 
ml of TYP media supplemented with 100 µg/ml ampicillin/carbenicillin and agitated 
overnight in an orbital incubator at 37°C. The following morning 1 litre of TYP media 
(supplemented with 100 µg/ml ampicillin/carbenicillin) was inoculated with 2 - 5 ml of the 
starter culture and agitated at 37°C until the OD600 reaches between 0.4 and 1 (ideally 0.6) as 
measured by a spectrophotometer (Biochrom, Cambridge, UK). A 1 ml pre-induction sample 
was collected, microfuged at 17,900 x g (Eppendorf 5417 R, Cambridge, UK) for 1 minute 
and 1 ml of glycerol added then the pellet stored at -80°C. Protein expression was induced by 
adding 0.5 mM dioxin free isopropyl-1-thio-β-D-galactopyranoside (IPTG; Melford 
Laboratories). Flasks were agitated for a further 4 - 6 hours post induction. A 1 ml post-
induction sample was taken and stored as for the pre-induction sample. The remaining culture 
was centrifuged at 2122 x g for 20 minutes at 4°C (Heraeus) and the supernatant discarded. 
The bacterial pellet was either resuspended in lysis buffer for immediate preparation of 
inclusion bodies (section 2.5.1), or in 10 - 15 ml d.H2O and stored at -20°C.  
 
2.4 Molecular  Biology 
2.4.1 Plasmid DNA miniprep 
A single transformed bacterial colony was placed in 5 ml LB media supplemented with 100 
μg/ml ampicillin/carbenicillin or 100 μg/ml kanamycin and incubated overnight in an orbital 
incubator at 37°C. Bacterial cells were pelleted by centrifugation at 2772 x g for 15 minutes 
at room temperature and the supernatant discarded. Plasmid DNA was extracted using a 
commercially available miniprep kit (Miniprep 250 kit; Qiagen or Zyppy plasmid miniprep 
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kit; Zymo Research, CA, USA) based on the alkaline lysis method. Extracted DNA was 
resuspended in milliQ d.H2O or elution buffer and stored a -20°C.  
 
2.4.2 Plasmid DNA maxiprep (Endotoxin free) 
A single bacterial colony previously transformed with plasmid DNA was used to inoculate a 
starter culture of 5 ml LB media (supplemented with 100 μg/ml ampicillin/carbenicillin) and 
shaken for 8 hours in an orbital incubator at 37°C.  0.5 - 2 ml of starter culture was used to 
inoculate between 100 and 500 ml of LB media (dependent on DNA yield output) which was 
subsequently shaken overnight in an orbital incubator at 37°C. The cultures were centrifuged 
at 2772 x g for 20 minutes at 4°C and the supernatant discarded. The bacterial pellet was 
treated using a commercial endotoxin-free maxi-prep kit (Qiagen, UK) to extract the plasmid 
DNA. Ethanol precipitated and dried DNA pellets were resuspended in 200 - 500 μl TE 
buffer or endotoxin free water and the concentration of eluted DNA quantified as outlined 
below. A maxi-prep typically yielded 700 μg of plasmid DNA. 
 
2.4.3 DNA quantification 
2 μl of eluted DNA following either a mini or maxiprep procedure was diluted in 198 μl 
milliQ d.H2O. The absorbency of this solution was then measured using a spectrophotometer 
(Biomate, Thermo Scientific, MA, USA) or 1 μl of DNA was measured using a nano-drop 
(Thermo Scientific) set to record at 260 nm wavelength. MilliQ d.H2O was used as a blank 
reference. An absorbency of 1 at 260 nm was assumed to indicate a DNA concentration of 50 
ng/μl (after the extinction coefficient for DNA and the dilution factor were taken into 
account). 
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2.4.4 DNA sequencing 
After each step of cloning strategy, the construct (500 ng total) was sent for sequencing by 
the DNA sequencing facility, Central Biotechnology Services, Cardiff University. For all 
samples, forward and reverse primers were also sent (MWG 50 pmol/μl). DNA was 
sequenced using ABI PRISM 3100-Avant Genetic Analyser (Applied Biosystems, UK) using 
silver sequencing and analysed using CLG Genomics workbench (Swansea, UK). 
 
2.4.5 Linearisation of DNA 
For the generation of stable cell transfectants, plasmid DNA that had been generated via the 
methods outlined above must be linearised in order for it to successfully integrate with C1R 
cell DNA. 25 μl of plasmid DNA (of 50 μg @ 2 μg/μl) was digested with 10 μl BglII (New 
England Biolabs), 20 μl of 10 x NEB buffer and 145 μl RNAse/DNAse free water (200 μl 
total). Plasmid DNA was digested for 18 hours at 37°C and digestion efficiency was 
measured by running the sample on a 1% agarose gel (see section 2.4.7). 
 
2.4.6 Ethanol precipitation 
200 µl of the linearised plasmid DNA was precipitated using ethanol to allow the removal of 
any remaining restriction enzymes that remained post overnight digestion. 400 µl of 100% 
ethanol (Sigma-Aldrich) was added, and the mixture incubated at room temperature for 10 
minutes. The reaction was centrifuged at 292 x g for 10 minutes and the supernatant carefully 
aspirated then discarded. 500 µl of 70% ethanol was used to resuspend the DNA pellet for 
washing. The same centrifugation step was repeated and the supernatant again discarded. The 
pellet was allowed to dry before being resuspended in 50 μl of endotoxin free water. 
Chapter 2 
 
104 
 
2.4.7 Agarose gel electrophoresis and extraction 
Agarose gels were generated by the addition of 1% agarose (W/V) with 50 ml of 1 x TAE 
buffer (10 x buffer: 48.4 g Tris base, 10.9 g glacial acetic acid, 2.92 g EDTA, 1.0 Litre 
d.H2O, pH 8.2). This was heated to dissolve all agarose and once cool either 5 μl of 10,000 x 
SYBR® Safe DNA gel stain or 10 ng/ml Ethidium Bromide (Life Technologies) were added 
and the gel was cast. Samples were mixed with 5 x loading buffer (Bioline, London, UK) 
before being loaded then run on the gel alongside gel loading marker (Bioline) at 75 V, 200 
mA for 40 minutes. Subsequently gels were analysed using a UV transilluminator (UVP, 
Cambridge, UK). For extraction, DNA bands were excised from agarose gels using an UV 
transilluminator and the DNA subsequently extracted from the gel fragment using a 
QIAquick gel extraction kit (Qiagen), according to the manufacturer’s instructions. 
 
2.4.8 Plasmid restriction digestion 
Restriction digestion enzymes were used to specifically target a restriction site of choice: 2 μl 
of miniprep was added to 1 μl of restriction enzyme of choice (New England Biolabs) and 2 
μl of the appropriate enzyme buffer (New England Biolabs) then made up to a final volume 
of 20 μl DNAse free water (adding BSA if required for buffer (New England Biolabs)). 
 
2.4.9 Vector/insert ligation 
Vectors and inserts were ligated by mixing insert and vector at different ratios with 1U DNA 
ligase (T4 DNA ligase Promega, Southampton, UK) and 3 μl DNA ligase buffer (Promega) 
and made to a final volume of 30 μl DNAse free water. Ligation reactions were left overnight 
at 16°C. 
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2.5 Protein Chemistry 
2.5.1 Inclusion body preparation 
Biotin-tagged MHCI heavy chains (wild type and mutant HLA A2), α and β TCR chains, 
human CD8α and β2m were all expressed under the control of the T7 promoter as insoluble 
inclusion bodies in the Escherichia coli strain BL21 (DE3) pLys (Life Technologies) (section 
2.3.2). To prepare inclusion bodies from IPTG-induced E. Coli the bacterial pellet from 1 
litre culture was re-suspended in 20 ml of lysis buffer (10 mM Tris pH8.1 (Sigma-Aldrich), 
10 mM MgCl2 (Sigma-Aldrich), 150 mM NaCl (Sigma-Aldrich) and 10% Glycerol (Fisher 
Scientific)). The bacterial suspension was then transferred to a 50 ml centrifuge tube (Falcon) 
and lysed by sonication to release the inclusion bodies. Inclusion bodies were purified by 
adding 5 volumes of Triton wash buffer (0.5% Triton X-100 (Sigma-Aldrich), 50 mM Tris 
pH8.1 (Sigma-Aldrich), 100 mM NaCl (Sigma-Aldrich), 10 mM EDTA (Sigma-Aldrich) and 
2 mM DTT (Sigma-Aldrich), pelleted by centrifugation at 2772 x g for 20 minutes at 4°C and 
the supernatant containing the bacterial cell debris discarded. This step was repeated 2 - 3 
times (a homogenizer was used each time to resolubilise the pellet in the Triton buffer). To 
check purity of the inclusion body preparation, a small sample was analysed via SDS-PAGE 
electrophoresis. Once purity had been achieved, the inclusion body pellet was denatured into 
8 M guanidine buffer (8 M guanidine (Sigma-Aldrich), 50 mM Tris pH8.1 (Sigma-Aldrich), 
100 mM NaCl (Sigma-Aldrich), 10 mM EDTA pH8 (Sigma-Aldrich) and 10 mM DTT 
(Sigma-Aldrich)). The concentration of the inclusion body preparation was determined using 
spectrophotometry (Biomate, Thermo Scientific) then stored in 1 ml aliquots at -80°C.  
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2.5.2 Production of soluble human biotinylated peptide-MHCI monomers 
For the manufacture of pMHCI monomers, 30 mg of HLA A2 heavy chain with a biotin tag 
and 30 mg of β2m inclusion body preparations were denatured separately in 10 ml 8 M urea 
buffer (8 M urea (Sigma-Aldrich), 50 mM Tris pH8.1 (Sigma-Aldrich), 100 mM NaCl 
(Sigma-Aldrich), 10 mM EDTA pH8 (Sigma-Aldrich) and 10 mM DTT (Sigma-Aldrich)) for 
30 minutes at 37°C. Refolding was initiated by adding (in the order described) 1 ml peptide 
(4 mg/ml in DMSO), 30 mg denatured β2m, 30 mg denatured heavy chain in 1 litre of a pre-
chilled cysteamine/cystamine redox buffer (100 mM Tris pH8.1 (Sigma-Aldrich), 400 mM L-
arginine HCL (Sigma-Aldrich), 2 mM EDTA (Sigma-Aldrich), 2.3 mM cysteamine and 3.7 
mM cystamine (Sigma-Aldrich) at 4°C while stirring vigorously. After stirring for 4 hours at 
4°C the refold was transferred into 12 KD cut-off dialysis tubing (Sigma-Aldrich), dialysed 
against 12 litres of d.H2O overnight then against 12 litres 10 mM Tris pH8.1 for 8 hours 
followed by another overnight dialysis in fresh 10 mM Tris pH8.1. Following equilibration of 
a 5 ml anion exchange column (Hi Trap Q HP; GE healthcare) with 10 mM Tris pH8.1, the 
refold was loaded onto the column and the protein eluted with a salt gradient (0 - 500 mM 
NaCl in 10 minutes/10 mM Tris pH8.1) (Figure 2.1 A). The eluted fractions were collected 
and 1 x protease inhibitors (500 μM AEBSF, 1 μg/ml Aprotinin, 1 μM E-64, 500 μM EDTA 
and 1 μM Leupeptin; Calbiochem, UK) added to prevent biotin tag cleavage, stored at 4°C 
and analysed by SDS-PAGE. If fractions contain correctly refolded pMHCI then SDS-PAGE 
shows two main bands: a band at ~35 KD (pMHCI heavy chain) and a band at ~12 KD 
(β2m). The pMHCI band is typically more prominent than the β2m (Figure 2.1 B). After 
analysis of the collected fractions by SDS-PAGE, the fractions containing the two correctly 
folded proteins were pooled, concentrated down to 500 μl using 10 KD cut off Ultrafree 
centrifugal filter (Millipore) and desalted using a 5 ml Hi Trap desalting column (GE 
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healthcare) equilibrated with 10 mM Tris pH8.1 (Sigma-Aldrich). Desalted pMHCI monomer 
fractions were collected, pooled and biotinylated in a 1 ml biotinylation reaction ~700 μl 
pooled protein, 100 μl BioMix A, 100 μl BioMix B and 1 μl (2.5 μg), Bir A enzyme (Avidity, 
Denver, USA) overnight at room temperature. The removal of excess biotin and buffer 
exchange into PBS or HBS-EP BIAcore buffer (BIAcore AB, UK) was performed by gel 
filtration (size exclusion) chromatography using either a Superdex HR 75 10/30 column or a 
Superdex HR 200 column (Amersham Pharmacia) equilibrated in PBS or HBS-EP BIAcore 
buffer (Figure 2.2). Fractions were collected, pooled and 1 x protease inhibitors added 
(Calbiochem). The final concentration of the pMHCI monomer was determined by 
spectrophotometry (Biomate, Thermo Scientific), aliquoted and stored at -80°C.  
 
2.5.3 Manufacture of soluble human T-cell receptor (TCR) 
For a 1 litre refold: 30 mg TCR chain and 30 mg TCR were denatured separately by 
incubating at 37°C for 30 minutes in 10 mls of 6 M guanidine buffer (6 M guanidine, 50 mM 
Tris pH 8.1, 100 mM NaCl, 10 mM EDTA pH 8 and 10 mM DTT) (Sigma-Aldrich). 
Refolding was initiated by simultaneously adding denatured TCR and  chains to 1 litre of 
refold buffer (5 M urea, 100 mM Tris pH8.1, 400 mM L-arginine HCL, 2.3 mM cysteamine 
and 3.7 mM cystamine) (Sigma-Aldrich) previously chilled to 4°C whilst stirring vigorously. 
After 3 - 4 hours the refold mixture was transferred to dialysis tubing (12 KD cut off; Sigma-
Aldrich) and dialysed overnight against 12 litres of d.H2O which had been pre-chilled (4C). 
The refold was then dialysed twice against 12 litres pre-chilled 10 mM Tris pH8.1 (4C) for 8 
hours. After equilibrating a HiTrapQ HP column (GE healthcare) in 10 mM Tris pH8.1 the 
TCR refold was loaded at a flow rate of 5 ml/minute. Protein was then eluted using a salt  
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Figure 2.1: (A) Typical anion exchange trace for pMHCI monomer refold eluted from 
column using a salt gradient. (B) Protein quality measured by loading 1μg of refold protein 
from eluted fractions (A) using SDS-PAGE (section 2.5.6) and visualised using Coomassie 
brilliant blue stain (section 2.5.6). 
Chapter 2 
 
109 
 
 
Figure 2.2: A typical gel filtration trace. Post anion exchange, correctly folded pMHCI 
protein is biotinylated. Post-biotinylation, using a size exclusion chromatography column, 
biotinylated protein (peak 1) is separated from excess biotin (peak 2). Correctly folded 
biotinylated pMHCI monomer is pooled, the concentration of protein determined and stored 
@ -80 °C. 
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                      A 
 
                       B 
 
Figure 2.3: (A) Typical anion exchange trace for TCR refold eluted from column using a salt 
gradient (section 2.5.3). (B) Protein quality measured by loading 1μg of refold protein from 
eluted fractions (A) using SDS-PAGE (section 2.5.6) and visualised using Coomassie 
brilliant blue stain (section 2.5.6). 
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gradient (0 - 500 mM NaCl in 10 minutes/10 mM Tris pH 8.1) (Figure 2.3 A) and fractions 
containing correctly folded TCR were identified by SDS-PAGE (Figure 2.4 B), pooled and 
stored at 4°C. 
 
2.5.4 Manufacture of soluble human CD8. 
4 litres of redox refolding buffer (0.2 M Tris pH8.1 (Sigma-Aldrich), 0.5 M L-arginine 
hydrochloride (Sigma-Aldrich), 10 mM EDTA pH8 (Sigma-Aldrich), 2.3 mM cysteamine, 
3.7 mM cystamine (both Sigma-Aldrich) was pre-chilled to 4°C. 240 mg of human sCD8α 
inclusion bodies were denatured in 60 ml 6 M Guanidine buffer (6 M guanidine (Sigma-
Aldrich), 50 mM Tris pH8.1 (Sigma-Aldrich), 100 mM NaCl (Sigma-Aldrich), 10 mM 
EDTA pH 8 (Sigma-Aldrich) and 10 mM DTT (Sigma-Aldrich)) at 37°C for 30 minutes. 
Refolding was initiated by adding 20 ml of the denatured sCD8α solution to pre-chilled redox 
buffer whilst stirring at 4°C. At 10 minutes intervals the second and third 20 ml volume of 
denatured sCD8α was added. After stirring for 1 - 3 hours in the cold room the refold mixture 
was concentrated to 200 ml with a MasterFlex L/S  (Cole/Palmer, London, UK) concentrator 
using a VivaFlow 200 filter (Sartorius, Goettingen, Germany) using a 10 KD cut off filter and 
placed in 12 KD cut off dialysis tubing. The 200 ml refold was first dialysed against 8 litres 
of d.H2O overnight, then for 6 hours against 8 litres of 10 mM MES (2-[N-
Morpholino]ethanesulfonic acid) pH 6 (Sigma-Aldrich) and finally against 8 litres of 10 mM 
MES pH 6 (Sigma-Aldrich) overnight. After dialysis the refold was filtered through a 0.45 
μM filter, diluted to a final volume of 1 litre with 10 mM MES pH6 (Sigma-Aldrich) and 
loaded onto a 5 ml Hi Trap SP cation exchange column (GE healthcare) pre-equilibrated in 
10 mM MES pH6 (Sigma-Aldrich). Protein was eluted from the column with a salt gradient 
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(0 – 500 mM NaCl in 10 minutes/10 mM Mes pH6) (Figure 2.4 A). The correctly folded 
sCD8αα was identified by SDS-PAGE (Figure 2.4 B), fractions collected, pooled, 1 x 
cocktail of protease inhibitors added (Calbiochem) then concentrated using an ultrafree 10 
KD cut off centrifugal filter (Millipore). Buffer exchange into PBS or HBS-EP BIAcore 
buffer and removal of aggregates was achieved by size exclusion using a Superdex HR 200 
column (Amersham Pharmacia). 
 
Table 2.5.5 FPLC (Fast protein liquid chromatography) 
The table outlines some of the properties of the Amersham Pharmacia columns used in this 
thesis. All the columns were used by attaching them to an automated FPLC system 
(Amersham Pharmacia). 
 
Column Description Use Column 
volume 
(mls) 
Flow 
rate 
(ml/min) 
Volume 
of 
sample 
added 
(mls) 
Volume 
of 
collected 
fractions 
(mls) 
HiTrap Q 
HP 
Anion 
exchange 
Purification of 
pMHCI 
monomers or 
TCR 
5 5 
500 - 
1000 
1 
HiTrap 
SP 
Cation 
exchange 
Purification of 
sCD8αα 
5 5 
500 - 
1000 
1 
HiTrap 
desalting 
Gel 
filtration 
Salt removal 
prior to 
biotinylation 
5 5 1 1 
Superdex 
HR 75 
Gel 
filtration 
Removal of 
excess biotin 
after 
biotinylation 
23 0.5 1 0.5 
Superdex 
HR 200 
Gel 
filtration 
Removal of 
excess biotin 
after 
biotinylation 
23 0.5 1 0.5 
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Figure 2.4: (A) Typical cation exchange trace for human CD8αα refold eluted from column 
using a salt gradient (section 2.5.4). (B) Protein quality measured by loading 1μg of refold 
protein from eluted fractions (A) using SDS-PAGE (section 2.5.6) and visualised using 
Coomassie brilliant blue stain (section 2.5.6). 
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2.5.6 Sodium dodecyl sulphate-polyacrylamide gel elecrophoresis (SDS-PAGE) 
Proteins were separated by SDS-PAGE using the Life Technologies X-Cell SureLock™ 
system. Pre-cast gels, 4-12% Bis/Tris gels were removed from storage packaging and 
cleaned. The gel was locked in place using the XCell SureLock™ running chamber. The 
chamber was filled using 1 x NuPage® MES SDS running buffer (Life Technologies). 
Samples were prepared by diluting 1:4 in 5 x non reducing sample buffer (125 mM Tris 
pH6.8, 4% SDS, 20% glycerol, 20 μg/ml bromothenol blue) or 5 x reducing buffer with the 
addition of 10% DTT then incubated at 95°C for 5 minutes. The samples and the molecular 
weight marker (Seeblue Plus2 marker, Life Technologies) were loaded into separate lanes on 
the gel. Gels were run at 180 V for 45 minutes at 200 mA and stained by agitating them for 1 
hour with Coomassie Blue staining solution (40% methanol (BDH), 7% acetic acid (BDH), 
0.025% Brilliant Blue G) (Life Technologies). The gels were destained by further agitation 
for a minimum of 1 hour with miliQ d.H2O for visualisation. 
 
2.5.7 Estimating protein concentration by spectrophotometry 
To determine the concentration of pMHCI, samples were diluted 1/100 in PBS or HBS-EP 
BIAcore buffer. Inclusion bodies were diluted 1 in 100 in 6 M guanidine buffer. Using a 
spectrophotometer (Biomate, Thermo Scientific) the machine was blank referenced using the 
buffers that the protein had been made in, i.e. guanidine buffer for inclusion bodies and either 
PBS or HBS-EP BIAcore buffer for refolded protein by FPLC. Readings at 280 nm 
wavelength were recorded and the protein concentration was calculated using the dilution 
factor and extinction co-efficient for each protein previously calculated from the amino acid 
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sequence. For example the extinction co-efficient for monomeric pMHCI is approximately 
0.46 (with some variation between different pMHCI).  
 
2.5.8 Surface Plasmon Resonance 
Prior to surface plasmon resonance, proteins to be flowed over the sensor chip surface were 
gel filtrated through a Superdex 75 or 200 column to remove any aggregates and to buffer 
exchange into HBS-EP buffer (BIAcore AB, UK) containing 10 mM HEPES pH 7.4, 150 nM 
NaCl, 3.4 mM EDTA and 0.005% Surfactant P20. Proteins were then concentrated to an 
absorbency of at least 10 (measured @ 280 nm) using a 10 KD cut off Ultrafree centrifugal 
filter (Millipore). A standard amine coupling kit (BIAcore AB) was used to activate the 
surface of a research grade CM5 sensor chip (BIAcore AB). Streptavidin was covalently 
coupled to the chip surface by injecting a 0.2 mg/ml streptavidin solution (Sigma-Aldrich) 
diluted in 10 mM sodium acetate pH 4.5 over the surface. Biotinylated pMHCI monomers 
diluted in HBS-EP buffer (BIAcore AB) were immobilized onto the chip surface at 
approximately 1000 response units (RU) in each flow cell. Serial dilutions of either sCD8αα 
or soluble TCR were flowed over the chip to generate kinetic data. Data was analysed using 
BIAeval, Excel and Origin version 6.1 (Microcal software). KD values were calculated both 
by linear Scatchard plots and non-linear analysis assuming 1:1 Langmuir binding (A + B  
AB) using non-linear curve fitting to the equation: AB = BABmax/(KD + B).  
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2.6 Tetramer technology 
2.6.1 Manufacture of pMHCI tetramers 
Streptavidin has four binding sites for biotin therefore pMHCI tetramers can be constructed 
by adding streptavidin to a solution of biotinylated pMHCI monomers in a 1:4 molar ratio. 
Tetramers were conjugated to R-phycoerythrin (PE) (Life Technologies), Allophycocyanin 
(APC) (Prozyme, CA, USA), Quantum Dot Q605 or Quantom Dot Q800 (Life 
Technologies), Brilliant Violet 421 (BV421) (Biolegend, San Diego, CA, USA) or 
unconjugated Streptavidin alone for use in flow cytometry. The volume of conjugated 
streptavidin required for each tetramer preparation was calculated and added in 5 aliquots of 
equal volume at 20 minutes intervals at 4°C, mixing the contents well each time. By adding 
streptavidin in aliquots as described the complete saturation of all four biotin binding sites for 
streptavidin is ensured with each addition. The tetramers were stored at 4°C for a period of up 
to four weeks or until the tetramer showed signs of degradation.  
 
2.6.2 pMHCI Tetramer decay experiments 
HLA A*0201 pMHCI tetramers and 1 x 10
6
 CD8
+
 T-cells were stained in 100 μl azide buffer 
(PBS, 0.1% NaN3/0.5% FCS (Sigma-Aldrich)) for 20 minutes on ice with a concentration of 
tetramer, previously determined by titration, that gave a starting mean fluorescence intensity 
(MFI) of 200; 5 μl of 7-Amino-actinomycin D (7-AAD, Viaprobe; BD Biosciences) was 
included so that dead cells could be gated out of the analysis. After washing twice in ice cold 
azide buffer, CD8
+
 T-cells were resuspended in azide buffer, split into 2 separate aliquots, 
and placed at room temperature. To one sample, an excess of unconjugated anti-HLA A2 
mAb (clone BB7.2, Serotec, UK) at 100 μg/ml was added to block tetramer rebinding. 10 μl 
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of cells were then taken at time points 0, 2, 5, 8, 10, 15, 20, and 30 minutes, resuspended in 
PBS and analysed using a FACSCalibur flow cytometer. The remaining sample was left 
without BB7.2 and used as a control. Decays were repeated for all tetramers on the same day 
and data analysed with FlowJo software (TreeStar, Ashland, OR). 
 
2.6.3 pMHCI tetramer association experiments 
1 x 10
6
 CD8
+
 T-cells were washed twice in PSG and resuspended in 200 μl PBS with or 
without unconjugated anti-human CD8 antibody. 5 μg/ml of pMHCI tetramer was applied to 
the cell suspension, and at indicated time points 10 μl aliquots were taken out and placed in 
individual FACS tubes containing 100 μl PBS. The aliquots were removed from the master 
mix at the following time points; 0, 1, 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 28, and 30 minutes. 
Data was acquired using a FACSCalibur flow cytometer (BD) and analysed with FlowJo 
software (TreeStar). 
 
2.7 Flow cytometry 
2.7.1 Antibodies 
2.7.2 Activating antibodies 
Anti-human CD3 antibodies (clone OKT3 or UCHT1) were purchased from Pharmingen, BD 
Biosciences (San Jose, CA). The following anti-human CD8 antibodies were used in this 
study; 
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Table 2.7.3. Unconjugated anti-human CD8 antibodies 
Antibody clone CD8 α or β Purchased from 
OKT8 α eBioscience, Hatfield, UK 
SK1 α BD Biosciences, New Jersey, 
USA 
MCD8 α IqProducts, Groningen, The 
Netherlands 
32/M4 α Santa Cruz Biotechnology 
Inc., Heidelberg, Germany 
C8/144B α Santa Cruz Biotechnology 
Inc. 
DK25 α DAKO, Stockport, UK 
2ST8.5H7 β Abcam, Cambridge, UK 
 
 
For experiments with mouse cells, the following anti-mouse CD8 antibodies were used in this 
study; 
Table 2.7.4. Unconjugated anti-mouse CD8 antibodies 
Antibody clone CD8 α or β Purchased from 
CT-CD8a α Caltag-Medsystems, 
Buckingham, UK 
53.6.7 α 
Biolegend, Cambridge, UK 
CT-CD8b β 
Caltag-Medsystems 
KT112 β hybridoma kindly provided 
by Prof. Rose Zamoyska 
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2.7.5 Fluorescent conjugated anti-human antibodies for detection of cell surface protein 
expression 
Anti-CD3
FITC, PerCP, PE-Cy7, H7APC
, anti-CD4
PE, PE-Cy-5.5, APC
, anti-CD8αFITC, PE, PerCP, PE-Cy7, APC, 
anti-CD8βPE, anti-TCRαβFITC, pan-TCRγδFITC, PE, anti-CD19Pacific Blue, anti-CD14Pacific Blue, 
anti-CD56
FITC, APC
, anti-CD107a
FITC
, Violet Live/Dead stain ViViD
Pacific Blue
, Aqua Live/Dead 
stain
AmCyan
, Anti-HLA-A2 BB7.2
FITC
, Violet Live/Dead stain
PacificBlue
 and Viaprobe
TM
. All 
antibodies were purchased from either BD Pharmingen, BD Biosciences (Oxford, UK), 
Caltag-Medsystems (CA, USA), AbD Serotec (Oxford, UK), Beckman Coulter (High 
Wycombe, UK), eBioscience (Hatfield, UK), DakoCytomation (Stockport, UK) or Miltenyi 
Biotec (Surrey, UK). For full antibody source, see below methods. 
 
2.7.6 Fluorescent conjugated anti-mouse antibodies for detection of cell surface protein 
expression 
Anti-CD4
Pacific Blue
, anti-CD45R/B220
FITC
, anti-CD3
PerCP-Cy5.5
.were purchased from BD 
Pharmingen, and BD Biosciences.  
 
2.7.7 Fluorescent conjugated anti-human antibodies for detection of intracellular 
protein expression 
Anti-IFN-γPE-Cy7, anti-TNF-αAPC, anti-MIP-1βPE were purchased from BD Pharmingen and 
BD Biosciences.  
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2.7.8 pMHCI tetramer staining of CD8
+
 T-cells clones and PBMC 
5 x 10
4
 CD8
+
 T-cells clones (unless otherwise stated) were re-suspended in 40 μl PBS and 
stained with 1 μg PE, BV421, QDot605 or QDot800-conjugated pMHCI tetramer (final 
concentration of 25 μg/ml) for 15 minutes at 37°C. Cells were then stained with either 3 μl 
Peridinin-Cholorophyll proteins (PerCP)-conjugated anti-human CD3 (clone SK7, BD 
Biosciences), 3 μl APC-conjugated anti-human CD8 (clone SK1, BD Biosciences) and 5 μl 
7-AAD for 20 minutes on ice or stained with 3 μl PE-Cy7 anti-human CD3 (clone SK7, BD 
Pharmingen), 3 μl FITC-conjugated anti-human CD8 (clone SK1, BD Biosciences) and 3 μl 
APC-conjugated anti-human CD4 (clone RPA-T4, BD Biosciences) and with LIVE/DEAD 
fixable violet for 20 minutes on ice. After washing twice in PBS, cells were resuspended in 
200 μl of PBS. Data was acquired using either a FACSCalibur, FACSCanto II or a modified 
FACSAria II flow cytometer (all BD Biosciences) and analysed with FlowJo software 
(TreeStar). 
 
2.5 x 10
5
 PBMC`s from an HLA A2 donor (unless otherwise stated) were re-suspended in 40 
μl PBS and stained with 0.5 μg PE-conjugated pMHCI tetramer (final concentration of 10 
μg/ml) for 15 minutes at 37°C. Cells were then stained with 3 μl Fluorescein Isothiocyanate 
(FITC)-conjugated anti-human γδ-TCR (clone YB5.B8; BD Biosciences) or 3 μl FITC-
conjugated anti-human CD56 (clone MEM188; Caltag-Medsystems, CA, USA) and 5 μl 7-
AAD for 20 minutes on ice. In parallel experiments, cells were also stained with 3 μl PerCP-
conjugated anti-human CD3 (clone SK7; BD Biosciences), 3 μl APC-conjugated anti-human 
CD8 (clone SK1; BD Biosciences) and 3 μl FITC-conjugated αβ-TCR (clone BMA 031; 
Serotec). After washing twice in PBS, cells were resuspended in 200 μl of PBS. Data was 
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acquired using a FACSCalibur flow Cytometer and analysed with FlowJo software 
(TreeStar). 
 
2.7.9 Anti-CD8 antibodies and pMHCI tetramer staining of CD8
+
 T-cells clones, lines 
and PBMC 
5 x 10
4
 CD8
+
 T-cell clones were resuspended in 20 μl PBS and pre-incubated with or without 
unconjugated anti-human CD8 antibodies at a final concentration of 100 μg/ml of clone 
OKT8, 32/M4, C8/144B and 2ST8.5H7, 50 μg/ml of clone MCD8, 6.25 μg/ml SK1 or 25 
μg/ml DK25 on ice for 20-25 minutes. Cells were also pre-incubated with 12.5, 6.25, 3.125 
and 1 μg/ml DK25 and 6.25, 3.125 and 1 μg/ml SK1 on ice for 20-25 minutes. Following 
antibody pre-incubation, PE, APC, or BV421 conjugated pMHCI tetramers folded around 
peptides specific for each CD8
+
 T-cell clone were added at a final concentration of 25 μg/ml 
and incubated at 37°C for 15 minutes prior to staining with 5 μl 7-AAD at 4°C for 30 
minutes. Data was acquired using either a FACSCalibur or FACSCantoII flow cytometer and 
analysed with FlowJo software (TreeStar). 
 
For human CD8
+
 T-cell lines, 5 x 10
4
 cells were pre-incubated with unconjugated anti-human 
CD8 antibodies at concentrations indicated above for 25 minutes on ice and then stained with 
cognate PE-conjugated tetramer (25 μg/ml) at 37°C for 15 minutes prior to staining with 5 μl 
amine-reactive fluorescent dye LIVE/DEAD Fixable Aqua (Life Technologies), 1 μl Pacific 
Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems), 1 μl Pacific Blue-
conjugated anti-human CD19 (clone SJ25-C1; Caltag-Medsystems), 3 μl PE-Cy5.5–
conjugated anti-human CD4 (clone S3.5; Caltag-Medsystems) and 3 μl FITC-conjugated 
anti-human CD8 (clone SK1; BD Biosciences) at 4°C for 20 minutes. 
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 For human PBMCs directly ex-vivo, 1 x 10
5
 cells were pre-incubated with anti-human CD8 
antibodies at concentrations as indicated above for 25 minutes on ice and then stained with 1 
μg HLA A2 APC-conjugated tetramer (25 μg/ml) at 37°C for 15 minutes prior to staining 
with 5 μl LIVE/DEAD Fixable Aqua (Life Technologies), 1 μl Pacific Blue-conjugated anti-
human CD14 (clone Tuk4, Caltag-Medsystems), 1 μl Pacific Blue-conjugated anti-human 
CD19 (clone SJ25-C1, Caltag-Medsystems), 3 μl FITC-conjugated anti-human CD3 (clone 
HIT3a, BD Biosciences), 3 μl PE-Cy5.5-conjugated anti-human CD4 (clone S3.5 Caltag-
Medsystems) and 3 μl PE-Cy7-conjugated anti-human CD8 (clone RPA-T8, BD Biosciences) 
at 4°C for 20 minutes. Data was acquired using either a FACSCanto II (BD Biosciences) and 
analyzed with FlowJo software (TreeStar). 
  
2.7.10 pMHCI tetramer staining of murine F5 transgenic T-cells 
5 x 10
4
 cells were pre-incubated with 100 μg/ml anti-mouse CD8 antibody (clone CT-CD8a; 
Caltag-Medsystems, clone 53.6.7; BioLegend, clone KT112; in-house, or clone CT-CD8b; 
Caltag-Medsystems) for 20-25 minutes on ice and then stained with cognate PE-conjugated 
H-2D
b
 tetramer (25 μg/ml) at 37°C for 15 minutes prior to staining with 5 μl LIVE/DEAD 
FixableAqua (Life Technologies), 1 μl Pacific Blue-conjugated anti-mouse CD4 (clone RM4-
5; BD Biosciences), 1 μl FITC-conjugated anti-mouse CD45R/B220 (clone RA3-6B2; BD 
Biosciences), and 1 μl PerCP-Cy5.5–conjugated anti-mouse CD3 (clone 17A2; BD 
Biosciences) at 4°C for 20 minutes. Data was acquired using either a FACSCanto II or a 
modified FACSAria II flow cytometer (both BD Biosciences) and analyzed with FlowJo 
software (TreeStar). 
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2.7.11 pMHCI tetramer staining of 293T CD8α 
2 x 10
5
 transfected 293T CD8α T-cells were incubated with 10 μg/ml of PE-conjugated 
tetramers for 15 minutes at 37°C, then stained with 5 μl 7-AAD and either 3 μl FITC-
conjugated anti-human CD8 (clone SK1; BD Biosciences) or 3 μl PE-conjugated anti-CD8β 
(clone 2ST8.5H7; Beckman-Coulter, High Wycombe, UK) for 30 minutes on ice, washed 
twice, and resuspended in PBS. Data was acquired using a FACSCalibur flow cytometer (BD 
Biosciences) and analyzed with FlowJo software (TreeStar). 
 
2.7.12 Antibody staining of PBMC 
2.5 x 10
5
 PBMC`s were stained with 3 μl PerCP-conjugated anti-human CD8 (clone SK1; 
BD Biosciences), 5 μl 7-AAD and either 3 μl FITC-conjugated anti-human αβ-TCR (clone 
BMA031; Serotec, UK), APC-conjugated anti-human CD56 (clone AF12-7H3; Miltenyi, 
CA, USA) or PE-conjugated anti-human γδ-TCR (clone YB5.B8; BD Biosciences) for 30 
minutes on ice, washed twice, and resuspended in PBS. Data was acquired using a 
FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo software 
(TreeStar). 
 
2.8 CD8
+
 T-cell effector function assays 
2.8.1 Intracellular Cytokine staining (ICS) 
PBMCs were harvested from a healthy donor and cultured with or without 1 mg/ml 
Phytohemagglutinin (PHA) (Alere, Cheshire, U.K.) and 25 ng/ml IL-15 (Promega, 
Hampshire, U.K.) for 7 days then washed and cultured overnight in R2 medium. A total of 5 
x 10
4
 PBMCs (un-stimulated or stimulated with PHA/IL-15) were resuspended in the 
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presence of 1 μl/ml brefeldin A (GolgiPlug; Sigma-Aldrich), 0.7 μl/ml monensin (GolgiStop; 
BD Biosciences) and 5 μl/ml FITC-conjugated anti-human CD107a (clone H4A3; BD 
Biosciences) then incubated with unconjugated anti-human CD8 antibodies at previously 
indicated concentrations for 18 hours at 37°C in a 5% CO2 atmosphere. After washing with 
PBS, cells were stained with 5 μl LIVE/DEAD Fixable Violet (ViViD; LifeTechnologies) at 
room temperature for 15 minutes. Subsequently, cells were washed and stained with 1 μl 
Pacific Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems), 1 μl Pacific 
Blue-conjugated anti-human CD19 (clone SJ25-C1; Caltag-Medsystems), 4 μl H7-APC-
conjugated anti-human CD3 (clone SK7; BD Biosciences) and 3 μl PE-Cy5.5-conjugated 
anti-human CD4 (clone S3.5; Caltag-Medsystems) at 4°C for 20 minutes. Cells were then 
washed an additional three times, resuspended in 200 μl BD Cytofix/Cytoperm and incubated 
at 4°C for 20 minutes. After three additional washes in 1 x Perm/Wash (BD Biosciences; 
diluted with d.H2O) cells were stained with 3 μl PE-Cy7-conjugated anti-human IFN-γ (clone 
B27; BD Biosciences), 3 μl APC-conjugated anti-human TNF-α (clone MAb11; BD 
Biosciences) and 3 μl PE-conjugated anti-human MIP-1β (clone D21-1351; BD Biosciences) 
at 4°C for 20 minutes. Cells were washed again three more times and resuspended in 200 μl 
Perm/Wash. Data was acquired using a modified FACSAria II flow cytometer (BD 
Biosciences) and analyzed with FlowJo software (Tree Star). 
 
2.8.2 Peptide activation assays 
3 x 10
4
 rested CD8
+
 T-cells were mixed with either HLA A*0201 wild-type, HLA A*0201 
227/8, HLA A*0201 QE, HLA A*0201 K
b
 expressing C1R B cells which have been 
previously pulsed with or without cognate peptide titrated from 10
-5 
M to 10
-11
 M for 1 hour 
or with unconjugated anti-CD8 antibodies as stated. Cells were either washed twice prior to 
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the addition of CD8
+
 T-cells to remove excess peptide or remained unwashed and incubated 
with or without secondary crosslinking by the addition of 5 μl anti-mouse IgG antibody 
(Beckman-Coulter) in a total volume of 100 μl in duplicate. Cells were then and incubated for 
4 hours for antibody blocking assays where stated or for 18 hours at 37°C in a 5% CO2 
atmosphere. Positive controls included: (i) target cells pulsed with 10
-7 
M cognate peptide; 
(ii) 10 μg/ml unconjugated anti-human CD3 antibody (UCHT1; BD Biosciences); (iii) 1 
μg/μl PHA (Alere-technologies, UK); or when using F5 transgenic mice (iv) 50 ng/ml 
phorbol myristate acetate (PMA) and 1 μg/ml ionomycin (Sigma-Aldrich). Negative controls 
included rested CD8
+
 T-cells alone and CD8
+
 T-cells incubated with target cells. 
Supernatants were harvested and assayed for MIP-1α, MIP-1β and RANTES using a 
Quantikine duoset ELISA kit (R&D Systems, Abingdon, UK). 
 
2.8.3 ELISA (Enzyme-linked immunosorbent assay for MIP-1α, MIP-1, IFN-, and 
RANTES 
All ELISAs were performed according to the manufacturer’s instructions using the advised 
reagents (Wash buffer, Regent diluents, Streptavidin HRP, Chromogen, Peroxide and Stop 
solution (all R&D systems)). Briefly 96 well ELISA microplates (R&D systems) were coated 
with 50 – 100 μl diluted capture antibody. Plates were incubated overnight at room 
temperature and washed three times using an AquaMax 2000 microplate washer (MDS 
analytical technologies, Sunnyvale, USA). Plates were then blocked for a minimum of 60 
minutes using reagent diluent. Plates were washed again and 50 – 100 μl of cell supernatant 
was added including 50 – 100 μl of serially diluted standard solution. Plated were incubated 
for 75 minutes and washed again and 100 μl of diluted detection antibody was added to each 
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well. Plates were incubated as recommended and washed prior to the addition of diluted 
Streptavidin-horseradish peroxidise. After a further incubation, plates were washed and 50 – 
100 μl of 1:1 solution of chromogen and peroxide added. Plates were incubated for 20 
minutes avoiding exposure to the light. 50 μl of stop solution (sulphuric acid) was then added 
and plates were read at 450 nm with a reference filter set at 570 nm (Bio-rad iMark 
microplate reader, Bio-rad, UK). 
 
2.8.4 Tetramer activation assays 
2.5 x 10
4
 CD8
+
 T-cell clones were incubated with HLA A2 or HLA A2
 
variant tetramers 
conjugated to QDot605 or QDot800, at 1 μg/ml overnight at 37°C. Supernatant was then 
harvested and assayed for MIP-1 production by ELISA (R&D). 2.5 x 104 CD8+ T-cell 
clones were incubated with HLA A2 or HLA A2
 
variant tetramers conjugated to PE at 1 and 
5 μg/ml for 4 hours at 37°C. CD8+ T-cell clones were also incubated with 5 μl/ml FITC-
conjugated anti-human CD107a (clone H4A3, BD Biosciences) and 0.7 μl/ml monensin 
(Golgi-Stop BD Biosciences) (Betts, Brenchley et al. 2003). Cells were then stained with 
APC-conjugated anti-human CD8 (Clone SK1, BD Biosciences) for 20 mins on ice. Data was 
acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software (Tree 
Star). 
 
2.8.5 Chromium Release Assay 
2 x 10
3
 CD8
+ 
T-cell clones were treated with unconjugated anti-human CD8 antibodies at 
varying concentrations in 100 μl R2 medium. 2 x 103 C1R-HLA A2 target cells (100 μl), 
labelled with 30 µCi of 
51
Cr (PerkinElmer, Cambridge, UK) per 10
6
 cells for 1 hour 
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previously, were subsequently added. Targets were also cultured alone (target spontaneous 
release) and with TritonX-100 (Sigma-Aldrich) at a final concentration of 5% (target total 
release). Cells were incubated at 37°C for 18 hours in a 5% CO2 atmosphere. For each 
sample, 20 µl supernatant was harvested and mixed with 150 μl OptiPhase Supermix 
Scintillation Cocktail (PerkinElmer). Plates were analyzed using a liquid scintillator and 
luminescence counter (MicroBeta TriLux; PerkinElmer) with Microbeta Windows 
Workstation software (PerkinElmer). Specific lysis was calculated according to the following 
formula: (experimental release - target spontaneous release/target total release - target 
spontaneous release) x 100. Each value was calculated as the average of triplicates and shown 
with SEM. 
 
2.8.6 CBA (Cytometric bead array) 
The supernatants that were generated from the experiments referred to in section 2.8.3, were 
assayed using the human Th1/Th2 Cytokine kit specific for IL-2, IL-4, IL-5, IL-10, TNF-α 
and IFN-γ (BD Biosciences) according to the manufacturer’s instructions. Briefly, 25 μl of 
cell supernatant was incubated with diluted R-phycoerythrin (PE)-conjugated detection 
antibodies and beads coated with the relevant capture antibodies at room temperature for 
three hours, after which the beads were washed twice with wash buffer (BD), and 
resuspended in PBS (Oxoid). The samples were acquired using a FACSCalibur (BD 
Biosciences) flow cytometer and the results analysed using the CBA 6 Bead analysis 
software (BD Biosciences). 
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3 
 
THE LOW SOLUTION BINDING AFFINITY OF THE pMHCI/CD8 INTERACTION 
IS ESSENTIAL FOR THE MAINTENANCE OF CD8
+
 T-CELL ANTIGEN 
SPECIFICITY  
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3.1 Introduction 
CD8 has the potential to engage all pMHCI complexes, both self and foreign, because it 
binds to largely non-polymorphic regions of the MHCI molecule. Recent publications suggest 
that the ability of CD8 to interact with non-stimulatory pMHCI complexes lowers T-cell 
activation thresholds and enables CD8
+
 T-cells to respond to low copy numbers of specific 
pMHCI (Yachi, Ampudia et al. 2005; Anikeeva, Lebedeva et al. 2006). It therefore remains 
unclear how the specificity of TCR recognition is maintained despite the potential for 
multiple pMHCI/CD8 interactions at the cell surface. One possibility resides in the fact that 
the binding of CD8 to MHCI is characterized by very low affinities and extremely rapid 
kinetics. In this chapter, I intend to probe the functional significance of the low solution 
affinity pMHCI/CD8 interaction using pMHCI molecules with super-enhanced CD8 binding 
properties.  
 
3.1.1 T-cell recognition of antigen involves the binding of two receptors (TCR and CD8) 
to a single ligand (pMHCI): implications for CD8
+
 T-cell activation 
The exquisite specificity of the TCR/pMHCI interaction is the critical factor in permitting 
specific T-cell activation. The TCR must be able to recognise a large number of different 
peptides presented at the cell surface whilst ensuring that it does not recognise self peptides. 
Whilst stimulation of the TCR is required for T-cell activation, stimulation through this 
receptor alone is inadequate for full and sustained T-cell activation. Signals provided by the 
co-receptor and other accessory molecules provide an extra stimulus that leads to activation 
of anti-apoptotic proteins and supporting cytokines (Watts and DeBenedette 1999). As 
previously discussed, the MHCI binding site for CD8 is physically distinct from the peptide-
Chapter 3 
 
131 
 
binding domains that are recognized by the TCR (Rudolph and Wilson 2002) and this spatial 
segregation allows both TCR and CD8 to bind a single MHCI molecule simultaneously (Gao, 
Tormo et al. 1997). Thus, T-cell recognition of antigen could involve the binding of two 
receptors (TCR and CD8) to a single ligand (pMHCI), a modus operandi that is unique to αβ 
T-cell biology. Indeed, a large proportion of CD8 and TCR molecules are constitutively 
associated on CD8
+ 
T-cells in the absence of TCR engagement by agonist ligands suggesting 
that the TCR and CD8 pre-exist as bi-specific receptors that can engage pMHCI agonist 
ligands in an ordered manner (Beyers, Spruyt et al. 1992; Suzuki, Kupsch et al. 1992; 
Doucey, Goffin et al. 2003; Demotte, Stroobant et al. 2008).  
 
Fluroesence Energy Resonance Transfer techniques (FRET) studies investigating the 
interaction of CD8 and TCR/CD3 with specific pMHCI suggest that TCR binding to pMHCI 
occurs first, thereby satisfying the antigen-specific component of the interaction, and that the 
recruitment of CD8 occurs subsequently (Yachi, Ampudia et al. 2005; Yachi, Ampudia et al. 
2006). Using T-cell hybridomas, this data pointed to a chronological sequence according to 
which the pivotal antigen specific proofreading event provided by the TCR occurs prior to the 
association of CD8 with the TCR/CD3 complex. This is often referred to as the 'sequential 
engagement model'. This mechanism would ensure that CD8 recruitment only results in the 
amplification of downstream signalling cascades for ligands that engage the TCR with 
favourable kinetics. In this scenario, the TCR could also discriminate between agonist and 
non-agonist pMHCI complexes, with CD8 recruitment being enabled only in the context of 
agonist-ligand interactions with the TCR. Indeed data by Yachi et al demonstrated that the 
kinetics of CD8 recruitment to the TCR ensures that the TCR can specifically distinguish 
between structurally similar peptides (Yachi, Ampudia et al. 2006). This was further 
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supported by Jiang et al who proposed that the induced recruitment of CD8 following 
TCR/pMHCI engagement serves to stabilize molecular contact between the CD8
+
 T-cell and 
the antigen presenting cell, thereby unveiling another potential role for CD8 (Jiang, Huang et 
al. 2010).  This data further supports the importance of CD8 in allowing the TCR to 
specifically distinguish between self and non-self peptides, thus highlighting the importance 
of CD8 in controlling T-cell specificity. 
 
3.1.2 Biophysical measurements of the TCR/pMHCI and pMHCI/CD8 interaction 
Surface plasmon resonance (SPR) has provided a reliable way of measuring very weak 
receptor-ligand interactions in real time. SPR uses soluble molecules therefore the technique 
can be used to measure the affinity and kinetics of the TCR/pMHCI interaction and 
pMHCI/CD8 interaction in the absence of cell surface effects. The results of these SPR 
studies are quite striking. The pMHCI/CD8 interaction is characterized by very low solution 
binding affinities (KD ~146 μM) (Table 1.1) and rapid kinetics (Koff ~18 s
-1
) (Wyer, Willcox 
et al. 1999; Gao, Willcox et al. 2000). Indeed, the affinity of the pMHCI/CD8 interaction is 
even lower than the corresponding values measured for conventional molecular binding 
events involved in cell-cell recognition, such as the CD2/CD48 interaction (KD = 60-90 μM) 
(Dustin, Golan et al. 1997; Wyer, Willcox et al. 1999).  
 
In stark contrast, the TCR/pMHCI interaction can be more than 1000-fold stronger than the 
pMHCI/CD8 interaction (KD range for agonists from 0.14 μM, the strongest natural 
TCR/pMHCI interaction measured to date) (Table 3.1) and exhibits considerably slower 
kinetics (Koff range for agonists from 0.01 to 1 s
-1
) (Davis, Boniface et al. 1998; Cole, 
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Pumphrey et al. 2007; Laugel, van den Berg et al. 2007; Varela-Rohena, Molloy et al. 2008; 
Stone, Chervin et al. 2009). Typical TCR/pMHCI interaction are characterised by KDs of 
between 0.1 and 50 µM (Table 3.1) as measured using surface plasmon resonance (SPR) 
(Bridgeman, Sewell et al. 2011). Although, recent data suggests that alloreactive and 
autoreactive TCR/pMHCI interactions may be outliers and can be characterised by a much 
weaker affinity (KD > 180 µM). It seems extremely unlikely that the striking biophysical 
characteristics of the pMHCI/CD8 interaction have occurred by accident. Indeed, this 
conclusion is strengthened by the finding that the pMHCI/CD8 interaction is capable of 
exerting the vast majority of its biological function when weakened even further (Hutchinson, 
Wooldridge et al. 2003), which suggests that CD8 has specifically evolved to operate at very 
low solution affinities. 
 
Table 3.1: Binding affinities of human TCR to pMHCI using SPR (Bridgeman, Sewell et 
al. 2011) 
Autoreactive, alloreactive, anti-cancer and anti-pathogen TCR/pMHC binding affinity 
measurements are shown in blue, green, red and black, respectively. 
 
TCR/pMHCI KD (μM)  
PP1 TCR/A*0201-ALW (Cole, Edwards et al. 2010) 270 ± 40 
LC13 TCR/B*4402-allo (Macdonald, Chen et al. 2009) 189 ± 7 
LC13 TCR/B*4405-allo (Macdonald, Chen et al. 2009) 49 ± 0.2 
A6 TCR/A*0201-HuD (Borbulevych, Piepenbrink et al. 2009) 48 ± 4 
MEL187.c5/A*0201-EAA (Cole, Edwards et al. 2010) 42 ± 0.3 
TEL TCR/A*0201-ILA (Cole, Pumphrey et al. 2007) 34 ± 2 
MEL187.c5/A*0201-ELA (Cole, Edwards et al. 2010) 18 ± 0.3 
MEL5 TCR/A*0201-ELA (Cole, Pumphrey et al. 2007; Cole, Edwards et al. 2010) 18 ± 1 
IG4 TCR/A*0201-NYESO (Chen, Stewart-Jones et al. 2005) 13.3 ± 0.4 
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gp100 TCR/A*0201-YLE (Cole, Pumphrey et al. 2007) 11 ± 0.5 
MEL5 TCR/A*0201-EAA (Cole, Edwards et al. 2010) 6.4 ± 0.04 
A6 TCR/A*0201-Tel1p (Laugel, Boulter et al. 2005; Borbulevych, Piepenbrink et al. 
2009) 41 ± 2 
RA14 TCR/A*0201-NLV (Gras, Saulquin et al. 2009) 27.7 ± 2.3 
AM3 TCR/A*2402-EBV (Cole, Pumphrey et al. 2007) 21 ± 0.8 
DM1 TCR/B*4403-EENL (Archbold, Macdonald et al. 2009) 9.4 ± 0.2 
LC13 TCR/B*0801-EBNA (Borg, Ely et al. 2005; Cole, Pumphrey et al. 2007) 9 ± 0.4 
CF34 TCR/B*0801-EBNA (Gras, Burrows et al. 2009) 8.9 ± 1.3 
AS01 TCR/A*0201-GLC (Miles, Bulek et al. 2010) 8.1 ± 1 
TCRCMV/A*0201-pp65 (Gakamsky, Lewitzki et al. 2007) 6.3 ± 1 
DM1 TCR/B*4402-EENL (Archbold, Macdonald et al. 2009) 6.3 ± 0.3 
GRB TCR/B*2702-Flu (Cole, Pumphrey et al. 2007) 6 ± 0.1 
JM22 TCR/A*0201-GIL (Willcox, Gao et al. 1999; Cole, Pumphrey et al. 2007) 5 ± 0.2 
TK3 TCR/B*3501-HPVG (Gras, Chen et al. 2010) 2.2 ± 0.2 
G10 TCR/A*0201-SL9 (Lee, Stewart-Jones et al. 2004) 2.2 ± 0.5 
A6 TCR/A*0201-Tax (Ding, Baker et al. 1999; Cole, Pumphrey et al. 2007) 2 ± 0.7 
B7 TCR/A2-Tax (Davis-Harrison, Armstrong et al. 2005) 1.35 ± 0.04 
DM1 TCR/B4405-EENL (Archbold, Macdonald et al. 2009) 0.3 ± 0.1 
868 TCR/A*0201-SL9 (Varela-Rohena, Molloy et al. 2008) 0.13 ± 0.01 
 
 
3.1.3 Summary and Aims 
It has been proposed that the stronger TCR/pMHCI interaction dominates thereby 
maintaining CD8
+
 T-cell specificity and that CD8 can only initiate its effects on signal 
transduction if the TCR/pMHCI interaction is of sufficient duration. This is consistent with 
the sequential engagement model of co-receptor function which proposes that the co-receptor 
is only recruited to the TCR once a stable TCR/pMHCI interaction has been established 
(Hampl, Chien et al. 1997; Madrenas, Chau et al. 1997). This led me to hypothesise that the 
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pMHCI/CD8 interaction must remain substantially weaker than the TCR/pMHCI interaction 
in order to maintain CD8
+
 T-cell specificity and efficient co-receptor function.  
 
Here I intend to probe the functional significance of the low solution binding affinity of the 
pMHCI/CD8 interaction in maintaining the specificity of TCR/pMHCI binding at the T-cell 
surface and pMHCI induced T-cell activation. In order to do this, I will use chimeric pMHCI 
molecules with super-enhanced affinities for CD8 that lie within the typical range for agonist 
TCR/pMHCI interactions (KD ~10 M). 
 
3.2 Results 
3.2.1 Generation of MHCI molecules with super-enhanced CD8 binding affinity 
Tetrameric fusion molecules comprising the α1/α2 peptide binding platform of HLA A*0201 
(A2 from hereon) and the α3 domain of H2-Kb (A2/Kb from hereon) enable the monitoring of 
CD8
+
 T-cell responses in A2 transgenic mice (Choi, Palmowski et al. 2002). This reflects a 
requirement for the murine MHCI α3 domain to engage murine CD8 (Purbhoo, Boulter et al. 
2001), thus enabling A2/K
b
 reagents to stain murine CD8
+
 T-cells with lower affinity 
TCR/pMHCI interactions (so-called ‘low avidity’ CD8+ T-cells) (Choi, Chen et al. 2003). 
The A2/K
b
 heavy chain folded with human β2m interacts strongly with human CD8 (KD ~10 
μM; compared to HLA A2 which binds to CD8 with a KD ~ 146 μM) but exhibits faithful 
HLA A2-restricted TCR binding properties (Choi, Chen et al. 2003; Wooldridge, van den 
Berg et al. 2005). Thus, fusing the murine α3 domain with A2 α1/α2 domains increases the 
strength of the pMHCI/CD8 interaction by approximately 15-fold without affecting the 
TCR/pMHCI interaction (Figure 3.1). 
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Figure 3.1: Wild-type and super enhanced pMHCI/CD8 binding affinity. A2/ K
b
 binding 
affinity to CD8 is increased to approximately 15 times the normal A2/CD8 binding when 
analysed by Surface Plasma Resonance. 
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3.2.2 Super-enhanced CD8 binding results in non-specific TCR/pMHCI interactions 
Monomeric pMHCI complexes cannot be used to examine TCR/pMHCI binding at the cell 
surface due to the extremely short half-life of such interactions. Increasing the valency of 
these molecules by avidin/biotin-based tetramerization overcomes this limitation and 
produces reagents that are invaluable for the identification and characterization of antigen-
specific CD8
+
 T-cells (Altman, Moss et al. 1996; Wooldridge, Lissina et al. 2009). Indeed, it 
is well established that wild-type tetrameric pMHCI reagents bind to cell surface TCR with 
exquisite specificity (Altman, Moss et al. 1996; Burrows, Kienzle et al. 2000). Thus, I 
generated A2/K
b
 tetrameric reagents to study the effect of super enhanced CD8 binding on 
the specificity of pMHCI ligand interactions at the cell surface.  
 
Wild-type pMHCI tetrameric reagents bearing cognate peptide stained an HLA A2 restricted 
CD8
+
 T-cell clone (MEL5) specific for the Melan-A-derived epitope ELAGIGILTV (residues 
26-35) (Figure 3.2 A). Non-cognate A2 tetramers folded around the human telomerase 
reverse transcriptase (hTERT)-derived epitope ILAKFHWL (residues 540-548) failed to stain 
the MEL5 CD8
+
 T-cell clone. However, A2/K
b
 ILAKFLHWL tetramers stained all 
ELAGIGILTV specific CD8
+
 T-cells.  To examine this effect in more detail, I stained fresh 
human PBMC with HLA A2 and A2/K
b
 tetramers.  Antigen-specific CD8
+
 T-cell populations 
were not identified in PBMC from healthy donors with either the A2 ELAGIGILTV or A2 
ILAKFLHWL tetramers (Figure 3.2 B). In contrast, both the A2/K
b
 ELAGIGILTV and 
A2/K
b
 ILAKFLHWL tetramers stained >85% of CD8
+
 T-cells in PBMC (Figure 3.2 B). 
Taken together, these data indicate that the exquisite specificity of tetrameric pMHCI 
reagents is lost when the strength of the pMHCI/CD8 interaction is increased by ~15-fold.  
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Figure 3.2: The exquisite specificity of pMHCI tetramer staining is lost when the 
strength of the pMHCI/CD8 interaction is increased by ~15-fold. (A) 5 x 10
4
 of the 
MEL5 CD8
+
 T-cell clone specific for the Melan-A-derived epitope ELAGIGILTV (residues 
26-35) was stained with 1 μg of the PE-conjugated tetramers A2 ELAGIGILTV, A2/Kb 
ELAGIGILTV, A2 ILAKFLHWL or A2/K
b
 ILAKFLHWL in 40 μl PBS for 15 minutes at 
37°C. Cells were then stained with either FITC-conjugated anti-human CD8, and 7-AAD for 
30 minutes on ice, washed twice and resuspended in PBS. Data were acquired using a 
FACSCalibur flow cytometer and analyzed with FlowJo software. (B) 2.5 x 10
5
 PBMC were 
resuspended in 40 μl PBS, then stained with 1 μg of either PE-conjugated tetramers A2 
ILAKFLHWL, A2/K
b
 ILAKFLHWL, or BV421-conjugated tetramers A2 ELAGIGILTV, or 
A2/K
b
 ELAGIGILTV for 15 minutes at 37°C. Each sample was subsequently stained with 
FITC-conjugated anti-human CD8, PerCP or PE-Cy7-conjugated anti-human CD3, APC-
conjugated anti-human CD4 and 7-AAD or LIVE/DEAD fixable Aqua for 30 minutes on ice, 
washed twice and resuspended in PBS. Data were acquired using a FACSCanto II flow 
cytometer and analysed with FlowJo software by gating on the live CD3
+
 population. 
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Therefore, the low solution affinities of the wild-type pMHCI/CD8 interaction are essential in 
maintaining pMHCI binding specificity at the cell surface. 
 
3.2.3 A2/K
b
 tetramers bind the majority of CD8
+
 T-cells in peripheral blood 
Non-cognate A2/K
b
 tetramers bind ~80% of the CD8α+ population in peripheral blood 
(Figure 3.2 B). Although CD8α is predominantly found on the surface of αβ TCR+ CD8+ T-
cells, it is also found on the surface of other lymphocytes, most notably some γδ T-cells and 
natural killer (NK) cells. Therefore, it was necessary to determine the identity of the CD8α+ 
cells that stained with A2/K
b
 tetramers. Staining of fresh ex-vivo PBMC isolated from healthy 
HLA A2
+
 donors revealed that CD8α was expressed on approximately 39%, 54% and 32% of 
the αβ TCR+, NK cell and γδ TCR+ populations respectively, with some variation between 
donors (Figure 3.3 A). The majority of γδ TCR+ (~93.6%) and NK cells (~77%) failed to 
stain with the A2/K
b
 ILAKFLHWL tetramer and no significant binding was observed with 
the corresponding HLA A2 tetramer (Figure 3.3 B). However, the vast majority of αβ 
TCR
+
/CD8
+
 cells within the lymphocyte population stained non-specifically with the A2/K
b
 
ILAKFLHWL tetramer (Figure 3.3 C). I hypothesised that most γδ TCR+ cells and NK cells 
might fail to bind A2/K
b
 tetramers because they express the CD8αα homodimer rather than 
the CD8αβ heterodimer, which is expressed exclusively on the surface of αβ TCR+/CD8+ T-
cells. Thus, a 293T cell line that expressed CD8αα was generated (Figure 3.4 A) to examine 
the ability of A2/K
b
 tetramers to bind this homodimeric form of the CD8 co-receptor on the 
cell surface. In contrast to both HLA A2 and HLA A2 D227K/T228A tetramers, which 
exhibit normal and abrogated interactions with CD8 respectively, A2/K
b
 tetramers bound to 
most (74.3%) of the CD8αα+ 293T cell transfectants (Figures 3.4 A&B); no binding was 
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Figure 3.3: A2/K
b
 tetramers bind the majority of αβ TCR+/CD8+ T-cells in peripheral 
blood. (A) 2.5 x 10
5
 PBMC from an A2
+
 donor were stained with PerCP-conjugated anti-
human CD8, 7-AAD and either FITC-conjugated anti-human αβ TCR, APC-conjugated anti-
human CD56 or PE-conjugated anti-human γδ TCR for 30 minutes on ice, washed twice and 
resuspended in PBS. (B) 2.5 x 10
5
 A2
+
 PBMC were stained with 10 μg/ml of the PE-
conjugated tetramers A2 ILAKFLHWL or A2/K
b
 ILAKFLHWL for 20 minutes at 37°C. 
After washing, cells were subsequently stained with 7-AAD and either FITC-conjugated anti-
human γδ TCR or FITC-conjugated anti-human CD56 for 30 minutes on ice, washed twice 
and resuspended in PBS. (C) 2.5 x 10
5
 A2
+
 PBMC were stained with 10 μg/ml of the PE-
conjugated tetramers A2 ILAKFLHWL or A2/K
b
 ILAKFLHWL for 20 minutes at 37°C. 
After washing, cells were stained with APC-conjugated anti-human CD8, FITC-conjugated 
anti-human αβ TCR and 7-AAD for 30 minutes on ice, washed twice and resuspended in 
PBS. In A, B and C, data were acquired using a FACSCalibur flow cytometer and analyzed 
with FlowJo software.  
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Figure 3.4: Non-specific A2/K
b
 tetramer binding is influenced by CD8 cell surface 
density. (A&B) 2 x 10
5
 non-transfected or CD8αα transfected 293T cells were incubated +/- 
10 μg/ml of the PE-conjugated tetramers A2 D227K/T228A ILAKFLHWL, A2 
ILAKFLHWL or A2/K
b
 ILAKFLHWL for 20 minutes at 37°C, then stained with 7-AAD and 
either FITC-conjugated anti-human CD8 or PE-conjugated anti-human CD8β for 30 minutes 
on ice, washed twice and resuspended in PBS. (C) 2.5 x 10
5
 PBMC were stained with PerCP-
conjugated anti-human CD8, 7-AAD and either FITC-conjugated anti-human αβ TCR, APC-
conjugated anti-human CD56 or PE-conjugated anti-human γδ TCR for 30 minutes on ice, 
washed twice and resuspended in PBS. In A, B and C, data were acquired using a 
FACSCalibur flow cytometer and analyzed with FlowJo software. 
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observed in the absence of CD8αα surface expression (Figure 3.4 A). Thus, A2/Kb tetramers 
are capable of binding to cell surface CD8αα. The question still remained as to why A2/Kb 
tetramers bind predominantly to the αβ TCR+/CD8+ T-cell population in peripheral blood and 
not to other cells that express CD8. Figure 3.4 B shows that A2/K
b
 tetramer staining is 
directly proportional to the level of CD8αα expression, such that only cells with a higher 
level of CD8αα expression stain with this reagent. Examination of PBMC from healthy 
donors revealed that αβ TCR+/CD8+ T-cells express high levels of CD8, whereas NK and γδ 
TCR
+
 cells express substantially lower levels (Figure 3.4 C). Therefore, increasing the 
strength of the pMHCI/CD8 interaction allows pMHCI ligand binding at the cell surface that 
can be mediated through the engagement of either CD8αα or CD8αβ. However, this result 
suggests that binding is only observed when cells express CD8 at levels above a certain 
threshold. Importantly, these data demonstrate that TCR expression is not required for cell 
surface binding of A2/K
b
 tetramers. 
 
3.2.4 A2/K
b
 tetramers activate CD8
+
 T-cell clones irrespective of TCR specificity 
It is well established that pMHCI tetramers can activate CD8
+
 T-cell clones bearing cognate 
TCR (as reviewed in (Wooldridge, Lissina et al. 2009). However, previous studies have 
shown that pMHCI tetrameric binding at the cell surface does not necessarily equate with 
activation by cell surface antigen (Purbhoo, Boulter et al. 2001; Schott and Ploegh 2002). To 
determine whether non-specific A2/K
b
 tetramer binding at the cell surface (Figures 3.2 - 3.4) 
could activate human CD8
+
 T-cell clones, ALF3 A2 restricted CD8
+
 T-cell clone specific for 
the Influenza A virus MP158-66 epitope GILGFVFTL was used (Cole, Edwards et al. 2010). 
Consistent with the findings above, when staining the ALF3 CD8
+
 T-cell clone with 
tetramers A2 ILAKFLHWL or A2/K
b
 ILAKFLHWL conjugated with either streptavidin-
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QDot605 or streptavidin-QDot800, no staining was observed with the A2 ILAKFLHWL 
whereas non–specific staining was observed with the A2/Kb ILAKFLHWL (Figure 3.5 A). 
On ligation, it is known that TCRs are down-regulated from the cell surface (Valitutti, Muller 
et al. 1995). This TCR down-regulation correlated with various functional readouts typical of 
CD8
+
 T-cell effector activity where both QDot 605 and QDot 800 A2/K
b
 ILAKFLHWL 
tetramers induced the release of MIP-1β non-specifically (Figure 3.5 B). Results similar to 
Figure 3.5 A&B were also obtained with tetramers conjugated to fluorochromes other than 
QDots (Appendix 1 Figure 4 A-F). This then eliminated the possibility of the tetramer 
fluorochrome being the cause for the non-specific activation by fluorochrome aggregation. 
Similar results were observed with SLYNTVATL-specific CD8
+
 T-cell clones 003 and 868 
bearing alternative cognate TCRs where non-cognate A2/K
b
 tetramers can induce release of 
IFN-γ, RANTES and CD107a (Appendix 1 Figure 4 D-F). Consistent with the staining 
patterns, the activation of CD8
+
 T-cells by non-cognate A2/K
b
 tetramers was less efficient 
than that induced by tetramers bearing the agonist peptide (Appendix 1 Figure 4 C-E). Thus, 
at least to some extent, the strong interaction between A2/K
b
 and CD8 can bypass the 
requirement for a specific TCR/pMHCI interaction and non-specifically activate human 
CD8
+
 T-cells. 
 
3.2.5 Cell surface-expressed A2/K
b
 activates CD8
+
 T-cells in the absence of cognate 
antigen 
To extend the investigation to the more natural situation of cell surface pMHCI presentation, 
C1R B-cells transfected with either HLA A2 or A2/K
b
 at similar cell surface MHCI densities 
were selected as targets for further experiments. Target cells expressing either HLA A2 or  
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Figure 3.5: Non-cognate A2/K
b
 tetramer induced activation is not influenced by 
flurochrome aggregation. (A) 5 x 10
4
 A2 restricted CD8
+
 T-cell clone ALF3 specific for the 
Influenza A virus MP158-66 epitope GILGFVFTL were stained with 10 μg/ml HLA A2 
ILAKFLHWL or A2/K
b
 ILAKFLHWL tetramer conjugated with either streptavidin-QDot605 
or streptavidin-QDot800 for 30 minutes at 37°C. After 2 washes with PBS, data were 
acquired using a modified FACSAria II and analysed with FlowJo software. (B) 2.5 x 10
4
 
ALF3 CD8
+
 T-cell clone were incubated with either HLA A2 ILAKFLHWL-Q605, A2/K
b 
ILAKFLHWL-Q605, HLA A2 ILAKFLHWL-Q800 or A2/K
b 
ILAKFLHWL-Q800 tetramer 
at 1 μg/ml overnight at 37°C. Supernatant was then harvested and assayed for MIP-1 
production by ELISA (R&D). The mean ± SD of two replicate assays is shown. 
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A2/K
b
 were incubated overnight with three HLA A2-restricted CD8
+
 T-cell clones (MEL5, 
003 and ILA1) with different peptide specificities (ELAGIGILTV, SLYNTVATL and 
ILAKFLHWL respectively). Targets that expressed HLA A2 failed to activate any of the 
CD8
+
 T-cell clones significantly above background (Figure 3.6 A). Remarkably, however, 
the A2/K
b
 targets stimulated MEL5, 003 and ILA1 CD8
+
 T-cell clones to produce significant 
amounts of MIP-1β in the absence of specific peptide (Figure 3.6 A). A2/Kb targets also 
elicited substantial levels of TNF-α and IFN-γ at titratable E:T ratios (Figure 3.6 B) and 
induced degranulation (Figure 3.6 C) in the absence of specific TCR/pMHCI interactions. 
 
3.2.6 Cell surface-expressed A2/K
b
 primes non-cognate CD8
+
 T-cell expansions 
Thymic output in healthy HLA A2
+
 individuals is known to generate a high frequency of 
naïve CD8
+
 T-cells that can recognize the self-antigen Melan-A26-35 (Zippelius, Pittet et al. 
2002); this system can be used to examine the priming of CD8
+
 T-cells directly ex-vivo 
(Salio, Palmowski et al. 2004). These observations were exploited to investigate the effect of 
super-enhanced pMHCI/CD8 binding on CD8
+
 T-cell priming. In priming experiments 
conducted with C1R target cells, the percentages of CD8
+
 T-cells specific for Melan-A26-35 
that were present after 10 days in culture were related to the context of the pMHCI/CD8 
interaction in which the cognate ELAGIGILTV peptide was presented. Thus, in the absence 
of a pMHCI/CD8 interaction (HLA A2 D227K/T228A C1R targets), only 1.5% of the CD8
+
 
T-cell population was specific for Melan-A26-35; in contrast, 5.6% and 5.7% of the CD8
+
 
population bound the HLA A2 ELAGIGILTV tetramer in the same experiment when priming 
was conducted with HLA A2 and A2/K
b
 C1R targets, respectively (Figure 3.7). Exposure to 
A2/K
b
 C1R targets also resulted in substantial expansions of the total CD8
+
 population 
(Figure 3.7). Similar results were obtained with multiple donors. Thus, target cells that 
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Figure 3.6: Cell surface-expressed A2/K
b
 activates CD8
+
 T-cell clones in the absence of 
cognate antigen. (A) 2.5 x 10
4
 MEL5, 003 or ILA1 CD8
+
 T-cell clones were incubated for 
12 hours at 37°C with 1 x 10
5
 C1R cells stably transfected to express equal levels of either 
A2 or A2/K
b
 at the cell surface. Supernatant was subsequently assayed for MIP-1β content by 
ELISA. The mean ± SD of two replicate assays is shown. (B) 2.5 x 10
4
 MEL5 were incubated 
for 12 hours at 37°C with 1 x 10
5
 C1R cells stably transfected to express either A2 or A2/K
b
 
at the cell surface. Supernatant was assayed for IFN-γ and TNF-α content by cytokine bead 
array. (C) CD107a expression by ILA1 and MEL5 following a 12 hour incubation at 37°C 
with C1R cells stably transfected to express either A2 or A2/K
b
 on the cell surface. For (A-
C), C1R cells were not previously pulsed with peptide. The mean ± SD of two replicate 
assays is shown. 
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Figure 3.7: Cell surface-expressed A2/K
b
 primes non-specific expansion of CD8
+
 cells. 1 
x 10
6
 A2
+
 PBMC were incubated with 2 x 10
5
 irradiated HLA A2 D227K/T228A, HLA A2 
or A2/K
b
 C1R cells that had previously been pulsed with 1 μM ELAGIGILTV (Melan-A26-35) 
peptide in R10. From day 3, IL-2 was added in increments to reach a maximum concentration 
of 200 IU/ml by day 10. Lines were subsequently stained with PE-conjugated HLA A2 
ELAGIGILTV tetramer followed by APC-conjugated anti-human CD8 and 7-AAD. Data 
were acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. 
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express MHCI molecules with super-enhanced CD8 binding properties can induce non-
specific expansions of CD8
+
 cells in the absence of cognate antigen. 
 
3.2.7 Non-specific A2/K
b
-mediated CD8
+
 T-cell activation and tetramer staining are not 
dependent on TCR restriction 
In earlier experiments, I demonstrated that A2/K
b
 tetramers bound to the majority of αβ 
TCR
+
CD8
+
 cells in PBMC derived from HLA A2
+
 donors (Figure 3.3). To exclude the 
possibility that this phenomenon was dependent on the presence of HLA A2-restricted TCRs, 
I performed staining experiments with HLA A2
-
 PBMC. As previously described, the A2/K
b
 
ILAKFLHWL tetramer bound non-specifically to the majority of CD8
+
 cells (Figure 3.8 A). 
Furthermore, A2/K
b
 tetramer binding favoured CD8
high
 cells and was abrogated by pre-
treatment with the anti-human CD8 mAb (clone DK25) (Figure 3.8 A). Thus, consistent with 
the data shown in Figure 3.4, non-specific A2/K
b
 tetramer binding is a CD8-mediated effect 
that is not dependent on the presence of HLA A2-restricted TCRs. In addition, I demonstrated 
in earlier experiments that A2/K
b
, both in soluble and cell-associated form, non-specifically 
activated HLA A2-restricted CD8
+
 T-cell clones (Figures 3.5 & 3.6). To confirm that these 
functional correlates of non-specific binding were similarly independent of HLA A2-
restricted TCR expression, the study was extended to test CD8
+
 T-cell clones restricted by 
other HLA molecules. Cell surface expressed A2/K
b
 activated all CD8
+
 T-cell clones 
regardless of restriction element (Figure 3.8 B). 
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Figure 3.8: Non-cognate A2/K
b
-mediated CD8
+
 T-cell clone activation and tetramer 
binding is not influenced by MHCI restriction. (A) 2.5 x 10
5
 PBMC were suspended in 
250 μl FACS buffer (2% FCS/PBS) and stained with FITC-conjugated anti-human A2 and 7-
AAD for 30 minutes on ice, then washed twice and resuspended in PBS. For pMHCI tetramer 
staining experiments, 2.5 x 10
5
 PBMC were suspended in 50 μl FACS buffer (2% FCS/PBS) 
and incubated +/- 10 μg/ml unconjugated anti-human CD8 for 20 minutes on ice, then stained 
with 10 μg/ml of the PE-conjugated tetramers HLA A2 ILAKFLHWL or A2/Kb 
ILAKFLHWL for 45 minutes on ice. After washing, cells were subsequently stained with 
APC-conjugated anti-human CD8 and 7-AAD, washed again and resuspended in PBS. Data 
were acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. (B) 
2.5 x 10
4
 CD8
+
 T-cell clones were incubated for 12 hours at 37°C with 1 x 10
5
 unpulsed C1R 
cells expressing either HLA A2 or A2/K
b
 on the cell surface. The following CD8
+
 T-cell 
clones were used: (i) the HLA A*6801-restricted clone c23, specific for the HIV-1 Tat-
derived epitope ITKGLGISYGR (residues 38-48); (ii) the HLA B*0702-restricted clone 
KD4, specific for the Epstein-Barr virus (EBV) EBNA3A-derived epitope RPPIFIRRL 
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(residues 379-387); (iii) the HLA B*0801-restricted clone LC13, specific for the EBV 
EBNA3A-derived epitope FLRGRAYGL (residues 339-347); and, (iv) the HLA B*3508-
restricted clone SB27, specific for the EBV BZLF1-derived epitope LPEPLPQGQLTAY 
(residues 52-64). Supernatant was subsequently assayed for MIP-1β content by ELISA. The 
mean ± SD of two replicate assays is shown. 
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3.3 Discussion 
CD8
+
 T-cells must be able to discriminate between very small numbers of foreign pMHCI 
within a sea of structurally related self peptide-MHCI molecules presented at the cell surface. 
CD8 binds to the non-polymorphic regions of the MHCI molecule (Gao, Tormo et al. 1997) 
and as a result has the potential to interact with any pMHCI molecule regardless of the 
peptide it presents. If the pMHCI/CD8 interaction was capable of independently initiating 
cell-cell recognition then the high density of pMHCI molecules on the nucleated cell surface 
would constantly initiate T-cell recognition. This is clearly not the case and it has been 
suggested that it is the low solution affinity of the pMHCI/CD8 interaction that prevents such 
non-specific activation (Wyer, Willcox et al. 1999). This led me to hypothesise that the 
pMHCI/CD8 interaction must remain substantially weaker than the TCR/pMHCI interaction 
in order to maintain CD8
+
 T-cell specificity and efficient co-receptor function.  
 
Here, I generated chimeric A2/K
b
 MHCI tetramers that increase the strength of the 
pMHCI/CD8 interaction by ~15-fold to probe the biophysical and functional significance of 
the low solution binding affinities observed for the pMHCI/CD8 interaction. Initially, I 
examined the effect of super-enhanced CD8 binding on pMHCI tetramer binding at the cell 
surface. Increasing the strength of the pMHCI/CD8 interaction by ~15-fold resulted in the 
total loss of pMHCI tetramer binding specificity. Thus, irrespective of restriction element and 
the presented peptide, A2/K
b
 tetramers bound to the surface of all CD8
+
 T-cell clones 
examined in this study and to the majority of CD8
+
 T-cells present within PBMC (Figures 
3.2, 3.3 & 3.8 A). In addition, A2/K
b
 tetramers bound to the cell surface in the absence of 
TCR expression (Figure 3.4) and non-specific binding was abrogated by pre-treatment with 
an anti-human CD8 antibody (Figure 3.8 A), thereby demonstrating that the observed loss of 
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pMHCI tetramer binding specificity was CD8-mediated and TCR-independent. These 
findings indicate that the low solution binding affinities observed for the pMHCI/CD8 
interaction are essential for the preservation of pMHCI ligand binding specificity at the cell 
surface.  
 
It has previously been documented that pMHCI tetramers are efficient activators of cognate 
CD8
+
 T-cell clones (reviewed in (Wooldridge, Lissina et al. 2009). However, pMHCI 
tetramer staining does not necessarily equate with cellular activation. Therefore, I examined 
the ability of A2/K
b
 to activate CD8
+
 T-cell clones. Notably, A2/K
b
 tetramers activated CD8
+
 
T-cell clones in a non-specific manner (Figure 3.5). Activation resulted in a full range of 
effector functions, including cytokine/chemokine release, degranulation and killing. Flow 
cytometric assessment of degranulation by analysis of CD107a mobilization revealed that 
CD8
+
 T-cell clones with higher surface expression of CD8 were the cells most likely to 
activate in response to A2/K
b
 molecules. These findings led me to examine the effects of cell-
surface presented antigen. Strikingly, exposure of PBMC to C1R target cells bearing A2/K
b
 
molecules caused a general non-specific expansion of CD8
+
 cells during the course of the 
experiment (Figure 3.7). Furthermore, A2/K
b
 C1R cells, unlike their wild-type HLA A2 
counterparts, were capable of stimulating effector function in all CD8
+
 T-cell clones tested 
regardless of specificity and MHCI restriction (Figure 3.6 & 3.8 B).  These findings cannot 
exclude the possibility that inclusion of the murine α3 domain induces conformational 
changes at the T-cell surface on binding to CD8 that favour non-cognate activation. However 
this seems unlikely as the TCR binding site is shown to be unaltered (Choi, Chen et al. 2003; 
Wooldridge, van den Berg et al. 2005). In addition, murine and human pMHCI/CD8αα co-
crystals exhibit similar binding orientations (Gao, Tormo et al. 1997; Kern, Teng et al. 1998). 
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These results are consistent with the observation that thymus leukaemia antigen (TL), which 
interacts strongly (KD = 12 μM) with cell surface CD8αα expressed by intraepithelial 
lymphocytes (IELs), can modulate T-cell responses independently of the TCR (Kern, Teng et 
al. 1998; Leishman, Naidenko et al. 2001; Tsujimura, Obata et al. 2003).  
 
The question still remained as to how does a super-enhanced pMHCI/CD8 interaction result 
in non-specific CD8
+
 T-cell activation? It has previously been demonstrated that an 
incremental increase in the pMHCI/CD8 interaction (HLA A2 Q115E) results in enhanced 
immunogenicity of cognate antigens and that this effect is mediated by enhanced early 
intracellular signal transduction (Cole and Gao 2004; Wooldridge, van den Berg et al. 2005). 
In contrast, the stimulatory properties of A2/K
b
 molecules exhibited no peptide specificity 
requirements whatsoever; indeed, cell surface-expressed A2/K
b
 was shown to activate even 
non-HLA A2-restricted CD8
+
 T-cell clones (Figure 3.8 B), thereby confirming that cognate 
TCR/pMHCI interactions are not required. Combined with the ability of A2/K
b
 to engage 
multiple CD8 molecules at the cell surface, these results suggest that A2/K
b
 cross-links CD8 
and induces activation in an ‘antibody-like’ manner. Indeed, this is consistent with previous 
studies demonstrating that antibody-induced CD8 cross-linking can induce T-cell signalling 
(Grebe, Clarke et al. 2004; Wooldridge, Lissina et al. 2007) and elicit downstream effector 
functions such as chemokine release (Wooldridge, Hutchinson et al. 2003); such effects are 
predictable given that the CD8α tail is coupled to p56lck, an essential component of the early 
intracellular signalling pathway (Veillette, Bookman et al. 1988). It is interesting to note that 
the murine pMHCI/CD8 interaction is significantly stronger (KD ~ 30 μM) than the 
equivalent human interaction (KD ~ 150μM) (Purbhoo, Boulter et al. 2001) but does not result 
in non-cognate CD8
+
 T-cell activation. It is therefore likely that a pMHCI/CD8 interaction 
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affinity threshold exists for the maintenance of CD8
+
 T-cell activation specificity. The 
strength of the murine pMHCI/CD8 interaction is 3-fold weaker than the strength of the 
interaction measured between A2/K
b
 and human CD8, thereby still operates at a level below 
this threshold.  
 
In summary, I have utilized chimeric MHCI molecules that exhibit a super-enhanced 
interaction with CD8 to probe the physical and functional significance of the low solution 
binding affinities previously described for the pMHCI/CD8 interaction. I found that 
increasing the strength of the pMHCI/CD8 interaction by ~15-fold resulted in: (i) total loss of 
pMHCI binding specificity at the cell surface; (ii) non-cognate pMHCI tetramer mediated 
activation; and, (iii) non-specific activation and proliferation triggered by cell surface-
expressed pMHCI molecules. Thus, the low solution binding affinity of the pMHCI/CD8 
interaction is essential for the preservation of pMHCI ligand binding specificity at the cell 
surface. Notably, my work highlights that pMHCI molecules with affinities for CD8 that lie 
within the typical range for agonist TCR/pMHCI interactions (KD ~10 μM) are able to 
activate CD8
+
 T-cells in the absence of a specific TCR/pMHCI interaction. Thus, the 
biophysical characteristics of the pMHCI/CD8 interaction are essential for the maintenance 
of CD8
+
 T-cell antigen specificity and T-cell homeostasis. 
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4 
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4.1 Introduction 
As previously discussed in Chapter 3, it is possible to induce CD8
+
 T-cell activation in the 
absence of a cognate TCR/pMHCI interaction using chimeric A2/K
b
 that exhibits a super-
enhanced affinity for CD8. The results presented in chapter 3 suggest that A2/K
b
 cross-links 
CD8 and induces activation in an “antibody-like” manner. As such I hypothesized that it 
would be possible to induce CD8
+
 T-cell activation independently of the TCR/pMHCI 
interaction using anti-CD8 antibodies. Anti-CD8 antibodies have been used extensively to 
examine the role of CD8 in CD8
+ 
T cell activation. However, as previous studies have 
yielded conflicting results, it is unclear from the literature whether anti-CD8 antibodies per se 
are capable of inducing effector function. Here I intend to examine the effects of multiple 
anti-CD8 antibodies on a panel of CD8
+
 T-cell clones with different specificities to address 
the apparent incongruity in the literature.  
 
4.1.1 Use of anti-CD8 antibodies to study the role of CD8 in T-cell activation 
Monoclonal antibodies recognise and bind to defined ‘epitopes’ with high affinity (KD < 10
-9
 
M) and specificity. In early studies, examining the behaviour of cells after the binding of 
specific antibody became a widely accepted method of studying the function of T cell surface 
antigens. Early studies showed that pre-incubation with anti-CD8 antibodies can block 
conjugate formation between effector and target cells (Norment and Littman 1988) and 
inhibit CD8
+
 T-cell activation in response to cognate pMHCI presented on the target cell 
surface (Nakayama, Shiku et al. 1979; Shinohara and Sachs 1979; Janeway 1992; Miceli and 
Parnes 1993). By cross-linking anti-CD8 antibodies using a secondary anti-IgG antibody, this 
resulted in the rapid phosphorylation of p56
lck
 thereby suggesting that cross-linking CD8 may 
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contribute directly to TCR triggering (Veillette, Bolen et al. 1989; Veillette, Zuniga-Pflucker 
et al. 1989; Luo and Sefton 1990). These findings provided key evidence that CD8 was 
important in the process of CD8
+
 T-cell activation. However, considerable heterogeneity 
between different CD8
+
 T-cells was apparent in terms of their ability to activate in the 
presence of anti-CD8 antibodies and, as a result, these reagents were used as tools to classify 
CD8
+
 T-cells as either CD8-dependent or CD8-independent (MacDonald, Glasebrook et al. 
1982). MacDonald et al suggested that the variations they observed were related to 
TCR/pMHCI affinity (as discussed in Chapter 5). In summary, anti-CD8 antibodies have 
been used to demonstrate that CD8 plays an important role in CD8
+
 T-cell activation and as 
tools to describe CD8
+
 T-cells as either ‘CD8-dependent’ or ‘CD8-independent’.  
 
4.1.2 Caveats of using anti-CD8 antibodies in the study of CD8 
Many studies have been performed using anti-CD8 antibodies and different tetrameric 
pMHCI complexes to study the role of CD8 in stabilising the TCR/pMHCI complex. These 
studies demonstrated that anti-CD8 antibodies can block the stable binding of tetrameric 
reagents to the cell surface (Daniels and Jameson 2000; Denkberg, Cohen et al. 2001; 
Campanelli, Palermo et al. 2002). However studies have been performed in the human and 
murine system that also highlight an enhancing effect of anti-CD8 antibodies on pMHCI 
tetramer binding (Murali-Krishna, Altman et al. 1998; Busch and Pamer 1999; Daniels and 
Jameson 2000; Devine, Hodsdon et al. 2004). To date, the precise mechanism of how anti-
CD8 antibodies may elicit varying effects when studying T-cells is not known. Anti-CD8 
antibodies are a rather blunt tool for dissecting the role of CD8 as these reagents are likely to 
affect all roles of the molecule. My laboratory has preferred to use point mutated MHCI with 
altered CD8 binding as these reagents specifically target the MHCI/CD8 interaction. Indeed 
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systems involving the use point mutated MHCI molecules were developed that fail to interact 
with CD8 (Potter, Rajan et al. 1989; Purbhoo, Boulter et al. 2001) and have allowed in-depth 
investigations into the role of CD8 in CD8
+
 T-cell activation.  
 
4.1.3 Can anti-CD8 antibodies induce CD8
+
 T-cell effector function? 
Antibody-mediated ligation of T-cell surface molecules, such as CD2, CD3 and CD28 (Clark, 
Law et al. 1988; Luhder, Huang et al. 2003), can result in effector function. In contrast, 
studies of antibody-mediated CD8 ligation in the absence of TCR engagement have yielded 
conflicting results. As previously discussed, early studies demonstrated that the induction of 
CD8 cross-linking at the cell surface can result in p56
lck
 phosphorylation similar to that seen 
with anti-CD3 antibodies (Veillette, Zuniga-Pflucker et al. 1989) and further studies showed 
that this cross-linking could elicit downstream effector functions, such as chemokine release 
(Wooldridge, Hutchinson et al. 2003) ERK1/2 phosphorylation and cytokine function  (Kim, 
Billard et al. 2010) and potent cytotoxicity (Tomonari and Spencer 1990). However, in 
conflict with these data, more recent studies suggest that CD8 ligation alone may actually 
deliver a negative signal (Grebe, Clarke et al. 2004; Abidi, Dong et al. 2008). Indeed Abidi et 
al studied specific serial analysis of gene expression (SAGE) genotypic analysis and 
highlighted that an anti-CD8 antibody can induce transcription in a CD8
+
 T-cell clone which 
is ultimately inhibitory to T-cell activation as it fails to induce NFAT-dependent 
transcription. However, the major caveat of this study was that the authors only studied a 
single CD8
+
 T-cell clone using a single anti-CD8 antibody (Abidi, Dong et al. 2008). These 
heterogeneous effects question the suitability of anti-CD8 antibodies for use in the 
characterisation of CD8 function (Jonsson, Boyce et al. 1989) and it is important that we 
understand these observations in more detail.  
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4.1.4 Summary and Aims 
To date, a cohesive explanation for these widely disparate findings with anti-CD8 antibodies 
has remained elusive. Furthermore, there has been no systematic study of the effects of 
multiple different anti-human CD8 antibodies on CD8
+
 T-cells with different TCR/pMHCI 
specificities. The aim of this study was to investigate the effect of cross-linking CD8 using 
anti-CD8 antibodies on T-cell function and the TCR/pMHCI interaction. I aimed to undertake 
a thorough study of the effects of anti-CD8 antibodies using multiple antibody clones and 
many different CD8
+ 
T-cells. I hoped that a comprehensive study might explain the wide 
variation in the results from other groups that have used these tools. 
 
4.2 Results 
4.2.1 Anti-CD8 antibodies can trigger T-cell effector function in the absence of TCR 
engagement 
Several studies suggest that antibody-mediated ligation of CD8 in the absence of TCR 
engagement can elicit downstream effector function (Veillette, Zuniga-Pflucker et al. 1989; 
Tomonari and Spencer 1990; Wooldridge, Hutchinson et al. 2003); however, others have 
reported the delivery of negative signals with this manipulation (Grebe, Clarke et al. 2004; 
Abidi, Dong et al. 2008). To reconcile these apparently disparate findings, I conducted a 
systematic study of the effects of multiple different anti-human CD8 antibodies on CD8
+
 T-
cells with several different specificities. For this purpose, I assembled a panel of anti-human 
CD8 antibodies that comprised six anti-CD8α antibodies (OKT8, SK1, MCD8, 32/M4, 
C8/144B and DK25) and one anti-CD8 antibody (2ST8.5H7). Six out of seven anti-human 
CD8 antibodies from the panel (SK1, MCD8, 32/M4, C8/144B, DK25 and 2ST8.5H7) did 
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not elicit any chemokine production when incubated with four different HLA A2-restricted 
CD8
+
 T-cell clones (ILA1, ALF3, MEL5 and MEL187.c5) with a total of three different 
specificities in the absence of specific pMHCI antigen (Figure 4.1 A-D). However, the anti-
CD8α antibody OKT8 induced MIP-1α, MIP-1 and RANTES release from all four HLA 
A2-restricted CD8
+
 T-cell clones (Figure 4.1 A-D) even when titrated down to a low 
concentration (1-100 µg/ml) (Figure 4.2 A&B). 
 
I extended my studies by measuring chemokine release by two non-HLA A2-restricted CD8
+
 
T-cell clones following incubation with each anti-human CD8 antibody. Both of these non-
HLA A2-restricted CD8
+
 T-cell clones produced MIP-1α, MIP-1 and RANTES in response 
to OKT8 but did not activate in the presence of the other antibodies tested (Figure 4.3). 
Remarkably, the highly antigen sensitive HLA B*3508-restricted EBV BZLF1-specific CD8
+
 
T-cell clone SB10 released >2000 pg/ml of each chemokine in response to OKT8 (Figure 4.3 
B). OKT8 was also incapable of staining the HLA DR*0101-restricted CD4
+
 T-cell clone C6 
(Figure 4.4 A) and failed to induce chemokine release from this clone (Figure 4.4 B-D). 
Thus, the stimulatory effects of OKT8 appear to be CD8
+
 T-cell-specific. 
 
The panel of seven anti-human CD8 antibodies was further tested in cytotoxicity assays with 
4 different CD8
+
 T-cell clones (MEL187.c5, ALF3, LC13 and SB10). Anti-human CD8 
antibodies incapable of inducing chemokine release failed to elicit cytotoxic activity in any of 
these four CD8
+
 T-cell clones (Figure 4.5). In contrast, SB10 CD8
+
 T-cell exhibited  
Chapter 4 
 
163 
 
 
Figure 4.1: Antibody-mediated CD8 ligation can trigger chemokine release from HLA 
A2-restricted CD8
+
 T-cells. 3 x 10
4
 ILA1 CD8
+
 T-cells (A), ALF3 CD8
+
 T-cells (B), MEL5 
CD8
+
 T-cells (C) or MEL187.c5 CD8
+
 T-cells (D) were incubated for 18 hours with each of 
the following individual anti-human CD8 antibodies in parallel: 100 g/ml OKT8, 6.25 
g/ml SK1, 50 g/ml MCD8, 100 g/ml 32/M4, 100 g/ml C8/144B, 25 g/ml DK25 and 
100 g/ml 2ST8.5H7 (CD8). The maximum possible antibody concentrations were used, 
determined by the concentration of the commercially available preparation in each case. For 
each CD8
+
 T-cell clone, 3 x 10
4
 C1R-A2 B-cells pulsed with cognate peptide at 10
-7 
M were 
used as positive controls. Supernatant was harvested and assayed for MIP-1α, MIP-1 and 
RANTES by ELISA. The mean ± SD of two replicate assays is shown. 
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Figure 4.2: OKT8 activity is still detectable at low antibody concentrations. 3 x 10
4
 (A) 
ALF3 or (B) MEL187.c5 were incubated with various concentrations of anti-human CD8 
antibody OKT8 (0-100 µg/ml) for 18 hours @ 37°C. For each CD8
+
 T-cell clone, 3 x 10
4
 
C1R-A2 B-cells pulsed with cognate peptide at 10
-7 
M were used as positive controls. 
Supernatant was harvested and assayed for MIP-1α, MIP-1 and RANTES by ELISA. 
Similar data was obtained for ILA1 and MEL5. The mean ± SD of two replicate assays is 
shown. 
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Figure 4.3: Antibody-mediated CD8 ligation can trigger chemokine release from non-
HLA A2-restricted CD8
+
 T-cells. 3 x 10
4
 LC13 CD8
+
 T-cells (A) or SB10 CD8
+
 T-cells (B) 
were incubated for 18 hours @ 37°C with each of the following individual anti-human CD8 
antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml SK1, 50 μg/ml MCD8, 100 μg/ml 
32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 μg/ml 2ST8.5H7 (CD8). For each 
CD8
+
 T-cell clone, 3 x 10
4
 HLA-matched B-cells pulsed with cognate peptide at 10
-7 
M were 
used as positive controls. Supernatant was harvested and assayed for MIP-1α, MIP-1 and 
RANTES by ELISA. The mean ± SD of two replicate assays is shown. 
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Figure 4.4: OKT8 activity is specific for CD8
+
 T-cells. (A) 5 x 10
4
 MEL5 CD8
+ 
T-cells or 
C6 CD4
+
 T-cells were stained with PE-conjugated anti-human CD4 (clone L200) at 4°C for 
25 minutes or incubated with 100 μg/ml unconjugated OKT8 at 4°C for 25 minutes, washed 
twice and incubated with FITC-conjugated anti-mouse IgG (serum IgG) at 4°C for a further 
25 minutes. Data were acquired using a FACSCalibur flow cytometer and analyzed using 
FlowJo software. (B-D) 3 x 10
4 
CD4
+ 
C6 T-cells were incubated for 18 hours @ 37°C with 
each of the following individual anti-human CD8 antibodies in parallel: 100 μg/ml OKT8, 
6.25 μg/ml SK1, 50 μg/ml MCD8, 100 μg/ml 32/M4, 100 μg/ml C8/144B (144B), 25 μg/ml 
DK25 and 100 μg/ml 2ST8.5H7 (CD8). The maximum possible antibody concentrations 
were used, determined by the concentration of the commercially available preparation in each 
case; the anti-human CD3 antibody UCHT1 (10 μg/ml) served as a positive control. 
Supernatant was harvested and assayed for MIP-1α (B), MIP-1 (C) and RANTES (D) by 
ELISA. The mean ± SD of two replicate assays is shown. 
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Figure 4.5: Cytotoxic activity triggered by the anti-human CD8 antibody OKT8.  2 x 10
3
 
LC13 CD8
+
 T-cells (A) or SB10 CD8
+
 T-cells (B) were incubated with each of the following 
individual anti-human CD8 antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml SK1, 50 
μg/ml MCD8, 100 μg/ml 32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 μg/ml 
2ST8.5H7 (CD8). The anti-human CD3 antibody UCHT1 (10 μg/ml) was used as a positive 
control. Cytotoxicity assays were then performed over a period of 18 hours @ 37°C as 
described in the Materials & Methods using 
51
Cr-labelled C1R-A2 B-cells as targets. The 
mean ± SD of three replicate assays is shown. 
 
 
 
 
 
 
 
Chapter 4 
 
168 
 
substantial cytotoxicity in response to stimulation with OKT8; lower levels of specific lysis 
were also induced in CD8
+
 T-cell clones LC13 (3.18%), ALF3 (5.1%) and MEL187.c5 
(3.8%) (Figure 4.5). These results are consistent with a previous study that describes an anti-
mouse CD8 antibody, KT112, capable of inducing cytotoxicity (Tomonari and Spencer 
1990). Collectively, these data indicate that considerable heterogeneity exists in the ability of 
anti-CD8 antibodies to activate CD8
+
 T-cells.  
 
4.2.2 OKT8 induces chemokine secretion in the absence of cytokine secretion 
Next, I examined the ability of antibody-mediated CD8 ligation to elicit cytokine release by 
CD8
+
 T-cells in the absence of TCR engagement. As expected, the anti-human CD8 
antibodies that did not elicit chemokine release or cytotoxic activity (SK1, MCD8, 32/M4, 
C8/144B, DK25 and 2ST8.5H7) also failed to induce IFN-, TNF-α or IL2 release (Figure 
4.6). Interestingly, OKT8 similarly failed to elicit cytokine production from the majority of 
CD8
+
 T-cell clones tested (Figure 4.6). Importantly, chemokine and cytokine assays were 
performed using the same supernatant, thereby confirming that OKT8 stimulated CD8
+
 T-
cells to secrete chemokines in the absence of cytokine production; one exception to this 
dichotomy occurred with CD8
+
 T-cell clone SB10, which released IFN- in response to 
treatment with OKT8. These data suggest that OKT8-mediated CD8 ligation delivers a signal 
that falls below the threshold required for cytokine production in most CD8
+
 T-cells.   
 
4.2.3 Neither secondary antibody cross-linking nor PHA/IL-15 treatment alters the 
functional phenotype of anti-human CD8 antibodies 
To probe the possibility that the degree of cross-linking mediated by each of the anti-human  
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Figure 4.6: Antibody-mediated chemokine release occurs in the absence of cytokine 
release. 3 x 10
4
 ILA1, ALF3, MEL5, MEL187.c5, LC13 or SB10 CD8
+
 T-cells were 
incubated for 18 hours @ 37°C with each of the following individual anti-human CD8 
antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml SK1, 50 μg/ml MCD8, 100 μg/ml 
32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 μg/ml 2ST8.5H7 (CD8). The anti-
human CD3 antibody UCHT1 (10 μg/ml) was used as a positive control. Supernatant was 
harvested and assayed for IFN- (A), TNF-α (B) and IL2 (C) by CBA. The mean ± SD of two 
replicate assays is shown. 
 
 
 
Chapter 4 
 
170 
 
CD8 antibodies tested could explain the functional heterogeneity observed between these 
reagents, I performed activation experiments with the addition of secondary antibodies. 
Secondary cross-linking of OKT8 increased the level of MIP-1α, MIP-1 and RANTES 
release by ILA1, ALF3, MEL187.c5, MEL5, LC13 and SB10 CD8
+
 T-cells above that 
observed with OKT8 alone (Figure 4.7 and data not shown). However, secondary antibody-
mediated cross-linking did not reverse the phenotype of the non-activating anti-human CD8 
antibodies (Figure 4.7). 
 
I also examined the effect of PHA/IL-15 treatment on the ability of anti-human CD8 
antibodies to elicit effector function from CD8
+
 T-cells in healthy donor PBMCs. PHA is 
capable of cross-linking glycosylated proteins at the T-cell surface. The seven anti-human 
CD8 antibodies tested did not elicit significant levels of effector function from CD8
+
 T-cells 
in untreated PBMCs (Figure 4.8 A). The six non-activating anti-human CD8 antibodies also 
failed to induce significant levels of CD8
+
 T-cell activation in PBMCs cultured for 7 days in 
PHA/IL-15 (Figure 4.8 B). In contrast, OKT8 activated CD8
+
 T-cells in PHA/IL-15-
stimulated PBMCs to release MIP-1 and degranulate as measured by surface mobilization of 
CD107a. Interestingly, OKT8 also induced IFN- and TNF-α production by CD8+ T-cells in 
PHA/IL-15-stimulated PBMCs, thereby suggesting that this treatment regimen synergistically 
lowered the activation threshold of the responding cells. OKT8 failed to activate CD4
+ 
T-
cells in PHA/IL-15-stimulated PBMCs (Figure 4.8 C) consistent with previously discussed 
data (Figure 4.4).  
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Figure 4.7: Secondary cross-linking does not alter the functional phenotype of anti-
human CD8 antibodies. 3 x 10
4
 ILA1 CD8
+
 T-cell clone were incubated with each of the 
following individual anti-human CD8 antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml 
SK1, 50 μg/ml MCD8, 100 μg/ml 32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 
μg/ml 2ST8.5H7 (CD8). The positive control comprised 3 x 104 C1R-A2 B-cells pulsed 
with cognate peptide at 10
-7 M. Antibodies were then crosslinked with the addition of 5 μl 
anti-mouse IgG antibody (serum IgG) and incubated for 18 hours at 37°C in a 5 % CO2 
atmosphere. Supernatant was harvested and assayed for MIP-1α (A), MIP-1 (B) and 
RANTES (C) by ELISA. Secondary cross-linking of OKT8 increased the levels of all 
analytes measured and also increased the levels of anti-CD3 antibody induced chemokine 
release. Similar results were obtained with all other CD8
+
 T-cell clones examined: ALF3, 
MEL5, MEL187.c5, LC13 and SB10. The mean ± SD of two replicate assays is shown. 
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4.2.4 OKT8 enhances pMHCI tetramer staining 
I next tested the effects of anti-human CD8 antibodies on the staining of ILA1, ALF3, 
MEL187.c5 and MEL5 CD8
+
 T-cells with cognate pMHCI tetramers. Three anti-human CD8 
antibody clones (SK1, DK25 and 2ST8.5H7) inhibited tetramer staining; clones MCD8, 
32/M4 and C4/144B had little or no effect on staining. In contrast, pre-incubation with OKT8 
enhanced cognate pMHCI tetramer staining of all four CD8
+
 T-cell clones (Figure 4.9). Thus, 
OKT8 can enhance the binding of pMHCI tetramers in a range of systems. These findings 
suggested that OKT8 might facilitate the identification of antigen-specific CD8
+
 T-cells 
within mixed cell populations. To test this idea, I examined pMHCI tetramer staining of 
CD8
+
 T-cell lines raised against the HLA A2-restricted EBV BMLF1-derived epitope 
GLCTLVAML (residues 259-267). OKT8 enhanced the staining intensity of cognate CD8
+
 
T-cells with HLA A2 tetramer folded around the GLCTLVAML peptide without concomitant 
increases in non-cognate tetramer binding (Figure 4.10 A&B). No increase in the percentage 
of tetramer
+
 cells was observed in this viral system (Figure 4.10 A&B) which was thought to 
reflect the high affinity interaction with pMHCI which is typical of anti-viral TCRs (Cole, 
Pumphrey et al. 2007). 
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Figure 4.8: Functional phenotype of antibodies not affected by PHA/IL-15 treatment of 
cells. PBMCs were harvested from healthy donors and cultured either without (A) or with 
(B&C) 1 μg/ml PHA and 25 ng/ml IL-15 for 7 days, then washed and cultured overnight in 
R2 medium. 5 x 10
4
 PBMCs were then incubated for 18 hours @ 37°C with each of the 
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following individual anti-human CD8 antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml 
SK1, 50 μg/ml MCD8, 100 μg/ml 32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 
μg/ml 2ST8.5H7 (CD8). The anti-human CD3 antibody UCHT1 (10 μg/ml) was used as a 
positive control. CD8
+
 T-cell effector functions were measured by intracellular cytokine 
staining and surface CD107a mobilization as described in the Materials & Methods. Data 
were acquired using a modified FACSAriaII™ flow cytometer and analyzed with FlowJo 
software. Results obtained by gating on either the CD8
+ 
(A&B) or CD4
+
 (C) population are 
shown and are representative of two separate experiments. Differences in the background 
levels of CD8
+
 T-cell activation were observed with the different anti-human CD8 antibodies 
tested in A&B which may reflect heterogeneity in CD8
+
 PBMC population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
175 
 
 
Figure 4.9: Anti-human CD8 antibodies can either enhance or inhibit the binding of 
pMHCI tetramers. 5 x 10
4
 ILA1 (A), ALF3 (B), MEL5 (C) or MEL187.c5 (D) CD8
+
 T-cell 
clones were preincubated at 4°C for 25 minutes with each of the following individual anti-
human CD8 antibodies in parallel: 100 μg/ml OKT8, 6.25 μg/ml SK1, 50 μg/ml MCD8, 100 
μg/ml 32/M4, 100 μg/ml C8/144B, 25 μg/ml DK25 and 100 μg/ml 2ST8.5H7 (CD8). CD8+ 
T-cells were subsequently stained with cognate PE-conjugated HLA A2 tetramers (25 μg/ml) 
and 5 μl 7-AAD at 37°C for 15 minutes, washed twice and resuspended in PBS. Data were 
acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. Relative 
MFI values with respect to pMHCI tetramer staining in the absence of pre-incubation with 
anti-CD8 antibody are shown. Fluorescence in the absence of added cognate tetramer (con) is 
shown in each case. Results shown are representative of four separate experiments using 
ILA1 and ALF3, and six separate experiments using MEL5 and MEL187.c5. 
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Figure 4.10: OKT8 enhances pMHCI tetramer staining in a mixed population. (A&B) 5 
x 10
4
 cells from a CD8
+
 T-cell line primed with the EBV BMLF1-derived epitope 
GLCTLVAML (residues 259-267) were either mock treated or incubated with 100 μg/ml 
OKT8 at 4°C for 25 minutes, then stained with either (A) HLA A2-ELAGIGILTV (non-
cognate) or (B) HLA A2-GLCTLVAML (cognate) APC-conjugated tetramer (25 μg/ml each) 
at 37°C for 15 minutes. (C&D)  5 x 10
4
 cells from a CD8
+
 T-cell line primed with the Melan-
A/MART-1-derived epitope ELAGIGILTV (residues 26-35) were either mock treated or 
incubated with 100 μg/ml OKT8 at 4°C for 25 minutes, then stained with either (C) HLA A2-
Chapter 4 
 
177 
 
FLAGIGILTV or (D) HLA A2-ELTGIGILTV PE-conjugated tetramer (25 μg/ml each) at 
37°C for 15 minutes. Cells were then stained with 5 μl amine-reactive fluorescent dye 
LIVE/DEAD Fixable Aqua. 1 μl Pacific Blue-conjugated anti-human CD14, 1 μl Pacific 
Blue-conjugated anti-human CD19, 3 μl PE-Cy5.5–conjugated anti-human CD4 and 3 μl 
FITC-conjugated anti-human CD8 at 4°C for 20 minutes. Data were acquired using a 
FACSCantoII flow cytometer and analyzed with FlowJo software. 
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Next, I hypothesized that OKT8-mediated enhancement of TCR/pMHCI binding at the cell 
surface might have beneficial effects on pMHCI tetramer staining with low affinity ligands, 
an effect that could prove very useful for the detection of T-cells with TCRs that bind weakly 
to cognate antigen, such as those that appear to predominate in anti-cancer and autoimmune 
responses (Cole, Pumphrey et al. 2007; Cole, Edwards et al. 2010). To test this hypothesis, I 
used two monoclonal CD8
+
 T-cell systems and a series of altered peptide ligands that vary in 
their affinity for cognate TCR by over 5-fold (Table 4.1 & Figure 4.11). Pre-incubation with 
OKT8 enhanced staining efficiency with all variant pMHCI tetramers, including low affinity 
variants (Table 4.1 & Figure 4.12). Consistent with this finding I also observed that OKT8 
increased both the staining intensity and percentage of antigen specific CD8
+
 T-cells detected 
when CD8
+
 T-cell lines raised against the HLA A2-restricted Melan-A/MART-1-derived 
epitope ELAGIGILTV (residues 26-35) were stained with HLA A2 tetramers folded around 
the low affinity peptide variants FLAGIGILTV or ELTGIGILTV (Figure 4.10 C&D).  
 
4.2.5 OKT8 enhances TCR/pMHCI on-rates at the cell surface 
To examine how OKT8 enhances antigen binding at the CD8
+
 T-cell surface in more detail, I 
examined the effects of this antibody on TCR/pMHCI kinetics using pMHCI tetramers. 
Differences in tetramer off-rates were minimal. However, pretreatment of CD8
+
 T-cells with 
OKT8 resulted in a significant increase in the TCR/pMHCI on-rate at the cell surface in each 
CD8
+
 T-cell clone tested (Figure 4.13). In contrast, DK25 inhibited pMHCI tetramer binding 
at the cell surface (Figure 4.13 B). OKT8 antibody-induced enhancement of pMHCI tetramer 
on-rates was also apparent with CD8-null tetramers (Figure 4.13 C). Collectively, these data  
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Figure 4.11: Surface plasmon resonance measurements of MEL5 and MEL187.c5 TCR 
binding to peptide variants complexed with HLA A2. (A-E) SPR equilibrium binding of 
soluble MEL5 TCR to HLA A2-ELAGIGILTV (A), HLA A2-FLAGIGILTV (B), HLA A2-
ELTGIGILTV (C), HLA A2-ELAGIGIITV (D) and HLA A2-FLAGIGIITV (E). (F-J) SPR 
equilibrium binding of soluble MEL187.c5 to HLA A2-ELAGIGILTV (F), HLA A2-
FLAGIGILTV (G), HLA A2-ELTGIGILTV (H), HLA A2-ELAGIGIITV (I) and HLA A2-
FLAGIGIITV (J). The mean response for each concentration is plotted (n = 3). The 
equilibrium dissociation constant (KD) values were calculated assuming 1:1 Langmuir 
binding and plotted using a nonlinear curve fit (y = (P1x)/(P2 + x)). 
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 MEL5 MEL5 MEL5 MEL187.c5 MEL187.c5 MEL187.c5 
Peptide KD  
(µM) 
 
Tetramer 
only (MFI) 
OKT8 + 
Tetramer 
(MFI) 
KD  (µM) 
 
Tetramer 
only (MFI) 
OKT8 + 
Tetramer 
(MFI) 
ELAGIGILTV 17 ± 1 855 917 18 ± 1 353 418 
FLAGIGILTV 92 ± 1 194 227 30 ± 2 300 373 
ELTGIGILTV 82 ± 4 36 87 37 ± 1 128 181 
ELAGIGIITV 77 ± 3 123 236 36 ± 3 195 257 
FLAGIGIITV 75 ± 3 367 426 47 ± 2 246 311 
 
Table 4.1: OKT8 increases tetramer staining of MEL5 and MEL187.c5 CD8
+
 T-cells 
with low affinity pMHCI variants. Summary of equilibrium binding analysis of MEL5 and 
MEL187.c5 TCRs with pMHCI variants, and the effect of OKT8 on HLA A2 tetramer 
staining. Raw SPR data are shown in Figure 4.11; flow cytometry data are shown in Figure 
4.12. 
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Figure 4.12: OKT8 increases tetramer staining with low affinity pMHCI variants. 5 x 
10
4
 MEL5 (A-E) or MEL187.c5 (F-J) CD8
+
 T-cells were either mock treated or incubated 
with 100 μg/ml OKT8 at 4°C for 25 minutes, then stained with cognate or variant PE-
conjugated HLA A2 tetramers (25 μg/ml) as indicated and 5 μl 7-AAD (BD Biosciences) at 
37°C for 15 minutes. Data were acquired using a FACSCalibur flow cytometer and analyzed 
with FlowJo software. 
 
Chapter 4 
 
182 
 
 
Figure 4.13: OKT8 increases TCR/pMHCI on-rates at the cell surface. 5 x 10
5
/ml ILA1 
(A) or ALF3 (B&C) CD8
+
 T-cells were removed from culture, washed twice and 
resuspended in 100 μl PBS with or without 100 μg/ml OKT8 or 25 μg/ml DK25, then 
incubated at 4°C for 25 minutes. Cognate PE-conjugated HLA A2 tetramer was added in 
each case at 5 μg/ml; at various time points as indicated, 12 μl of cell suspension was 
removed and analyzed using a FACSCalibur flow cytometer with FlowJo software. In panel 
(C), the CD8-null (D227K/T228A) cognate HLA A2 tetramer was used (Purbhoo, Boulter et 
al. 2001). 
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indicate that OKT8 enhances pMHCI tetramer pMHCI tetramer staining by increasing the on-
rate Furthermore, OKT8 antibody-mediated augmentation of antigen binding at the cell 
surface occurs independently of the pMHCI/CD8 interaction. 
 
4.2.6 Stimulatory and Inhibitory anti-CD8 antibodies bind to different CD8 epitopes 
I have thus far demonstrated that there is considerable heterogeneity in the ability of anti-
CD8 antibodies to induce activation in the absence of TCR engagement, and in influencing 
subsequent pMHCI tetramer binding and CD8
+
 T-cell sensitivity to pMHCI antigen. 
Monoclonal antibodies bind to ‘defined’ epitopes with high affinity (KD <10
-9 
M). Thus, I 
hypothesized that anti-CD8 antibodies might exert differential effects because they bind to 
distinct CD8 epitopes. To address this, I performed a series of antibody-blocking 
experiments. Pre-incubation with OKT8 was shown to block the binding of further OKT8 
antibody demonstrating that the system can be used effectively to judge antibody binding 
sites (Figure 4.14) 
 
Pre-incubation with OKT8 did not block the subsequent binding of SK1, DK25 or anti-CD8 
antibody suggesting that OKT8 binds to a site that is distinct from the binding sites of these 
antibodies. Conversely, DK25, SK1 and anti-CD8 antibody did not significantly block the 
binding of OKT8 to the T-cell surface. Anti-CD8 antibodies that block pMHCI tetramer 
binding would appear to bind similar epitopes on CD8. This result is consistent with a 
previous report using a murine system (Devine, Hodsdon et al. 2004). Thus, antibody-
blocking experiments suggest that the unique enhancing properties of OKT8 are a result of  
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Figure 4.14: OKT8 binds to a distinct epitope compared to other CD8 antibodies. 5 x 
10
4
 ALF3 CD8+ T-cells were removed from culture, washed twice and resuspended in 40 μl 
PBS with or without 100 μg/ml OKT8, 6.25 μg/ml SK1, 25 μg/ml DK25 or 100 μg/ml 
2ST8.5H7 (CD8) then incubated at 4°C for 25 minutes. 3 μl of fluorochrome conjugated 
anti-human CD8 antibodies, APC-conjugated OKT8, PE-conjugated SK1, APC-conjugated 
DK25 or PE-conjugated CD8β, were then added and incubated at 4°C for 25 minutes along 
with LIVE/DEAD fixable violet, washed with PBS. Data were acquired using a 
FACSCantoII flow cytometer and analyzed with FlowJo software. 
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binding to a specific site on CD8, which is distinct from the site bound by blocking CD8 
antibodies (Figure 4.15). 
4.2.7 OKT8 F(ab´)2 fragments can enhance tetramer staining and elicit T-cell effector 
function 
Antibodies can be digested by papain or pepsin to produce Fab or F(ab´)2 fragments, 
respectively. These enzymatically generated fragments have been used extensively in the past 
to study the structure and function of antibodies. I examined the ability of OKT8 Fab and 
F(ab´)2 fragments to induce chemokine release in the absence of TCR engagement and 
enhance pMHCI tetramer staining. Fab fragments of OKT8 do not retain any ability to 
activate CD8
+
 T-cells or have any significant effect on pMHCI tetramer staining (Figure 4.16 
A&B). Interestingly, OKT8 F(ab´)2 fragments do retain some ability to enhance pMHCI 
tetramer activation and elicit chemokine release (Figure 4.16 A&B). OKT8 mediated effects 
are diminished by pepsin digestion but this is consistent with similar observations when anti-
human CD3 antibodies are digested by this enzyme (Figure 4.16 C) (Woodle, Thistlethwaite 
et al. 1991; Herold, Burton et al. 2003; Chatenoud and Bluestone 2007). Overall, it appears 
that whole OKT8 antibody is more efficient at exerting effects on pMHCI tetramer binding 
and CD8
+
 T cell activation. However, the data suggests that F(ab´)2 fragments are capable of 
cross-linking CD8 at the cell surface to some degree and that the ability of OKT8 to exert its 
effects are not entirely Fc´ dependant.  
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Figure 4.15: A schematic displaying binding sites of the enhancing anti-CD8 antibody 
OKT8. Mutational analysis of a single CD8 α chain reveals distinct distal binding site of 
OKT8 (red box) compared to other anti-CD8 antibodies (blue box) proximal to pMHCI 
(figure taken from © (Sanders, Fox et al. 1991)), originally published in the Journal of 
Experimental Medicine, 174(2): 371-9. 
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Figure 4.16: OKT8 F(ab´)2 fragments can enhance tetramer staining and elicit T-cell 
effector function. (A) 5 x 10
4
 MEL5 were either mock treated or incubated with 100 μg/ml 
OKT8, 100 μg/ml OKT8 Fab or 100 μg/ml OKT8 F(ab´)2 then subsequently stained with PE-
conjugated HLA A2 ELAGIGILTV tetramer (25 μg/ml) and stained with LIVE/DEAD® 
Fixable Aqua. Data were acquired using a FACSCantoII flow cytometer and analyzed with 
FlowJo software. (B) 3 x 10
4
 MEL5 or ALF3 were incubated with either 100 μg/ml OKT8, 
100 μg/ml Fab OKT8, 100 μg/ml F(ab´)2 OKT8 or 100 μg/ml OKT8 Fc´ for 18 hours @ 
37°C. Supernatant was harvested and assayed for MIP-1α, MIP-1 and RANTES by ELISA. 
(C) 3 x 10
4
 MEL5 or ALF3 were incubated with either 10 μg/ml OKT3 or 10 μg/ml F(ab´)2 
OKT3 for 18 hours @ 37°C. Supernatant was harvested and assayed for MIP-1α, MIP-1 and 
RANTES by ELISA. The mean ± SD of three replicate assays is shown and only MIP-1β is 
shown. 
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4.2.8 Anti-mouse CD8 antibodies can trigger T-cell effector function in the absence of 
TCR engagement 
To extend these findings beyond human systems, I examined the effect of the anti-mouse 
CD8α antibody CT-CD8a and the anti-mouse CD8 antibody CT-CD8b on pMHCI tetramer 
staining and CD8
+
 T-cell activation in the absence of TCR engagement. I observed that CT-
CD8a inhibited tetramer staining of mouse transgenic F5 CD8
+
 T-cells, whereas CT-CD8b 
enhanced tetramer staining of the same antigen-specific population (Figure 4.17 A). These 
results are consistent with previous findings (Wooldridge, Hutchinson et al. 2003). 
Interestingly, despite exerting opposite effects on pMHCI tetramer staining, both of these 
anti-mouse CD8 antibodies were capable of inducing MIP-1 production in the absence of 
TCR engagement from both naïve and antigen-exposed F5 CD8
+
 T-cells (Figure 4.17 B). 
This effect was shown to be CD8-specific and occurred in the absence of any concomitant 
IL2 release. The anti-mouse CD8 antibodies, 53.6.7 and KT112, were both shown to enhance 
pMHCI tetramer staining and induced small amounts of MIP-1β production (Figure 4.17 
A&B). Therefore, I identified three different phenotypes (Table 4.2) within a panel of four 
different anti-mouse CD8 antibodies which further underscores the considerable 
heterogeneity in this group of reagents.  
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Figure 4.17: Anti-mouse CD8 antibodies can exhibit the same phenotype as OKT8. (A) 5 
x 10
4
 naïve mouse transgenic F5 T-cells were either mock treated or incubated with 100 
μg/ml CT-CD8a, 100 μg/ml 53.6.7, 100 μg/ml CT-CD8b or 100 μg/ml KT112 at 4°C for 25 
minutes, then stained with 25 μg/ml PE-conjugated H-2Db tetramer folded around 
ASNENMDAM (cognate peptide) or KAVYNFATC (non-cognate peptide corresponding to 
the lymphocytic choriomeningitis virus GP1-derived epitope spanning residues 33-41) at 
37°C for 15 minutes. Additional stains were conducted as described in the Materials and 
Methods. Data were acquired using a modified FACSAriaII flow cytometer and analyzed 
with FlowJo software. (B) 3 x 10
4
 naïve mouse transgenic F5 T-cells were incubated at 37°C 
for 18 hours with either 100 μg/ml CT-CD8a, 100 μg/ml 53.6.7, 100 μg/ml CT-CD8b or 100 
μg/ml KT112, or with PMA (50 ng/ml) and ionomycin (1 μg/ml). Supernatants were 
harvested and assayed for MIP-1 by ELISA. The mean ± SD of two replicate assays is 
shown. 
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Antibody 
Clone 
α or β Tetramer 
binding 
MIP-1β IFN-γ IL-2 
CT-CD8a α Inhibit Yes No No 
53.6.7 α Enhance Weak* No No 
CT-CD8b β Enhance Yes No No 
KT112 β Enhance Weak NT NT 
 
Table 4.2: The heterogeneity of anti-mouse CD8 antibodies. The effects exerted by anti-
mouse CD8 antibodies on pMHCI tetramer binding and CD8
+
 T-cell activation in the absence 
of TCR engagement. 
*
53.6.7 elicited low levels of MIP-1β production from F5 naive CD8+ 
T-cells, F5 CD8
+
 T-cell lines and blasted BALB/c CD8
+
 cells, but not from naive BALB/c 
CD8
+
 cells. NT = Not Tested. 
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Antibody 
Clone 
α or 
β 
Tetramer 
binding 
MIP-1β MIP-1α RANTE
S 
IFN-γ TNF-α IL-2 Cyto- 
toxicity 
OKT8 α Enhance Yes Yes Yes No 
(Y*) 
No 
(Y*) 
No Yes 
SK1 α Inhibit No No No No No No No 
MCD8 α Neutral No No No No No No No 
32/M4 α Neutral No No No No No No No 
C8/144B α Neutral No No No No No No No 
DK25 α Inhibit No No No No No No No 
2ST8.5H7 β Inhibit No No No No No No No 
 
Table 4.3: The heterogeneity of anti-human CD8 antibodies. The effects exerted by anti-
human CD8 antibodies on pMHCI tetramer binding and CD8
+
 T-cell activation in the 
absence of TCR engagement. 
*
OKT8 was shown to elicit IFN-γ and TNF-α release by SB10 
and PHA/IL-15 stimulated PBMC. 
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4.3 Discussion 
Anti-CD8 antibodies are integral to the flow cytometric detection of pMHCI-restricted T-
cells and have been used extensively in the past to identify an important role for CD8 in 
CD8
+
 T-cell activation (Nakayama, Shiku et al. 1979; Shinohara and Sachs 1979; Norment, 
Salter et al. 1988; Miceli and Parnes 1993). Most studies have concluded that anti-CD8 
antibodies inhibit the recognition of cognate antigen (MacDonald, Glasebrook et al. 1982; 
Janeway 1992). Furthermore, a recent study provided evidence that a single anti-CD8 
antibody could deliver a negative signal to a CD8
+
 T-cell clone in the absence of cognate 
antigen (Abidi, Dong et al. 2008). In contrast, however, earlier studies concluded that anti-
CD8 antibodies could activate CD8
+
 T-cells (Veillette, Zuniga-Pflucker et al. 1989; 
Tomonari and Spencer 1990). Thus, contradictory effects of antibody-mediated CD8 ligation 
have been reported and the overall picture remains unclear. To clarify this issue, I examined 
the ability of seven different monoclonal anti-human CD8 antibodies to activate six different 
human CD8
+
 T-cell clones specific for a total of five different pMHCI antigens.  
 
In the absence of cognate antigen, the anti-human CD8 antibody OKT8 induced chemokine 
release from all six human CD8
+
 T-cell clones tested and cytotoxic activity in all four human 
CD8
+
 T-cell clones tested (Figures 4.1-4.3 & 4.5). Interestingly, this activation appeared to 
occur in the absence of any detectable cytokine release, with the exception of CD8
+
 T-cell 
clone SB10, which released IFN- (Figure 4.6). It is well established that a hierarchy of CD8+ 
T-cell effector functions exists with respect to antigen sensitivity (Valitutti, Muller et al. 
1996; Price, Sewell et al. 1998); thus, each function exhibits a distinct activation threshold 
that must be exceeded for triggering to occur. These findings suggest that OKT8 delivers a 
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positive signal to CD8
+
 T-cells that is generally sufficient to exceed the activation threshold 
required for chemokine release and cytotoxic activity, but is not sufficient to trigger cytokine 
release in the majority of CD8
+
 T-cells. In contrast to OKT8, the anti-human CD8α antibody 
clones SK1, MCD8, C8/144B, 32/M4 and DK25, and the anti-human CD8 antibody clone 
2ST8.5H7, did not induce any measurable T-cell effector functions in the absence of cognate 
antigen. It was not possible to reverse the phenotype of the non-activating anti-human CD8 
antibodies by secondary antibody-mediated cross-linking or PHA/IL-15 treatment (Figures 
4.7 & 4.8). Thus, I conclude that anti-CD8 antibodies can exert differential effects on CD8
+
 
T-cells. These findings help to reconcile previous disparate observations and suggest that 
previous reports in the literature may not be intrinsically contradictory, but rather reflective of 
the considerable heterogeneity that characterizes the ability of anti-CD8 antibodies to induce 
CD8
+
 T-cell effector function.  
 
To examine the effects of OKT8 on antigen binding at the T-cell surface, I used soluble 
pMHCI tetramer technology. Pre-incubation with OKT8 enhanced the capture of cognate 
pMHCI tetramers from solution and produced higher intensity staining (Figure 4.9 & 4.10). 
Accordingly, OKT8 enhanced the identification of CD8
+
 T-cells with low and high affinity 
TCR/pMHCI interactions (Figure 4.10 & 4.12 & Table 4.1), such as those that typically 
predominate in tumour-specific and autoimmune responses (Cole, Pumphrey et al. 2007). The 
other anti-CD8 antibodies in the panel either exerted inhibitory effects on pMHCI tetramer 
binding (SK1, DK25 and 2ST8.5H7) or displayed no biologically significant activity in this 
regard (MCD8, 32/M4 and C8/144B). Thus, OKT8 can be used as a tool to improve pMHCI 
tetramer staining; this property may be especially useful in the context of low avidity antigen-
specific CD8
+
 T-cell populations.  
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The findings described above suggest that OKT8 has properties that are distinct from other 
anti-human CD8 antibodies. To extend these results, I conducted additional experiments with 
the anti-mouse CD8α antibody CT-CD8a and the anti-mouse CD8 antibody CT-CD8b. CT-
CD8a was shown to inhibit pMHCI tetramer staining, whereas CT-CD8b enhanced pMHCI 
tetramer binding, consistent with a previous report (Wooldridge, Hutchinson et al. 2003). 
Despite their differential effects on pMHCI tetramer binding, both of these anti-mouse CD8 
antibodies activated CD8
+
 T-cells efficiently (Figure 4.17). These results demonstrate that the 
ability of anti-CD8 antibodies to elicit CD8
+
 T-cell effector function does not always 
correlate with their effect on pMHCI tetramer staining. In addition, a third phenotype was 
identified in the mouse system; the anti-mouse CD8α antibody 53.6.7 and the anti-mouse 
CD8β antibody KT112 both enhanced pMHCI tetramer staining but only induced the release 
of MIP-1β (Figure 4.17 & Table 4.2). Taken together, these data further underline the 
heterogeneity that exists within this group of reagents. 
 
The mechanism by which anti-CD8 antibodies exert either inhibitory or stimulatory effects 
on pMHCI recognition remains elusive. Previous studies have shown that anti-CD8 
antibodies retain their effects in the absence of a pMHCI/CD8 interaction (Van Seventer, Van 
Lier et al. 1986; Hoo and Kranz 1993; Campanelli, Palermo et al. 2002; Wooldridge, 
Hutchinson et al. 2003). Here, I confirmed that the enhancing effects of OKT8 on HLA A2 
tetramer on-rate at the cell surface are still apparent in the context of CD8-null MHCI 
molecules (Figure 4.13); thus, these effects are independent of any interaction between 
pMHCI and CD8. Subtle local re-arrangements of the TCR relative to CD8 on pMHCI 
engagement are required for optimal CD8
+
 T-cell activation (Block, Johnson et al. 2001; Lee 
and Kranz 2003). By extension, it seems likely that anti-CD8 antibodies exert their effects by 
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interfering with, or enhancing, this surface receptor topology. The observation that anti-CD4 
antibodies can block cell surface intermolecular interactions essential for calcium flux and 
inhibit subsequent synapse formation is consistent with this hypothesis (Krummel, Sjaastad et 
al. 2000). Furthermore, it has been previously demonstrated that anti-CD4 antibodies can 
interfere with pMHCII tetramer binding despite the fact that the pMHCII/CD4 interaction 
does not stabilize TCR/pMHCII interactions (Wooldridge, Scriba et al. 2006). I have also 
shown that OKT8 binds to a site which is distinct from all of the other anti-human CD8 
antibodies tested within this panel (Figure 4.14) which may provide an explanation for its 
unique phenotype. 
 
In summary, I have shown that: (i) heterogeneity exists in the ability of anti-CD8 antibodies 
to activate CD8
+
 T-cells; (ii) antibody-mediated ligation of CD8 in the absence of TCR 
engagement can induce chemokine release and cytotoxic activity, largely in the absence of 
cytokine release; (iii) the anti-human CD8 antibody OKT8 can enhance pMHCI tetramer 
staining; and, (iv) anti-murine CD8 antibodies (CT-CD8a and CT-CD8b) can activate CD8
+
 
T-cells in the absence of TCR engagement despite differential effects on pMHCI tetramer 
staining (Table 4.2 & 4.3). Thus, anti-CD8 antibodies can have potent effects on 
TCR/pMHCI binding kinetics and activation. These effects vary according to the antibody 
clone under investigation and should be taken into account when interpreting studies using 
these reagents. Furthermore, the ability of antibody-mediated CD8 engagement to activate 
CD8
+
 T-cells underscores the importance of co-receptor function in CD8
+
 T-cell signalling. 
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5.1 Introduction 
As a result of my findings in chapters 3 & 4, it is clear that CD8 has a potent ability to tune 
the antigen specific CD8
+
 T-cell response. In chapter 4, I demonstrated that antibodies that 
target CD8 can have dramatic effects on pMHCI tetramer binding and CD8
+
 T-cell 
activation. I was able to characterize anti-CD8 antibodies capable of blocking pMHCI 
tetramer binding and subsequent pMHCI-induced CD8
+
 T-cell activation, suggesting that 
targeting CD8 may be useful in situations where blocking unwanted CD8
+
 T-cell activation 
may be beneficial. It is beginning to emerge that CD8
+
 T-cells play an important role in the 
pathogenesis of common autoimmune diseases such as type-1 diabetes (T1D from heron) and 
Multiple Sclerosis (MS from hereon). As such, therapies that target autoreactive CD8
+
 T-cell 
attack are highly desirable.  
 
5.1.1 Role of CD8
+
 T-cells in the pathogenesis of common autoimmune diseases 
It has been traditionally theorised that autoimmune disorders such as T1D, MS, and 
Rheumatoid Arthritis are attributed to CD4
+
 T-cells. However there is growing evidence to 
suggest that CD8
+
 T-cells also contribute to the disease processes, most notably in MS, T1D 
and also Psoriasis. MS is the most common neurological disorder of young adults affecting 
over 1 million adults worldwide. MS is an inflammatory disease of the central nervous 
system (CNS) which destroys oligodendrocytes, neurons and axons. MS patients harbour 
CD8
+
 T-cells specific for multiple central nervous system antigens and CD8
+
 T-cells have 
been shown to be enriched in MS plaques (Huseby, Huseby et al. 2012; Friese and Fugger 
2009). T1D results in a total loss of self-tolerance and the destruction of insulin-producing β-
cells in the islets of langerhans of the pancreas. This destruction is dominated by 
Chapter 5 
 
199 
 
lymphocytes, many of which are CD8
+
 T-cells that specifically target epitopes derived from 
β-cell proteins (Roep and Peakman 2011; Coppieters, Dotta et al. 2012). Currently there is no 
known cure for T1D and the condition results in life-long insulin dependence, which is an 
expensive course of treatment. As of 2011 the incidence of T1D in the UK was ~0.3 million 
people at a cost of ~£0.3 billion to the NHS (www.diabetes.nhs.uk). It is of no doubt that 
there is a need for new treatments for autoimmune disorders. Therefore the timing of this 
study is very important as it may aid in the development of potential new treatments for these 
diseases. 
 
5.1.2 Autoreactive TCR/pMHCI interactions are characterized by low affinity 
Advances in understanding the molecular mechanisms which govern recognition of pMHCI 
antigen reveal key intrinsic differences between pathogen and autoreactive CD8
+
 T-cells that 
could be exploited for therapeutic benefit. Extensive biophysical studies have revealed that 
pathogen specific CD8
+
 T-cells display a high affinity for foreign pMHCI (range KD 1 - 50 
M) (Bridgeman, Sewell et al. 2011). In contrast, TCRs with a high affinity for tissue 
specific antigens (TSAs) are eliminated from the repertoire during thymic selection. 
Autoreactive TCRs that escape negative selection are characterized by structural defects that 
reduce the overall stability of the complex and result in KD values >100 M (Yin, Li et al. 
2012) Biophysical measurements of a further four diabetogenic MHCI restricted TCRs 
suggest that the average TCR/pMHCI affinity in this disease context may actually be 
characterised by KDs >200 M (unpublished data). This then suggests that this activation 
pathway would be highly dependent on CD8 for activation. I decided to test the hypothesis 
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that targeting CD8 could be used to block autoreactive CD8
+ 
T-cell activation in the absence 
of any affect on pathogen specific CD8
+
 T-cell immunity. 
 
5.1.3 Low affinity TCR/pMHCI interactions are highly CD8 dependent  
Previous studies using CD8
+ 
T-cell clones and hybridomas have demonstrated that the degree 
of CD8 dependency for efficient antigen recognition roughly correlates with the potency of 
the peptide ligand as defined by the concentration of peptide required to elicit half maximum 
activation in dose dependent titrations (as reviewed in (Laugel, Cole et al. 2011)). Indeed 
Holler et al showed that using the murine 2C TCR system, T-cell hybridomas were not fully 
activated in the absence of CD8 expression by agonist ligands with KD > 100 nM (Holler, 
Holman et al. 2000; Holler and Kranz 2003). The same group also showed that with a 
TCR/pMHCI KD > 3 μM antigen recognition became strictly dependent on the presence of 
the co-receptor. They posited that the majority of CD8
+
 T-cells that express TCRs specific to 
antigen in a natural setting were likely to demonstrate a degree of dependence on the co-
receptor. This theory was then further supported by studies showing that dependency on CD8 
for CD8
+
 T-cell activation by altered peptide ligands correlated well with the EC50 (Laugel, 
van den Berg et al. 2007; Wooldridge, Laugel et al. 2010). Ligands with a KD > 35-40 μM 
displayed some degree of CD8 dependency in peptide titration assays (Laugel, van den Berg 
et al. 2007; Wooldridge, Laugel et al. 2010). It was also shown in these studies that 
recognition of TCR ligands with very low affinities (KD values > 100-200 μM) are entirely 
CD8-dependent. It is important to note that the quantitative differences observed between the 
Holler and Laugel studies are likely due to the different systems being used in each study. 
The Holler study used the murine 2C TCR system which has a stronger TCR/pMHCI 
interaction than the human CD8
+ 
T-cell clones used in the Laugel study. It would therefore be 
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of interest to determine the range of TCR/pMHCI and their reliance on CD8 to respond 
adequately to cognate ligands in different systems. Overall there is a direct relationship 
between CD8 dependency of the CD8
+
 T-cell for activation and the affinity of the 
TCR/pMHCI interaction, where very weak TCR/pMHCI affinity interactions are entirely 
CD8 dependent. Interestingly, the level of CD8 dependency exhibited by the CD8
+
 T-cell has 
also been shown to be affected by the ligand density on the target cell. When using anti-CD8 
antibodies to block CD8
+
 T-cell activation, increasing levels of pMHCI density can bypass 
antibody blockade (Alexander, Damico et al. 1991; Hoo and Kranz 1993; Viola, Salio et al. 
1997).  
 
5.1.4 Exploiting CD8 dependency in pathological settings 
On the basis of published literature, I predict that stronger pathogen specific TCR/pMHCI 
interactions will show little dependence on CD8 for activation. In stark contrast, autoreactive 
TCR/pMHCI interactions are very weak and likely to be highly CD8 dependent. As such, I 
hypothesise that the stark differences between typical pathogen specific and autoreactive 
TCR/pMHCI interactions can be exploited in order to preferentially target CD8
+ 
T-cell 
mediated autoimmune attack without interfering with pathogen specific immunity. Thus CD8 
may be a desirable target in pathological scenarios where the TCR/pMHCI binding affinity is 
CD8 dependent, i.e. KDs > 100 μM such as autoimmune disorders. 
 
I decided to study the effects of CD8 dependency and the effect of using inhibitory anti-CD8 
antibodies where this weak interaction applies. The 1E6 CD8
+
 T-cell clone specific for the 
autoantigen preproinsulin peptide ALWGPDPAAA (PPI15–24) (Skowera, Ellis et al. 2008), 
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which has recently been measured biophysically using surface plasmon resonance, shows that 
this TCR binds to the cognate ligand ALWGPDPAAA with a KD ~278 μM (Bulek, Cole et 
al. 2012). This provided an excellent candidate to examine the CD8 dependency of T-cell 
activation from a clinically relevant setting. In the human autoimmune disease type-1 
diabetes, CD8
+
 T-cells are focussed on the islets of Langerhans and destroy β cells via the 
recognition of β cell–specific peptides presented by HLA class I molecules, leading to a 
lifelong dependence on insulin (Skowera, Ellis et al. 2008). To date no study has been 
conducted to examine the possibility that targeting CD8 using anti-CD8 antibodies can 
preferentially block highly dependent autoreactive CD8
+
 T-cells that recognise a defined 
epitope on the surface of pancreatic β cells. 
 
5.1.5 Use of antibodies to inhibit CD8
+
 T-cell activation 
It has long been known that anti-CD8 antibodies can be used to block the activation of some 
CD8
+
 T-cells (MacDonald, Glasebrook et al. 1982). MacDonald et al used a murine system 
to highlight the heterogeneity in the functional output of multiple anti-CD8 antibodies where 
some antibodies could inhibit T-cell activation whereas others were shown to have no effect. 
These heterogeneous effects have been further supported and observed in multiple 
subsequent studies including our own (see chapter 4). Importantly, it was suggested that 
heterogeneity in the ability of CD8
+
 T-cells to activate in the presence of inhibitory anti-CD8 
antibodies was thought to correlate with the strength of the TCR/pMHCI interaction. I will 
test this theory in this chapter and also investigate the possibility that this can be exploited for 
therapeutic benefit.  
 
Chapter 5 
 
203 
 
5.1.6 Summary and Aims 
The aim of this chapter was to examine the potential use of anti-CD8 antibodies to 
preferentially block autoreactive CD8
+
 T-cell activation.  
Using multiple CD8
+
 T-cell clones which vary in TCR/pMHCI binding affinities I aim: 
 
 To investigate the relationship between TCR/pMHCI affinity and CD8 dependence. 
 To investigate the possibility that targeting the CD8 co-receptor can be used to block 
autoreactive CD8
+
 T-cell activation in the absence of any effect on pathogen specific 
CD8
+
 T-cell responses. 
 
5.2 Results 
5.2.1 CD8 dependency is governed by TCR/pMHCI binding affinity 
I examined how CD8 dependency is governed by the strength of the TCR/pMHCI interaction. 
Stable C1R B-cell (Storkus, Howell et al. 1987) transfectants expressing A2 wild-type and 
HLA A2 DT227/8KA (Purbhoo, Boulter et al. 2001) were used to study the effect of wild-
type and abrogated pMHCI/CD8 interaction, respectively whilst not effecting the 
TCR/pMHCI interaction. When C1R wild-type and 227/8 B-cells were pulsed with cognate 
ligands for multiple HLA A2 restricted CD8
+
 T-cell clones, each with varying TCR/pMHCI 
binding affinities, differences in levels of T-cell activation can be seen (Figure 5.1 A-H).  
CD8
+
 T-cell clones which have a high TCR/pMHCI binding affinity are less dependent on 
CD8. The CD8
+
 T-cell clone ALF8, specific for the Influenza A virus MP158-66 epitope 
GILGFVFTL, elicits a very sensitive and high level of T-cell activation. ALF8 is relatively 
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unaffected by the abrogation of CD8 using C1R 227/8 B-cells (Figure 5.1 A&B) which is not 
surprising given the relatively strong binding affinity of the TCR/pMHCI interaction KD of 
2.6 μM (Table 5.1 & Appendix 3).  
 
I then examined more CD8
+
 T-cell clones with varying TCR/pMHCI affinities (Table 5.1), 
i.e. MEL5, specific for the Melan-A-derived epitope ELAGIGILTV (residues 26-35) (KD = 
18 μM) (Cole, Pumphrey et al. 2007; Cole, Edwards et al. 2010), ILA1 specific for the 
human telomerase reverse transcriptase (hTERT)-derived epitope ILAKFLHWL (residues 
540-548) (KD = 36 μM) (Cole, Pumphrey et al. 2007) and 1E6, specific for the restricted 
autoantigen preproinsulin peptide ALWGPDPAAA (PPI15–24) (KD = 278 μM) (Cole, Edwards 
et al. 2010; Bulek, Cole et al. 2012). Decreasing the strength of the TCR/pMHCI interaction 
was accompanied by an increase in CD8-dependency and revealed an extremely high level of 
CD8-dependency in the autoimmune 1E6 CD8
+
 T-cell clone (Figure 5.1 G&H). Activation of 
the 1E6 CD8
+
 T-cell clone in the absence of CD8 engagement resulted in almost 100% 
impairment of MIP-1β release and no detectable production of IFN-γ (Figure 5.1 G&H). In 
summary, this data demonstrates that CD8 dependency is governed by the TCR/pMHCI 
binding affinity. 
 
5.2.2 Anti-CD8 antibodies can efficiently block pMHCI tetramer binding when the 
TCR/pMHCI interaction is extremely weak 
As previously discussed in chapter 4, there are multiple anti-CD8 antibody phenotypes 
including those that are capable of blocking tetramer binding at the cell surface. The two  
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Figure 5.1: The level of CD8 dependency of CD8
+
 T-cells increases as the TCR/pMHCI 
interaction decreases. (A-H) 6 x 10
4
 C1R-A*0201 (CD8 wild-type) or C1R-A*0201 227/8 
(CD8 abrogated) B-cells were pulsed with cognate peptide from 10
-11 
to 10
-5 
M in duplicate 
for 1 hour @ 37°C. Excess peptide was washed off twice with PSG. 3 x 10
4
 ALF3, MEL5, 
ILA1 or 1E6 CD8
+
 T-cell clones were incubated with pulsed C1R B-cells for 4 hours @ 
37°C. Supernatant was harvested and assayed for MIP-1 and IFN-γ by ELISA. The mean ± 
SD of two replicate assays is shown. 
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CD8
+
 T-cell 
clone 
1E6 ILA1 MEL5 ALF3 ALF8 
Epitope ALWGPDPAAA ILAKFLHWL ELAGIGILTV GILGFVFTL GILGFVFTL 
TCR/pMHCI 
KD μM 
278 36 18 5.4
1
 2.6
1
 
 
Table 5.1: TCR/pMHCI binding affinities of different target restricted CD8
+
 T-cell 
clones. Summary of the TCR/pMHCI binding affinities of different CD8
+
 T-cell clones used. 
1
 See Appendix 3 for SPR Biophysical data. 
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Figure 5.2: Weak TCR/pMHCI interactions are extremely susceptible to blockade with 
anti-CD8 antibodies. 5 x 10
4 
(A) ALF3 (KD 5.4 μM), (B) MEL5 (KD 18 μM), (C) ILA1 (KD 
36 μM), and (D) 1E6 (KD 278 μM), CD8
+
 T-cells were removed from culture, washed twice 
and resuspended in 40 μl PBS with or without anti-human CD8 antibody at SK1 6.25 μg/ml 
or DK25 12.5 μg/ml, then incubated at 4°C for 25 minutes. Cognate PE or BV421-conjugated 
HLA A*0201 tetramer was added in each case at 25 μg/ml at 37°C for 15 minutes. Data were 
acquired using a FACSCantoII flow cytometer and analyzed with FlowJo software. 
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most effective blocking antibodies were clones SK1 and DK25. Pre-incubation with SK1 and 
DK25 resulted in reduced levels of pMHCI tetramer binding to all CD8
+
 T-cell clones tested 
(Figure 5.2 A-D) albeit to a differing extent. As TCR/pMHCI interaction strength is reduced 
then the effect of CD8 blocking antibody on pMHCI tetramer binding becomes more 
dramatic (Figure 5.2 B-D). In fact, the most dramatic effect was observed (>95% blockade) 
on pMHCI tetramer staining of 1E6 CD8
+
 T-cell clones with both blocking antibodies 
(Figure 5.2 D). Therefore, pMHCI binding at the cell surface is extremely susceptible to anti-
CD8 antibody mediated blockade if the TCR/pMHCI interaction is weak. 
 
5.2.3 Titration of antibody reveals concentration for efficient blockade of autoreactive 
TCR/pMHCI interactions 
Next, I wanted to assess whether it is possible to identify a concentration of blocking anti-
CD8 antibody that can efficiently block tetramer binding to autoreactive CD8
+
 T-cells (1E6) 
in the absence of any significant effect on higher affinity TCR/pMHCI interactions (typical of 
pathogen specific CD8
+
 T-cells). I therefore proceeded to titrate the concentration of the most 
inhibitory antibody DK25 to identify a threshold concentration (Figure 5.3 A-H). The 
inhibitory effect of the antibody was titrated to a level where a decrease in the concentration 
resulted in an increase in tetramer binding (Figure 5.3 A-H). Use of DK25 at a concentration 
of 1 μg/ml resulted in ~80% inhibition of tetramer binding to the autoreactive 1E6 CD8+ T-
cell clone (Figure 5.3 H). This concentration had little or no effect on the tetramer binding to 
MEL5 and ALF8 where the TCR/pMHCI interaction is much stronger (Figure 5.3 A-D) 
(Table 5.1). Therefore at a concentration of 1 μg/ml, DK25 can be used to block autoreactive 
TCR/pMHCI interactions at the cell surface whilst not affecting the stronger TCR/pMHCI 
interactions of anti-viral and some anti-tumour responses.  
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Figure 5.3: Antibody blocking of tetramer binding can be titrated to a low level in the 
context of weak TCR/pMHCI interactions whilst not affecting stronger TCR/pMHCI 
interactions. 5 x 10
4 
(A) ALF8, (B) MEL5 and (C) 1E6 CD8
+
 T-cells were removed from 
culture, washed twice and resuspended in 40 μl PBS with or without anti-human CD8 
antibody DK25 at 12.5 μg/ml, 6.25 μg/ml, 3.125 μg/ml or 1 μg/ml then incubated at 4°C for 
25 minutes. Cognate PE-conjugated HLA A*0201 tetramer was added in each case at 25 
μg/ml at 37°C for 15 minutes. Data were acquired using a FACSCantoII flow cytometer and 
analyzed with FlowJo software. Data is presented in the left column as percentage of 
maximal tetramer staining whereas data in the right column represents percentage of 
inhibition of tetramer staining. 
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5.2.4 CD8 antibodies efficiently block activation when the TCR/pMHCI affinity is weak 
The results from my pMHCI tetramer blocking experiments suggest that blocking anti-CD8 
antibodies can be used to preferentially target T-cells with weak affinity TCR/pMHCI 
interactions (Figure 5.3). This observation is important because it suggests that targeting CD8  
could be a desirable strategy for blocking the activation of CD8
+
 T-cells characterised by low 
affinity TCR/pMHCI interactions such as the autoreactive CD8
+
 T-cell clone 1E6 which can 
directly target and kill islet β-cells. In order to test this hypothesis I decided to test the ability 
of DK25 to block 1E6 recognition of its cognate ligand ALWGPDPAAA (KD ~278 μM) and 
an altered peptide ligand YQFGPDPAAA, identified in a previous study which is capable of 
binding to the 1E6 TCR with high affinity (KD ~9 μM) (Table 5.2) (Wooldridge, Ekeruche-
Makinde et al. 2012). This falls within the typical affinity range observed for pathogen 
specific TCR/pMHCI interactions (Table 5.1 & 5.2 & Appendix 3). This provides a 
monoclonal T cell system to examine the effect of DK25 on T-cell activation where the only 
parameter that is varied is the affinity of the TCR/pMHCI interaction.  
 
In the absence of anti-CD8 antibody, the 1E6 CD8
+
 T-cell clone can be seen to be killing 
targets presenting ALW and YQF, the level of killing is directly proportional to the binding 
affinity of the TCR/pMHCI interaction (Figure 5.4 A). However in the presence of anti-CD8 
antibody DK25, at both concentrations tested the killing of targets presenting cognate ALW 
antigen as measured by chromium release is inhibited by 100% (Figure 5.4 B). At the higher 
concentration of DK25 used (1 μg/ml) some effect on the killing of targets presenting the 
high affinity ligand YQF was observed (Figure 5.4 C). However, no inhibition of YQF was 
observed when this concentration was lowered to 0.5 μg/ml. Therefore targeting CD8 can be  
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CD8
+
 T-cell clone 1E6 
Epitope ALWGPDPAAA YQFGPDPAAA 
TCR/pMHCI 
KD μM 
278 9
1
 
 
Table 5.2: TCR/pMHCI binding affinities of different ligands recognized by the 1E6 
CD8
+
 T-cell clone. Summary of the TCR/pMHCI binding affinities of wild-type and 
enhanced peptide ligand specific for the 1E6 CD8
+
 T-cell clones used.
 1
 See Appendix 3 for 
SPR Biophysical data. 
 
 
 
 
 
Chapter 5 
 
212 
 
 
Figure 5.4: Targeting CD8 can be used to block autoreactive CD8
+ 
T-cell killing. 2x10
3
 
C1R A2 wt target cells were labelled with 30 µCi of 
51
Cr (Perkin Elmer, Cambridge, UK) per 
10
6
 cells for 1 hour at 37°C. Targets were also cultured alone (target spontaneous release) and 
with TritonX-100 (Sigma-Aldrich) at a final concentration of 5% (target total release). 
Targets were pulsed with either (A&B) ALWGPDPAAA, or (A&C) YQFGPDPAAA for 1 
hour at 37˚C. 1x104 HLA-A*0201-restricted 1E6  ALWGPDPAAA (PPI15–24) CD8
+
 T-cell 
clone were then plated out to a final volume of 60 l R10 at an E:T ratio of 5:1 with or 
without purified anti-human CD8 antibody (DK25) @ 1 μg/ml and 0.5 μg/ml. Cells were 
incubated at 37˚C for 4 hours in a 5% CO2 atmosphere. For each sample, 10 µl supernatant 
was harvested and mixed with 150 l OptiPhase Supermix Scintillation Cocktail (Perkin 
Elmer). Plates were analyzed using a liquid scintillator and luminescence counter (MicroBeta 
TriLux; Perkin Elmer) with Microbeta Windows Workstation software (Perkin Elmer). 
Specific lysis was calculated according to the following formula: (experimental release - 
target spontaneous release/target total release - target spontaneous release) x 100. The mean ± 
SD of three replicate assays is shown. 
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used to inhibit 1E6 CD8
+
 T-cell clone recognition of cognate antigen by 100% whilst 
retaining the ability to kill antigens characterised by higher affinity TCR/pMHCI interactions.  
 
5.2.5 Blocking CD8 antibodies can be used to achieve complete inhibition of 
autoreactive CD8
+
 T-cell activation whilst retaining anti-viral CD8
+
 T-cell activation 
I decided to examine the ability of the blocking anti-CD8 antibody (DK25) to inhibit 
activation of the autoreactive CD8
+
 T-cell clone 1E6 compared to its ability to inhibit 
pathogen specific CD8
+
 T-cell activation. Using the CD8 independent anti-viral ALF8 CD8
+
 
T-cell clone and the ‘highly’ CD8 dependent autoreactive 1E6 CD8+ T-cell clone, a similar 
effect was seen to that of the tetramer binding. I observed 100% blockade of 1E6 T-cell 
activation when DK25 was used at a concentration of 1 μg/ml (Figure 5.5 A). In stark 
contrast, the same concentration of DK25 had a very minimal effect on activation of the 
relatively CD8 independent ALF8 CD8
+ 
T-cell clone (Figure 5.5 B). This highlighted a 
concentration of blocking anti-CD8 antibody where complete inhibition of autoreactive CD8
+
 
T-cells activation is observed whilst anti-viral CD8
+
 T-cell activation remains intact.  
 
Next, I decided to test the efficacy of DK25 on more CD8
+
 T-cell clones including those that 
are restricted by different HLA class molecules. Here, I used the autoreactive CD8
+
 T-cell 
clones 1E6 (HLA A2 restricted), 3F2 (HLA A2 restricted) and 4C6 (HLA A*2402 restricted) 
which have all been previously shown to kill pancreatic islet β-cells (Knight, Kronenberg et 
al. 2012; Skowera, Ellis et al. 2008). I also compared these autoreactive clones to the CD8 
independent anti-viral CD8
+
 T-cell clones ALF3 (HLA A2 restricted), NLV2 (HLA A2 
restricted) and SBS1 (HLA B*3508 restricted). The result obtained was the same as the effect  
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Figure 5.5: Titration of anti-CD8 antibody reveals concentration for optimal inhibition 
of autoreactive CD8
+
 T-cell activation. (A&B) 6.0 x 10
4
 HLA A2*0201 C1R with wild-
type pMHCI/CD8 interaction where pre-incubated with titrated cognate peptides @ 10
-5
M to 
10
-11
M (A) ALWGPDPAAA, (B) GILGFVFTL for 1 hour @ 37°C. Cells were then washed 
twice using 100 μl of PSG @ 561 x g for 5 minutes. 3 x 104 1E6  ALWGPDPAAA (PPI15–24) 
CD8
+
 T-cell clone or ALF8 GILGFVFTL (MP158-66) epitope which had been pre-incubated 
for 60 minutes @ 37°C with purified anti-human CD8 antibody (DK25) @ 1 μg/ml where 
then added to each sample and incubated for 4 hours @ 37°C. Supernatants were harvested 
and assayed for MIP-1β production by ELISA (RandD Medsystems) and performed 
according to the manufacturer’s instructions. The mean ± SD of two replicate assays is 
shown. 
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Figure 5.6: Titration of anti-CD8 antibody reveals concentration for optimal inhibition 
of autoreactive CD8
+
 T-cell activation. 6.0 x 10
4
 HLA A2*0201 C1R were pre-incubated 
with titrated cognate peptides @ 10
-5
M to 10
-11
M (A) ALWGPDPAAA, (B) 
ALWGPDPAAA, (D) GILGFVFTL, (E) NLVPMVATV or (C) A*2402 K562 with 
LWMRLLPLL or (F) HLA B*3508 C1R with LPEPLPQGQLTAY for 1 hour @ 37°C. Cells 
were then washed twice using 100 μl of PSG @ 1500 rpm for 5 minutes. 3 x 104 (A) 1E6 
(PPI15–24), (B) 3F2 (PPI15–24), (C) 4C6 (PPI3-11), (D)  ALF3 (M158-66), (E) NLV2 (CMV-
pp65495-503), or (F) SBS1 (EBV-BZLF152-64) CD8
+
 T-cell clone pre-incubated for 60 minutes 
@ 37°C with purified anti-human CD8 antibody (DK25) @ 1, 0.5 and 0.25 μg/ml where then 
added to each sample and incubated for 4 hours @ 37°C. Supernatants were harvested and 
assayed for MIP-1β production by ELISA (RandD Medsystems) and performed according to 
the manufacturer’s instructions. The mean ± SD of two replicate assays is shown. 
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described above. Thus, regardless of the MHCI restriction CD8
+
 T-cell clones with lower 
affinity TCR/pMHC interactions, as typified by autoimmune T-cells, are more CD8-
dependent (Figure 5.6 A-C). In contrast, the DK25 antibody was seen to have minimal effect 
on the activation of all anti-viral CD8
+
 T-cell clones tested regardless of the MHCI restriction 
(Figure 5.6 D-F). 
 
5.3 Discussion 
Over the last decade there has been a substantial amount of evidence accumulating in the 
literature to suggest that CD8
+
 T-cells play a significant role in the pathogenesis of common 
autoimmune diseases such as T1D (Roep and Peakman 2011; Coppieters, Dotta et al. 2012), 
MS (Huseby, Huseby et al. 2012; Friese and Fugger 2009) and Psoriasis (Prinz 2003). 
Strategies that specifically target this important cell type are therefore highly desirable. 
However, it would be dangerous to use treatments that mediate a non-specific inhibition of 
CD8
+
 T-cell activation because CD8
+
 T-cells play an essential role in defending our bodies 
against pathogen attack. Therefore, strategies that specifically target autoreactive T-cells 
whilst leaving pathogen specific CD8
+
 T-cells untouched could have a role in treating these 
diseases. It is emerging that autoreactive TCR/pMHCI interactions are characterised by low 
affinity compared to typical pathogen specific TCR/pMHCI interactions. Based on previous 
studies I predicted that this would make self reactive CD8
+
 T-cells highly dependent on CD8 
for activation. If autoreactive CD8
+
 T-cells are characterized by high levels of CD8-
dependency then CD8 would represent a desirable target to block unwanted autoreactive 
CD8
+
 T-cell activation. I decided to conduct a study in order to test this hypothesis. 
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I examined how CD8-dependency is influenced by the strength of the TCR/pMHCI 
interaction. Previous data supports the theory that CD8-dependency is directly linked to the 
affinity of the TCR/pMHCI interaction where a weak TCR/pMHCI interaction is highly CD8 
dependent and the reverse is also true (Holler, Lim et al. 2001; Holler and Kranz 2003; 
Laugel, van den Berg et al. 2007). A panel of four CD8
+
 T-cell clones were shown to be 
either highly CD8 independent, ALF8 CD8
+
 T-cell clone (Figure 5.1 A&B), moderately CD8 
dependent, MEL5 CD8
+
 T-cell clone and ILA1 CD8
+
 T-cell clone (Figure 5.1 C-F), or highly 
CD8 dependent, 1E6 CD8
+
 T-cell clone (Figure 5.1 G&H) for CD8
+
 T-cell activation. The 
level of CD8 dependency by this panel of CD8
+
 T-cell clones each with varying TCR/pMHCI 
affinities (Table 5.1) demonstrated a direct correlation between the TCR/pMHCI binding 
affinity and the requirement of CD8 for efficient CD8
+
 T-cell activation. 
 
One approach to target the CD8 co-receptor is the use of anti-CD8 antibodies. In a previous 
chapter (chapter 4), I characterized a panel of anti-CD8 antibodies which allowed me to 
select two antibodies with a blocking phenotype for further study. I examined the ability of 
these antibodies to disrupt TCR/pMHCI interactions at the cell surface. The effect of the 
blocking antibodies was shown to be most dramatic for the highly CD8-dependent 1E6 CD8
+
 
T-cell clone, a clinically relevant in-vivo T1D specific CD8
+
 T-cell clone, where tetramer 
staining could be inhibited by >95% (Figure 5.2 D & 5.3 G&H). Overall, targeting CD8 is a 
very efficient way of blocking pMHCI staining to the cell surface when the TCR/pMHCI 
interaction is extremely weak, with little or no effect observed with higher affinity 
TCR/pMHCI interactions typical of pathogen specific CD8
+
 T-cells.  
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To examine the effect of the blocking antibody in directly inhibiting epitope specific killing 
by the 1E6 CD8
+
 T-cell clone, killing assays were performed using targets bearing the 
cognate ligand (ALWGPDPAAA) and high affinity ligand (YQFGPDPAAA) representative 
of antigens that CD8
+
 T-cells may be exposed to in the periphery (Figure 5.4 A-C) (Table 
5.2). As expected the levels of killing observed correlated with the TCR/pMHCI affinity of 
the ligand tested (Figure 5.4 A). Killing on recognition of cognate ligand was inhibited in the 
presence of anti-CD8 antibody, whereas no effect was observed on the recognition of the 
high affinity ligand (Figure 5.4 B&C). In addition, the same concentration of antibody had a 
very minimal effect on the inhibition of the anti-viral ALF8 CD8
+
 T-cell clone rendering 
these pathogen specific CD8
+
 T-cells intact (Figure 5.5 B). Further investigation 
demonstrated that all autoimmune CD8
+
 T-cells tested within this study, 1E6, 3F2 and 4C6, 
restricted by different HLA class molecules, can be completely blocked using anti-CD8 
antibodies (Figure 5.6 A-C). Simultaneously, a very minimal effect and in one case no 
blocking effect was seen on all anti-viral CD8
+
 T-cell clones tested (Figure 5.6 D-F). This 
data supports the theory that targeting CD8 has the strong potential to inhibit autoreactive 
CD8
+
 T-cell activation and killing whilst ensuring that pathogen specific CD8
+
 T-cells can 
remain able to identify and kill their targets. 
 
There have been many studies highlighting the potential use of antibodies in autoreactive 
settings however none have examined the potential of anti-CD8 antibody mediated blockade. 
There has been extensive data highlighting the use of anti-CD3 antibodies in the study of 
T1D. Interestingly anti-CD3 antibodies have been shown to reverse diabetes onset in Non-
obese diabetic (NOD) mice which was the initial basis for the use of this antibody in human 
clinical trials (Chatenoud, Thervet et al. 1994; Herold, Hagopian et al. 2002; Keymeulen, 
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Vandemeulebroucke et al. 2005). Indeed in human studies the use of anti-CD3 antibodies 
have been shown to preserve islet β cell function by up to two years and can increase insulin 
production (Herold, Gitelman et al. 2009). The mechanism by which the anti-CD3 antibodies 
is thought to be having its effect has been shown to be as a result of an induction of 
regulatory T cells, which may play a key role in maintaining tolerance and has been reported 
to be TGFβ-dependent (Cobbold, Castejon et al. 2004; You, Leforban et al. 2007). However 
data does suggest that the anti-CD3 antibody, despite undergoing Fc modification results in 
side effects relating to cytokine release and a transient EBV viral reactivation (Keymeulen, 
Vandemeulebroucke et al. 2005; Chatenoud and Bluestone 2007). Interestingly none of the 
anti-CD8 antibodies tested in chapter 4 induced any cytokine release which may make them 
desirable.  
 
Previous studies have also examined the use of both anti-CD4 and anti-CD8 antibodies in 
therapeutic design for T1D. These studies have pointed to the use of these antibodies to 
induce tolerance and halt diabetes onset (Phillips, Parish et al. 2009; Yi, Diz et al. 2012). 
Similarly to the use of anti-CD3 antibodies, non-depleting anti-CD4 antibodies have been 
shown to induce regulatory T-cells. Whereas the tolerance which is induced by the use of 
non-depleting anti-CD8 antibodies is dependent on IL-10 (Parish, Bowie et al. 1998; Parish 
and Cooke 2005; Phillips, Parish et al. 2009). In contrast to previous studies which have 
alluded to a role for anti-CD8 antibodies in the induction of tolerance, it is important to note 
that the study described in this chapter is aimed at examining the ability of anti-CD8 
antibodies to preferentially block autoreactive CD8
+
 T-cell activation which could be a more 
targeted means of controlling disease symptoms. 
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There are currently treatments that are available and approved for the treatment of 
autoimmune and inflammatory diseases, or those in the later stages of development. These 
agents usually rely on the induction of profound and/or long-lasting immunosuppression and 
their effect can be achieved by global depletion of entire cell types or lineages in the 
periphery. These agents can also induce immunosuppression by preventing peripheral 
leukocyte trafficking and transport in and out of lymphoid organs and also target the systemic 
activity of cytokines involved in disease pathogenesis (Dinarello 2010; Rammohan and 
Shoemaker 2010; Steward-Tharp, Song et al. 2010). These drugs have been shown to possess 
good efficacy, however the side effects can be quite adverse. Anti-CD3 treatment in T1D is 
an example where the side effects of the drug could potentially outweigh the benefits of the 
drug where severe reactivation of latent viral infections would be clinically deleterious. 
 
The data provided here has highlighted that targeting CD8 can preferentially inhibit 
pathogenic CD8
+
 T-cell responses directed against clinically relevant autoreactive self-
determinants and leave cellular immunity to anti-viral and microbial pathogens largely intact. 
This could also be explored further using agents that target the CD8 binding site on MHCI 
such as soluble versions of the inhibitory Immunoglobulin like transcript (ILT2) receptor. 
High affinity forms of the soluble ILT2 receptor have been manufactured by phage display 
and have been shown to interact with MHCI with extremely high affinities at nanomolar 
levels and have been shown to inhibit CD8
+
 T-cell activation (Moysey, Li et al. 2010). It 
would be of interest to study the effect that this molecule has in the context of both 
autoreactive and anti-viral CD8
+
 T-cells used in this study as this may overcome any issues 
of having to generate an antibody molecule for use in-vivo (Moysey, Li et al. 2010).  To fully 
examine this strategy of using engineered molecules as previously described, the effect these 
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molecules pose on cancer immune-surveillance, thymic selection and also on naive T-cells in 
the periphery would have to be fully examined.  
 
It would also be useful to study the effect of anti-CD8 antibodies in the NOD mouse system 
examining the effect of both blocking and enhancing phenotypes of anti-CD8 antibodies in-
vivo. Interestingly, the distinct epitope required for binding for anti-CD8 antibodies may 
potentially underlie future directed therapy targets. Blocking antibodies appear to bind to a 
site which is distant and distinct from the activatory antibody binding site in both the murine 
and human systems (Figure 4.15) (Sanders, Fox et al. 1991, Devine, Hodsdon et al. 2004). 
Further studies of both epitope regions may allow for design of therapies aimed at either 
enhancing or inhibiting CD8
+
 T-cell function and may uncover further heterogeneity of these 
regions, similarly to those seen in the murine system (chapter 4). 
 
In summary, I have shown that: (i) as the TCR/pMHCI affinity increases, the level of CD8 
dependency exhibited by the CD8
+
 T-cell clone decreases; (ii) anti-CD8 antibodies can be 
used to block the binding of cognate tetramer to CD8
+
 T-cells and the inhibition is more 
dramatic when the CD8
+
 T-cell clone becomes increasingly CD8 dependent; (iii) inhibition of 
tetramer staining using anti-CD8 antibodies can be titrated to low levels ensuring highly CD8 
dependent CD8
+
 T-cells are inhibited whilst highly CD8 independent CD8
+
 T-cells are not 
impaired; and, (iv) an optimal concentration of blocking anti-CD8 antibody can completely 
inhibit the activation and epitope specific killing of the highly CD8-dependent 1E6 CD8
+
 T-
cell clone, an autoreactive T1D specific CD8
+
 T-cell. This concentration of antibody was 
shown to have a no effect on highly CD8-independent pathogen specific CD8
+
 T-cell clones. 
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My results show that CD8-blockade can specifically inhibit activation of autoimmune CD8
+
 
T-cells. This approach therefore warrants further investigation as a potential therapeutic tool. 
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6.1 Introduction 
6.1.1 CD8 focussing: a novel role for CD8 in T-cell activation? 
Previous results chapters have underlined the potent ability of CD8 to modulate the antigen 
specific CD8
+
 T-cell response, especially chapter 3 where a super-enhanced interaction with 
CD8 was shown to result in non-specific activation. Multiple roles for CD8 in CD8
+ 
T-cell 
activation have been demonstrated. CD8 has been shown to modify the affinity of the 
TCR/pMHCI interaction, in addition to modulating the triggering threshold of the TCR 
(Gakamsky, Luescher et al. 2005). A previous mathematical analysis of these modulatory 
effects predicted that CD8 could alter the functional avidity of a CD8
+ 
T-cell for its agonists 
and act to re-arrange the relative potencies of each of its potential agonists (van den Berg, 
Wooldridge et al. 2007). If true then this would allow CD8
+ 
T-cells to increase their 
functional sensitivity for one agonist, while decreasing their functional sensitivity for other 
potential agonists. This potential “focussing mechanism” could be extremely important 
because it would allow each CD8
+ 
T-cell to centre recognition on a particular subset of 
potential agonist ligands.  
 
6.1.2 CD8
+ 
T-cells are inherently crossreactive 
Early studies suggested that individual TCRs only recognize a single pMHCI. However, 
studies published in the 1990s demonstrated that T-cells can recognize several peptides 
(Wraith, Bruun et al. 1992; Bhardwaj, Kumar et al. 1993; Reay, Kantor et al. 1994; Evavold, 
Sloan-Lancaster et al. 1995; Wucherpfennig and Strominger 1995; Hemmer, Fleckenstein et 
al. 1997; Kersh, Shaw et al. 1998). Since then, observations of TCR degeneracy have 
continued to accumulate in the literature (Hausmann, Martin et al. 1999; Kissler, Anderton et 
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al. 2002; Crawford, Huseby et al. 2004; Lee, Stewart-Jones et al. 2004; Nino-Vasquez, 
Allicotti et al. 2004; Kan-Mitchell, Bajcz et al. 2006; Dai, Huseby et al. 2008; Ishizuka, 
Grebe et al. 2009). The majority of previous studies of TCR degeneracy utilized small 
peptide sets (2-200) or estimates based on peptide library screening where it is necessary to 
make assumptions about individual peptide concentrations. A recent study examined ~4000 
peptides, although this number still only represents an extremely small portion of the entire 
peptide universe. Despite the caveats of previous studies, two independent studies suggested 
that individual MHCII-restricted TCRs can recognize ~10
6
 peptides (Hiemstra, van Veelen et 
al. 1999; Maynard, Petersson et al. 2005). Wilson et al suggested that MHCI-restricted TCRs 
might exhibit lower levels of degeneracy (Wilson, Wilson et al. 2004), although, no attempt 
had been made to quantify this. In an attempt to rectify this, a recent study performed a 
comprehensive analysis and demonstrated that a single autoimmune TCR (1E6) can 
recognize over one million different peptide sequences in the context of a single MHCI 
(Wooldridge, Ekeruche-Makinde et al. 2012). Recent data from the laboratory suggests that 
not all MHCI-restricted TCRs recognize one million peptides but for most the number is still 
quite large. This remarkable promiscuity explains how a limited TCR repertoire (~25 million) 
can recognize the multitude of peptides that can be presented by MHCI (~8x10
14
) and is 
therefore essential for the provision of effective CD8
+
 T-cell immunity. 
 
6.1.3 CD8 controls levels of T-cell crossreactivity 
Recent data suggests that CD8
+ 
T-cell crossreactivity is controlled by CD8. Data by 
Wooldridge et al showed that CD8 extends the range of pMHCI ligands that can be seen by 
an individual cell surface bound TCR, thereby ensuring that the peripheral CD8
+ 
T-cell 
repertoire is optimally poised to negotiate the competing demands of responsiveness in the 
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face of danger and quiescence in the presence of self (Wooldridge, Laugel et al. 2010). The 
authors used combinatorial peptide library (CPL) screens to assess the levels of 
crossreactivity exhibited by a CD8
+ 
T-cell. In the absence of a pMHCI/CD8 interaction, the 
level of CD8
+ 
T-cell activation by the CPL screens was very minimal. However, on 
increasing the strength of the pMHCI/CD8 interaction, the range of ligands (i.e. number of 
peptides) recognized by an individual TCR was increased. In addition, increasing the strength 
of the pMHCI/CD8 interaction resulted in a change in the pattern of the ligands recognised 
by an individual TCR (Wooldridge, Laugel et al. 2010). This data suggests that CD8 is 
exerting a focussing effect and I intend to examine this effect in more detail during this 
chapter.  
 
6.1.4 Summary and Aims 
TCRs are inherently degenerate recognizing a large number of different peptides. 
Mathematical analysis suggests that CD8 is a key regulator of TCR degeneracy allowing a 
single T-cell to focus on different ligands by adjusting its fine sensitivity to potential 
agonists. This would manifest in the ability of CD8 to re-arrange the relative potencies of 
each of its potential agonists (van den Berg, Wooldridge et al. 2007). I intend to test whether 
such a mechanism exists, using multiple CD8
+
 T-cell clones and multiple altered peptide 
ligands (APLs). I will examine how the strength of the pMHCI/CD8 interaction influences 
the potency of multiple ligands in three different monoclonal systems.  
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6.2 Results 
6.2.1 MHCI mutations that alter the strength of the pMHCI/CD8 interaction 
To study the effect of varying the strength of the pMHCI/CD8 interaction at the cell surface 
on the potency of multiple ligands for an individual TCR, I used a panel of C1R B-cell lines 
stably transfected with mutant MHCI. Each C1R had been previously transfected with MHCI 
molecules that bear mutations in the CD8 binding domain which either abrogate (HLA A2 
227/8KA), retain wild-type properties (HLA A2) (Purbhoo, Boulter et al. 2001), increase 
CD8 binding (HLA A2 Q115E) (Wooldridge, Lissina et al. 2007) or greatly increase CD8 
binding (HLA A2 K
b
) (Wooldridge, Clement et al. 2010) (Figure 6.1). A previous study used 
SPR to demonstrate that these mutations do not affect the strength of the TCR/pMHCI 
interaction (Wooldridge, van den Berg et al. 2005). 
 
6.2.2 Examining the effect that pMHCI/CD8 affinity exerts on functional sensitivity of 
the TCR/pMHCI interaction 
In order to perform a comprehensive study to examine the effect that the strength of the 
pMHCI/CD8 interaction exerts on the functional sensitivity of the TCR/pMHCI interaction, I 
decided to examine three different CD8
+
 T-cell clones: ILA1, MEL5 and 1E6. For each of 
these TCR clonotypes, I selected a panel of peptide ligands which included superagonists, 
cognate ligands and weak agonists for all three monoclonal CD8
+
 T-cell systems (Table 6.1). 
The majority of these agonists were designed using combinatorial peptide library technology 
(Ekeruche-Makinde, Clement et al. 2012). TCR/pMHCI biophysical data was already 
available for some of the peptide ligands and I performed surface plasmon resonance to 
measure the strength of some of the other TCR/pMHCI interactions. It was not possible to  
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Figure 6.1: Mutant MHCI stably transfected into C1R B-cells can be used to alter the 
strength of the pMHCI/CD8 interaction without any affect on TCR/pMHCI binding. 
SPR was used to measure the strength of the pMHCI/CD8 interaction following mutation of 
the CD8 binding site. MHCI mutants were then stably transfected into C1R-B-cells using a 
pcDNA3.1 vector 
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Name MHCI restriction Epitope KD  
(μM) 
ILA1 HLA*A0201 ILAKFLHWL 36
1
 
ILA1 HLA*A0201 ILAKYLHWL 242
1
 
ILA1 HLA*A0201 ILGKFLHRL 16.5 
+ 
2.5
6
 
ILA1 HLA*A0201 ILGKFLHWL 3.7
1
 
MEL5 HLA*A0201 ELAGIGILTV 17 
+
 1
1
 
MEL5 HLA*A0201 ELTGIGILTV 82 
+
 4
2
 
MEL5 HLA*A0201 FATGIGIITV 3 
+
 1
3
 
MEL5 HLA*A0201 ILAGIGILTV nm 
1E6 HLA*A0201 ALWGPDPAAA 278
4
 
1E6 HLA*A0201 AQWGPDFAAV nm
1
 
1E6 HLA*A0201 WQYWPDSMSA nm
1
 
1E6 HLA*A0201 RQWGPDPAAV 14
5
 
1E6 HLA*A0201 YQFGPDFPIA 9
6
 
 
Table 6.1: Biophysical measurements of multiple different TCR/pMHCI interactions in 
three different monoclonal CD8
+
 T-cell systems. Superagonists are shown in red, cognate 
ligands in black and weak agonists in green. 1 - (Laugel, van den Berg et al. 2007), 2 - 
(Clement, Ladell et al. 2011), 3 - (Ekeruche-Makinde, Clement et al. 2012), 4 - (Bulek, Cole 
et al. 2012), 5 - (Knight, Kronenberg et al. 2012), 6 – see Appendix 4, nm = not measured, 
nm
1
 = non-measurable 
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obtain biophysical data for the weak agonists in the 1E6 system because their affinity for the 
TCR is below the level that can be measured by SPR. 
 
I examined the recognition of all peptides in the context of an abrogated, wild type, slightly 
enhanced and greatly enhanced pMHCI/CD8 interaction by ILA1 (Figure 6.2), MEL5 (Figure 
6.3) and 1E6 (Figure 6.4). Activation was measured by both IFN- and MIP-1 ELISA. Dose 
response curves were fitted (with the assistance of Dr Hugo van den Berg, Warwick 
University) to all peptide titration results and pEC50s calculated. The data was then used to 
examine the way in which the pMHCI/CD8 interaction modulates the TCR/pMHCI 
interaction for multiple agonists. 
 
6.2.3 Differential modulation of TCR/pMHCI functional sensitivity by CD8  
Using the curves fitted in Figures 6.2, 6.3 and 6.4, it was possible to calculate the pEC50 for 
all ligands examined. pEC50 is defined as minus 1 x the base 10 logarithm (p) of the 50% 
efficacy concentration (EC50). Therefore a greater functional sensitivity is indicated by a 
larger pEC50 value. Abrogating the pMHCI/CD8 interaction had a significant impact on the 
recognition of all peptide ligands in all three monoclonal CD8
+ 
T-cell systems (ILA1, MEL5 
and 1E6). This is consistent with a previous study which showed that CD8 has a major 
impact on the number of peptide ligands that can be recognized by the TCR (Wooldridge, 
Laugel et al. 2010). When the strength of the pMHCI/CD8 interaction is increased then two 
different effects could be observed. In general, for weak agonists, increasing the strength of 
the pMHCI/CD8 interaction resulted in a steady improvement in functional sensitivity 
(monotone) (Figure 6.5). 
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Figure 6.2: The influence that CD8 exerts on recognition of multiple ligands. (A-P) 6 x 
10
4
 HLA A2 C1R with varying pMHCI/CD8 interactions were pre-incubated with titrated 
APL peptides @ 10
-5
M to 10
-12
M ILAKFLWHWL, ILAKYLWHWL, ILGKLFWRWL and 
ILGKFLWHWL for 1 hour @ 37°C. Excess peptide was removed by washing twice with 
PSG. 3 x 10
4
 ILA1 (hTERT) (residues 540-548) CD8
+
 T-cell clone where then added to each 
sample and incubated for 4 hours @ 37°C. Supernatants were harvested and assayed for MIP-
1β and IFN-γ production by ELISA (RandD Medsystems) and performed according to the 
manufacturer’s instructions. Data is displayed as scaled dose response curves, ●: read-out is 
MIP-1β; ○: read-out is IFN-γ. Assays were performed in duplicate. 
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Figure 6.3: The influence that CD8 exerts on recognition of multiple ligands. (A-P) 6 x 
10
4
 HLA A2 C1R with varying pMHCI/CD8 interactions were pre-incubated with titrated 
APL peptides @ 10
-5
M to 10
-12
M ELAGIGILTV, ELTGIGILTV, FATGIGIITV and 
ILAGIGILTV for 1 hour @ 37°C. Excess peptide was removed by washing twice with PSG. 
3 x 10
4
 MEL5 (Melan-A-residues 26-35) CD8
+
 T-cell clone where then added to each sample 
and incubated for 4 hours @ 37°C. Supernatants were harvested and assayed for MIP-1β and 
IFN-γ production by ELISA (RandD Medsystems) and performed according to the 
manufacturer’s instructions. Data is displayed as scaled dose response curves, ●: read-out is 
MIP-1β; ○: read-out is IFN-γ. Assays were performed in duplicate. 
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Figure 6.4: The influence that CD8 exerts on recognition of multiple ligands.  (A-T) 6 x 
10
4
 HLA A2 C1R with varying pMHCI/CD8 interactions were pre-incubated with titrated 
APL peptides @ 10
-5
M to 10
-12
M ALWGPDPAAA, AQWGPDFAAV, WQYWPDSMSA, 
RQWGPDPAAV, YQFGPDFPIA for 1 hour @ 37°C. Excess peptide was removed by 
washing twice with PSG. 3 x 10
4
 1E6 (PPI15–24) CD8
+
 T-cell clone where then added to each 
sample and incubated for 4 hours @ 37°C. Supernatants were harvested and assayed for MIP-
1β and IFN-γ production by ELISA (RandD Medsystems) and performed according to the 
manufacturer’s instructions. Data is displayed as scaled dose response curves, ●: read-out is 
MIP-1β; ○: read-out is IFN-γ. Assays were performed in duplicate. 
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In contrast, for superagonists, increasing the strength of the pMHCI/CD8 interaction resulted 
in an increase followed by a decrease in functional sensitivity (non-monotone) (Figure 6.5). 
These trends indicate that the relative distances between the pEC50 values for the various 
ligands to a given CD8
+
 T-cell clone can be modulated through CD8 (Figure 6.6). This was 
particularly pronounced in the MEL5 system where CD8 was able to mediate a complete 
change in the order of ligand potency. In the context of a wild-type pMHCI/CD8 interaction, 
the order of ligand potency was ILAGIGILTV > FATGIGIITV > ELAGIGILTV > 
ELTGIGILTV (Figure 6.5). However, in the context of a super-enhanced interaction with 
CD8 the order of ligand potency was ELAGIGILTV > ILAGIGILTV > ELTGIGILTV > 
FATGIGIITV, which is entirely different (Figure 6.5). The data indicate that CD8 has a 
differential effect on the recognition of peptide ligands and is capable of re-arranging the 
relative potencies of each potential agonist.  
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Figure 6.5: Differential modulation of TCR/pMHCI functional sensitivity by CD8. (A-
C) Using data generated from Figures 6.2, 6.3 & 6.4, pEC50 values of each ligand used in 
(A) ILA1, (B) MEL5 and (C) 1E6 CD8+ T-cell clone were plotted against each stably 
transfected C1R A2 B-cells each with varying pMHCI/CD8 affinities. 
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Figure 6.6: Curve representing the dependence of functional sensitivity on the 
TCR/pMHCI off-rate. The stabilising effect of the pMHCI/CD8 interaction may render a 
weak agonist (A) into a suboptimal (B) or even optimal agonist (C). A suboptimal agonist (B) 
may become optimal (C) and subsequently suboptimal again (D) as the strength of the 
pMHCI/CD8 interaction further increases. A ligand that is already optimal in the absence of 
the pMHCI/CD8 interaction (C) may become suboptimal (D) or weaker (E). 
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6.3 Discussion 
CD8
+
 T-cells are inherently crossreactive recognizing a large range of different peptide 
ligands. It is well established that CD8 can enhance the sensitivity of antigen recognition by a 
range of different mechanisms and it is assumed that CD8 would enhance the recognition of 
all potential ligands for an individual TCR to the same extent. However a recent 
mathematical analysis predicted that CD8 may exert a differential effect on the functional 
sensitivity of individual ligands. This is expected to manifest as a "focussing effect" whereby 
CD8 could act to re-arrange the relative potencies of the ligands recognized by an individual 
TCR. In this chapter I examined the effect that altering the strength of the pMHCI/CD8 
interaction exerts on the recognition of multiple ligands in three different monoclonal CD8
+
 
T-cell systems. I demonstrated that in all three systems, CD8 acts to differentially modulate 
the functional sensitivity of the TCR/pMHCI interaction. The data presented here highlights a 
novel role for CD8 in T-cell activation.  
 
My findings suggest that although the TCR can recognize multiple different ligands, CD8 
acts to focus the TCR onto a range of ligands which might be an important mechanism for 
avoiding autoreactivity. This focus is likely to be dynamic i.e. CD8 can alter the range of 
ligands that are seen at high functional sensitivity at any one time. Understanding this could 
be useful therapeutically in order to refocus the CD8
+
 T-cell response away from targeting 
self pMHCI. Here I have only examined the effect of increasing the strength of the 
pMHCI/CD8 interaction but other mechanisms, such as alterations in the expression level of 
CD8 at the cell surface, may have a similar effect. This CD8 focussing effect may control and 
optimize the degree of crossreactivity and antigen sensitivity of CD8
+
 T-cells at various 
stages of T-cell development. Mechanisms that regulate CD8, both during thymic education 
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and in the periphery, include transcriptional inhibition of CD8 expression in double-positive 
thymocytes (Bosselut, Guinter et al. 2003), selective co-receptor internalization following 
antigenic stimulation (Maile, Siler et al. 2005), switching to the expression of the CD8aa 
isoform (reviewed in (Gangadharan and Cheroutre 2004)), changes in the pattern of 
glycosylation (Daniels, Devine et al. 2001; Moody, Chui et al. 2001; Daniels, Hogquist et al. 
2002), and cytokine signals that transcriptionally tailor CD8 co-receptor expression (Park, 
Adoro et al. 2007). It is likely that these mechanisms work together to fine-tune the degree of 
functional crossreactivity at particular stages of development, facilitating selection of the 
TCR repertoire in the thymus while restraining deleterious activation in the periphery. 
 
In addition, I observed that CD8 can limit the functional sensitivity of the TCR/pMHCI 
interaction, i.e. CD8 can control the kinetic window of TCR/pMHCI activation where 
optimal ligands can become sub-optimal ligands. When the pMHCI/CD8 interaction is 
greatly increased in conjunction with strong TCR/pMHCI agonists, CD8
+
 T-cell activation 
decreases (Figures 6.2, 6.3 and 6.4). This decrease in CD8
+
 T-cell activation is only observed 
when both the pMHCI/CD8 and TCR/pMHCI interactions are increased above wild-type 
levels. This suggests that CD8 can limit the kinetic window of T-cell activation which may be 
important in preventing unwanted T-cell activation. This effect was seen in all CD8
+
 T-cell 
systems restricted by different epitopes (Figure 6.5). 
 
The precise mechanism to explain how CD8 focussing is controlling CD8
+
 T-cell sensitivity 
is unknown. Interestingly, increasing the pMHCI/CD8 interaction by >10 fold has been 
previously shown to maximally stabilise the TCR/pMHCI interaction (Wooldridge, van den 
Berg et al. 2005) This >10 fold increase may interfere with the rapid TCR/pMHCI 
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dissociation required to allow serial engagement of the TCR, which is thought to be critical 
for CD8
+
 T-cell activation (Valitutti, Muller et al. 1995). Alternatively, alterations in the 
kinetics of the pMHCI/CD8 interaction may have significant affects on CD8
+
 T-cell 
activation. Data suggests that recruitment of CD8 to the same pMHCI as the TCR can 
enhance synergistic adhesion which amplifies ligand discrimination (Jiang, Huang et al. 
2010). Yachi et al used FRET to show that in the presence of CD8, the TCR can specifically 
distinguish between structurally similar peptides via the kinetics of CD8 recruitment to the 
TCR (Yachi, Ampudia et al. 2006). The kinetics of the pMHCI/CD8 interaction (Koff 18s
-1
) 
are considerably faster than that measured for agonist TCR/pMHCI interactions (Koff = 0.01-
0.63s
-1
). As a result there is the potential for many pMHCI/CD8 interactions to take place 
during a single TCR/pMHCI interaction. This may be critical for optimal CD8
+
 T-cell 
activation. Extreme increases in the strength of the pMHCI/CD8 interaction may interfere 
with the rapid association/dissociation of CD8 with pMHCI engaged by the TCR therefore 
compromising the serial recruitment of signalling molecules to the TCR/CD3 complex and 
prevent the TCR from recognising self-reactive peptides. 
 
In summary, I have shown that CD8 can exert a differential effect on TCR/pMHCI functional 
sensitivity. This can result in a re-arrangement of the relative potencies of the ligands for an 
individual TCR and can also limit the functional sensitivity of the TCR/pMHCI interaction 
where optimal ligands can become sub-optimal ligands. This study highlights the significance 
of CD8 in ensuring that a CD8
+
 T-cell cannot become hyper-activated by focussing the CD8
+
 
T-cell on ligands that bind within specific kinetic window. The data presented here supports 
the theory that CD8 is playing a significant role in the TCR triggering event and influences 
the kinetic parameters of CD8
+
 T-cell activation, which has important implications and 
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potential disease relevance. It would be very interesting to study the effect of CD8 focussing 
in models where natural polymorphisms in the MHCI binding domain exist that may enhance 
or even abrogate pMHCI/CD8 affinity. The phenomenon described here could also be further 
studied by altering the levels of both CD8αα and CD8αβ expression at the cell surface and 
analysing the effect that exerts on the recognition of a range of APL. This is discussed further 
in chapter 7. 
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7 Discussion 
In this thesis, I have furthered our knowledge of the role that CD8 plays in T-cell activation 
and identified CD8 as a potential target for therapy during autoimmune disease. I have also 
highlighted a novel "focussing" role for CD8 in controlling CD8
+
 T-cell recognition of 
pMHCI antigen.  
 
7.1 Increased knowledge of the role that CD8 plays in T-cell activation  
7.1.1 The role of the low solution binding affinity of pMHCI/CD8 
To date no study has investigated the biological significance of the low solution binding 
affinity of the pMHCI/CD8 interaction. In Chapter 3 I investigated the effect of increasing 
the strength of pMHCI/CD8 interaction by 15 fold. The pMHCI/CD8 interaction is 
characterized by very low solution binding affinities (KD ~146 μM) and rapid kinetics (Wyer, 
Willcox et al. 1999; Gao, Willcox et al. 2000). In stark contrast, the TCR/pMHCI interaction 
can be more than 100-fold stronger than the pMHCI/CD8 interaction (KD range for agonists 
from 0.13 μM, the strongest natural TCR/pMHCI interaction measured to date) and exhibits 
considerably slower kinetics (Davis, Boniface et al. 1998; Cole, Pumphrey et al. 2007; 
Laugel, van den Berg et al. 2007; Varela-Rohena, Molloy et al. 2008; Stone, Chervin et al. 
2009). It seems extremely unlikely that the striking biophysical characteristics of the 
pMHCI/CD8 interaction have occurred by accident. In Chapter 3 I demonstrated that there is 
a complete loss of T-cell specificity when the pMHCI/CD8 interaction is increased by 15 
fold. This data suggests that CD8 has specifically evolved to operate at very low solution 
affinities and the low solution binding affinity is essential for the maintenance of CD8
+
 T-cell 
antigen specificity and T-cell homeostasis. It has been previously shown that the pMHC/CD8 
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interaction retained the majority of its ability to augment antigen recognition by CD8
+
 T-cells 
even when this interaction was reduced to an extremely low affinity (KD <500 μM). This 
result is relevant to the pMHCII/CD4 interaction which still augments antigen recognition 
despite being extremely weak (KD <1000 μM) (Hutchinson, Wooldridge et al. 2003). My 
results suggest that T-cell co-receptors have evolved to function at uniquely low affinities in 
order to ensure that the TCR/pMHC interaction dominates TCR/pMHCI/CD8 or 
TCR/pMHCII/CD4 interactions at the cell surface thereby upholding antigen specificity. 
 
7.1.2 The use of anti-CD8 antibodies to activate CD8
+
 T-cells 
Data from Chapter 3 indicated that an increase in pMHCI/CD8 interaction by 15 fold results 
in a complete loss of T-cell specificity. This result suggested that it might be possible to 
induce T-cell activation by cross-linking CD8 and the TCR using anti-CD8 antibodies. In 
Chapter 4 I examined the potential for anti-CD8 antibodies to induce T-cell activation. Anti-
CD8 antibodies have been used widely to investigate the role of CD8 in CD8
+
 T-cell 
activation. Many studies have concluded that anti-CD8 antibodies can inhibit the 
TCR/pMHCI interaction (MacDonald, Glasebrook et al. 1982; Janeway 1992), whereas 
contrasting studies have concluded that anti-CD8 antibodies can enhance TCR/pMHCI 
interaction and can even activate CD8
+
 T-cells (Veillette, Zuniga-Pflucker et al. 1989; 
Tomonari and Spencer 1990). I decided that it was important to address these contradictory 
findings because of the widespread use of anti-CD8 antibodies in CD8 biology. Therefore, I 
assembled a panel of seven different monoclonal anti-human CD8 antibodies and four anti-
mouse human CD8 antibodies. This is the first time that a comprehensive panel of anti-CD8 
antibodies have been compared in the same study. Interestingly, the data showed that 
multiple functional phenotypes exist within the anti-CD8 antibodies and that it is possible to 
Chapter 7 
 
244 
 
induce CD8
+
 T-cell activation independently of the TCR/pMHCI interaction. This correlated 
with the ability of one antibody (OKT8) to enhance TCR/pMHCI tetramer binding. 
Conversely anti-CD8 antibodies can also block TCR/pMHCI binding suggesting that both the 
enhancing and inhibitory effects of these antibodies are by the same mechanism. Interestingly 
the enhancing antibody OKT8 induces CD8 mediated ligation with release of chemokines 
and cytotoxicity in the absence of cytokine release. This may further highlight the importance 
of the function of CD8 in CD8
+
 T-cell signalling. 
 
In summary, multiple phenotypes exist across anti-CD8 antibodies. The effects observed 
using these antibodies may highlight the potential for targeting different binding sites on CD8 
to design therapeutic agents that either block or enhance T-cell activation. My study has 
identified and classified multiple phenotypes across a panel of anti-CD8 antibodies. The 
differing effects varied according to the antibody clone under investigation and suggest that 
caution should be taken when interpreting studies using these reagents.  
 
7.1.3 Identification of a novel CD8 “focussing” mechanism 
CD8 has been shown to play a major role in controlling the activation threshold of individual 
T-cells. The data I have shown in Chapter 6 reveals a novel mechanism termed “CD8 
focussing” where CD8 controls the levels of activation of individual TCRs by identifying a 
specific kinetic window which ensures that a CD8
+ 
T-cell cannot become over activated and 
therefore restricts subsequent non-specific activation. Here I used multiple CD8
+
 T-cell 
clones with APLs, each with different binding affinities to the TCR, in conjunction with C1R 
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B-cell lines which had been stably transfected with mutant MHCI that enhance or abrogate 
pMHCI/CD8 binding.  
 
I found that CD8 can exert a differential effect on TCR/pMHCI functional sensitivity i.e. 
CD8 can act to re-arrange the relative potencies of the ligands for an individual TCR. This is 
the first time this has been presented and also supports mathematical modelling by van den 
Berg et al (van den Berg, Wooldridge et al. 2007) who predicted that a T-cell can alter its 
functional avidity for its agonists and rearrange the relative potencies of each of its potential 
agonists. I have demonstrated that this is indeed the case and showed that a T-cell can 
specifically increase its sensitivity for one agonist while decreasing its sensitivity for other 
potential ligands. This focussing mechanism means that TCR degeneracy would be inherently 
dynamic, allowing each TCR to have a wide range of agonists while avoiding 
autorecognition. The precise mechanism to explain CD8 focussing is still unknown and 
would require further study. One potential mechanism may be due to an increase in the 
optimal dwell-time of ligands to serially trigger TCRs. CD8 can increase the dwell-time by 
approximately 2.2 fold. Thus CD8 may be increasing the dwell-time of a weak ligand and 
increase it to optimal dwell-time levels. If ligands that are already near optimal, then an 
increase in dwell-time may inhibit the ability of these ligands to serially trigger TCRs. This 
study moves to highlight the importance of CD8 in the T-cell triggering event and disease 
relevance which may lead to improved therapy design. 
 
Taken together, the data provided here highlights the importance of CD8 in homeostatic 
CD8
+
 T-cell activation. I have demonstrated that the low solution binding affinity of the 
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pMHCI/CD8 interaction is essential for the maintenance of T-cell specificity. CD8
+
 T-cells 
can become non-specifically activated independently of the TCR/pMHCI interaction by 
super-enhancing the pMHCI/CD8 and also by the use of anti-CD8 antibodies. In addition, I 
have identified a novel function termed "CD8 focussing" where CD8 can act to re-arrange the 
relative potencies of the ligands recognized by an individual TCR.  
 
7.2 The therapeutic potential of targeting CD8   
The design of efficient and safe therapies that target T-cell activity faces major challenges. 
On the one hand, targeting the entire T-cell compartment threatens harmful 
immunosuppression. On the other hand, specific T-cell targeting approaches require detailed 
knowledge of the putative self-antigens that drive autoimmune pathogenesis, which is 
presently an unrealistic goal considering the tremendous diversity of potential T-cell antigens 
and the vast allelic variability within the human MHC locus.  
 
Recent advances have significantly improved the understanding of the role that CD8 plays 
during antigen recognition. Previously, it was thought that CD8 involvement was critical in 
the majority of CD8
+
 T-cell responses. Because of this, a number of studies have been 
performed to examine the effect of blocking the pMHCI/CD8 interaction using soluble CD8 
variants (Sewell, Gerth et al. 1999; Cole, Rizkallah et al. 2007), antibodies (Wooldridge, 
Scriba et al. 2006) and other small molecules (Choksi, Jameson et al. 1998; Kern, Hussey et 
al. 1999), However, it is now appreciated that CD8 does not contribute equally in all CD8
+
 T-
cell responses in that the degree of CD8-dependence is inversely related to the strength of the 
TCR/pMHCI interaction (Holler, Holman et al. 2000; Holler and Kranz 2003; Laugel, van 
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den Berg et al. 2007; Wooldridge, Laugel et al. 2010). In fact, detailed biochemical and 
cellular investigations have established that the CD8 co-receptor is essential for the 
recognition of weak, low affinity ligands but dispensable for potent, high affinity ligands 
(Holler, Holman et al. 2000; Holler and Kranz 2003). This knowledge holds translational 
promise, especially in the setting of autoimmunity where TCR/pMHCI interactions are 
generally very weak (Bridgeman, Sewell et al. 2011; Bulek, Cole et al. 2012).  
 
I hypothesised that CD8 blockade should enable the selective targeting of weak TCR/pMHCI 
interactions without affecting high affinity cognate TCRs. In support of this idea, 
accumulated evidence, suggests that self-reactive (autoimmune) CD8
+
 T-cells, bear weaker 
binding TCRs to cognate ligand compared to non-self and alloreactive CD8
+
 T-cells (van der 
Merwe and Davis 2003; Laugel, Boulter et al. 2005; Cole, Pumphrey et al. 2007; Macdonald, 
Chen et al. 2009; Cole, Edwards et al. 2010; Bulek, Cole et al. 2012). Therefore, therapeutic 
targeting of CD8 may be useful in the setting of autoimmune diseases including type-1 
diabetes (Skowera, Ellis et al. 2008; Wong, Siew et al. 2008; Faustman and Davis 2009), 
multiple sclerosis (Friese and Fugger 2009), vitiligo (van den Boorn, Konijnenberg et al. 
2009), neurodegenerative diseases such as certain paraneoplastic syndromes (Darnell and 
Posner 2003), Hashimotos throiditis, autoimmune myocarditis and autoimmune hepatitis 
(Walter and Santamaria 2005).  
 
7.3 Blockade of CD8
+
 T-cell function using anti-CD8 antibodies 
The results in Chapter 4 demonstrate that it is possible to use anti-CD8 antibodies to block 
pMHCI tetramer binding at the cell surface. Importantly it has long been known that anti-
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CD8 antibodies could be used to block the activation of multiple CD8
+
 T-cells (MacDonald, 
Glasebrook et al. 1982). However no study incorporated the use of these blocking antibodies 
in a setting where high levels of CD8-dependency are important. Indeed it has been shown 
that very low TCR/pMHCI binding affinities characterised by KD values >100-200 μM are 
entirely CD8-dependent. These KD values are found to be characteristic of autoreactive 
TCRs. In this thesis, I demonstrated that anti-CD8 antibodies efficiently block the activation 
of CD8
+
 T-cells characterised by low affinity TCR/pMHCI interactions. I then went on to 
show that anti-CD8 antibodies can be used to inhibit the activation of a diabetogenic CD8
+
 T-
cell clone. The effect of the anti-CD8 antibodies is less profound if TCR/pMHCI binding 
affinities are <30 μM. This suggests that anti-CD8 antibodies could be used as a direct 
therapeutic agent in autoimmune disorders without compromising CD8
+
 T-cells that 
recognize viral or tumour targets. 
 
In this thesis I have studied a strategy to block autoreactive T-cell activation using antibodies. 
This is in contrast to the use of antibodies to induce tolerance which has been studied in a 
type-1 diabetes setting. Diabetes onset has been shown to be halted in the NOD mouse using 
non-depletive anti-CD4 and anti-CD8 antibodies (Phillips, Parish et al. 2009). There has also 
been extensive data highlighting the use of anti-CD3 antibodies in the study of type-1 
diabetes. Interestingly anti-CD3 antibodies have been shown to reverse diabetes onset in 
NOD mice and was the initial basis for the use of this antibody in human clinical trials 
(Chatenoud, Thervet et al. 1994; Herold, Hagopian et al. 2002; Keymeulen, 
Vandemeulebroucke et al. 2005). Indeed in human studies, the use of anti-CD3 antibodies has 
been shown to increase islet β cell function by up to two years and can increase insulin 
production (Herold, Gitelman et al. 2009). It is thought that this is due to the induction of 
Chapter 7 
 
249 
 
regulatory T-cells, which may play a key role in maintaining tolerance and have been 
reported to be TGFβ-dependent (Cobbold, Castejon et al. 2004; You, Leforban et al. 2007). It 
will be interesting to examine the pros and cons of blocking versus tolerance strategies in 
future studies. 
 
7.4 Future prospective studies 
7.4.1 Identification of a pMHCI/CD8 KD threshold for non-specific activation 
In Chapter 3 I demonstrated that increasing the strength of the pMHCI/CD8 interaction by 
approximately 15 fold (KD 9.4 μM) results in the T-cell becoming activated independently of 
the TCR/pMHCI interaction and subsequently a loss in CD8
+
 T-cell specificity. Therefore 
between a KD of 9.4 and 98 μM there may exist a threshold of pMHCI/CD8 affinity where 
the increase in this interaction switches from being advantageous to being detrimental in 
terms of CD8
+
 T-cell specificity. It would be of great importance to identify this threshold 
level in further study of CD8 in CD8
+
 T-cell activation. This may allow for a further 
understanding of the kinetics of the pMHCI/CD8 interaction and its potential implications in 
TCR/pMHCI specificity and activation. 
 
7.4.2 Identifying the precise mechanism by which anti-CD8 antibodies elicit CD8
+
 T-cell 
effector function 
As discussed in Chapter 4, multiple phenotypes exist in anti-CD8 antibodies (both human and 
mice). The precise mechanism by which each phenotype is exerted is still conjecture. To 
definitively assess the molecular interaction of the anti-CD8 antibodies at the cell surface, 
both fluorescence resonance energy transfer FRET and also bioluminescence resonance 
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energy transfer BRET techniques can be used. FRET can be performed by microscopy to 
quantify the extent and kinetics of molecular interactions between fluorophore-tagged 
proteins within  sub-cellular regions such as the immunological synapse (Zal, Zal et al. 2002). 
Therefore FRET can be used to visualise differences in the TCR/pMHCI/CD8 interaction. 
The introduction of anti-CD8 antibodies into this system would help to understand the 
mechanism of action for each anti-CD8 antibody tested in this thesis, most notably those that 
both enhance and inhibit the TCR/pMHCI interaction. Another way to study this interaction 
is using BRET which works on the similar premise to FRET however uses bioluminescent 
markers instead of fluorescence, increasing the stability of the interaction which becomes 
more suitable for protein-protein interactions (Pfleger, Seeber et al. 2006). 
 
7.4.3 Altering CD8 expression levels at the cell surface 
Data from Chapter 6 highlighted a potential new role for CD8 in controlling the window of 
ligands that are available to a TCR. However, these experiments were conducted using MHCI 
mutations with a varied interaction with CD8. It is more likely that in-vivo this focussing 
effect is achieved by altering the cell surface levels of CD8. It has been shown that CD8 
levels at the cell surface are very dynamic and change during the course of an immune 
response. It will be important to construct a system where levels of CD8 can be altered in 
order to repeat the study of APL recognition.  
 
7.4.4 Solving the human CD8αβ heterodimer crystal structure 
To date, a soluble human CD8αβ heterodimer has yet to be assembled. This is mainly due to 
the preference of human CD8α to homodimerise during manufacture. If this problem was 
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addressed and solved then this would allow for biophysical data for the human heterodimer to 
be determined for the first time. Murine studies concluded that CD8αα and CD8αβ bind 
murine pMHCI with similar affinity (Sun and Kavathas 1997) (Arcaro, Gregoire et al. 2001; 
Wang, Natarajan et al. 2009). However observations made by Chang and colleagues after 
studying the crystal structures of murine CD8αα and CD8αβ highlighted important 
differences that could lead to subtle binding differences to MHCI (Chang, Tan et al. 2005). 
Jiang and colleagues confirmed that the murine CD8αα and CD8αβ do bind to MHCI with 
similar affinity, though indeed subtle differences were noted in the affinity of the interaction 
(Wang, Natarajan et al. 2009).  
 
It is possible that the binding of CD8αα and CD8αβ to the MHCI may be different in the 
human system. The average murine pMHCI/CD8 interaction is approximately 5 times as 
strong as the human pMHCI/CD8 interaction, i.e. murine pMHCI/CD8 KD ~ 30µM, whereas 
human pMHCI/CD8 KD ~ 146µM as measured by SPR (Purbhoo, Boulter et al. 2001). These 
differences observed in the murine CD8αα and CD8αβ binding affinity to pMHCI may 
translate into the human system. It would also be of interest to study the differences in 
binding interactions using the newly developed 2D micropipette adhesion frequency assays 
(Jiang, Huang et al. 2010).  
 
Another advantage in successfully manufacturing soluble CD8αβ would allow for crystal 
structures and co-crytsal structures of CD8αβ with varying allelic pMHCI, which would 
provide an interesting insight as to the exact orientation of binding. This could potentially 
allow for designed therapies based on structural information. It would also be of interest to 
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solve the co-crystal structure of both enhancing and inhibitory anti-CD8 antibodies to 
pMHCI/CD8αα/αβ. This would help to visualise direct molecular interactions between the 
antibody and CD8; thereby facilitating the design of immune based therapies (Shore, Issafras 
et al. 2008). 
 
7.4.5 Developing novel therapeutics that inhibit the pMHCI/CD8 interaction 
My preliminary experiments suggest that the phenotype of CD8 antibodies might be 
determined by the binding site of the epitope. Therefore it may be possible to design 
therapeutics that target specific sites on CD8 in order to achieve either inhibitory or 
activatory effects. The enhancing effects that are seen by the antibody clone OKT8 may be 
due to the position that this antibody binds. Indeed Sanders et al identified that OKT8 binds 
to a distinct site compared to anti-CD8 antibodies with an inhibitory phenotype (Figure 4.15) 
(Sanders, Fox et al. 1991). Further studies may allow for design of therapies aimed at either 
enhancing or inhibiting CD8
+
 T-cell function and may uncover further heterogeneity of these 
regions as seen in the murine system (Chapter 4). 
 
The use of antibodies in therapy is dramatically on the rise, therefore the timing of this study 
is very significant. By the late 1990s many monoclonal antibodies were in advanced clinical 
development and as of 2004, there were 15 monoclonal antibodies licensed for clinical use 
and only one licensed for use in an infectious disease (Rous sarcoma virus (RSV) infection) 
as reviewed in (Casadevall, Dadachova et al. 2004). However as of 2010 more than 30 mAbs 
are licensed for therapy covering a large range of pathologies including oncogenic and 
inflammatory disorders with many more antibodies in clinical trials including 26 at Phase III 
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as reviewed in (Beck, Wurch et al. 2010) indicating a dramatic increase in the use of 
antibodies as therapeutic agents. 
 
7.5 Concluding Remarks 
To date there are studies that suggest that CD8 is not essential for CD8
+
 T-cell activation (as 
reviewed in (van der Merwe and Dushek 2011). Recent studies have suggested that CD8 has 
important implications in controlling T-cell homeostasis and is essential in controlling 
TCR/pMHCI stability and T-cell crossreactivity (Wooldridge, van den Berg et al. 2005; 
Wooldridge, Laugel et al. 2010). This thesis has further demonstrated the need for CD8 in 
controlling T-cell specificity, identified CD8 as a potential target for immune based therapies 
and identified a novel potential role for CD8 in controlling the specificity of ligands that a T-
cell can recognise. Taking all of these findings together, it is clear that CD8 is playing a 
critical role in T-cell activation and the findings of this thesis would definitely warrant further 
study of CD8. This would allow for the potential modulation of CD8 as a therapeutic target in 
T-cell responses. 
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MHC Class I Molecules with Superenhanced CD8 Binding
Properties Bypass the Requirement for Cognate TCR
Recognition and Nonspecifically Activate CTLs
Linda Wooldridge,*,1 Mathew Clement,*,1 Anna Lissina,* Emily S. J. Edwards,*
Kristin Ladell,* Julia Ekeruche,* Rachel E. Hewitt,† Bruno Laugel,* Emma Gostick,*
David K. Cole,* Reno Debets,‡ Cor Berrevoets,‡ John J. Miles,*,x Scott R. Burrows,x
David A. Price,* and Andrew K. Sewell*
CD8+ CTLs are essential for effective immune defense against intracellular microbes and neoplasia. CTLs recognize short peptide
fragments presented in association with MHC class I (MHCI) molecules on the surface of infected or dysregulated cells. Ag
recognition involves the binding of both TCR and CD8 coreceptor to a single ligand (peptide MHCI [pMHCI]). The TCR/pMHCI
interaction confers Ag specificity, whereas the pMHCI/CD8 interaction mediates enhanced sensitivity to Ag. Striking biophysical
differences exist between the TCR/pMHCI and pMHCI/CD8 interactions; indeed, the pMHCI/CD8 interaction can be >100-fold
weaker than the cognate TCR/pMHCI interaction. In this study, we show that increasing the strength of the pMHCI/CD8
interaction by ∼15-fold results in nonspecific, cognate Ag-independent pMHCI tetramer binding at the cell surface. Furthermore,
pMHCI molecules with superenhanced affinity for CD8 activate CTLs in the absence of a specific TCR/pMHCI interaction to
elicit a full range of effector functions, including cytokine/chemokine release, degranulation and proliferation. Thus, the low
solution binding affinity of the pMHCI/CD8 interaction is essential for the maintenance of CTL Ag specificity. The Journal of
Immunology, 2010, 184: 000–000.
C
D8+ CTLs recognize antigenic determinants in the form of
short peptides derived from endogenous proteins bound to
MHC class I (MHCI) molecules on the surface of target cells
and play a critical role in immune defense against intracellular
pathogens and tumors. Ag specificity is conferred by the TCR, which
interacts with the peptide-binding platform formed by the a1 and a2
domains of MHCI (1, 2). In contrast, the surface gp CD8 binds to in-
variant regions of MHCI and is capable of enhancing cellular sensi-
tivity to Ag by up to six orders of magnitude (3, 4). CD8 mediates this
profound enhancement of Ag sensitivity through a number of distinct
mechanisms: 1) enhancement of the TCR/peptide MHCI (pMHCI)
association rate (5–7); 2) stabilization of the TCR/pMHCI interaction
(8, 9); 3) recruitment of essential kinases to the intracellular side of the
TCR/CD3/z complex (10, 11); and 4) localization of TCR/pMHCI
complexes within specialized membrane microdomains that are en-
riched for early intracellular signal transduction molecules and are
thought to act as privileged sites for TCR-mediated cascade initiation
(12, 13).
TheMHCIbinding site forCD8 is separate from thepeptide-binding
domains that are recognizedby theTCR (2) and this spatial segregation
allows both TCR and CD8 to bind a single MHCI molecule simulta-
neously (14). Thus, CTL recognition ofAg involves the binding of two
receptors (TCR and CD8) to a single ligand (pMHCI), a modus oper-
andi that is unique toabTcell biology. The pMHCI/CD8 interaction is
characterized by very low solution affinities (KD ∼150 mM) and rapid
kinetics (Koff∼18 s21) (15, 16). Indeed, the affinity of the pMHCI/CD8
interaction is even lower than the corresponding values measured for
conventional molecular binding events involved in cell-cell recogni-
tion, such as the CD2/CD48 interaction (KD = 60–90 mM) (15, 17). In
stark contrast, the TCR/pMHCI interaction can be more than 100-fold
stronger than the pMHCI/CD8 interaction (KD range for agonists from
0.14 mM, the strongest natural TCR/pMHCI interaction measured to
date) and exhibits considerably slower kinetics (Koff range for agonists
0.01–1 s21) (1, 6, 18–20). It seems extremely unlikely that the striking
biophysical characteristics of the pMHCI/CD8 interaction have oc-
curred by accident. Indeed, this conclusion is strengthened by the
finding that the pMHCI/CD8 interaction is capable of exerting the vast
majority of its biological function when weakened even further (21),
which suggests thatCD8has specifically evolved to operate at very low
solution affinities.
In this study,we probe the functional significance of the low solution
affinity pMHCI/CD8 interaction using pMHCI molecules with super-
enhanced CD8 binding properties. Notably, we find that pMHCI mol-
eculeswith affinities forCD8 that liewithin the typical range for agonist
TCR/pMHCI interactions (KD∼10mM) are able to activateCTL in the
absence of a specific TCR/pMHCI interaction. Thus, the biophysical
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characteristics of the pMHCI/CD8 interaction are essential for the
maintenance of CTL Ag specificity.
Materials and Methods
Cells
TheCTLclones 003 andNT1and theCTL line 868 are all specific for theHIV-1
p17 Gag-derived epitope SLYNTVATL (residues 77–85) restricted by HLA
Ap0201 (A2 from this point forward) (22, 23). The followingA2-restrictedCTL
clones were also used in this study: 1)Mel13, specific for theMelan-A–derived
epitope ELAGIGILTV (residues 26–35); and 2) ILA1, specific for the human
telomerase reverse transcriptase (hTERT)-derived epitope ILAKFLHWL
(residues 540–548) (6, 24). In addition, the following non-A2–restricted CTL
cloneswere used: 1) theHLAAp6801-restrictedCTLclone c23, specific for the
HIV-1 Tat-derived epitope ITKGLGISYGR (residues 38–48) (25); 2) the HLA
Bp0702-restricted CTL clone KD4, specific for the EBV EBNA3A-derived
epitope RPPIFIRRL (residues 379–387); 3) the HLA Bp0801-restricted CTL
clone LC13, specific for the EBV EBNA3A-derived epitope FLRGRAYGL
(residues 339–347) (26, 27); and 4) the HLA Bp3508-restricted CTL clone
SB27, specific for the EBV BZLF1-derived epitope LPEPLPQGQLTAY (res-
idues 52–64) (28, 29). All CTLs were maintained in RPMI 1640 (Life Tech-
nologies, Rockville, MD) containing 100 U/ml penicillin (Life Technologies),
100 mg/ml streptomycin (Life Technologies), 2 mM L-glutamine (Life Tech-
nologies), and 10% heat inactivated FCS (Life Technologies) (R10) supple-
mented with 2.5% Cellkines (Helvetica Healthcare, Geneva, Switzerland), 200
IU/ml IL-2 (PeproTech, Rocky Hill, NJ) and 25 ng/ml IL-15 (PeproTech).
PBMCs were isolated by standard Ficoll-Hypaque density gradient centrifu-
gation from healthy donor blood. The 293T-CD8a cells were manufactured by
introducing pBullet-human CD8a (30, 31) into 293T cells using vesicular
stomatitis virus-pseudotyped Moloney murine leukemia virus particles. The
293T-CD8a cells were cultured in DMEM (Life Technologies) supplemented
with 20% FCS (Life Technologies), 1 mM sodium pyruvate (Life Technolo-
gies), 100 U/ml penicillin (Life Technologies), 100 mg/ml streptomycin (Life
Technologies), and 2 mM L-glutamine (Life Technologies). Hmy.2 C1R B
(C1R) cells expressing full-length A2 and variants thereof were generated as
described previously (21).
pMHCI tetramers
Tetrameric complexes of wild-type pMHCI molecules and mutants thereof
were produced, stored and used as described previously (9, 21). The following
A2-restricted peptide epitopes were used to refold the pMHCI molecules used
in this study: SLYNTVATL (HIV-1 p17 Gag, residues 77–85), LLFGYPVYV
(HTLV-1 Tax, residues 11–19), GLCTLVAML (EBV BMLF1, residues 259–
267),NLVPMVATV(CMVpp65, residues495–503),ELAGIGILTV(Melan-A,
residues 26–35), and ILAKFLHWL (hTERT, residues 540–548). Tetrameric or
multimeric pMHCI reagents were constructed by the addition of streptavidin
conjugated to PE, quantum dot 605 or quantum dot 800 (Life Technologies) at
the appropriate molar ratios.
Abs
The following mAbs were used in this study: purified anti-human CD8 (clone
DK-25;Dako,Carpinteria,CA),allophycocyanin-conjugatedanti-humanCD8
(cloneRPA-T8;BDBiosciences, San Jose, CA), FITC-conjugated anti-human
CD8 (cloneSK1;BDBiosciences), PerCP-conjugated anti-humanCD8 (clone
SK1; BD Biosciences), PE-conjugated anti-human CD8b (clone 2ST8.5H7;
Beckman Coulter, Fullerton, CA), PerCP-conjugated anti-human CD3 (clone
SK7; BD Biosciences), FITC-conjugated anti-human ab-TCR (clone BMA
031; Serotec, Oxford, U.K.), FITC-conjugated or PE-conjugated anti-human
gd-TCR (clone YB5.B8; BD Pharmingen, San Diego, CA), allophycocyanin-
conjugated anti-human CD56 (clone AF12-7H3; Miltenyi Biotec, Auburn,
CA), FITC-conjugated anti-human CD56 (clone MEM188; Caltag Labora-
tories, Burlingame, CA ), FITC-conjugated anti-A2 (clone BB7.2; Serotec),
and FITC-conjugated anti-human CD107a (clone H4A3; BD Biosciences).
Unless specified, the anti-human CD8 mAbs used in this study target the
a-chain of the coreceptor dimer. Dead cells were excluded from flow cyto-
metric analyses with 7-amino-actinomycin D (7-AAD; BD Biosciences).
Flow cytometry
For pMHCI tetramer staining, 2.5 3 106 PBMC, 5 3 104 CTLs or 2 3 105
293T cells (untransfected or CD8a-transfected) were resuspended in PBS or
FACS buffer (2% FCS/PBS) and stained with pMHCI tetramer at the con-
centrations indicated for 20–30 min at 37˚C. Cells were subsequently stained
with combinations of themAbsdescribed previously for 30min on ice. Prior to
staining, 293T cells were treated with Versene (Life Technologies) for 10 min
at 37˚C. For anti-CD8 mAb blocking experiments: 2.5 3 106 PBMCs were
pretreated with 10 mg/ml unconjugated anti-CD8 mAb (clone DK-25; Dako)
for 20minon ice prior to stainingwith 10mg/mlpMHCI tetramer for 45minon
ice. For A2 typing: 2.53 106 PBMCswere stainedwith 5ml FITC-conjugated
anti-A2 mAb (clone BB7.2; Serotec) for 30 min on ice. Samples were then
washed twice and resuspended in PBS. Data were acquired using a FACSCa-
libur or FACSAria II flow cytometer (BD Biosciences) and analyzed with ei-
therCellQuest (BDBiosciences) or FlowJo (Tree Star, Ashland,OR) software.
TCR downregulation assay
The105 003CTLsperwellwere resuspended in a 96-well round-bottomedplate
with various concentrations of the indicated PE-conjugated tetramers (A2
SLYNTVATL, A2/Kb SLYNTVATL, A2 LLFGYPVYV, or A2/Kb LLFGY-
PVYV) diluted in 40 ml RPMI 1640 containing 2% FCS plus penicillin,
streptomycin, and glutamine as described previously (R2) for 30 min at 37˚C.
Cells were then washed, resuspended in ice-cold azide buffer (0.1% azide/2%
FCS/PBS), and subsequently stained with FITC-conjugated anti–ab-TCR
(clone BMA 031; Serotec), 7-AAD (BD Biosciences), and allophycocyanin-
conjugated anti-CD8 (clone RPA-T8; BDBiosciences) for 30 min on ice. After
two additional washes, cells were resuspended in ice-cold azide buffer. Data
were acquired using a FACSCalibur flow cytometer and analyzed with Cell-
Quest software (BD Biosciences).
Cytokine/chemokine assays: ELISA, cytometric bead array,
and ELISPOT
CTLswere incubated with C1RA2 cells, C1RA2/Kb cells, or medium alone at
different E:Tratios overnight at 37˚C. Subsequent to incubation, the supernatant
was harvested and assayed for MIP-1b, IFN-g, or RANTES by ELISA (R&D
Systems, Minneapolis, MN). Remaining supernatant was assayed with the
humanTh1/Th2 cytokine kit (BDBiosciences) according to themanufacturer’s
instructions; data were acquired using a FACSCalibur flow cytometer and an-
alyzed with CBA software (BD Biosciences). For tetramer-based ELISPOT
assays, 23 103 CTL6 pMHCI tetramer at 1 mg/ml were applied to duplicate
wells of PVDF-backed plates (Millipore, Bedford, MA) precoated with IFN-g
captureAb1-DIK(Mabtech,Nacka,Sweden) in a total volumeof200mlR2and
incubated for 4 h at 37˚C. To exclude activation by cognate peptide represen-
tation or fluorochrome-mediated aggregation, cognate A2 D227K/T228A tet-
ramers were included as controls; these tetramers do not bind CD8 and did not
activate 003 or 868 CTLs, despite efficient staining in both cases (data not
shown). Plates were developed according to the manufacturer’s instructions
(Mabtech) and spots were counted using an automated ELISpot Reader System
ELR02 (Autoimmun Diagnostika GmbH, Strassberg, Germany).
Degranulation assay
Surface CD107a mobilization was used to assess degranulation as described
previously (32).Briefly,CTLswere incubated for 4hat 37˚Cwith eitherC1RA2
cells, C1R A2/Kb cells or medium alone at different E:T ratios; alternatively,
CTLs were incubated with various pMHCI tetramers. Both FITC-conjugated
anti-CD107a (clone H4A3; BD Biosciences) and 0.7 ml/ml monensin (Golgi-
Stop;BDBiosciences)wereaddedprior to incubation.Subsequent to incubation,
the cells were washed twice and resuspended in PBS. Data were acquired using
a FACSCalibur flow cytometer and analyzed with FlowJo software (Tree Star).
CTL priming assay
TransfectedC1Rcellswerepulsedwith1mMELAGIGILTV(Melan-A26–35)
peptide for 90 min, irradiated, and washed once in RPMI 1640 medium.
Pulsed, irradiated C1R cells (2 3 105) were incubated with 106 fresh A2+
human PBMCs in R10; 200 IU/ml IL-2 was added on day 3. CD8+ cells
specific for Melan-A26–35 were quantified on day 10 with wild-type A2
ELAGIGILTV tetramer.
Results
Generation of MHCI molecules with superenhanced CD8
binding affinity
Tetrameric fusion molecules comprising the a1/a2 peptide binding
platform of A2 and the a3 domain of H2-Kb (A2/Kb from this point
forward) enable the monitoring of CD8+ T cell responses in A2
transgenic mice (33). This reflects a requirement for the murine
MHCI a3 domain to engage murine CD8 (11), thus enabling A2/Kb
reagents to stain murine CTL with lower affinity TCR/pMHCI in-
teractions (so-called “low avidity” CTLs) (22). The A2/Kb H chain
foldedwith humanb2m interacts strongly with humanCD8 (KD∼10
mM, compared with A2 that binds to CD8 with a KD ∼150 mM) but
exhibits unaltered A2-restricted TCR binding properties (9, 22).
Thus, fusing themurinea3 domainwithA2a1/a2 domains increases
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the strength of the pMHCI/CD8 interaction by ∼15-fold without af-
fecting the TCR/pMHCI interaction.
Superenhanced CD8 binding results in nonspecific pMHCI
ligand interactions
MonomericpMHCIcomplexescannotbeusedtoexamineTCR/pMHCI
bindingat thecell surfacebecauseof theextremelyshorthalf-lifeofsuch
interactions. Increasing thevalencyof thesemolecules byavidin/biotin-
based tetramerization overcomes this limitation and produces reagents
that are invaluable for the identification and characterization of Ag-
specific CTLs (34, 35). Indeed, it is well established that wild-type
tetrameric pMHCI reagents bind to cell surface TCR with exquisite
specificity (34, 36). Thus, A2/Kb tetrameric reagents were generated to
study the effect of superenhanced CD8 binding on the specificity of
pMHCI ligand interactions at the cell surface.
Wild-type pMHCI tetrameric reagents bearing cognate peptide
stained three distinct A2-restricted CTLs specific for SLYNTVATL
(HIV-1 p17 Gag77–85), each expressing a different TCR (19, 22, 23)
(Fig. 1A). Noncognate A2 LLFGYPVYV (HILV-1 Tax11–19) tet-
ramers failed to stain any of these in vitro expanded CTL populations
to any notable extent. However, A2/Kb LLFGYPVYV tetramers
stained all SLYNTVATL-specific CTLs; in addition, both the A2/Kb
SLYNTVATL and A2/Kb LLFGYPVYV tetramers stained the non-
cognate CD8+ cell population in the 868 CTL line (Fig. 1A). To ex-
amine this effect in more detail, we used A2 and A2/Kb tetramers to
stain fresh human PBMCs. Ag-specific CD8+ cell populations were
not identified in PBMCs from healthy donors with either the A2
SLYNTVATL or A2 LLFGYPVYV tetramers (Fig. 1B). In contrast,
both the A2/Kb SLYNTVATL and A2/Kb LLFGYPVYV tetramers
stained.85% of CD8+ cells in PBMCs (Fig. 1B); similar data were
obtainedwithA2/KbGLCTLVAML(EBVBMLF1259–267) andA2/K
b
NLVPMVATV (CMVpp65495–503) tetramers (data not shown). Taken
together, these data indicate that the exquisite specificity of tetra-
meric pMHCI reagents is lost when the strength of the pMHCI/CD8
FIGURE 1. The exquisite specificity
of pMHCI tetramer staining is lost
when the strength of the pMHCI/CD8
interaction is increased by ∼15-fold. A,
The 003orNT1CTLclones (105 cells) or
the 868 CTL line (2.5 3 105 cells), all
specific for HIV-1 p17 Gag77–85, were
stained with 1 mg of the PE-conjugated
tetramers A2 SLYNTVATL, A2/Kb
SLYNTVATL,A2LLFGYPVYV, orA2/
Kb LLFGYPVYV in 20 ml PBS for 20
min at 37˚C. Cells were then stainedwith
allophycocyanin-conjugated anti-CD8
and 7-AAD for 30 min on ice, washed
twice, and resuspended inPBS.Datawere
acquired using a FACSCalibur flow cy-
tometer and analyzed with CellQuest
software. B, 2.5 3 105 PBMCs were
suspended in 250 ml FACS buffer (2%
FCS/PBS), then stained with 1 mg of the
PE-conjugated tetramers A2 SLYNT-
VATL, A2/Kb SLYNTVATL, A2 LLFG-
YPVYV, or A2/Kb LLFGYPVYV for 20
min at 37˚C. Each sample was sub-
sequently stained with allophycocyanin-
conjugated anti-CD8, PerCP-conjugated
anti-CD3, and 7-AAD for 30 min on ice,
washed twice, and resuspended in FACS
buffer. Data were acquired using
a FACSCalibur flow cytometer and ana-
lyzed with CellQuest software by gating
on the live CD3+ population. The values
shown represent the percent of CD3+
CD8+ cells that stain with the indicated
tetramer.
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interaction is increased by ∼15-fold. Thus, the low solution affinities
of the wild-type pMHCI/CD8 interaction are required to maintain
pMHCI binding specificity at the cell surface.
A2/Kb tetramers bind the majority of CTLs in peripheral blood
Noncognate A2/Kb tetramers were observed to bind ∼80% of the
CD8a+ population in peripheral blood (Fig.1B). Although CD8a is
predominantly found on the surface of ab-TCR+ CTLs, it is also
found on the surface of other lymphocytes, most notably some gd
T cells and NK cells.We therefore sought to determine the identity of
the CD8a+ cells that stain with A2/Kb tetramers. Staining of fresh ex
vivo PBMCs isolated from healthy A2+ donors revealed that CD8a
was expressed on ∼39%, 54%, and 32% of the ab-TCR+, NK cells,
and gd-TCR+ populations, respectively, with some variation between
donors (Fig. 2A). The majority of gd-TCR+ (∼93.6%) and NK cells
(∼77%) failed to stainwith theA2/Kb ILAKFLHWL (hTERT540–548)
tetramer and no significant binding was observed with the corre-
sponding A2 tetramer (Fig. 2B). However, the vast majority of
ab-TCR+/CD8+ cells within the lymphocyte population stained
nonspecifically with the A2/Kb ILAKFLHWL tetramer (Fig. 2C).
Wehypothesized thatmostgd-TCR+ cells andNKcellsmight fail
to bind A2/Kb tetramers because they express the CD8aa homo-
dimer rather than theCD8ab heterodimer, which is expressed on the
surface of CTLs. Thus, we generated a 293T cell line that expressed
CD8aa (Fig. 3A) to examine the ability of A2/Kb tetramers to bind
this homodimeric form of the CD8 coreceptor on the cell surface. In
contrast to both A2 and A2 D227K/T228A tetramers, which exhibit
normal and abrogated interactions with CD8, respectively, A2/Kb
tetramers bound to most (74.3%) of the CD8aa+ 293 T cell trans-
fectants (Fig. 3A, 3B); no binding was observed in the absence of
CD8aa surface expression (Fig. 3A). Thus, A2/Kb tetramers are
capable of binding to cell surface CD8aa.
Why do A2/Kb tetramers bind predominantly to the CTL pop-
ulation in peripheral blood and not to other cells that express CD8?
Fig. 3B shows that A2/Kb tetramer staining is directly proportional to
the level ofCD8aa expression, such that only cellswith a higher level
FIGURE 2. A2/Kb tetramers bind the
majority of CTLs in peripheral blood. A,
2.53 105 PBMCs from an A2+ donor were
stained with PerCP-conjugated anti-CD8,
7-AAD, and either FITC-conjugated anti–-
ab-TCR, allophycocyanin-conjugated anti-
CD56 or PE-conjugated anti–gd-TCR for
30 min on ice, washed twice, and re-
suspended in PBS.B, 2.53105A2+ PBMCs
were stained with 10 mg/ml of the PE-
conjugated tetramers A2 ILAKFLHWL or
A2/Kb ILAKFLHWL for 20 min at 37˚C.
After washing, cells were subsequently
stained with 7-AAD and either FITC-con-
jugated anti–gd-TCR or FITC-conjugated
anti-CD56 for 30 min on ice, washed twice,
and resuspended in PBS. C, 2.5 3 105 A2+
PBMCs were stained with 10 mg/ml of the
PE-conjugated tetramers A2 ILAKFLHWL
or A2/Kb ILAKFLHWL for 20 min at
37˚C. After washing, cells were stained
with allophycocyanin-conjugated anti-CD8,
FITC-conjugated anti–ab-TCR and 7-AAD
for 30 min on ice, washed twice, and re-
suspended in PBS. In A, B, and C, data were
acquired using a FACSCalibur flow cy-
tometer and analyzed with FlowJo software.
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ofCD8aa expression stainwith this reagent. Examination of PBMCs
from healthy donors revealed that CD8+ab-TCR+ cells express high
levels of CD8, whereas NK and gd-TCR+ cells express substantially
lower levels (Fig. 3C). Therefore, increasing the strength of the
pMHCI/CD8 interaction allows pMHCI ligand binding at the cell
surface that can be mediated through the engagement of either
CD8aa or CD8ab. However, our results suggest that binding is only
observed when cells express CD8 at levels above a certain threshold.
Importantly, these data demonstrate that TCR expression is not re-
quired for cell surface binding of A2/Kb tetramers.
A2/Kb tetramers activate CTLs irrespective of TCR specificity
It is well established that pMHCI tetramers can activate CTLs bearing
cognate TCR [reviewed in (35)]. However, previous studies have
shown that pMHCI tetrameric binding at the cell surface does not
necessarily equate with activation (11, 37). Thus, we next examined
whether nonspecific A2/Kb tetramer binding at the cell surface
(Figs. 1–3) could activate human CTLs. Initially, we studied the A2-
restricted SLYNTVATL-specific CTL clone 003 (23). Consistent with
our findings previously stated, both A2 SLYNTVATL and A2/Kb
SLYNTVATL tetramers stained 003 CTLs efficiently, as did the
noncognate A2/Kb LLFGYPVYV tetramer; no staining was observed
with theA2LLFGYPVYV tetramer (Fig. 4A). On ligation, it is known
that TCRs are downregulated from the cell surface (38). The cognate
A2 tetramer was able to induce significant TCR downregulation, even
at tetramer concentrations well below the limits of detection by flow
cytometry; no TCR downregulation was observed with the non-
cognate A2 LLFGYPVYV tetramer (Fig. 4B). In contrast, however,
both the A2/Kb SLYNTVATL and A2/Kb LLFGYPVYV tetramers
inducedTCRdownregulation, although this occurred to a lesser extent
with the noncognate form compared with either of the cognate tet-
ramers (Fig. 4B). This TCR downregulation correlated with various
functional readouts typical of CTL effector activity, including the
production of RANTES (Fig. 4C), IFN-g, and MIP-1b (data not
shown). Similar results were observed with SLYNTVATL-specific
CTLs bearing an alternative cognate TCR (Fig. 4D, 4E). Consistent
with the staining patterns (Fig. 4A), the activation of CTLs by non-
cognate A2/Kb tetramers was less efficient than that induced by tet-
ramers bearing the agonist peptide (Fig. 4C–E).
To dissect this effect further at the single-cell level within a clonal
CTL population, we used a flow cytometric assay for degranulation
based on the detection of CD107a mobilized on to the cell surface
(32). The noncognate A2/Kb tetramer, in this case folded around the
GLCTLVAML peptide, induced degranulation in 15% of 003 CTLs
at a concentration of 5 mg/ml (Fig. 4F); the cognate A2 SLYNT-
VATL and A2/Kb SLYNTVATL tetramers induced almost 40%
degranulation (data not shown). Notably, the cells that degranulated
in response to the A2/Kb GLCTLVAML tetramer were contained
FIGURE 3. Nonspecific A2/Kb tetramer binding is influenced byCD8 cell surface density. A and B, 23 105 293T cells were incubated6 10mg/ml of the PE-
conjugated tetramers A2 D227K/T228A ILAKFLHWL, A2 ILAKFLHWL, or A2/Kb ILAKFLHWL for 20 min at 37˚C, then stained with 7-AAD and either
FITC-conjugated anti-CD8or PE-conjugated anti-CD8b for 30min on ice,washed twice, and resuspended in PBS.C, 2.53105 PBMCswere stainedwith PerCP-
conjugated anti-CD8, 7-AAD, and either FITC-conjugated anti–ab-TCR, allophycocyanin-conjugated anti-CD56, or PE-conjugated anti–gd-TCR for 30min on
ice, washed twice, and resuspended in PBS. In A, B, and C, data were acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software.
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almost exclusively within the tetramerhighCD8high population (Fig.
4F). Thus, at least to some extent, the strong interaction between
A2/Kb and CD8 can bypass the requirement for a specific TCR/
pMHCI interaction and nonspecifically activate human CTLs.
Cell surface-expressed A2/Kb activates CTLs in the absence of
cognate Ag
To extend our investigation to the effects of cell surface pMHCI pre-
sentation, C1R cells were transfected with either A2 or A2/Kb; stable
transfectants expressing similar cell surface MHCI densities were se-
lected as targets for further experiments. Target cells expressing either
A2 or A2/Kb were incubated overnight with three A2-restricted CTL
clones with different peptide specificities (Mel13, 003, and ILA1).
Targets that expressed A2 failed to activate any of the CTL clones
significantly above background (Fig. 5A). Remarkably, however, the
A2/Kb targets stimulated Mel13, 003, and ILA1 CTLs to produce
significant amounts of MIP-1b in the absence of specific peptide (Fig.
5A).A2/Kb targets also elicited substantial levels ofTNFa and IFN-g at
titratable E:T ratios (Fig. 5B), induced degranulation (Fig. 5C), and
induced significant levels of killing (data not shown) in the absence of
specific TCR/pMHCI interactions.
Cell surface-expressedA2/Kb primes noncognateCTL expansions
Thymic output in healthyA2+ individuals is known to generate a high
frequency of naı¨ve CD8+ T cells that can recognize the self-Ag
Melan-A26–35 (39); this system can be used to examine the priming of
CTLs directly ex vivo (40). We exploited these observations to in-
vestigate the effect of superenhanced pMHCI/CD8 binding on CTL
priming. In priming experiments conductedwithC1R target cells, the
percentages of CTLs specific forMelan-A26–35 thatwere present after
10 d in culture were related to the context of the pMHCI/CD8 in-
teraction in which the cognate ELAGIGILTV peptidewas presented.
FIGURE 4. A2/Kb tetramers can activate CTLs in the absence of a specific TCR/pMHCI interaction.A, 105 003CTLswere suspended in 20ml PBS and stained
with the PE-conjugated tetramersA2 SLYNTVATL,A2/Kb SLYNTVATL,A2 LLFGYPVYV, or A2/Kb LLFGYPVYVat the indicated concentrations and 7-AAD
for 20min at 37˚C. Cells were then washed twice and resuspended in PBS. Data were acquired using a FACSCalibur flow cytometer and analyzed with CellQuest
software. B, 105 003 CTLs were suspended in 40 ml R2 with the PE-conjugated tetramers A2 SLYNTVATL, A2/Kb SLYNTVATL, A2 LLFGYPVYV, or A2/Kb
LLFGYPVYVat the indicated concentrations for 30 min at 37˚C. Cells were subsequently stained with FITC-conjugated anti–ab-TCR, 7-AAD, and allophy-
cocyanin-conjugated anti-CD8 for 30 min on ice in azide buffer (0.1% azide/2% FCS/PBS). After two washes, data were acquired using a FACSCalibur flow
cytometer and analyzedwith CellQuest software.C, 53 105 003CTLs were incubatedwith the PE-conjugated tetramers A2 SLYNTVATL,A2/Kb SLYNTVATL,
A2 LLFGYPVYV, or A2/Kb LLFGYPVYVat the indicated concentrations. After 4 h at 37˚C, supernatants were harvested and assayed for RANTES, IFN-g and
MIP-1b content by ELISA (only RANTES shown). D, 2 3 103 868 CTLs were incubated for 4 h at 37˚C with 1 mg/ml of the PE-conjugated tetramers A2
SLYNTVATL,A2/KbSLYNTVATL,A2LLFGYPVYV, orA2/KbLLFGYPVYVin an IFN-gELISpot assay.E, 1.253105 868CTLswere incubatedwith 1mg/ml
of the PE-conjugated tetramers A2 SLYNTVATL, A2/Kb SLYNTVATL, A2 LLFGYPVYV, or A2/Kb LLFGYPVYV for 4 h at 37˚C. The supernatant was sub-
sequently assayed for MIP-1b content by ELISA. Panels (C–E) show the mean6 SD of two replicate assays. Results similar to (A–E) were also obtained with
tetramers conjugated to fluorochromes other than PE (data not shown). F, 003 CTLs were incubated with the PE-conjugated tetramers A2 SLYNTVATL, A2/Kb
SLYNTVATL,A2GLCTLVAML,orA2/KbGLCTLVAMLat the indicated concentrations for 4 h at 37˚C, then stainedwith allophycocyanin-conjugated anti-CD8
for 20min on ice and assayed for CD107amobilization as described inMaterials andMethods. The inset plot shows staining for allophycocyanin-conjugated anti-
CD8 on the x-axis and PE-conjugatedA2/KbGLCTLVAML tetramer (5mg/ml) on the y-axis. Backgated tetramer+CD107a+ cells are shown in black and tetramer+
CD107a2 cells are shown in gray. TetramerhighCD8high cells are preferentially activated by the A2/Kb tetramer.
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Thus, in the absenceof a pMHCI/CD8 interaction (A2D227K/T228A
C1R targets), only 1.5% of the CD8+ cell population was specific for
Melan-A26–35; in contrast, 5.6% and 5.7% of the CD8
+ population
bound the A2 ELAGIGILTV tetramer in the same experiment when
priming was conducted with A2 and A2/Kb C1R targets, respectively
(Fig. 6). Exposure to A2/Kb C1R targets also resulted in substantial
expansions of the total CD8+ population (Fig. 6). Similar results
were obtained with multiple donors (data not shown). Thus, target
cells that expressMHCImolecules with superenhancedCD8-binding
properties can induce nonspecific expansions of CD8+ cells in the
absence of cognate Ag.
Nonspecific A2/Kb-mediated CTL activation and tetramer
staining are not dependent on TCR expression
In earlier experiments, we observed that A2/Kb tetramers bound to
the majority of ab-TCR+CD8+ cells in PBMCs derived from A2+
donors (Fig. 2). To exclude the possibility that this phenomenon was
dependent on the presence of A2-restricted TCRs, we conducted
staining experiments with A22 PBMCs. As previously, the A2/Kb
ILAKFLHWL tetramer bound nonspecifically to the majority of
CD8+ cells (Fig. 7A). Furthermore, A2/Kb tetramer binding favored
CD8high cells and was abrogated by pretreatment with the anti-CD8
mAbDK25 (Fig. 7A). Thus, consistent with the data shown in Fig. 3,
nonspecific A2/Kb tetramer binding is a CD8-mediated effect that is
not dependent on the presence ofA2-restrictedTCRs. In addition, we
demonstrated in earlier experiments that A2/Kb, both in soluble and
cell-associated form, nonspecifically activated A2-restricted CTL
(Figs. 4, 5). To confirm that these functional correlates of nonspecific
binding were similarly independent of A2-restricted TCR expres-
sion, we extended our studies to CTL clones restricted by non-A2
MHCI molecules. In all cases, cell surface-expressed A2/Kb acti-
vated CTL clones regardless of restriction element (Fig. 7B).
Discussion
CD8 has the potential to engage all pMHCI complexes, both self
and foreign, because it binds to largely nonpolymorphic regions of
the MHCI molecule. Indeed, recent publications suggest that the
ability of CD8 to interact with nonstimulatory pMHCI complexes
lowers T cell activation thresholds and enables CTLs to respond to
low copy numbers of specific pMHCI (41, 42). It therefore remains
unclear how the specificity of TCR recognition is maintained,
despite the potential for multiple pMHCI/CD8 interactions at the
cell surface. One possibility resides in the fact that the binding of
CD8 to MHCI is characterized by very low affinities and ex-
tremely rapid kinetics. In this study, we have generated chimeric
A2/Kb MHCI molecules that increase the strength of the pMHCI/
CD8 interaction by ∼15-fold to probe the biophysical and func-
tional significance of the low solution binding affinities observed
for the pMHCI/CD8 interaction.
Initially, we examined the effect of superenhanced CD8 binding on
pMHCItetramerbindingat thecell surface. Increasingthestrengthof the
pMHCI/CD8interactionby∼15-fold resulted in the total lossofpMHCI
FIGURE 5. Cell surface-expressed A2/Kb activates
CTLs in the absence of cognate Ag. A, 2.5 3 104
Mel13, 003, or ILA1 CTLs were incubated for 12 h at
37˚C with 105 C1R cells stably transfected to express
equal levels of either A2 or A2/Kb at the cell surface.
Supernatant was subsequently assayed for MIP-1b
content by ELISA. The mean 6 SD of two replicate
assays is shown. B, 2.5 3 104 Mel13 CTLs were in-
cubated for 12 h at 37˚C with 105 C1R cells stably
transfected to express either A2 or A2/Kb at the cell
surface. Supernatant was assayed for IFN-g and TNFa
content by cytokine bead array. C, CD107a expression
by ILA1 and Mel13 CTLs after a 12-h incubation at
37˚CwithC1Rcells stably transfected to express either
A2 or A2/Kb on the cell surface. For (A–C), C1R cells
were not previously pulsed with peptide.
FIGURE 6. Cell surface-expressed A2/Kb primes nonspecific expansion
of CD8+ cells. 106 A2+ PBMCs were incubated with 2 3 105 irradiated A2
D227K/T228A,A2, or A2/Kb C1R cells that had previously been pulsedwith
1 mM ELAGIGILTV (Melan-A26–35) peptide in R10. From day 3, IL-2 was
added in increments to reach a maximum concentration of 200 IU/ml by day
10. Lines were subsequently stained with PE-conjugated A2 ELAGIGILTV
tetramer, followed by allophycocyanin-conjugated anti-CD8 and 7-AAD.
Data were acquired using a FACSCalibur flow cytometer and analyzed with
FlowJo software.
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tetramer binding specificity. Thus, irrespective of restriction element
and the presented peptide, A2/Kb tetramers bound to the surface of all
CTL clones examined in this study and to the majority of CTLs present
within PBMCs (Figs. 1, 2, 7A). In addition, A2/Kb tetramers bound to
the cell surface in the absence of TCR expression (Fig. 3) and non-
specific binding was abrogated by pretreatment with an anti-CD8 Ab
(Fig. 7A), thereby demonstrating that the observed loss of pMHCI tet-
ramer binding specificity was CD8 mediated and TCR independent.
These findings indicate that the low solution binding affinities observed
for the pMHCI/CD8 interaction are essential for the preservation of
pMHCI ligand binding specificity at the cell surface.
IthaspreviouslybeendocumentedthatpMHCItetramersareefficient
activators of cognate CTLs [reviewed in (35)]. However, pMHCI tet-
ramer staining does not necessarily equate with cellular activation.
Therefore, we proceeded to examine the ability of A2/Kb tetramers to
activate CTL clones. Notably, we found that A2/Kb tetramers activated
CTL clones in a nonspecific manner (Fig. 4). Activation resulted in
a full range of effector functions, including cytokine/chemokine re-
lease, degranulation, and killing. Flow cytometric assessment of de-
granulation by analysis of CD107a mobilization revealed that CTLs
with higher surface expression of CD8 were the cells most likely to
activate in response toA2/Kbmolecules. This finding led us to examine
the effects of cell-surface presentedAg. Strikingly, exposure of PBMCs
to C1R target cells bearing A2/Kb molecules caused a general non-
specific expansion of CD8+ cells during the course of the experiment
(Fig. 6). Furthermore, A2/Kb C1R cells, unlike their wild-type A2
counterparts, were capable of stimulating effector function in all CTL
clones tested regardless of specificity and MHCI restriction (Figs. 5,
7B). Although we cannot exclude the possibility that inclusion of the
murinea3domain induces conformational changes at theTcell surface
onbinding toCD8 that favor noncognate activation, this seemsunlikely
given that: 1) theTCRbindingsite remainsunaltered (9, 22); 2) adegree
of noncognate activation can be observed in long-term assays with
nonchimeric human MHCI molecules that exhibit incrementally en-
hanced CD8 binding (data not shown); and 3) murine and human
pMHCI/CD8aa cocrystals exhibit similar binding orientations (14,
43). Furthermore, these results are consistent with the observation that
thymus leukemia Ag, which interacts strongly (KD∼12 mM) with cell
surface CD8aa expressed by intraepithelial lymphocytes, can modu-
late T cell responses independently of the TCR (44–46).
How does a superenhanced pMHCI/CD8 interaction result in
nonspecific CTL activation?We have previously demonstrated that
an incremental increase in the pMHCI/CD8 interaction (A2Q115E)
results in enhanced immunogenicity of cognate Ags and that this
effect is mediated by enhanced early intracellular signal trans-
duction (9, 47). In contrast, the stimulatory properties of A2/Kb
molecules exhibited no peptide specificity requirements whatso-
ever; indeed, cell surface-expressed A2/Kb was shown to activate
even non-A2–restricted CTL clones (Fig. 7B), thereby confirming
that cognate TCR/pMHCI interactions are not required. Combined
with the ability of A2/Kb to engage multiple CD8 molecules at the
cell surface, these results suggest that A2/Kb cross-links CD8 and
induces activation in an “Ab-like” manner. Indeed, this is con-
sistent with previous studies demonstrating that Ab-induced CD8
FIGURE 7. Noncognate A2/Kb-mediated CTL activation and tetramer binding is not influenced byMHCI restriction.A, 2.53 105 PBMCswere suspended
in 250ml FACSbuffer (2%FCS/PBS) and stainedwith FITC-conjugated anti-A2 and 7-AAD for 30min on ice, thenwashed twice, and resuspended in PBS. For
pMHCI tetramer staining experiments, 2.53 105 PBMCs were suspended in 50ml FACS buffer (2% FCS/PBS) and incubated6 10mg/ml unconjugated anti-
CD8 for 20min on ice, then stainedwith 10mg/ml of the PE-conjugated tetramers A2 ILAKFLHWLorA2/Kb ILAKFLHWL for 45min on ice. After washing,
cells were subsequently stained with allophycocyanin-conjugated anti-CD8 and 7-AAD, washed again, and resuspended in PBS. Data were acquired using
a FACSCalibur flow cytometer and analyzed with FlowJo software.B, 2.53 104 CTLs were incubated for 12 h at 37˚Cwith 105 unpulsed C1R cells expressing
either A2 or A2/Kb on the cell surface. The following CTL clones were used: 1) the HLAAp6801-restricted CTL clone c23, specific for the HIV-1 Tat-derived
epitope ITKGLGISYGR (residues 38–48); 2) the HLA Bp0702-restricted CTL clone KD4, specific for the EBV EBNA3A-derived epitope RPPIFIRRL
(residues 379–387); 3) theHLABp0801-restricted CTL cloneLC13, specific for the EBVEBNA3A-derived epitope FLRGRAYGL (residues 339–347); and 4)
the HLA Bp3508-restricted CTL clone SB27, specific for the EBV BZLF1-derived epitope LPEPLPQGQLTAY (residues 52–64). Supernatant was sub-
sequently assayed for MIP-1b content by ELISA. The mean6 SD of two replicate assays is shown.
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cross-linking can induce T cell signaling (48, 49) and elicit
downstream effector functions, such as chemokine release (50);
such effects are predictable given that the CD8a tail is coupled to
p56lck, an essential component of the early intracellular signaling
pathway (10). It is interesting to note that the murine pMHCI/CD8
interaction is significantly stronger (KD ∼30 mM) than the
equivalent human interaction (KD ∼150 mM) (11), but does not
result in noncognate CTL activation. It is therefore likely that
a pMHCI/CD8 interaction affinity threshold exists for the main-
tenance of CTL activation specificity. The strength of the murine
pMHCI/CD8 interaction is 3-fold weaker than the strength of the
interaction measured between A2/Kb and human CD8, thereby
still operating at a level below this threshold.
In summary, we used chimeric MHCI molecules that exhibit
a superenhanced interaction with CD8 to probe the physical and
functionalsignificanceof the lowsolutionbindingaffinitiespreviously
described for the pMHCI/CD8 interaction. We found that increasing
the strengthof the pMHCI/CD8 interactionby∼15-fold resulted in: 1)
total loss of pMHCI binding specificity at the cell surface; 2) non-
cognate pMHCI tetramer-mediated activation; and 3) nonspecific
activation and proliferation triggered by cell surface-expressed
pMHCI molecules. Thus, the low solution binding affinity of the
pMHCI/CD8 interaction is essential for the preservation of pMHCI
ligand binding specificity at the cell surface and its attendant func-
tional repercussions.
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Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector
Function in the Absence of TCR Engagement and Improve
Peptide–MHCI Tetramer Staining
Mathew Clement,* Kristin Ladell,* Julia Ekeruche-Makinde,* John J. Miles,*
Emily S. J. Edwards,* Garry Dolton,* Tamsin Williams,* Andrea J. A. Schauenburg,*
David K. Cole,* Sarah N. Lauder,* Awen M. Gallimore,* Andrew J. Godkin,*
Scott R. Burrows,† David A. Price,* Andrew K. Sewell,*,1 and Linda Wooldridge*,1
CD8+ T cells recognize immunogenic peptides presented at the cell surface bound to MHCI molecules. Ag recognition involves the
binding of both TCR and CD8 coreceptor to the same peptide–MHCI (pMHCI) ligand. Specificity is determined by the TCR,
whereas CD8 mediates effects on Ag sensitivity. Anti-CD8 Abs have been used extensively to examine the role of CD8 in CD8+
T cell activation. However, as previous studies have yielded conflicting results, it is unclear from the literature whether anti-CD8
Abs per se are capable of inducing effector function. In this article, we report on the ability of seven monoclonal anti-human CD8
Abs to activate six human CD8+ T cell clones with a total of five different specificities. Six of seven anti-human CD8 Abs tested did
not activate CD8+ T cells. In contrast, one anti-human CD8 Ab, OKT8, induced effector function in all CD8+ T cells examined.
Moreover, OKT8 was found to enhance TCR/pMHCI on-rates and, as a consequence, could be used to improve pMHCI tetramer
staining and the visualization of Ag-specific CD8+ T cells. The anti-mouse CD8 Abs, CT-CD8a and CT-CD8b, also activated CD8+
T cells despite opposing effects on pMHCI tetramer staining. The observed heterogeneity in the ability of anti-CD8 Abs to trigger
T cell effector function provides an explanation for the apparent incongruity observed in previous studies and should be taken into
consideration when interpreting results generated with these reagents. Furthermore, the ability of Ab-mediated CD8 engagement
to deliver an activation signal underscores the importance of CD8 in CD8+ T cell signaling. The Journal of Immunology, 2011,
187: 000–000.
C
D8+ T cells are essential for the control of viral infection
and the natural eradication of cancer. CD8+ T cells rec-
ognize short peptides, 8–13 aa in length, presented at the
target cell surface bound to MHCI molecules. T cell Ag recog-
nition is unique in nature because it involves the binding of
a single ligand (peptide–MHC [pMHC]) by two receptors (TCR
and coreceptor) (1, 2). The CD8 glycoprotein, which serves as the
coreceptor on MHCI-restricted T cells, acts to enhance the Ag
sensitivity of CD8+ T cells by binding to a largely invariant region
of MHCI at a site distinct from the TCR docking platform. CD8
has multiple enhancing effects on early T cell activation events,
which include the following: 1) promotion and stabilization of
TCR/pMHCI binding at the cell surface (3–5); 2) recruitment of
essential signaling molecules to the intracellular side of the TCR/
CD3/z complex (6–11); and 3) localization of TCR/pMHCI com-
plexes within specialized membrane microdomains that act as
potentially privileged sites for initiation of the TCR-mediated
signaling cascade (12, 13). CD8 binding also controls the level of
T cell cross-reactivity (14) and can differentially affect the de-
ployment of CD8+ T cell effector functions (15).
Anti-CD8 Abs have been used widely to investigate the role of
CD8 in CD8+ T cell activation. Early studies showed that pre-
incubation with anti-CD8 Abs can block conjugate formation
between effector and target cells (16) and inhibit CD8+ T cell
activation in response to cognate pMHCI presented on the target
cell surface (17–20). These findings provided key evidence that
CD8 was important in the process of CD8+ T cell activation.
However, considerable heterogeneity between different CD8+
T cells was apparent in terms of their ability to activate in the
presence of anti-CD8 Abs, and as a result, these reagents were
used as tools to classify CD8+ T cells as either CD8 dependent or
CD8 independent (21, 22). Ab-mediated ligation of T cell surface
molecules, such as CD2, CD3, and CD28 (23, 24), can result in
effector function. In contrast, studies of Ab-mediated CD8 liga-
tion in the absence of TCR engagement have yielded conflicting
results. Early studies demonstrated that induction of CD8 cross-
linking at the cell surface can result in p56lck phosphorylation
similar to that seen with anti-CD3 Abs (25) and elicit downstream
effector functions, such as chemokine release (26) and potent
cytotoxicity (27). However, in conflict with these data, more re-
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cent studies suggest that CD8 ligation alone may actually deliver
a negative signal (28, 29).
To date, a cohesive explanation for these widely disparate
findings with anti-CD8 Abs has remained elusive. Furthermore,
there has been no systematic study of the effects of multiple dif-
ferent anti-human CD8 Abs on CD8+ T cells with different spe-
cificities. In this article, we report on the ability of a panel of
seven monoclonal anti-human CD8 Abs to induce chemokine/
cytokine release and cytotoxicity by six different human CD8+
T cell clones specific for a total of five different pMHCI Ags. The
data, supported by parallel observations in a mouse system, reveal
that considerable heterogeneity exists in the ability of anti-CD8
Abs to activate CD8+ T cells. These results elucidate the apparent
incongruity that has been observed in previous studies and man-
date that the disparate effects of anti-CD8 Abs are considered in
the interpretation of results generated with these reagents.
Materials and Methods
Cells
The following HLA A*0201-restricted CD8+ T cell clones were used in
this study: 1) ILA1, specific for the human telomerase reverse tran-
scriptase-derived epitope ILAKFLHWL (residues 540–548) (30, 31); 2)
ALF3, specific for the influenza A matrix protein (M1)-derived epitope
GILGFVFTL (residues 58–66); and 3) MEL5 and MEL187.c5, specific for
the Melan-A–derived epitope ELAGIGILTV (residues 26–35) (32). The
HLA B*0801-restricted CD8+ T cell clone LC13 is specific for the EBV
EBNA3A-derived epitope FLRGRAYGL (residues 339–347) (33), and the
HLA B*3508-restricted CD8+ T cell clone SB10 is specific for the EBV
BZLF1-derived epitope LPEPLPQGQLTAY (residues 52–64) (34). The
HLA DR*0101-restricted CD4+ T cell clone C6 recognizes the influenza A
hemagglutinin-derived epitope PKYVKQNTLKLAT (residues 307–319).
CD8+ T cell lines specific for the EBV BMLF1-derived epitope
GLCTLVAML (residues 280–288), restricted by HLA A*0201, were gen-
erated as described previously (35). Naive mouse CD8+ T cells were ob-
tained by harvesting splenocytes from transgenic F5 mice. A significant
percentage of CD8+ T cells within the splenic population of these mice
express the F5 TCR, which recognizes the H-2Db–restricted influenza H17
nucleoprotein-derived epitope ASNENMDAM (36). C1R-A*0201 target
cells were generated as described previously (37).
Anti-CD8 Abs
The following anti-human CD8a Ab clones were used in this study: 1)
unconjugated or allophycocyanin-conjugated OKT8 (eBioscience, Hat-
field, U.K.); 2) unconjugated, FITC-conjugated, or R-PE–conjugated SK1
(BD Biosciences, Oxford, U.K.); 3) unconjugated MCD8 (IqProducts,
Groningen, The Netherlands); 4) unconjugated 32/M4 (Santa Cruz Bio-
technology, Heidelberg, Germany); 5) unconjugated C8/144B (Santa Cruz
Biotechnology); and 6) allophycocyanin-conjugated DK25 (DakoCyto-
mation, Stockport, U.K.). The anti-human CD8b Ab clone 2ST8.5H7 was
also used, either in unconjugated or in PE-conjugated form (Abcam,
Cambridge, U.K.). In functional assays, the maximum possible Ab con-
centrations were used, determined by the concentration of the commer-
cially available preparation in each case. For experiments with mouse
cells, the following unconjugated anti-mouse CD8 Abs were used: 1) anti-
CD8a clone CT-CD8a (Caltag-Medsystems, Buckingham, U.K.); 2) anti-
CD8a clone 53.6.7 (BioLegend, Cambridge, U.K.); 3) anti-CD8b clone
KT112 (hybridoma provided by Prof. R. Zamoyska, School of Biological
Sciences, University of Edinburgh); and 4) anti-CD8b clone CT-CD8b
(Caltag-Medsystems).
Generation of OKT8 Fab, F(ab9)2 and Fc9 fragments
A total of 250 mg of the anti-human CD8 Ab OKT8 or the anti-human CD3
Ab OKT3 were digested to yield Fab and Fc9 fragments using a Pierce Fab
micropreparation kit (ThermoScientific, Rockford, IL); F(ab9)2 fragments
were produced similarly using a Pierce F(ab9)2 micropreparation kit (Thermo-
Scientific). IgG fragmentation was performed according to the manufac-
turer’s instructions.
CD8+ T cell effector function assays
T cells (3 3 104) were mixed with anti-CD8 Abs at the indicated con-
centrations, either with or without secondary cross-linking by the addition
of 5 ml anti-mouse IgG Ab (Beckman Coulter, High Wycombe, U.K.), and
incubated overnight at 37˚C in a 5% CO2 atmosphere. Positive controls
included the following: 1) target cells pulsed with 1027 M cognate peptide;
2) 10 mg/ml anti-human CD3 Ab (UCHT1; BD Biosciences); or 3) 50 ng/
ml PMA and 1 mg/ml ionomycin (Sigma-Aldrich, Dorset, U.K.). Super-
natants were harvested and assayed for MIP1a, MIP1b, and RANTES by
ELISA (R&D Systems, Abingdon, U.K.) and for IFN-g, TNF-a, and IL-2
by cytometric bead array (Th1/Th2 kit; BD Biosciences), according to the
manufacturer’s instructions in each case; mouse MIP1b and IL-2 assays
were performed by ELISA (R&D Systems). Cytometric bead array (CBA)
data were acquired using a FACSCalibur flow cytometer and analyzed with
CBA 6 Bead analysis software (BD Biosciences). CD107a mobilization
was used to measure T cell degranulation by flow cytometry as described
previously (38). For chromium release assays, 23 103 T cells were treated
with anti-CD8 Abs at the indicated concentrations in 100 ml RPMI 1640
medium (Life Technologies, Paisley, U.K.) supplemented with 100 U/ml
penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technolo-
gies), 2 mM L-glutamine (Life Technologies), and 2% heat-inactivated
FCS (Life Technologies) (R2 medium). C1R-A*0201 target cells (2 3
103), labeled with 30 mCi 51Cr (Perkin Elmer, Cambridge, U.K.) per 106
cells for 1 h previously, were subsequently added. Targets were also cul-
tured alone (target spontaneous release) and with Triton X-100 (Sigma-
Aldrich) at a final concentration of 5% (target total release). Cells were
incubated at 37˚C for 18 h in a 5% CO2 atmosphere. For each sample, 20
ml supernatant was harvested and mixed with 150 ml OptiPhase Supermix
Scintillation Cocktail (Perkin Elmer). Plates were analyzed using a liquid
scintillator and luminescence counter (MicroBeta TriLux; Perkin Elmer)
with Microbeta Windows Workstation software (Perkin Elmer). Specific
lysis was calculated according to the following formula: (experimental
release 2 target spontaneous release/target total release 2 target sponta-
neous release) 3 100.
pMHCI tetramer staining and flow cytometry
Soluble biotinylated pMHCI monomers were produced as described pre-
viously (3). Tetrameric pMHCI reagents (tetramers) were constructed by
the addition of either PE-conjugated streptavidin (Life Technologies) or
allophycocyanin-conjugated streptavidin (Prozyme, Hayward, CA) at a
pMHCI:streptavidin molar ratio of 4:1. For human CD8+ T cell clones,
5 3 104 cells were preincubated with anti-CD8 Ab as indicated for 25 min
on ice and then stained with cognate PE-conjugated tetramer (25 mg/ml) at
37˚C for 15 min (reviewed in Ref. 39) prior to staining with 5 ml 7-ami-
noactinomycin D (Viaprobe; BD Biosciences) at 4˚C for 30 min. For hu-
man CD8+ T cell lines, 5 3 104 cells were preincubated with anti-CD8 Ab
as indicated for 25 min on ice and then stained with cognate PE-conjugated
HLA A*0201 tetramer (25 mg/ml) at 37˚C for 15 min prior to staining with
the amine-reactive fluorescent dye LIVE/DEAD Fixable Aqua (Life
Technologies), Pacific Blue-conjugated anti-human CD14 (clone Tuk4;
Caltag-Medsystems), Pacific Blue-conjugated anti-human CD19 (clone
SJ25-C1; Caltag-Medsystems), PE-Cy5.5–conjugated anti-human CD4
(clone S3.5; Caltag-Medsystems), and FITC-conjugated anti-human CD8
(clone SK1; BD Biosciences) at 4˚C for 20 min. For human PBMCs di-
rectly ex vivo, 1 3 105 cells were preincubated with anti-CD8 Ab as in-
dicated for 25 min on ice and then stained with allophycocyanin-
conjugated HLA A*0201 tetramer (25 mg/ml) at 37˚C for 15 min prior
to staining with LIVE/DEAD Fixable Aqua (Life Technologies), Pacific
Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems),
Pacific Blue-conjugated anti-human CD19 (clone SJ25-C1; Caltag-
Medsystems), FITC-conjugated anti-human CD3 (clone HIT3a; BD Bio-
sciences), PE-Cy5.5–conjugated anti-human CD4 (clone S3.5; Caltag-
Medsystems), and PE-Cy7–conjugated anti-human CD8 (clone RPA-T8;
BD Biosciences) at 4˚C for 20 min. For mouse experiments, 5 3 104 cells
were preincubated with 100 mg/ml CT-CD8a (Caltag-Medsystems), 53.6.7
(BioLegend), KT112 (in-house), or CT-CD8b (Caltag-Medsystems) for 25
min on ice and then stained with cognate PE-conjugated H-2Db tetramer
(25 mg/ml) at 37˚C for 15 min prior to staining with LIVE/DEAD Fixable
Aqua (Life Technologies), Pacific Blue-conjugated anti-mouse CD4 (clone
RM4-5; BD Biosciences), FITC-conjugated anti-mouse CD45R/B220
(clone RA3-6B2; BD Biosciences), and PerCP-Cy5.5–conjugated anti-
mouse CD3 (clone 17A2; BD Biosciences) at 4˚C for 20 min. Data were
acquired using either a FACSCantoII or a modified FACSAriaII flow cy-
tometer (both BD Biosciences) and analyzed with FlowJo software (Tree
Star, Ashland, OR).
Intracellular cytokine staining
PBMCs were harvested from a healthy donor and cultured with or without
1 mg/ml PHA (Alere, Cheshire, U.K.) and 25 ng/ml IL-15 (Promega,
Hampshire, U.K.) for 7 d and then washed and cultured overnight in R2
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medium. A total of 5 3 104 PBMCs (unstimulated or stimulated with
PHA/IL-15) were resuspended in the presence of 1 ml/ml brefeldin A
(GolgiPlug; Sigma-Aldrich), 0.7 ml/ml monensin (GolgiStop; BD Bio-
sciences), and 5 ml/ml anti-CD107a-FITC (clone H4A3; BD Biosciences)
and then incubated with anti-human CD8 Abs at the indicated concen-
trations for 18 h at 37˚C in a 5% CO2 atmosphere. After washing with
PBS, cells were stained with LIVE/DEAD Fixable Violet (ViViD; Life
Technologies), Pacific Blue-conjugated anti-human CD14 (clone Tuk4;
Caltag-Medsystems), and Pacific Blue-conjugated anti-human CD19
(clone SJ25-C1; Caltag-Medsystems) at room temperature for 15 min.
Subsequently, cells were washed and stained with H7-allophycocyanin–
conjugated anti-human CD3 (clone SK7; BD Biosciences) and PE-Cy5.5–
conjugated anti-human CD4 (clone S3.5; Caltag-Medsystems) at 4˚C for
20 min, then washed an additional three times, resuspended in 200 ml BD
Cytofix/Cytoperm, and incubated at 4˚C for 20 min. After three additional
washes in Perm/Wash (BD Biosciences), cells were stained with PE-Cy7–
conjugated anti-human IFN-g (clone B27; BD Biosciences), allophyco-
cyanin-conjugated anti-human TNF-a (clone MAb11; BD Biosciences),
and PE-conjugated anti-human MIP1b (clone D21-1351; BD Biosciences)
at 4˚C for 20 min, washed again three more times, and resuspended in
200 ml Perm/Wash. Data were acquired using a modified FACSAriaII
flow cytometer (BD Biosciences) and analyzed with FlowJo software
(Tree Star).
Tetramer kinetics experiments
For tetramer association assays, 5 3 105 CD8+ T cells were washed twice
and resuspended in 200 ml PBS with or without anti-human CD8 Ab and
then incubated with cognate tetramer (5 mg/ml). At indicated time points,
12 ml of the cell suspension was removed and acquired using a FACSCa-
libur flow cytometer (BD Biosciences). Data were analyzed using FlowJo
software (Tree Star). Tetramer decay analysis was performed as described
previously (3).
Surface plasmon resonance analysis
Soluble TCRs derived from the MEL5 and MEL187.c5 CD8+ T cell clones
were manufactured as described previously (40–42). Binding analysis was
performed using a BIAcore 3000 equipped with a CM5 sensor chip (43).
Between 200 and 400 response units of biotinylated pMHCI was immo-
bilized to streptavidin, which was chemically linked to the chip surface.
The pMHCI was injected at a slow flow rate (10 ml/min) to ensure uniform
distribution on the chip surface. Combined with the small amount of
pMHCI bound to the chip surface, this reduced the likelihood of off-rate
limiting mass transfer effects. The MEL5 TCR and MEL187.c5 TCRs
were purified and concentrated to ∼100 mM on the day of surface plasmon
resonance analysis to reduce the likelihood of TCR aggregation affecting
the results. For equilibrium analysis, eight serial dilutions were carefully
prepared in triplicate for each sample and injected over the relevant sensor
chips at 25˚C. The TCRs were injected over the chip surface at a flow rate
of 45 ml/min. Results were analyzed using BIAevaluation 3.1, Microsoft
Excel, and Origin 6.1. The equilibrium binding constant (KD) values were
calculated using a nonlinear curve fit (y = [P1x]/[P2 + x]).
Results
Anti-CD8 Abs can trigger T cell effector function in the
absence of TCR engagement
Several studies suggest that Ab-mediated ligation of CD8 in the
absence of TCR engagement can elicit downstream effector
function (25–27); however, others have reported the delivery of
negative signals with this manipulation (28, 29). To reconcile
these apparently disparate findings, we conducted a systematic
study of the effects of multiple different anti-human CD8 Abs on
CD8+ T cells with several different specificities. For this purpose,
we used a panel of anti-human CD8 Abs that comprised six anti-
CD8a Abs (OKT8, SK1, MCD8, 32/M4, C8/144B, and DK25)
and one anti-CD8b Ab (2ST8.5H7). Six of seven anti-human CD8
Abs from the panel (SK1, MCD8, 32/M4, C8/144B, DK25, and
2ST8.5H7) did not elicit any chemokine production when in-
cubated with four different HLA A*0201-restricted CD8+ T cell
clones (ILA1, ALF3, MEL5, and MEL187.c5) with a total of three
different specificities in the absence of specific pMHCI Ag (Fig.
1). However, the anti-CD8a Ab OKT8 induced MIP1a, MIP1b,
and RANTES release from all four HLA A*0201-restricted CD8+
T cell clones (Fig. 1). Chemokine secretion was apparent over
a range of OKT8 concentrations (Supplemental Fig. 1).
In addition, we measured chemokine release by two non-HLA
A*0201-restricted CD8+ T cell clones following incubation with
each anti-human CD8 Ab from the panel. Both of these non-HLA
A*0201-restricted CD8+ T cell clones produced MIP1a, MIP1b,
and RANTES in response to OKT8 but did not activate in the
presence of the other Abs tested (Fig. 2). Remarkably, the highly
Ag-sensitive HLA B*3508-restricted EBV BZLF1-specific CD8+
T cell clone SB10 released .2000 pg/ml of each chemokine in
response to OKT8 (Fig. 2B). OKT8 was incapable of staining the
HLA DR*0101-restricted CD4+ T cell clone C6 (Supplemental
Fig. 2A) and failed to induce chemokine release from this clone
(Supplemental Fig. 2B–D). Thus, the stimulatory effects of OKT8
appear to be CD8+ T cell specific.
The panel of seven anti-human CD8 Abs was further tested
in cytotoxicity assays with four different CD8+ T cell clones
(MEL187.c5, ALF3, LC13, and SB10). Anti-human CD8 Abs that
were incapable of inducing chemokine release failed to elicit cy-
totoxic activity in any of these four CD8+ T cell clones (Fig. 3). In
contrast, SB10 CD8+ T cells exhibited substantial cytotoxicity in
response to stimulation with OKT8; lower levels of specific lysis
FIGURE 1. Ab-mediated CD8 ligation can trigger chemokine release
from HLA A*0201-restricted CD8+ T cells. A total of 3 3 104 ILA1 CD8+
T cells (A), ALF3 CD8+ T cells (B), MEL5 CD8+ T cells (C), or MEL187.
c5 CD8+ T cells (D) were incubated for 18 h with each of the following
individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml
SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml
DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The maximum possible Ab
concentrations were used, determined by the concentration of the com-
mercially available preparation in each case. For each CD8+ T cell clone,
3 3 104 C1R-A*0201 B cells pulsed with cognate peptide at 1027 M were
used as positive controls. 0 represents T cells only. Supernatant was har-
vested and assayed for MIP1a, MIP1b, and RANTES by ELISA. Error
bars represent SDs.
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were also induced in the CD8+ T cell clones LC13 (3.18%), ALF3
(5.1%), and MEL187.c5 (3.8%) (Fig. 3; data not shown). These
results are consistent with a previous study that described a mouse
anti-CD8 Ab, KT112, capable of inducing cytotoxicity (27). Col-
lectively, these data indicate that considerable heterogeneity exists
in the ability of anti-CD8 Abs to activate CD8+ T cells.
OKT8 induces chemokine secretion in the absence of cytokine
secretion
Next, we examined the ability of Ab-mediated CD8 ligation to elicit
cytokine release by CD8+ T cells in the absence of TCR engage-
ment. As expected, the anti-human CD8 Abs that did not elicit
chemokine release or cytotoxic activity (SK1, MCD8, 32/M4, C8/
144B, DK25, and 2ST8.5H7) also failed to induce IFN-g, TNF-a,
or IL-2 release (Fig. 4). Interestingly, OKT8 similarly failed to
elicit cytokine production from the majority of CD8+ T cell clones
tested (Fig. 4). Importantly, chemokine and cytokine assays were
performed using the same supernatant, thereby confirming that
OKT8 stimulated CD8+ T cells to secrete chemokines in the ab-
sence of cytokine production; one exception to this dichotomy
occurred with the CD8+ T cell clone SB10, which released IFN-g
in response to treatment with OKT8. These data suggest that
OKT8-mediated CD8 ligation delivers a signal that falls below the
threshold required for cytokine production in most CD8+ T cells.
Neither secondary Ab cross-linking nor PHA/IL-15 treatment
alter the functional phenotype of anti-human CD8 Abs
To probe the possibility that the degree of cross-linking mediated
by each of the anti-human CD8 Abs tested could explain the
functional heterogeneity observed between these reagents, we
performed activation experiments with the addition of secondary
Abs. Secondary cross-linking of OKT8 increased the level of
MIP1a, MIP1b, and RANTES release by ILA1, ALF3, MEL5,
MEL187.c5, LC13, and SB10 CD8+ T cells above that observed
with OKT8 alone (Fig. 5; data not shown). However, secondary
Ab-mediated cross-linking did not reverse the phenotype of the
nonactivating anti-human CD8 Abs (Fig. 5).
We also examined the effect of PHA/IL-15 treatment on the
ability of anti-human CD8 Abs to elicit effector function from
CD8+ T cells in healthy donor PBMCs. PHA is capable of cross-
linking glycosylated proteins at the T cell surface. The seven anti-
human CD8 Abs tested did not substantially activate CD8+ T cells
in untreated PBMCs (Fig. 6A). The six nonactivating anti-human
CD8 Abs also failed to induce substantial levels of CD8+ T cell
activation in PBMCs cultured for 7 d in PHA/IL-15 (Fig. 6B). In
contrast, OKT8 activated CD8+ T cells in PHA/IL-15–stimulated
PBMCs to release MIP1b and degranulate as measured by surface
mobilization of CD107a. Interestingly, OKT8 also induced IFN-g
FIGURE 3. The anti-human CD8 Ab OKT8 can trigger cytotoxic ac-
tivity. A total of 23 103 LC13 CD8+ T cells (A) or SB10 CD8+ T cells (B)
were incubated with each of the following individual anti-human CD8 Abs
in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/
ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml DK25, and 100 mg/ml
2ST8.5H7 (CD8b). The anti-human CD3 Ab UCHT1 (10 mg/ml) served as
a positive control. Cytotoxicity assays were then performed over a period
of 18 h as described in Materials and Methods using 51Cr-labeled C1R-
A*0201 B cells as targets. Error bars represent SDs.
FIGURE 4. Anti-CD8 Ab-mediated chemokine release occurs in the
absence of cytokine release. A total of 3 3 104 ILA1, ALF3, MEL5,
MEL187.c5, LC13, or SB10 CD8+ T cells were incubated for 18 h with
each of the following individual anti-human CD8 Abs in parallel: 100 mg/
ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/
ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The
anti-human CD3 Ab UCHT1 (10 mg/ml) served as a positive control. Su-
pernatant was harvested and assayed for IFN-g (A), TNF-a (B), and IL-2
(C) by CBA.
FIGURE 2. Ab-mediated CD8 ligation can trigger chemokine release
from non-HLA A*0201-restricted CD8+ T cells. A total of 3 3 104 LC13
CD8+ T cells (A) or SB10 CD8+ T cells (B) were incubated for 18 h with
each of the following individual anti-human CD8 Abs in parallel: 100 mg/
ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/
ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). For each
CD8+ T cell clone, 3 3 104 HLA-matched B cells pulsed with cognate
peptide at 1027 M were used as positive controls. Supernatant was har-
vested and assayed for MIP1a, MIP1b, and RANTES by ELISA. Error
bars represent SDs.
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and TNF-a production by CD8+ T cells in PHA/IL-15–stimulated
PBMCs, thereby suggesting that this treatment regimen syner-
gistically lowered the activation threshold of the responding cells.
OKT8 failed to activate CD4+ T cells in PHA/IL-15–stimulated
FIGURE 7. Anti-human CD8 Abs can either enhance or in-
hibit the binding of pMHCI tetramers. A total of 5 3 104 ILA1
(A), ALF3 (B), MEL5 (C), or MEL187.c5 (D) CD8+ T cells
were preincubated at 4˚C for 25 min with each of the following
individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8,
6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/
ml C8/144B (144B), 25 mg/ml DK25, and 100 mg/ml
2ST8.5H7 (CD8b). CD8+ T cells were subsequently stained
with cognate PE-conjugated HLA A*0201 tetramers (25 mg/
ml) and 7-aminoactinomycin D as described in Materials and
Methods. Data were acquired using a FACSCalibur flow
cytometer and analyzed with FlowJo software. Relative median
fluorescence intensity (MFI) values with respect to pMHCI
tetramer staining in the absence of preincubation with anti-
CD8 Ab are shown. Fluorescence in the absence of added
cognate tetramer (con) is shown in each case. Data are repre-
sentative of four separate experiments using ILA1 and ALF3
CD8+ T cells, and six separate experiments using MEL5 and
MEL187.c5 CD8+ T cells.
FIGURE 6. PHA/IL-15 treatment does not alter the functional pheno-
type of anti-human CD8 Abs. PBMCs were harvested from healthy donors
and cultured either without (A) or with (B, C) 1 mg/ml PHA and 25 ng/ml
IL-15 for 7 d and then washed and cultured overnight in R2 medium. A
total of 5 3 104 PBMCs were then incubated for 18 h with each of the
following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8,
6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ml C8/
144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The anti-hu-
man CD3 Ab UCHT1 (10 mg/ml) served as a positive control. CD8+ T cell
effector functions were measured by intracellular cytokine staining and
surface CD107a mobilization as described in Materials and Methods. Data
were acquired using a modified FACSAriaII flow cytometer and analyzed
with FlowJo software. Results obtained by gating on either the CD3+CD42
(A, B) or CD4+ (C) population are shown for a representative experiment
(n = 2). Minor differences in background levels of CD8+ T cell activation
were observed with the non-OKT8 anti-human CD8 Abs (A, B); this may
reflect heterogeneity within the CD8+ PBMC population.
FIGURE 5. Secondary crosslinking does not alter the functional phe-
notype of anti-human CD8 Abs. A total of 3 3 104 ILA1 CD8+ T cells
were incubated with each of the following individual anti-human CD8 Abs
in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/
ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml DK25, and 100 mg/ml
2ST8.5H7 (CD8b). The positive control comprised 3 3 104 C1R-A*0201
B cells pulsed with cognate peptide at 1027 M. Abs were then cross-linked
with the addition of 5 ml anti-mouse IgG Ab (serum IgG) and incubated for
18 h at 37˚C in a 5% CO2 atmosphere. Supernatant was harvested and
assayed for MIP1a (A), MIP1b (B), and RANTES (C) by ELISA. Sec-
ondary cross-linking of OKT8 increased the levels of all analytes mea-
sured; this also applied to anti-CD3 Ab-induced chemokine release (data
not shown). Similar results were obtained with all other CD8+ T cell clones
tested: ALF3, MEL5, MEL187.c5, LC13, and SB10 (data not shown).
Error bars represent SDs.
The Journal of Immunology 5
 o
n
 O
ctober 12, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
PBMCs (Fig. 6C), consistent with previously discussed data
(Supplemental Fig. 2).
OKT8 enhances pMHCI tetramer staining
Next, we tested the effects of anti-human CD8 Abs on the stain-
ing of ILA1, ALF3, MEL5, and MEL187.c5 CD8+ T cells with
cognate pMHCI tetramers. Three anti-human CD8 Ab clones
(SK1, DK25, and 2ST8.5H7) inhibited tetramer staining; clones
MCD8, 32/M4, and C8/144B had little or no effect on staining.
However, preincubation with OKT8 enhanced cognate pMHCI
tetramer staining of all four CD8+ T cell clones (Fig. 7). Thus,
OKT8 can enhance the binding of pMHCI tetramers in a range of
systems. These findings suggested that OKT8 might facilitate
the identification of Ag-specific CD8+ T cells within mixed cell
populations. To test this idea, we examined pMHCI tetramer
staining of CD8+ T cell lines raised against the HLA A*0201-
restricted EBV BMLF1-derived epitope GLCTLVAML (residues
280–288). OKT8 enhanced the staining intensity of cognate CD8+
T cells with the relevant pMHCI tetramer without concomitant
increases in noncognate HLA A*0201 tetramer binding (Fig. 8A,
8B). No increase in the percentage of tetramer+CD8+ cells was
observed in the presence of OKT8 (Fig. 8A, 8B), which likely
reflects the high-affinity TCR/pMHCI interactions that character-
ize antiviral CD8+ T cell populations (41).
We hypothesized that OKT8-mediated enhancement of TCR/
pMHCI binding at the cell surface might have beneficial effects
on pMHCI tetramer staining with low-affinity ligands, an effect that
could prove very useful for the detection of CD8+ T cells with
TCRs that bind weakly to cognate Ag, such as those that appear to
predominate in anticancer and autoimmune responses (32, 41). To
test this hypothesis, we used two monoclonal CD8+ T cell systems
and a series of altered peptide ligands that vary in their affinity for
cognate TCR by .5-fold (Table I, Supplemental Fig. 3). Pre-
incubation with OKT8 enhanced staining efficiency with all var-
iant pMHCI tetramers, including low-affinity variants (Table I,
Supplemental Fig. 4). Consistent with this finding, OKT8 in-
creased both the staining intensity and the percentage of Ag-
specific events detected when CD8+ T cell lines raised against
the HLA A*0201-restricted Melan-A–derived epitope ELAGI-
GILTV (residues 26–35) were stained with HLA A*0201
tetramers folded around the low-affinity peptide variants
FLAGIGILTV or ELTGIGILTV (Fig. 8C, 8D).
OKT8 enhances TCR/pMHCI on-rates at the cell surface
To examine how OKT8 enhances Ag binding at the CD8+ T cell
surface in more detail, we examined the effects of this Ab on
TCR/pMHCI kinetics using pMHCI tetramers. Differences in
tetramer off-rates were minimal (data not shown). However, pre-
treatment of CD8+ T cells with OKT8 resulted in a significant
increase in the TCR/pMHCI on-rate at the cell surface in each
CD8+ T cell clone tested (Fig. 9). In contrast, DK25 inhibited
pMHCI tetramer binding at the cell surface (Fig. 9B). OKT8 Ab-
FIGURE 8. OKT8 enhances pMHCI tetramer staining in mixed cell
populations.A andB, A total of 53 104 cells from a CD8+ T cell line primed
with the EBV BMLF1-derived epitope GLCTLVAML (residues 280–288)
were either mock treated or incubated with 100 mg/ml OKT8 at 4˚C for 25
min and then stained with either noncognate HLA A*0201-ELAGIGILTV
(A) or cognate HLA A*0201-GLCTLVAML (B) APC-conjugated tetramer
(25 mg/ml each) at 37˚C for 15 min. C and D, A total of 53 104 cells from
a CD8+ T cell line primed with theMelan-A–derived epitope ELAGIGILTV
(residues 26–35) were either mock treated or incubated with 100 mg/ml
OKT8 at 4˚C for 25 min and then stained with either HLA A*0201-FLA-
GIGILTV (C) or HLA A*0201-ELTGIGILTV (D) PE-conjugated tetramer
(25mg/ml each) at 37˚C for 15 min. Additional stains were performed as
detailed in Materials and Methods. Data were acquired using a FACSCan-
toII flow cytometer and analyzed with FlowJo software.
Table I. OKT8 increases tetramer staining of MEL5 and MEL187.c5 CD8+ T-cells with low-affinity pMHCI ligands
Peptidea
MEL5
KD (mM)
MEL5
Tetramer Only
(MFI)
MEL5
OKT8 +
Tetramer (MFI)
MEL187
KD (mM)
MEL187
Tetramer Only
(MFI)
MEL187
OKT8 +
Tetramer (MFI)
ELAGIGILTV 17 6 1 855 917 18 6 1 353 418
FLAGIGILTV 92 6 1 194 227 30 6 2 300 373
ELTGIGILTV 82 6 4 36 87 37 6 1 128 181
ELAGIGIITV 77 6 3 123 236 36 6 3 195 257
FLAGIGIITV 75 6 3 367 426 47 6 2 246 311
Summary of equilibrium binding analysis of MEL5 and MEL187.c5 TCRs with pMHCI variants and the effect of OKT8 on HLA A*0201 tetramer
staining. Raw surface plasmon resonance data are shown in Supplemental Fig. 3; flow cytometry data are shown in Supplemental Fig. 4.
aAmino acid residues marked in bold and underlined indicate substitutions made in the ELAGIGILTV peptide backbone.
MFI, median fluorescence intensity.
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induced enhancement of pMHCI tetramer on-rates was also ap-
parent with CD8-null tetramers (Fig. 9C). Collectively, these data
indicate that OKT8 enhances pMHCI tetramer staining by in-
creasing the on-rate. Furthermore, OKT8 Ab-mediated augmen-
tation of Ag binding at the cell surface occurs independently of the
pMHCI/CD8 interaction.
OKT8 F(ab9)2 fragments can enhance tetramer staining and
elicit CD8+ T cell effector function
Abs can be digested by papain or pepsin to produce Fab or F(ab9)2
fragments, respectively. These enzymatically generated fragments
have been used extensively in the past to study the structure and
function of Abs. We examined the ability of OKT8 Fab and
F(ab9)2 fragments to enhance pMHCI tetramer staining and to
induce chemokine release in the absence of TCR engagement.
Not surprisingly, Fab fragments of OKT8 failed to activate CD8+
T cells or enhance pMHCI tetramer staining (Fig. 10A, 10B).
Interestingly, however, OKT8 F(ab9)2 fragments retained some
ability to enhance pMHCI tetramer staining and elicit chemokine
release (Fig. 10A, 10B). OKT8-mediated effects were diminished
by pepsin digestion, but anti-human CD3 Abs were similarly im-
paired functionally after digestion with this enzyme (Fig. 10C);
this latter effect has been described previously (44–46). Thus, it
appears that intact OKT8 exerts effects on pMHCI tetramer
binding and CD8+ T cell activation more efficiently than derived
F(ab9)2 fragments. However, cellular activation by OKT8 F(ab9)2
fragments confirms that this effect is not entirely Fc9 dependent.
Anti-mouse CD8 Abs can trigger CD8+ T cell effector function
in the absence of TCR engagement
To extend these findings beyond human systems (summarized in
Table II), we examined the effects of the anti-mouse CD8a Ab
CT-CD8a and the anti-mouse CD8b Ab CT-CD8b on pMHCI
tetramer staining and CD8+ T cell activation in the absence of
TCR engagement. We observed that CT-CD8a inhibited tetramer
staining of mouse transgenic F5 CD8+ T cells, whereas CT-CD8b
enhanced tetramer staining of the same Ag-specific population
(Fig. 11A). These results are consistent with our previous findings
(26). Interestingly, despite opposing effects on pMHCI tetramer
staining, both of these anti-mouse CD8 Abs induced MIP1b
production in the absence of TCR engagement from both naive
and Ag-exposed F5 CD8+ T cells (Fig. 11B; data not shown).
These effects were shown to be CD8-specific and occurred in the
absence of any concomitant IL-2 release (data not shown). The
anti-mouse CD8 Abs 53.6.7 and KT112 both enhanced pMHCI
tetramer staining and induced small amounts of MIP1b production
FIGURE 10. OKT8 F(ab9)2 fragments can enhance pMHCI tetramer staining and elicit CD8
+ T cell effector function. A, A total of 5 3 104 MEL5 CD8+
T cells were either mock treated or incubated with 100 mg/ml OKT8, 100 mg/ml OKT8 Fab, or 100 mg/ml OKT8 F(ab9)2 and then stained with PE-
conjugated HLA A*0201-ELAGIGILTV tetramer (25 mg/ml) as described in Materials and Methods. Data were acquired using a FACSCantoII flow
cytometer and analyzed with FlowJo software. B, A total of 33 104 MEL5 or ALF3 CD8+ T cells were incubated with 100 mg/ml OKT8, 100 mg/ml OKT8
Fab, 100 mg/ml OKT8 F(ab9)2, or 100 mg/ml OKT8 Fc9 for 18 h. Supernatant was harvested and assayed for MIP1a, MIP1b, and RANTES by ELISA. C, A
total of 3 3 104 MEL5 or ALF3 CD8+ T cells were incubated with either 10 mg/ml OKT3 or 10 mg/ml OKT3 F(ab9)2 for 18 h. Supernatant was harvested
and assayed for MIP1a, MIP1b, and RANTES by ELISA (only MIP1b is shown). Data in A–C are representative of three separate experiments. Error bars
represent SDs.
FIGURE 9. OKT8 increases TCR/pMHCI on-rates at the cell surface. A total of 5 3 105 ILA1 (A) or ALF3 (B, C) CD8+ T cells were removed from
culture, washed twice, and resuspended in 100 ml PBS with or without 100 mg/ml OKT8 or 25 mg/ml DK25 and then incubated at 4˚C for 25 min. Cognate
PE-conjugated HLA A*0201 tetramer was added in each case at 5 mg/ml. At various time points as indicated, 12 ml cell suspension was removed and
acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. In C, the CD8-null (D227K/T228A) cognate HLA A*0201 tetramer was
used (10).
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(Fig. 11A, 11B). Thus, three different phenotypes were identified
within a panel of four different anti-mouse CD8 Abs (Table III),
which further underscores the considerable heterogeneity that
exists within this group of reagents.
Discussion
Anti-CD8 Abs are integral to the flow cytometric detection of
pMHCI-restricted T cells and have been used extensively in the
past to identify an important role for CD8 in CD8+ T cell activa-
tion (16–18, 20). Most studies have concluded that anti-CD8 Abs
inhibit the recognition of cognate Ag (19, 21, 22). Furthermore,
a recent study provided evidence that a single anti-CD8 Ab could
deliver a negative signal to a CD8+ T cell clone in the absence of
cognate Ag (29). In contrast, however, earlier studies concluded
that anti-CD8 Abs could activate CD8+ T cells (25, 27). Thus,
contradictory effects of Ab-mediated CD8 ligation have been
reported and the overall picture remains unclear. To clarify this
issue, we examined the ability of seven different monoclonal anti-
human CD8 Abs to activate six different human CD8+ T cell
clones specific for a total of five different pMHCI Ags.
In the absence of cognate Ag, the anti-human CD8 Ab OKT8
induced chemokine release from all six human CD8+ T cell clones
tested and cytotoxic activity in all four human CD8+ T cell clones
tested (Figs. 1–3). Interestingly, this activation appeared to occur
in the absence of any detectable cytokine release, with the ex-
ception of CD8+ T cell clone SB10, which released IFN-g (Fig. 4).
It is well established that a hierarchy of CD8+ T cell effector
functions exists with respect to Ag sensitivity (47, 48); thus, each
function exhibits a distinct activation threshold that must be
exceeded for triggering to occur. Our findings suggest that OKT8
delivers a positive signal to CD8+ T cells that is generally suffi-
cient to exceed the activation threshold required for chemokine
release and cytotoxic activity but is not sufficient to trigger cy-
tokine release in the majority of CD8+ T cells. In contrast to
OKT8, the anti-human CD8a Ab clones SK1, MCD8, C8/144B,
32/M4, and DK25 as well as the anti-human CD8b Ab clone
2ST8.5H7 did not induce any measurable T cell effector functions
in the absence of cognate Ag. It was not possible to reverse the
phenotype of the nonactivating anti-human CD8 Abs by secondary
Ab-mediated cross-linking or PHA/IL-15 treatment (Figs. 5, 6).
Thus, we conclude that anti-CD8 Abs can exert differential ef-
fects on CD8+ T cells. These findings help to reconcile disparate
observations and suggest that previous reports in the literature
may not be intrinsically contradictory but rather reflective of the
considerable heterogeneity that characterizes the ability of anti-
CD8 Abs to induce CD8+ T cell effector function.
Anti-CD8 Ab-mediated activation of CD8+ T cells is consis-
tent with a recent report, in which we demonstrated that MHCI
molecules with superenhanced CD8 binding properties can also
activate CD8+ T cells in the absence of a specific TCR/pMHCI
interaction (49). Furthermore, thymus leukemia Ag interacts
strongly (KD = 12 mM) with cell surface CD8aa expressed by
intraepithelial lymphocytes and can modulate T cell responses
independently of the TCR (50–52). These studies all demonstrate
that the engagement of CD8 in the absence of cognate Ag bind-
ing to the TCR can activate CD8+ T cells and, collectively, un-
derscore the importance of CD8 in T cell signaling.
To examine the effects of OKT8 on Ag binding at the CD8+
T cell surface, we used soluble pMHCI tetramer technology,
which has transformed the study of Ag-specific CD8+ T cells by
FIGURE 11. Anti-mouse CD8 Abs can exhibit the same phenotype as
OKT8. A, A total of 53 104 naive mouse transgenic F5 T cells were either
mock treated or incubated with 100 mg/ml CT-CD8a, 100 mg/ml 53.6.7,
100 mg/ml CT-CD8b, or 100 mg/ml KT112 at 4˚C for 25 min and then
stained with cognate PE-conjugated H-2Db tetramer (25mg/ml) as de-
scribed in Materials and Methods. No staining was observed under any of
the conditions shown with a control H-2Db tetramer folded around the
lymphocytic choriomeningitis virus GP1-derived epitope KAVYNFATC
(residues 33–41). Data were acquired using a modified FACSAriaII flow
cytometer and analyzed with FlowJo software. Results were obtained by
gating on the CD3+CD42 population. B, A total of 3 3 104 naive mouse
transgenic F5 T cells were incubated at 37˚C for 18 h with 100 mg/ml CT-
CD8a, 100 mg/ml 53.6.7, 100 mg/ml CT-CD8b, 100 mg/ml KT112, or 50
ng/ml PMA and 1 mg/ml ionomycin. Supernatants were harvested and
assayed for MIP1b by ELISA. Error bars represent SDs.
Table II. The heterogeneity of anti-human CD8 Abs
Ab Clone a or b
Tetramer
Binding MIP1b MIP1a RANTES IFN-g TNF-a IL-2 Cytoxicity
OKT8 a Enhance Yes Yes Yes Noa Noa No Yes
SK1 a Inhibit No No No No No No No
MCD8 a Neutral No No No No No No No
32/M4 a Neutral No No No No No No No
C8/144B a Neutral No No No No No No No
DK25 a Inhibit No No No No No No No
2ST8.5H7 b Inhibit No No No No No No No
Summary of the effects exerted by anti-human CD8 Abs on pMHCI tetramer binding and CD8+ T cell activation in the
absence of TCR engagement.
aOKT8 was shown to elicit IFN-g and TNF-a release by SB10 and PHA/IL-15–stimulated PBMC.
Table III. The heterogeneity of anti-mouse CD8 Abs
Ab Clone a or b
Tetramer
Binding MIP1b IFN-g IL-2
CT-CD8a a Inhibit Yes No No
53.6.7 a Enhance Weaka No No
CT-CD8b b Enhance Yes No No
KT112 b Enhance Weak NT NT
Summary of the effects exerted by anti-mouse CD8 Abs on pMHCI tetramer
binding and CD8+ T cell activation in the absence of TCR engagement.
a53.6.7 elicited low levels of MIP1b production from naive F5 CD8+ T cells, F5
CD8+ T cell lines, and blasted BALB/c CD8+ cells but not from naive BALB/c CD8+
cells (data not shown).
NT, not tested.
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enabling their visualization, enumeration, phenotypic character-
ization, and isolation from ex vivo samples. Preincubation with
OKT8 enhanced the capture of cognate pMHCI tetramers from
solution and produced higher intensity staining (Figs. 7–9). Ac-
cordingly, OKT8 enhanced the identification of CD8+ T cells with
low-affinity TCR/pMHCI interactions (Fig. 8, Table I), such as
those that typically predominate in tumor-specific and autoim-
mune responses (41). The other anti-CD8 Abs examined in this
study either exerted inhibitory effects on pMHCI tetramer binding
(SK1, DK25, and 2ST8.5H7) or displayed no biologically sig-
nificant activity in this regard (MCD8, 32/M4, and C8/144B).
Thus, OKT8 can be used as a tool to improve pMHCI tetramer
staining; this property may be especially useful in the context of
low-avidity Ag-specific CD8+ T cell populations.
The findings described above suggest that OKT8 has properties
that are distinct from other anti-human CD8 Abs. Furthermore,
these properties are not entirely Fc9 dependent (Fig. 10). To extend
these results, we conducted additional experiments with the anti-
mouse CD8a Ab CT-CD8a and the anti-mouse CD8b Ab CT-
CD8b. CT-CD8a was shown to inhibit pMHCI tetramer staining,
whereas CT-CD8b enhanced pMHCI tetramer binding, consistent
with a previous report (26). Despite their differential effects on
pMHCI tetramer binding, both of these anti-mouse CD8 Abs ac-
tivated CD8+ T cells efficiently (Fig. 11). These results demon-
strate that the ability of anti-CD8 Abs to elicit CD8+ T cell
effector function does not always correlate with their effect on
pMHCI tetramer staining. This lack of correspondence was fur-
ther supported by the identification of a third phenotype in the
mouse system. The anti-mouse CD8a Ab 53.6.7 and the anti-
mouse CD8b Ab KT112 both enhanced pMHCI tetramer stain-
ing but only activated CD8+ T cells weakly (Table III). Taken to-
gether, these data further underline the heterogeneity that exists
within this group of reagents.
The mechanism by which anti-CD8 Abs exert either inhibitory
or stimulatory effects on pMHCI recognition remains elusive. Pre-
vious studies have shown that anti-CD8 Abs retain their effects in
the absence of a pMHCI/CD8 interaction (26, 53–55). In this study,
we confirm that the enhancing effects of OKT8 on HLA A*0201
tetramer on-rate at the cell surface are still apparent in the context
of CD8-null MHCI molecules (Fig. 9); thus, these effects are in-
dependent of any interaction between pMHCI and CD8. Subtle
local rearrangements of the TCR relative to CD8 on pMHCI en-
gagement are required for optimal CD8+ T cell activation (56, 57).
By extension, it seems likely that anti-CD8 Abs exert their effects
by interfering with, or enhancing, this surface receptor topology.
The observation that anti-CD4 Abs can block cell surface in-
termolecular interactions essential for calcium flux and inhibit
subsequent synapse formation is consistent with this hypothesis
(58). Furthermore, we have previously demonstrated that anti-
CD4 Abs can interfere with pMHCII tetramer binding even
though the pMHCII/CD4 interaction does not stabilize TCR/
pMHCII interactions (59).
In summary, we have shown the following: 1) heterogeneity
exists in the ability of anti-CD8 Abs to activate CD8+ T cells; 2)
Ab-mediated ligation of CD8 in the absence of TCR engagement
can induce chemokine release and cytotoxic activity, largely in the
absence of cytokine release; 3) the anti-human CD8 Ab OKT8 can
enhance pMHCI tetramer staining; and 4) anti-mouse CD8 Abs
(CT-CD8a and CT-CD8b) can activate CD8+ T cells in the ab-
sence of TCR engagement despite differential effects on pMHCI
tetramer staining. Thus, anti-CD8 Abs can have potent effects on
TCR/pMHCI binding kinetics and activation. These effects vary
according to the Ab clone under investigation and should be taken
into account when interpreting studies using these reagents. Fur-
thermore, the ability of Ab-mediated CD8 engagement to activate
CD8+ T cells underscores the importance of coreceptor function in
CD8+ T cell signaling.
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Appendices 
 
 
Appendix 3. Surface plasmon resonance measurements of 1E6, ALF8, and 1LA TCR 
binding to peptide variants complexed with HLA A*0201. SPR equilibrium binding of 
soluble of (A) 1E6 TCR to HLA A*0201-YQFGPDFPIA, (B) ALF3 TCR to HLA A*0201-
GILGFVFTL, (C) ALF8 TCR to HLA A*0201-GILGFVFTL and (D) ILA1 TCR to HLA 
A*0201-ILGKFLHRL. The mean response for each concentration is plotted (n = 3). The 
equilibrium dissociation constant (KD) values were calculated assuming 1:1 Langmuir 
binding and plotted using a nonlinear curve fit (y = (P1x)/(P2 + x)). 
